Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
A1BG		ENSG00000121410	Alpha-1-B glycoprotein	19	58345178-58353499	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016673, HPA044252	Supported				Liver cancer:3.97e-4 (favourable)	Tissue enriched	Tissue enriched	331	liver: 505.6	fallopian tube: 1.5	Cell line enhanced		HEK 293: 2.2;REH: 3.0
A2M	CPAMD5, FWP007, S863-7	ENSG00000175899	Alpha-2-macroglobulin	12	9067664-9116229	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002265, CAB017621	Supported					Expressed in all	Expressed in all			lung: 1920.7	Cell line enhanced		AF22: 726.1;ASC diff: 146.4;Hep G2: 419.1;SK-MEL-30: 170.2
A2ML1	CPAMD9, FLJ25179, p170	ENSG00000166535	Alpha-2-macroglobulin like 1	12	8822472-8887001	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038847, HPA038848	Enhanced					Tissue enhanced	Tissue enriched	6	esophagus: 479.2	skin: 85.5	Cell line enhanced		HMC-1: 9.6;hTCEpi: 3.9;SK-BR-3: 10.3
AADACL2	MGC72001	ENSG00000197953	Arylacetamide deacetylase like 2	3	151733916-151761339	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	14	skin: 31.1	breast: 2.3	Not detected		
ABAT	GABAT	ENSG00000183044	4-aminobutyrate aminotransferase	16	8674565-8784575	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041528, HPA041690	Enhanced	Supported	Supported	Mitochondria	Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 164.5;kidney: 135.3;liver: 175.2	thyroid gland: 47.5	Cell line enhanced		Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
ABHD1	FLJ36128, LABH1	ENSG00000143994	Abhydrolase domain containing 1	2	27123789-27130812	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044390	Uncertain					Mixed	Tissue enriched	17	testis: 30.0	liver: 1.7	Cell line enhanced		RPMI-8226: 1.1;T-47d: 3.0;U-266/70: 2.4;U-266/84: 1.9
ABHD10	FLJ11342	ENSG00000144827	Abhydrolase domain containing 10	3	111979010-111993363	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA036991, HPA036992, HPA066081	Supported		Approved	Mitochondria	Renal cancer:4.72e-9 (favourable), Cervical cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 62.1	Expressed in all		
ABHD14A-ACY1		ENSG00000114786	ABHD14A-ACY1 readthrough	3	51974706-51989183	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036174, HPA036175, HPA038153	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 1.7	kidney: 0.7	Cell line enhanced		HUVEC TERT2: 1.3;SH-SY5Y: 1.3
ABHD15		ENSG00000168792	Abhydrolase domain containing 15	17	29560547-29567137	Predicted secreted proteins	Evidence at protein level	HPA014470	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			adipose tissue: 20.5	Mixed		
ABI3BP	DKFZP586L2024, NESHBP, TARSH	ENSG00000154175	ABI family member 3 binding protein	3	100749156-100993515	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044127	Uncertain				Renal cancer:6.14e-4 (favourable)	Mixed	Mixed			gallbladder: 158.4	Cell line enhanced		hTEC/SVTERT24-B: 841.3;hTERT-HME1: 650.5;TIME: 1525.7
AC006116.20		ENSG00000267710		19	56272769-56310450	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	699	epididymis: 120.3	ovary,thyroid gland: 0.1	Not detected		
AC009133.22		ENSG00000277669		16	29663279-29695144	Predicted secreted proteins	Evidence at protein level	HPA011887	Uncertain					Not detected	Tissue enhanced		colon: 2.6;duodenum: 1.8;spleen: 1.0	lung: 0.4	Cell line enhanced		BEWO: 44.0;EFO-21: 114.1;SH-SY5Y: 19.3
AC011513.3		ENSG00000267881		19	41708612-41761282	Predicted secreted proteins	Evidence at transcript level	HPA011041	Approved					Tissue enhanced	Group enriched	11	colon: 41.2;esophagus: 10.3	appendix: 2.4	Not detected		
AC114783.1		ENSG00000237524		2	126898882-126902097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	183	testis: 57.8	kidney: 0.3	Not detected		
AC136352.2		ENSG00000277666		Unmapped	100123-101141	Predicted secreted proteins	Evidence at protein level	HPA003342	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
AC233755.1		ENSG00000275063		Unmapped	41444-41876	Predicted secreted proteins	Evidence at transcript level								Tissue enhanced		urinary bladder: 1019.5	tonsil: 662.1	Cell line enriched	8	REH: 129.3
ACACB	ACC2, ACCB, HACC275	ENSG00000076555	Acetyl-CoA carboxylase beta	12	109116595-109268226	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006554	Enhanced				Renal cancer:1.15e-5 (favourable), Pancreatic cancer:1.93e-4 (favourable)	Expressed in all	Tissue enriched	6	adipose tissue: 194.8	parathyroid gland: 30.6	Cell line enriched	13	ASC diff: 152.8
ACAN	AGC1, CSPG1, CSPGCP, MSK16	ENSG00000157766	Aggrecan	15	88803443-88875354	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016377, HPA038241, HPA038242	Enhanced				Renal cancer:1.47e-6 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 5.0	testis: 3.3	Cell line enriched	5	WM-115: 28.1
ACE	ACE1, CD143, DCP1	ENSG00000159640	Angiotensin I converting enzyme	17	63477061-63498380	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002426, CAB002921, HPA029298, HPA069790	Enhanced		Approved	Vesicles		Expressed in all	Tissue enhanced		duodenum: 178.9;small intestine: 291.6	testis: 83.7	Cell line enhanced		ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACHE	YT	ENSG00000087085	Acetylcholinesterase (Cartwright blood group)	7	100889994-100896974	Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019704, HPA027098			Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 58.5	cerebral cortex: 14.1	Cell line enhanced		BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ACP2	LAP	ENSG00000134575	Acid phosphatase 2, lysosomal	11	47239302-47248906	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 41.2	Expressed in all		
ACP5	HPAP, TRAP	ENSG00000102575	Acid phosphatase 5, tartrate resistant	19	11574660-11579008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002584, HPA057655, HPA059463	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		lung: 254.0	lymph node: 86.3	Cell line enhanced		BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5
ACP7	FLJ16165, PAPL, PAPL1	ENSG00000183760	Acid phosphatase 7, tartrate resistant (putative)	19	39083913-39111493	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042005, HPA042613	Uncertain					Group enriched	Group enriched	6	cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3	epididymis,prostate: 0.5	Cell line enhanced		hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5
ACR		ENSG00000100312	Acrosin	22	50738196-50745334	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA048687	Enhanced					Not detected	Tissue enriched	57	testis: 58.0	spleen: 1.0	Not detected		
ACRBP	CT23, OY-TES-1, SP32	ENSG00000111644	Acrosin binding protein	12	6638075-6647460	Predicted secreted proteins	Evidence at protein level	HPA039081, HPA039082	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	19	testis: 432.5	thyroid gland: 22.6	Cell line enhanced		HMC-1: 5.8;U-266/70: 11.3;U-266/84: 7.3
ACRV1	D11S4365, SP-10, SPACA2	ENSG00000134940	Acrosomal vesicle protein 1	11	125671522-125681123	Predicted secreted proteins	Evidence at protein level	HPA038718, HPA038719	Enhanced					Mixed	Tissue enriched	40	testis: 153.6	epididymis: 3.8	Mixed		
ACTL10	C20orf134	ENSG00000182584	Actin like 10	20	33666498-33668525	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 22.1	prostate: 1.4	Cell line enhanced		RPMI-8226: 3.3;SiHa: 3.6
ACTR3C	ARP11	ENSG00000106526	ARP3 actin-related protein 3 homolog C	7	150243916-150323725	Predicted intracellular proteins	Evidence at transcript level	HPA055957	Uncertain					Mixed	Tissue enriched	6	parathyroid gland: 87.3	adrenal gland: 15.8	Cell line enhanced		CAPAN-2: 27.5;RT4: 21.3;SiHa: 18.9
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
ACVR1C	ACVRLK7, ALK7	ENSG00000123612	Activin A receptor type 1C	2	157526767-157629005	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007982, HPA011933	Approved					Mixed	Tissue enriched	8	adipose tissue: 34.1	ovary: 4.3	Cell line enhanced		ASC diff: 7.5;HDLM-2: 4.8
ACVRL1	ACVRLK1, ALK1, HHT, HHT2, ORW2	ENSG00000139567	Activin A receptor like type 1	12	51906908-51923361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007041	Approved					Expressed in all	Tissue enhanced		placenta: 126.4	lung: 76.4	Cell line enhanced		ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
ACYP1		ENSG00000119640	Acylphosphatase 1	14	75053221-75069483	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034944	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 46.4	Expressed in all		
ADAM10	CD156c, HsT18717, kuz, MADM	ENSG00000137845	ADAM metallopeptidase domain 10	15	58588807-58749978	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001709, HPA050670	Approved		Supported	Vesicles<br>Plasma membrane	Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
ADAM12	MCMPMltna, MLTN	ENSG00000148848	ADAM metallopeptidase domain 12	10	126012381-126388455	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030866, HPA030867, HPA030868	Enhanced		Supported	Plasma membrane	Renal cancer:2.39e-14 (unfavourable)	Mixed	Tissue enriched	8	placenta: 237.2	cervix, uterine: 29.7	Cell line enhanced		fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0
ADAM15	MDC15	ENSG00000143537	ADAM metallopeptidase domain 15	1	155050566-155062775	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011633, HPA072878	Uncertain		Uncertain	Vesicles	Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Cell line enhanced		PC-3: 305.3
ADAM17	CD156B, cSVP, TACE	ENSG00000151694	ADAM metallopeptidase domain 17	2	9488486-9555792	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010738, CAB025906, HPA051575	Approved		Supported	Cytosol	Urothelial cancer:4.23e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.8	Expressed in all		
ADAM18	ADAM27, tMDCIII	ENSG00000168619	ADAM metallopeptidase domain 18	8	39584489-39730064	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	85	testis: 8.4	all non-specific tissues: 0.0	Not detected		
ADAM22	MDC2	ENSG00000008277	ADAM metallopeptidase domain 22	7	87934143-88202889	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050325			Approved	Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 47.6	prostate: 18.2	Cell line enhanced		Karpas-707: 58.7;SH-SY5Y: 81.7
ADAM28	ADAM23, eMDCII, MDC-Lm, MDC-Ls	ENSG00000042980	ADAM metallopeptidase domain 28	8	24294040-24359018	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA074034	Enhanced		Approved	Plasma membrane<br>Mitochondria	Endometrial cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 435.5	stomach: 104.6	Cell line enriched	10	CAPAN-2: 24.6
ADAM29	CT73, svph1	ENSG00000168594	ADAM metallopeptidase domain 29	4	174829668-174978180	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	145	testis: 73.3	endometrium: 0.5	Not detected		
ADAM32		ENSG00000197140	ADAM metallopeptidase domain 32	8	39106990-39284911	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044156, HPA062151	Enhanced		Approved	Nucleus<br>Vesicles		Not detected	Tissue enriched	35	testis: 28.7	skin: 0.8	Cell line enhanced		U-2 OS: 1.1
ADAM33	C20orf153, dJ964F7.1, DKFZp434K0521	ENSG00000149451	ADAM metallopeptidase domain 33	20	3667965-3682246	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067152, HPA071758	Approved		Uncertain	Nuclear speckles<br>Plasma membrane		Mixed	Mixed			endometrium: 103.3	Cell line enhanced		ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1
ADAM7	EAPI, GP-83	ENSG00000069206	ADAM metallopeptidase domain 7	8	24440930-24526970	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008879	Enhanced					Group enriched	Tissue enriched	199	epididymis: 4534.6	seminal vesicle: 22.7	Group enriched	23	BEWO: 2.3;NB-4: 3.9;RPMI-8226: 1.1;SH-SY5Y: 1.9
ADAM8	CD156, CD156a, MS2	ENSG00000151651	ADAM metallopeptidase domain 8	10	133262403-133276868	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064637	Approved				Renal cancer:3.99e-10 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 43.8;spleen: 32.9	appendix: 30.1	Cell line enhanced		A-431: 51.7;BEWO: 78.4;CAPAN-2: 61.7;HaCaT: 61.1;HDLM-2: 42.3;U-87 MG: 33.6
ADAM9	CORD9, KIAA0021, MCMP, MDC9, Mltng	ENSG00000168615	ADAM metallopeptidase domain 9	8	38996869-39105144	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004000			Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.7	Expressed in all		
ADAMDEC1	M12.219	ENSG00000134028	ADAM like decysin 1	8	24384285-24406013	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		colon: 210.9;rectum: 339.7;small intestine: 476.3	duodenum: 189.1	Group enriched	7	U-266/70: 8.1;U-266/84: 1.9
ADAMTS1	C3-C5, KIAA1346, METH1	ENSG00000154734	ADAM metallopeptidase with thrombospondin type 1 motif 1	21	26835747-26845409	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016394	Uncertain				Head and neck cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 412.9	adipose tissue: 279.9	Cell line enhanced		BJ: 346.6;hTEC/SVTERT24-B: 277.6
ADAMTS10	ADAM-TS10	ENSG00000142303	ADAM metallopeptidase with thrombospondin type 1 motif 10	19	8580242-8610735	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040223	Uncertain		Uncertain	Cytosol	Renal cancer:4.55e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 5.9	Cell line enhanced		NB-4: 24.4;REH: 9.3
ADAMTS12		ENSG00000151388	ADAM metallopeptidase with thrombospondin type 1 motif 12	5	33523535-33892192	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035973, HPA075079	Uncertain		Approved	Nucleoli<br>Mitochondria	Urothelial cancer:6.78e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 9.8	Cell line enhanced		hTEC/SVTERT24-B: 48.2;U-2 OS: 38.4
ADAMTS14		ENSG00000138316	ADAM metallopeptidase with thrombospondin type 1 motif 14	10	70672803-70762441	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA034605			Uncertain	Cytosol		Mixed	Tissue enhanced		gallbladder: 10.9;placenta: 11.1	urinary bladder: 4.4	Cell line enhanced		CAPAN-2: 8.0;K-562: 9.5;RH-30: 5.3;U-138 MG: 8.8
ADAMTS15		ENSG00000166106	ADAM metallopeptidase with thrombospondin type 1 motif 15	11	130448974-130476641	Predicted secreted proteins	Evidence at transcript level	HPA042867	Uncertain		Approved	Cytosol	Urothelial cancer:5.63e-5 (unfavourable), Glioma:9.00e-4 (favourable), Lung cancer:9.72e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 30.3;placenta: 23.7	breast: 11.0	Cell line enhanced		ASC diff: 49.3;ASC TERT1: 30.1;EFO-21: 34.5
ADAMTS16	ADAMTS16s	ENSG00000145536	ADAM metallopeptidase with thrombospondin type 1 motif 16	5	5140330-5320304	Predicted secreted proteins	Evidence at protein level						Renal cancer:3.29e-5 (favourable)	Mixed	Tissue enhanced		gallbladder: 9.9;ovary: 11.2	adipose tissue: 6.3	Cell line enhanced		hTEC/SVTERT24-B: 3.9;U-2197: 5.3
ADAMTS17	FLJ16363, FLJ32769	ENSG00000140470	ADAM metallopeptidase with thrombospondin type 1 motif 17	15	99971589-100342005	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062487			Approved	Nucleus		Mixed	Mixed			endometrium: 3.4	Cell line enhanced		HEK 293: 8.0;SK-MEL-30: 3.4;WM-115: 4.0
ADAMTS18	ADAMTS21	ENSG00000140873	ADAM metallopeptidase with thrombospondin type 1 motif 18	16	77247813-77435114	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044326	Uncertain					Mixed	Tissue enriched	16	placenta: 29.1	cervix, uterine: 1.8	Group enriched	7	HUVEC TERT2: 6.7;TIME: 2.0;U-87 MG: 4.7
ADAMTS19		ENSG00000145808	ADAM metallopeptidase with thrombospondin type 1 motif 19	5	129460265-129738683	Predicted secreted proteins	Evidence at transcript level	HPA056171, HPA058438	Uncertain		Approved	Vesicles<br>Midbody		Tissue enhanced	Group enriched	13	cervix, uterine: 16.8;endometrium: 16.9;placenta: 5.4;smooth muscle: 9.2	adrenal gland: 0.9	Group enriched	7	MCF7: 12.3;SH-SY5Y: 37.6
ADAMTS2	ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP	ENSG00000087116	ADAM metallopeptidase with thrombospondin type 1 motif 2	5	179110851-179345430	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028444	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:1.71e-8 (unfavourable)	Expressed in all	Mixed			placenta: 14.7	Cell line enhanced		HHSteC: 100.5;HSkMC: 69.6
ADAMTS20	GON-1	ENSG00000173157	ADAM metallopeptidase with thrombospondin type 1 motif 20	12	43353866-43551921	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027608, HPA027609	Uncertain					Not detected	Not detected			placenta: 0.8	Cell line enhanced		Karpas-707: 2.6;NTERA-2: 2.8;U-266/70: 3.1;U-266/84: 1.5
ADAMTS3	ADAMTS-4, KIAA0366	ENSG00000156140	ADAM metallopeptidase with thrombospondin type 1 motif 3	4	72280969-72569386	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA021368, HPA021369	Uncertain		Approved	Intermediate filaments		Mixed	Tissue enhanced		parathyroid gland: 7.3	testis: 3.5	Cell line enhanced		AF22: 13.0;HEL: 12.6;K-562: 10.9;U-2 OS: 8.7
ADAMTS5	ADAMTS11, ADMP-2	ENSG00000154736	ADAM metallopeptidase with thrombospondin type 1 motif 5	21	26917912-26966513	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA005661, CAB025996, HPA030906, HPA030908	Approved		Supported	Nucleoplasm	Renal cancer:2.46e-4 (unfavourable), Thyroid cancer:8.54e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 42.4	ovary: 24.3	Cell line enhanced		ASC diff: 26.2;fHDF/TERT166: 12.4;RH-30: 40.0;U-87 MG: 14.5
ADAMTS6	ADAM-TS6	ENSG00000049192	ADAM metallopeptidase with thrombospondin type 1 motif 6	5	65148736-65481920	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA043441	Enhanced					Mixed	Tissue enhanced		placenta: 2.7	gallbladder: 2.3	Cell line enhanced		HBF TERT88: 13.0;hTEC/SVTERT24-B: 12.5;TIME: 11.8;U-2197: 15.1
ADAMTS7	ADAM-TS7, DKFZp434H204	ENSG00000136378	ADAM metallopeptidase with thrombospondin type 1 motif 7	15	78759203-78811431	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045284, HPA048453	Uncertain		Supported	Vesicles	Stomach cancer:9.53e-4 (unfavourable)	Mixed	Tissue enhanced		endometrium: 7.2	heart muscle: 4.3	Cell line enriched	9	HMC-1: 229.5
ADAMTS8	ADAM-TS8, FLJ41712, METH2	ENSG00000134917	ADAM metallopeptidase with thrombospondin type 1 motif 8	11	130404925-130428993	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at transcript level	HPA066349	Approved				Endometrial cancer:1.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 10.9;lung: 15.5	seminal vesicle: 5.5	Cell line enhanced		HMC-1: 3.2;NTERA-2: 1.8;U-2 OS: 8.7
ADAMTS9	KIAA1312	ENSG00000163638	ADAM metallopeptidase with thrombospondin type 1 motif 9	3	64515654-64688000	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028567, HPA028577, HPA028601	Approved		Approved	Endoplasmic reticulum<br>Vesicles		Expressed in all	Tissue enhanced		placenta: 45.1	adipose tissue: 32.1	Cell line enhanced		RPTEC TERT1: 20.9;SH-SY5Y: 136.2;WM-115: 27.9
ADAMTSL1	ADAMTSR1, C9orf94, FLJ35283	ENSG00000178031	ADAMTS like 1	9	17906563-18910950	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057437	Uncertain					Mixed	Tissue enhanced		endometrium: 24.1	smooth muscle: 18.7	Cell line enhanced		ASC TERT1: 81.0;hTEC/SVTERT24-B: 62.6;TIME: 164.0;U-138 MG: 93.4
ADAMTSL2	KIAA0605	ENSG00000197859	ADAMTS like 2	9	133532164-133575519	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045634, HPA053812	Approved		Approved	Vesicles	Colorectal cancer:5.01e-4 (unfavourable), Pancreatic cancer:6.70e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 29.0	kidney: 11.2	Cell line enhanced		Hep G2: 4.9;RPMI-8226: 6.9;SH-SY5Y: 31.9
ADAMTSL3	KIAA1233, punctin-2	ENSG00000156218	ADAMTS like 3	15	83654086-84039842	Predicted secreted proteins	Evidence at protein level	HPA034773, HPA034774	Approved		Approved	Vesicles		Mixed	Mixed			placenta: 14.9	Group enriched	6	EFO-21: 11.2;RPTEC TERT1: 10.6;TIME: 10.7;U-2 OS: 2.4
ADAMTSL4	DKFZP434K1772, TSRC1	ENSG00000143382	ADAMTS like 4	1	150549369-150560937	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA006279	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 88.9	lung: 32.3	Cell line enhanced		ASC TERT1: 64.0;BEWO: 191.0;K-562: 60.1
ADAMTSL5	THSD6	ENSG00000185761	ADAMTS like 5	19	1505018-1513604	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044050			Approved	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 29.0	smooth muscle: 17.4	Mixed		
ADCYAP1	PACAP	ENSG00000141433	Adenylate cyclase activating polypeptide 1	18	904943-912172	Predicted secreted proteins	Evidence at protein level	HPA065887		Approved			Renal cancer:2.91e-6 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7	testis: 5.6	Cell line enriched	17	SCLC-21H: 20.8
ADCYAP1R1	PAC1, PAC1R, PACAPR	ENSG00000078549	ADCYAP receptor type I	7	31052461-31111479	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030739, HPA049877	Enhanced		Supported	Vesicles	Endometrial cancer:5.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 137.1;fallopian tube: 46.8	cervix, uterine: 20.7	Group enriched	6	AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
ADGRA3	FLJ38547, GPR125, PGR21	ENSG00000152990	Adhesion G protein-coupled receptor A3	4	22345071-22516054	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008904	Uncertain					Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
ADGRB2	BAI2	ENSG00000121753	Adhesion G protein-coupled receptor B2	1	31727117-31764893	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052612, HPA054617			Supported	Centrosome	Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)	Tissue enhanced	Tissue enriched	14	cerebral cortex: 72.3	adrenal gland: 5.1	Cell line enhanced		SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
ADGRE3	EMR3	ENSG00000131355	Adhesion G protein-coupled receptor E3	19	14619117-14690027	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA015638	Uncertain					Not detected	Tissue enhanced		appendix: 8.7;spleen: 8.6	lung: 3.9	Cell line enriched	50	HMC-1: 39.7
ADGRE5	CD97, TM7LN1	ENSG00000123146	Adhesion G protein-coupled receptor E5	19	14380501-14408725	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013707	Enhanced		Approved	Cytosol	Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 140.3	Mixed		
ADGRF1	GPR110, hGPCR36, PGR19	ENSG00000153292	Adhesion G protein-coupled receptor F1	6	46997703-47042363	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038438	Approved				Renal cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9	gallbladder: 9.4	Group enriched	9	A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
ADGRG1	GPR56, TM7LN4, TM7XN1	ENSG00000205336	Adhesion G protein-coupled receptor G1	16	57610652-57665580	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046065	Uncertain				Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 349.0	Cell line enhanced		SK-MEL-30: 229.9
ADGRG5	GPR114, PGR27	ENSG00000159618	Adhesion G protein-coupled receptor G5	16	57542421-57591681	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007133	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Cervical cancer:4.25e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.2;tonsil: 8.8	appendix,spleen: 5.9	Cell line enriched	8	HMC-1: 31.8
ADGRG6	FLJ14937, GPR126	ENSG00000112414	Adhesion G protein-coupled receptor G6	6	142301854-142446266	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017346	Approved				Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 67.2	liver: 36.9	Cell line enhanced		HUVEC TERT2: 133.3;MCF7: 118.0
ADGRV1	DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1	ENSG00000164199	Adhesion G protein-coupled receptor V1	5	90529344-91164437	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067503	Approved		Approved	Lipid droplets		Mixed	Tissue enriched	11	adrenal gland: 261.4	kidney: 22.9	Cell line enhanced		AF22: 15.3;HAP1: 23.8;NTERA-2: 11.7;SCLC-21H: 13.1
ADI1	APL1, ARD, FLJ10913, HMFT1638, MTCBP-1, mtnD, SIPL	ENSG00000182551	Acireductone dioxygenase 1	2	3497361-3519736	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035403, HPA035404	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			liver: 228.3	Expressed in all		
ADIG	MGC39724, RP5-1100H13.2, SMAF1	ENSG00000182035	Adipogenin	20	38581195-38588463	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA041124	Uncertain					Tissue enhanced	Group enriched	10	epididymis: 5.1;testis: 16.1;thyroid gland: 3.4	seminal vesicle: 0.8	Not detected		
ADIPOQ	ACDC, ACRP30, adiponectin, AdipoQ, apM1, GBP28	ENSG00000181092	Adiponectin, C1Q and collagen domain containing	3	186842690-186858463	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB046467, HPA051767	Uncertain					Group enriched	Tissue enriched	17	adipose tissue: 937.7	breast: 56.0	Cell line enriched	475	ASC diff: 213.8
ADM	AM	ENSG00000148926	Adrenomedullin	11	10304680-10307397	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016075	Approved				Renal cancer:6.33e-4 (unfavourable), Liver cancer:7.56e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 158.5	Cell line enhanced		ASC diff: 519.0;U-138 MG: 397.2
ADM2	AM2, FLJ21135	ENSG00000128165	Adrenomedullin 2	22	50481556-50486440	Predicted secreted proteins	Evidence at transcript level						Thyroid cancer:2.72e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 19.2	kidney: 5.8	Cell line enhanced		HHSteC: 30.8;Karpas-707: 27.1
ADM5	AM5, C19orf76	ENSG00000224420	Adrenomedullin 5 (putative)	19	49688664-49690575	Predicted secreted proteins	Evidence at transcript level						Urothelial cancer:6.74e-4 (favourable)	Mixed	Mixed			skin: 2.6	Mixed		
ADPGK	ADP-GK, DKFZp434B195	ENSG00000159322	ADP dependent glucokinase	15	72751369-72785846	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045194, HPA058525	Approved		Approved	Centrosome	Renal cancer:4.52e-7 (unfavourable), Prostate cancer:2.22e-4 (unfavourable)	Expressed in all	Mixed			lung: 25.1	Expressed in all		
AEBP1	ACLP	ENSG00000106624	AE binding protein 1	7	44104361-44114562	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009966, HPA047724, HPA063595, HPA064970	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:9.31e-9 (unfavourable), Glioma:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 300.4	Cell line enhanced		BJ: 163.5;fHDF/TERT166: 162.3;WM-115: 116.5
AFM	ALB2, ALBA	ENSG00000079557	Afamin	4	73481683-73504001	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017006, HPA052437	Enhanced				Liver cancer:1.80e-4 (favourable)	Tissue enriched	Tissue enriched	6	liver: 468.3	kidney: 80.9	Cell line enriched	6	CACO-2: 1.3
AFP	FETA, HPAFP	ENSG00000081051	Alpha fetoprotein	4	73431138-73456174	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010607, HPA023600, CAB024283, CAB025339	Approved		Uncertain	Cytosol		Group enriched	Tissue enhanced		liver: 1.9	breast: 0.5	Cell line enriched	158	Hep G2: 1466.5
AGA	ASRG	ENSG00000038002	Aspartylglucosaminidase	4	177430770-177442503	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031415, HPA031417	Enhanced				Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 35.3	Expressed in all		
AGER	RAGE, SCARJ1	ENSG00000204305	Advanced glycosylation end-product specific receptor	6	32180968-32184324	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB011682, HPA064436	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enriched	181	lung: 889.2	thyroid gland: 4.9	Cell line enhanced		HEK 293: 2.5;U-266/70: 2.6
AGR2	AG2, HAG-2, PDIA17, XAG-2	ENSG00000106541	Anterior gradient 2, protein disulphide isomerase family member	7	16791811-16833433	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007912	Enhanced		Approved	Cytosol	Renal cancer:8.79e-5 (unfavourable), Liver cancer:1.15e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 1322.0;stomach: 1307.3	cervix, uterine: 939.5	Cell line enhanced		A549: 239.4;RPTEC TERT1: 465.3;RT4: 298.0;T-47d: 1243.5
AGR3	BCMP11, hAG-3, HAG3, PDIA18	ENSG00000173467	Anterior gradient 3, protein disulphide isomerase family member	7	16859405-16881987	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053942	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles		Tissue enhanced	Tissue enhanced		fallopian tube: 354.7;small intestine: 259.5	rectum: 233.8	Cell line enriched	52	T-47d: 316.6
AGRN	AGRIN	ENSG00000188157	Agrin	1	1020123-1056118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040090	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.2	Cell line enhanced		EFO-21: 223.9
AGRP	Agrt, ART, ASIP2	ENSG00000159723	Agouti related neuropeptide	16	67482571-67483813	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA041017	Uncertain	Supported				Mixed	Group enriched	5	adrenal gland: 5.8;epididymis: 24.7	lung: 3.0	Not detected		
AGT	SERPINA8	ENSG00000135744	Angiotensinogen	1	230702523-230714297	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001557, CAB025798	Supported					Group enriched	Tissue enhanced		cerebral cortex: 226.5;liver: 649.6	gallbladder: 133.7	Cell line enhanced		CACO-2: 60.4;Hep G2: 401.1;THP-1: 150.6
AGTRAP	ATRAP	ENSG00000177674	Angiotensin II receptor associated protein	1	11736084-11754802	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044120	Approved		Supported	Vesicles	Liver cancer:6.57e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 92.6	Expressed in all		
AHCYL2	KIAA0828	ENSG00000158467	Adenosylhomocysteinase like 2	7	129225023-129430211	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053128	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.08e-7 (favourable), Head and neck cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			rectum: 194.5	Cell line enriched	9	HDLM-2: 218.4
AHSG	A2HS, FETUA, HSGA	ENSG00000145192	Alpha 2-HS glycoprotein	3	186612923-186621318	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001524, HPA001525, CAB026209	Enhanced		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	1903	liver: 2823.4	testis: 1.4	Cell line enriched	64	Hep G2: 1410.0
AIG1	AIG-1, dJ95L4.1, FLJ10485	ENSG00000146416	Androgen induced 1	6	143060496-143340304	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060766	Approved		Approved	Golgi apparatus	Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 153.1	Expressed in all		
AKAP10	D-AKAP2, MGC9414, PRKA10	ENSG00000108599	A-kinase anchoring protein 10	17	19904302-19978343	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028901	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
ALAS2	ASB	ENSG00000158578	5'-aminolevulinate synthase 2	X	55009055-55031064	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001638	Approved					Mixed	Tissue enriched	7	bone marrow: 335.6	placenta: 51.0	Group enriched	173	HEL: 42.0;K-562: 61.5
ALB		ENSG00000163631	Albumin	4	73397114-73421412	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB006262, HPA031024, HPA031025	Supported		Enhanced	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:7.87e-4 (unfavourable)	Tissue enriched	Tissue enriched	220	liver: 105947.0	kidney: 482.5	Cell line enriched	33	Hep G2: 3030.6
ALG1	CDG1K, HMAT1, HMT-1, Mat-1	ENSG00000033011	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase	16	5033960-5087379	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060392	Approved		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG9	DIBD1	ENSG00000086848	ALG9, alpha-1,2-mannosyltransferase	11	111782195-111871581	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038575	Approved		Approved	Endoplasmic reticulum	Renal cancer:7.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
ALKAL1	AUGB, FAM150A, UNQ9433	ENSG00000196711	ALK and LTK ligand 1	8	52534037-52565507	Predicted secreted proteins	Evidence at protein level	HPA027368	Uncertain					Mixed	Tissue enhanced		gallbladder: 3.5;thyroid gland: 3.6	cervix, uterine: 1.7	Cell line enhanced		CAPAN-2: 1.1
ALKAL2	AUGA, FAM150B	ENSG00000189292	ALK and LTK ligand 2	2	279558-288851	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 257.4	ovary: 83.0	Cell line enriched	22	AF22: 137.0
ALPI		ENSG00000163295	Alkaline phosphatase, intestinal	2	232456123-232460032	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA038764, HPA038765, HPA051699	Supported		Approved	Plasma membrane		Tissue enhanced	Group enriched	31	duodenum: 203.2;small intestine: 212.1	colon: 6.6	Cell line enriched	10	CACO-2: 5.9
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced		Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
ALPP		ENSG00000163283	Alkaline phosphatase, placental	2	232378534-232382889	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026327, HPA038764, HPA038765, HPA051699	Enhanced		Approved	Plasma membrane	Pancreatic cancer:4.33e-4 (unfavourable)	Tissue enhanced	Group enriched	14	cervix, uterine: 25.5;placenta: 45.5	fallopian tube: 2.5	Group enriched	6	HaCaT: 311.4;SiHa: 103.4
ALPPL2		ENSG00000163286	Alkaline phosphatase, placental like 2	2	232406843-232410714	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB020698, HPA038764, HPA038765, HPA051699	Supported		Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		fallopian tube: 1.5	lung: 0.7	Group enriched	29	BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
AMBN		ENSG00000178522	Ameloblastin	4	70592256-70607288	Disease related genes, Predicted secreted proteins	Evidence at protein level							Group enriched	Not detected			cerebral cortex: 0.3	Cell line enriched	9	HEK 293: 6.2
AMBP	EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI	ENSG00000106927	Alpha-1-microglobulin/bikunin precursor	9	114060127-114078472	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001497, CAB069436	Approved				Endometrial cancer:1.20e-4 (favourable)	Tissue enriched	Tissue enriched	23	liver: 5176.2	gallbladder: 230.0	Cell line enriched	113	Hep G2: 861.2
AMELX	AIH1, AMG	ENSG00000125363	Amelogenin, X-linked	X	11293413-11300761	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Not detected			epididymis: 0.4	Not detected		
AMELY	AMGL	ENSG00000099721	Amelogenin, Y-linked	Y	6865918-6874027	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.2	Not detected		
AMH	MIS	ENSG00000104899	Anti-Mullerian hormone	19	2249309-2252073	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA066973			Approved	Vesicles<br>Aggresome	Colorectal cancer:9.21e-5 (unfavourable)	Mixed	Tissue enriched	6	testis: 1.6	cerebral cortex: 0.2	Cell line enhanced		HEK 293: 15.7;NTERA-2: 6.5;REH: 6.4;SH-SY5Y: 8.2
AMTN	RSTI689, UNQ689	ENSG00000187689	Amelotin	4	70518540-70532742	Predicted secreted proteins	Evidence at protein level	HPA036136, HPA036137	Uncertain					Group enriched	Tissue enhanced		stomach: 6.9;tonsil: 24.9	prostate: 3.3	Cell line enhanced		hTERT-HME1: 3.4;MCF7: 2.6
AMY1A	AMY1	ENSG00000237763	Amylase, alpha 1A (salivary)	1	103655290-103664554	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB004310, HPA045394, HPA045399, HPA046980	Supported					Not detected	Tissue enriched	79	salivary gland: 8875.9	cervix, uterine: 111.7	Not detected		
AMY1B	AMY1	ENSG00000174876	Amylase, alpha 1B (salivary)	1	103687415-103696680	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Tissue enhanced	Tissue enriched	15	salivary gland: 1841.0	cervix, uterine: 126.4	Not detected		
AMY1C	AMY1	ENSG00000187733	Amylase, alpha 1C (salivary)	1	103750406-103758690	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Not detected	Tissue enhanced		cervix, uterine: 33.0;salivary gland: 101.8	pancreas: 26.4	Not detected		
AMY2A	AMY2	ENSG00000243480	Amylase, alpha 2A (pancreatic)	1	103616811-103625780	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, CAB045960, HPA046980	Enhanced					Tissue enriched	Tissue enriched	313	pancreas: 31329.4	ovary: 99.9	Not detected		
AMY2B	AMY2	ENSG00000240038	Amylase, alpha 2B (pancreatic)	1	103553815-103579534	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Tissue enriched	Tissue enriched	66	pancreas: 6585.9	salivary gland: 99.6	Cell line enhanced		EFO-21: 9.6
ANG	RAA1, RNASE5	ENSG00000214274	Angiogenin	14	20684177-20698971	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable)	Tissue enriched	Tissue enriched	27	liver: 1565.4	stomach: 57.0	Cell line enriched	5	Hep G2: 105.0
ANGEL1	Ccr4e, KIAA0759	ENSG00000013523	Angel homolog 1	14	76786178-76826246	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000948	Uncertain		Approved	Nucleoplasm	Lung cancer:3.43e-4 (favourable), Pancreatic cancer:5.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 68.3	Expressed in all		
ANGPT1	Ang1, KIAA0003	ENSG00000154188	Angiopoietin 1	8	107249482-107498055	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB017815, HPA018793, HPA018816	Enhanced				Renal cancer:4.40e-4 (favourable)	Mixed	Tissue enhanced		seminal vesicle: 46.2	lung: 32.9	Cell line enhanced		ASC diff: 60.0;HEL: 46.9;HSkMC: 105.6;U-138 MG: 70.1;WM-115: 46.8
ANGPT2	Ang2	ENSG00000091879	Angiopoietin 2	8	6499651-6563409	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB011437, CAB017626	Approved				Renal cancer:1.52e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Cervical cancer:7.99e-5 (unfavourable), Stomach cancer:3.87e-4 (unfavourable), Melanoma:4.48e-4 (unfavourable)	Expressed in all	Mixed			placenta: 19.6	Group enriched	7	HMC-1: 17.8;HSkMC: 34.2;HUVEC TERT2: 62.9;WM-115: 24.3
ANGPT4		ENSG00000101280	Angiopoietin 4	20	869899-916317	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB013260, CAB013305	Uncertain					Not detected	Tissue enhanced		cervix, uterine: 5.4	adipose tissue: 2.7	Group enriched	92	ASC diff: 23.2;BEWO: 47.4
ANGPTL1	ANG3, ANGPT3, AngY, ARP1	ENSG00000116194	Angiopoietin like 1	1	178849705-178871052	Predicted secreted proteins	Evidence at protein level	HPA009976	Approved				Renal cancer:5.11e-4 (favourable), Liver cancer:8.73e-4 (favourable)	Mixed	Tissue enhanced		placenta: 190.2	smooth muscle: 96.7	Group enriched	18	ASC diff: 102.1;ASC TERT1: 41.7;HHSteC: 54.1;HSkMC: 106.7
ANGPTL2	ARP2, HARP	ENSG00000136859	Angiopoietin like 2	9	127087332-127122883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040933, HPA041299	Approved		Approved	Golgi apparatus	Renal cancer:3.32e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 114.9	Cell line enhanced		ASC diff: 96.3;ASC TERT1: 66.5;BJ hTERT+: 165.9;HSkMC: 70.1
ANGPTL3	ANGPT5	ENSG00000132855	Angiopoietin like 3	1	62597487-62606159	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038097	Approved					Tissue enriched	Tissue enriched	6	liver: 356.4	kidney: 55.7	Not detected		
ANGPTL4	ARP4, FIAF, HFARP, NL2, PGAR, pp1158	ENSG00000167772	Angiopoietin like 4	19	8363289-8374373	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007879, CAB033770	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 78.7	liver: 43.2	Cell line enhanced		HBEC3-KT: 161.5;TIME: 92.8;U-138 MG: 64.0
ANGPTL5		ENSG00000187151	Angiopoietin like 5	11	101890674-101916522	Predicted secreted proteins	Evidence at protein level	HPA038516	Uncertain					Not detected	Tissue enhanced		ovary: 27.1	breast: 7.2	Cell line enhanced		ASC diff: 1.8
ANGPTL6	AGF, ARP5	ENSG00000130812	Angiopoietin like 6	19	10092338-10102796	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		liver: 11.0	lymph node: 3.9	Cell line enriched	9	HMC-1: 51.7
ANGPTL7	AngX, CDT6	ENSG00000171819	Angiopoietin like 7	1	11189341-11195981	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		seminal vesicle: 9.3	gallbladder: 5.8	Cell line enriched	434	SCLC-21H: 48.4
ANGPTL8	C19orf80, RIFL, TD26	ENSG00000130173	Angiopoietin like 8	19	11237450-11241943	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042131			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.84e-6 (unfavourable)	Tissue enriched	Group enriched	20	adipose tissue: 13.7;liver: 63.8	epididymis: 1.9	Group enriched	28	Hep G2: 24.9;MCF7: 16.3
ANK1	ANK, SPH1	ENSG00000029534	Ankyrin 1	8	41653220-41896762	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004842, HPA056953	Supported					Mixed	Tissue enriched	5	skeletal muscle: 348.3	heart muscle: 63.9	Group enriched	5	HEL: 84.7;K-562: 96.3;RH-30: 157.8
ANKDD1A	FLJ25870	ENSG00000166839	Ankyrin repeat and death domain containing 1A	15	64911902-64958700	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040757	Approved		Approved	Nucleoplasm		Mixed	Mixed			spleen: 15.0	Cell line enhanced		Karpas-707: 17.4;RT4: 14.8;U-266/84: 17.5
ANKRD54	LIAR	ENSG00000100124	Ankyrin repeat domain 54	22	37830855-37849327	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA071287	Approved		Approved	Nucleoplasm<br>Microtubules<br>Midbody	Endometrial cancer:7.38e-5 (favourable), Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 35.8	Expressed in all		
ANOS1	ADMLX, KAL, KAL1, KALIG-1, WFDC19	ENSG00000011201	Anosmin 1	X	8528874-8732186	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	cerebral cortex: 32.3;lung: 64.7;parathyroid gland: 48.5;thyroid gland: 15.5	testis: 7.3	Group enriched	5	NTERA-2: 36.7;U-2 OS: 18.3
ANTXR1	ATR, FLJ10601, FLJ21776, TEM8	ENSG00000169604	Anthrax toxin receptor 1	2	69013178-69249327	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054785			Uncertain	Vesicles	Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 180.5	Cell line enhanced		LHCN-M2: 286.7
AOAH		ENSG00000136250	Acyloxyacyl hydrolase	7	36512949-36724549	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021666, HPA026716	Uncertain					Expressed in all	Tissue enhanced		spleen: 88.9	appendix: 45.9	Group enriched	6	HDLM-2: 3.4;NB-4: 16.7;THP-1: 13.5;U-937: 6.8
AOC1	ABP1, DAO	ENSG00000002726	Amine oxidase, copper containing 1	7	150824627-150861504	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA031032, HPA031033	Approved				Prostate cancer:1.71e-4 (favourable)	Group enriched	Tissue enhanced		placenta: 716.9;small intestine: 247.6	duodenum: 183.2	Cell line enhanced		CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
AOC2	DAO2, RAO	ENSG00000131480	Amine oxidase, copper containing 2	17	42844600-42850707	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA057779	Uncertain				Urothelial cancer:2.47e-4 (favourable)	Tissue enhanced	Group enriched	5	adipose tissue: 6.2;testis: 5.8	spleen: 1.2	Cell line enhanced		ASC diff: 7.7
APCDD1	B7323	ENSG00000154856	APC down-regulated 1	18	10454628-10489948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.39e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 153.1	cerebral cortex: 60.6	Cell line enhanced		AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6
APCS	MGC88159, PTX2, SAP	ENSG00000132703	Amyloid P component, serum	1	159587825-159588865	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007817, HPA053294	Supported					Tissue enriched	Tissue enriched	25	liver: 1851.8	gallbladder: 73.5	Cell line enhanced		RH-30: 1.1
APELA	ELA, Ende, tdl	ENSG00000248329	Apelin receptor early endogenous ligand	4	164877004-164898965	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		prostate: 6.3	kidney: 2.1	Cell line enriched	5	NTERA-2: 39.7
APLN	apelin, XNPEP2	ENSG00000171388	Apelin	X	129645259-129654937	Predicted secreted proteins	Evidence at transcript level						Renal cancer:9.61e-5 (unfavourable), Cervical cancer:2.92e-4 (unfavourable), Lung cancer:6.09e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Group enriched	Tissue enhanced		placenta: 79.6	lung: 20.8	Cell line enriched	6	HUVEC TERT2: 421.2
APLP2	APPH, APPL2	ENSG00000084234	Amyloid beta precursor like protein 2	11	130069837-130144811	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039319	Approved		Approved	Vesicles	Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1056.8	Expressed in all		
APOA1		ENSG00000118137	Apolipoprotein A1	11	116835751-116837950	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016778, HPA046715	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 8458.6;small intestine: 4128.6	duodenum: 1609.4	Cell line enriched	15	Hep G2: 1951.8
APOA2		ENSG00000158874	Apolipoprotein A2	1	161222292-161223631	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025885	Supported					Tissue enriched	Tissue enriched	1068	liver: 18325.0	bone marrow: 17.1	Cell line enriched	8	Hep G2: 11388.0
APOA4		ENSG00000110244	Apolipoprotein A4	11	116820700-116823306	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001352, HPA002549, CAB068250, CAB068251, CAB068252	Enhanced		Approved	Vesicles		Tissue enriched	Group enriched	126	duodenum: 2211.8;small intestine: 3441.1	liver: 22.3	Cell line enhanced		BEWO: 7.4;CACO-2: 6.6;Hep G2: 5.1;NB-4: 4.6;RPMI-8226: 8.2;SH-SY5Y: 11.1
APOA5	APOA-V, RAP3	ENSG00000110243	Apolipoprotein A5	11	116789367-116792420	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	273	liver: 259.2	testis: 0.9	Cell line enriched	54	Hep G2: 40.9
APOB		ENSG00000084674	Apolipoprotein B	2	21001429-21044073	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016070, HPA049793	Supported		Supported	Vesicles<br>Cytosol		Tissue enriched	Group enriched	120	duodenum: 182.8;liver: 618.9;small intestine: 333.2	adipose tissue: 3.1	Cell line enriched	25	Hep G2: 734.4
APOC1		ENSG00000130208	Apolipoprotein C1	19	44914247-44919349	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051518	Supported				Liver cancer:1.15e-7 (favourable)	Tissue enriched	Tissue enriched	7	liver: 7257.2	adrenal gland: 1113.0	Cell line enhanced		Hep G2: 389.1;HSkMC: 242.1;SK-MEL-30: 203.2
APOC2		ENSG00000234906	Apolipoprotein C2	19	44945982-44949565	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA055877	Supported					Tissue enriched	Tissue enriched	59	liver: 4214.4	small intestine: 71.0	Cell line enhanced		Hep G2: 463.1;HMC-1: 196.0;THP-1: 841.9
APOC3		ENSG00000110245	Apolipoprotein C3	11	116829706-116833072	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065365			Approved	Nucleoplasm<br>Nucleoli<br>Cell Junctions	Renal cancer:6.87e-5 (unfavourable), Liver cancer:3.77e-4 (favourable)	Tissue enriched	Tissue enriched	7	liver: 8677.3	small intestine: 1178.4	Group enriched	17	CACO-2: 85.2;Hep G2: 190.9
APOC4		ENSG00000267467	Apolipoprotein C4	19	44942238-44945496	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062671	Approved					Tissue enriched	Tissue enriched	124	liver: 347.3	testis: 2.8	Cell line enhanced		HEL: 1.5;SK-MEL-30: 2.0
APOD		ENSG00000189058	Apolipoprotein D	3	195568702-195584205	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040520	Enhanced		Approved	Plasma membrane	Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)	Expressed in all	Tissue enriched	7	breast: 4620.2	adipose tissue: 670.2	Cell line enhanced		ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1
APOE	AD2	ENSG00000130203	Apolipoprotein E	19	44905754-44909393	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008363, HPA065539, HPA068768, CAB069921	Enhanced		Approved	Vesicles		Expressed in all	Expressed in all			adrenal gland: 1801.1	Cell line enhanced		ASC diff: 1276.1;Hep G2: 626.6;HSkMC: 991.4;SK-MEL-30: 1417.0
APOF		ENSG00000175336	Apolipoprotein F	12	56360569-56362823	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	111	liver: 220.1	prostate: 1.9	Cell line enriched	9	Hep G2: 3.0
APOH	B2G1, BG	ENSG00000091583	Apolipoprotein H	17	66212033-66256525	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001654, HPA003732, CAB022214	Enhanced		Supported	Golgi apparatus	Liver cancer:2.39e-7 (favourable), Renal cancer:1.10e-6 (unfavourable)	Tissue enriched	Tissue enriched	278	liver: 9090.4	kidney: 32.7	Cell line enriched	17	Hep G2: 846.7
APOL1	APOL	ENSG00000100342	Apolipoprotein L1	22	36253010-36267530	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018885, CAB056156	Supported				Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Cell line enhanced		EFO-21: 233.1;HDLM-2: 156.1;RT4: 120.9
APOL3	APOLIII, CG12-1	ENSG00000128284	Apolipoprotein L3	22	36140330-36166177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036228			Approved	Nuclear bodies<br>Mitochondria	Renal cancer:1.23e-5 (unfavourable), Breast cancer:6.82e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 38.5;Karpas-707: 42.5
APOL4	APOLIV	ENSG00000100336	Apolipoprotein L4	22	36189124-36204840	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049797, HPA055435	Approved		Supported	Vesicles	Urothelial cancer:2.40e-6 (favourable), Renal cancer:2.00e-5 (unfavourable), Ovarian cancer:3.45e-4 (favourable)	Expressed in all	Mixed			prostate: 26.7	Cell line enhanced		BEWO: 19.1;HDLM-2: 103.0;K-562: 21.3;SCLC-21H: 56.9
APOM	ApoM, G3a, NG20	ENSG00000204444	Apolipoprotein M	6	31652416-31658210	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034086, HPA051006	Approved		Approved	Golgi apparatus		Tissue enriched	Mixed			testis: 5.6	Mixed		
ARHGAP36	FLJ30058	ENSG00000147256	Rho GTPase activating protein 36	X	131058242-131089883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002064	Enhanced		Approved	Nucleus<br>Vesicles<br>Plasma membrane		Tissue enriched	Tissue enriched	19	adrenal gland: 137.8	cerebral cortex: 7.4	Cell line enriched	173	SH-SY5Y: 188.2
ARHGAP45	HA-1, HMHA1, KIAA0223	ENSG00000180448	Rho GTPase activating protein 45	19	1065923-1086628	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019816	Enhanced				Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 56.4;lymph node: 66.6;spleen: 77.8	bone marrow: 44.0	Cell line enhanced		Karpas-707: 72.0;U-266/70: 99.7
ARHGDIG	RHOGDI-3	ENSG00000242173	Rho GDP dissociation inhibitor gamma	16	268727-283010	Predicted intracellular proteins	Evidence at protein level	HPA078260			Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 131.1;duodenum: 44.2	small intestine: 17.9	Cell line enhanced		HEK 293: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
ARMC5	FLJ13063	ENSG00000140691	Armadillo repeat containing 5	16	31458080-31467166	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041524, HPA063706	Approved		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:1.97e-6 (favourable)	Expressed in all	Mixed			bone marrow: 13.2	Cell line enhanced		NB-4: 37.4
ARSA		ENSG00000100299	Arylsulfatase A	22	50622754-50628173	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005554, CAB025183	Enhanced		Uncertain	Golgi apparatus<br>Cytosol	Endometrial cancer:2.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 37.4	Cell line enhanced		Karpas-707: 58.2
ARSB		ENSG00000113273	Arylsulfatase B	5	78777209-78986087	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA037770, HPA037771	Enhanced		Approved	Golgi apparatus	Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 18.2	Expressed in all		
ARSE	CDPX, CDPX1	ENSG00000157399	Arylsulfatase E (chondrodysplasia punctata 1)	X	2934632-2968310	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060518, HPA070651	Approved		Supported	Golgi apparatus	Colorectal cancer:8.95e-4 (favourable)	Mixed	Tissue enhanced		kidney: 41.3;liver: 49.3	pancreas: 23.9	Cell line enhanced		A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
ARSI	FLJ16069, SPG66	ENSG00000183876	Arylsulfatase family member I	5	150296343-150339307	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038386, HPA038398	Uncertain		Approved	Golgi apparatus	Urothelial cancer:1.19e-4 (unfavourable), Lung cancer:9.11e-4 (unfavourable)	Mixed	Mixed			skin: 5.7	Cell line enhanced		HaCaT: 27.7;hTEC/SVTERT24-B: 30.9;U-87 MG: 38.4
ARSK	DKFZp313G1735, TSULF	ENSG00000164291	Arylsulfatase family member K	5	95555074-95605064	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042384	Approved		Approved	Nucleus<br>Vesicles	Liver cancer:2.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 22.7	thyroid gland: 8.5	Expressed in all		
ART3		ENSG00000156219	ADP-ribosyltransferase 3	4	76011184-76112802	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011268	Enhanced					Tissue enhanced	Tissue enhanced		skeletal muscle: 77.0;testis: 174.4	heart muscle: 29.1	Group enriched	7	NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
ART4	CD297, DO, DOK1	ENSG00000111339	ADP-ribosyltransferase 4 (Dombrock blood group)	12	14825569-14843495	Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA075664			Approved	Rods & Rings		Tissue enhanced	Tissue enhanced		liver: 27.2;spleen: 26.9	gallbladder: 15.1	Cell line enhanced		AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
ART5		ENSG00000167311	ADP-ribosyltransferase 5	11	3638503-3642316	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA041637, HPA044099	Uncertain				Renal cancer:1.85e-4 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 10.2;testis: 22.6	endometrium: 5.1	Cell line enhanced		BEWO: 2.9;HEK 293: 1.9;U-2 OS: 2.1
ARTN	ENOVIN, EVN, NBN	ENSG00000117407	Artemin	1	43933320-43937241	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Ovarian cancer:8.18e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 21.2	seminal vesicle: 12.2	Cell line enhanced		A-431: 60.4;HaCaT: 62.8;HBEC3-KT: 45.5
ASAH1	AC, ACDase, ASAH, FLJ21558, PHP32	ENSG00000104763	N-acylsphingosine amidohydrolase 1	8	18055992-18084998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005468	Supported				Renal cancer:3.08e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 547.6	Expressed in all		
ASAH2		ENSG00000188611	N-acylsphingosine amidohydrolase 2	10	50182778-50248610	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA061171	Supported		Approved	Focal adhesion sites		Mixed	Group enriched	17	duodenum: 83.5;small intestine: 71.3	stomach: 4.6	Mixed		
ASIP	AGTIL, ASP	ENSG00000101440	Agouti signaling protein	20	34194569-34269344	Predicted secreted proteins	Evidence at protein level	HPA048636	Uncertain		Supported	Vesicles		Mixed	Group enriched	5	epididymis: 18.1;ovary: 7.4;skin: 5.7	breast: 2.0	Cell line enhanced		CACO-2: 2.6
ASPN	FLJ20129, PLAP1, SLRR1C	ENSG00000106819	Asporin	9	92456205-92482506	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008435, HPA024230	Approved		Uncertain	Nucleoplasm	Renal cancer:1.64e-7 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 115.6;smooth muscle: 161.0	gallbladder: 104.1	Cell line enhanced		ASC TERT1: 11.2;BJ hTERT+: 4.6;HHSteC: 19.2
ASTL	ovastacin, SAS1B	ENSG00000188886	Astacin like metalloendopeptidase	2	96123850-96138436	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA015620	Uncertain					Mixed	Tissue enhanced		bone marrow: 2.4	seminal vesicle: 1.4	Not detected		
ATAT1	C6orf134, Em:AB023049.7, FLJ13158, MEC17	ENSG00000137343	Alpha tubulin acetyltransferase 1	6	30626842-30646823	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046816, HPA050999	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:1.03e-5 (unfavourable), Renal cancer:7.78e-5 (unfavourable), Urothelial cancer:1.35e-4 (favourable)	Expressed in all	Mixed			epididymis: 4.4	Cell line enhanced		AF22: 7.3
ATG5	APG5, APG5L, ASP, hAPG5	ENSG00000057663	Autophagy related 5	6	106045423-106325791	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034432, CAB037309, HPA042973	Enhanced		Approved	Centrosome	Renal cancer:8.73e-4 (unfavourable), Liver cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.3	Expressed in all		
ATP13A1	ATP13A, CGI-152, FLJ31858, KIAA1825	ENSG00000105726	ATPase 13A1	19	19645198-19663693	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031798, HPA049717	Approved		Approved	Vesicles	Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.5	Expressed in all		
ATP6AP1	16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3	ENSG00000071553	ATPase H+ transporting accessory protein 1	X	154428632-154436516	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015218	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 209.7	Expressed in all		
ATP6AP2	APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR	ENSG00000182220	ATPase H+ transporting accessory protein 2	X	40579372-40606848	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA003156	Approved				Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 893.4	Expressed in all		
AVP	ADH, ARVP	ENSG00000101200	Arginine vasopressin	20	3082556-3084724	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025318, HPA071892	Supported	Supported				Not detected	Not detected			bone marrow,testis: 0.5	Cell line enriched	9	NB-4: 1.4
AZGP1	ZA2G, ZAG	ENSG00000160862	Alpha-2-glycoprotein 1, zinc-binding	7	99966720-99976157	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012582, CAB016087, CAB032276	Enhanced				Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)	Group enriched	Tissue enhanced		breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5	kidney: 294.4	Cell line enhanced		Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0
AZU1	AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC	ENSG00000172232	Azurocidin 1	19	825097-832018	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055851	Enhanced					Mixed	Tissue enriched	525	bone marrow: 1311.2	skin: 2.4	Cell line enriched	6	THP-1: 722.4
B2M		ENSG00000166710	Beta-2-microglobulin	15	44711477-44718877	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002572, HPA006361	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			lymph node: 5119.8	Expressed in all		
B3GALNT1	B3GALT3, beta3Gal-T3, galT3, GLOB, P1	ENSG00000169255	Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)	3	161083883-161105384	Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041204			Approved	Vesicles		Expressed in all	Mixed			thyroid gland: 47.9	Cell line enhanced		RT4: 111.0
B3GALNT2	MGC39558	ENSG00000162885	Beta-1,3-N-acetylgalactosaminyltransferase 2	1	235449923-235504481	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA012502, HPA050662	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			smooth muscle: 15.9	Expressed in all		
B3GLCT	B3GALTL, B3Glc-T, B3GTL	ENSG00000187676	Beta 3-glucosyltransferase	13	31199936-31332276	Disease related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			endometrium: 21.1	Cell line enhanced		HDLM-2: 54.9
B3GNT8	B3GALT7, beta3Gn-T8, BGALT15	ENSG00000177191	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	19	41425359-41428730	Predicted secreted proteins	Evidence at protein level	HPA043669	Enhanced				Pancreatic cancer:9.31e-6 (favourable), Endometrial cancer:4.11e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 15.5;small intestine: 16.8	esophagus: 10.7	Cell line enhanced		HMC-1: 5.7;HUVEC TERT2: 2.9;U-937: 4.3
B3GNT9	MGC4655	ENSG00000237172	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9	16	67148105-67151214	Predicted secreted proteins	Evidence at protein level	HPA052743, HPA062734	Approved		Supported	Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Tissue enhanced		parathyroid gland: 49.9	thyroid gland: 28.2	Cell line enhanced		SiHa: 49.7
B4GALNT1	beta1-4GalNAc-T, GALGT, SPG26	ENSG00000135454	Beta-1,4-N-acetyl-galactosaminyltransferase 1	12	57623410-57633355	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008968, HPA015128	Enhanced				Renal cancer:3.18e-14 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 26.2	seminal vesicle: 4.0	Cell line enhanced		EFO-21: 33.8;HDLM-2: 29.7
B4GALT4	beta4Gal-T4	ENSG00000121578	Beta-1,4-galactosyltransferase 4	3	119211732-119241103	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046819, HPA063546	Approved		Supported	Golgi apparatus	Liver cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 75.8	Expressed in all		
B9D1	B9, EPPB9, MKS9	ENSG00000108641	B9 domain containing 1	17	19337554-19378182	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022957	Approved				Renal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 102.1	Mixed		
BACE2	AEPLC, ALP56, CEAP1, DRAP	ENSG00000182240	Beta-site APP-cleaving enzyme 2	21	41167801-41282518	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035416	Approved				Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)	Expressed in all	Mixed			stomach: 30.5	Cell line enhanced		SK-BR-3: 43.8;WM-115: 41.2
BAG6	BAT3, D6S52E, G3	ENSG00000204463	BCL2 associated athanogene 6	6	31639028-31652705	Predicted intracellular proteins	Evidence at protein level	CAB020704, HPA045116, HPA053291	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 135.9	Expressed in all		
BCAM	CD239, LU	ENSG00000187244	Basal cell adhesion molecule (Lutheran blood group)	19	44809059-44821420	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005654	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:5.94e-6 (favourable), Endometrial cancer:1.24e-5 (unfavourable), Colorectal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 174.7	Cell line enhanced		HaCaT: 278.4;SK-BR-3: 217.2;T-47d: 152.4
BCAN	BEHAB, CSPG7, MGC13038	ENSG00000132692	Brevican	1	156641390-156659532	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA007865, CAB025862	Enhanced	Supported				Group enriched	Tissue enriched	24	cerebral cortex: 428.3	epididymis: 18.0	Cell line enhanced		HDLM-2: 67.3;K-562: 92.6;U-266/84: 84.7
BCAR1	CAS, CASS1, Crkas, P130Cas	ENSG00000050820	BCAR1, Cas family scaffolding protein	16	75228187-75268053	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000443, HPA042282	Approved	Supported	Approved	Plasma membrane<br>Cytosol	Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable)	Expressed in all	Mixed			spleen: 41.0	Mixed		
BCHE	CHE1, CHE2, E1	ENSG00000114200	Butyrylcholinesterase	3	165772904-165837472	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001560	Approved				Head and neck cancer:1.06e-4 (unfavourable)	Group enriched	Tissue enhanced		liver: 265.5	endometrium: 67.7	Cell line enriched	7	Karpas-707: 542.1
BCKDHB		ENSG00000083123	Branched chain keto acid dehydrogenase E1 subunit beta	6	80106647-80346270	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA031580	Approved				Renal cancer:5.54e-9 (favourable)	Expressed in all	Expressed in all			liver: 39.9	Expressed in all		
BCO2	B-DIOX-II, BCDO2, FLJ34464	ENSG00000197580	Beta-carotene oxygenase 2	11	112175467-112224699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039825, HPA040695	Uncertain					Mixed	Tissue enhanced		heart muscle: 21.7;liver: 25.7	adrenal gland: 16.9	Cell line enhanced		CAPAN-2: 5.2;HHSteC: 10.3
BDNF		ENSG00000176697	Brain derived neurotrophic factor	11	27654893-27722058	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009564, HPA031440, HPA056104	Enhanced		Supported	Nuclear speckles<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 11.9	epididymis: 4.9	Cell line enhanced		BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3
BGLAP	OCN	ENSG00000242252	Bone gamma-carboxyglutamate protein	1	156241962-156243321	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			skin: 2.1	Cell line enhanced		U-87 MG: 2.8
BGN	DSPG1, SLRR1A	ENSG00000182492	Biglycan	X	153494939-153509554	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003157, CAB003678	Enhanced		Approved	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:6.00e-8 (unfavourable)	Expressed in all	Mixed			gallbladder: 501.3	Cell line enhanced		BJ: 258.4;BJ hTERT+: 318.9;fHDF/TERT166: 430.9;hTEC/SVTERT24-B: 230.0;HUVEC TERT2: 458.3;U-138 MG: 240.7
BMP1	PCOLC	ENSG00000168487	Bone morphogenetic protein 1	8	22164736-22212326	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA014572	Enhanced				Renal cancer:3.37e-9 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 21.1	smooth muscle: 10.5	Mixed		
BMP10		ENSG00000163217	Bone morphogenetic protein 10	2	68865481-68871517	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	91	heart muscle: 327.8	liver: 3.5	Not detected		
BMP15	GDF9B	ENSG00000130385	Bone morphogenetic protein 15	X	50910784-50916607	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.3	Not detected		
BMP2	BMP2A	ENSG00000125845	Bone morphogenetic protein 2	20	6767664-6780280	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA058610, CAB078457			Enhanced	Vesicles		Expressed in all	Mixed			thyroid gland: 31.2	Cell line enhanced		CACO-2: 25.6;HeLa: 13.4;hTERT-HME1: 13.5;RT4: 19.5
BMP3		ENSG00000152785	Bone morphogenetic protein 3	4	81030965-81057531	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		urinary bladder: 20.6	lung: 8.7	Cell line enhanced		AF22: 10.7;Daudi: 12.2;RT4: 11.3;SK-BR-3: 4.6
BMP4	BMP2B	ENSG00000125378	Bone morphogenetic protein 4	14	53949736-53958761	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB006863, HPA066235	Enhanced					Expressed in all	Mixed			placenta: 64.1	Cell line enhanced		CACO-2: 100.3;CAPAN-2: 262.8;Hep G2: 222.2;U-2 OS: 93.4
BMP6	VGR, VGR1	ENSG00000153162	Bone morphogenetic protein 6	6	7726797-7881422	Predicted secreted proteins	Evidence at protein level	CAB002773, HPA062683	Approved		Approved	Mitochondria	Breast cancer:6.45e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 33.4	lung: 10.4	Cell line enhanced		HUVEC TERT2: 162.0;Karpas-707: 72.0;SiHa: 90.3;TIME: 73.2
BMP7	OP-1	ENSG00000101144	Bone morphogenetic protein 7	20	57168748-57266629	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057757			Approved	Nucleus<br>Nucleoli<br>Vesicles	Endometrial cancer:2.91e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 76.7	placenta: 36.8	Cell line enhanced		Daudi: 124.6;MCF7: 154.9;SK-BR-3: 95.4;U-698: 163.1
BMP8A		ENSG00000183682	Bone morphogenetic protein 8a	1	39491646-39525935	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	19	thyroid gland: 82.0	testis: 4.4	Cell line enhanced		U-2197: 12.8;U-266/70: 5.4;U-266/84: 4.6
BMP8B	BMP8, OP-2	ENSG00000116985	Bone morphogenetic protein 8b	1	39757182-39788861	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 33.5	adrenal gland: 7.5	Cell line enhanced		THP-1: 80.8;U-266/84: 37.5;WM-115: 56.0
BMPER	CRIM3, Cv2	ENSG00000164619	BMP binding endothelial regulator	7	33904911-34155872	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018083		Supported				Tissue enhanced	Mixed			placenta: 9.5	Cell line enhanced		fHDF/TERT166: 17.5;HBF TERT88: 23.1;hTEC/SVTERT24-B: 16.0;U-138 MG: 24.5
BNC1	BNC, HsT19447	ENSG00000169594	Basonuclin 1	15	83255903-83284714	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA063183, HPA066947, HPA077428			Enhanced	Nucleoplasm		Tissue enhanced	Tissue enhanced		testis: 56.0	esophagus: 11.8	Cell line enhanced		HBEC3-KT: 83.5;hTCEpi: 92.6;hTERT-HME1: 95.2
BOC	CDON2	ENSG00000144857	BOC cell adhesion associated, oncogene regulated	3	113211003-113287459	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025806, HPA060778, HPA061787	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable)	Mixed	Mixed			fallopian tube: 51.7	Cell line enhanced		AN3-CA: 73.4;ASC diff: 77.9;BJ hTERT+: 34.1
BOLA1	CGI-143	ENSG00000178096	BolA family member 1	1	149887890-149900798	Predicted secreted proteins	Evidence at protein level	HPA007005	Approved				Liver cancer:5.88e-4 (unfavourable), Ovarian cancer:6.41e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 15.6	Cell line enhanced		MCF7: 42.0
BPI	BPIFD1	ENSG00000101425	Bactericidal/permeability-increasing protein	20	38260149-38337505	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA061284	Enhanced					Not detected	Tissue enriched	37	bone marrow: 961.6	testis: 25.9	Group enriched	5	AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1
BPIFA1	bA49G10.5, LUNX, PLUNC, SPLUNC1	ENSG00000198183	BPI fold containing family A member 1	20	33235995-33243311	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025669	Supported					Tissue enriched	Group enriched	8	cervix, uterine: 9.8;lung: 26.5	urinary bladder: 2.2	Not detected		
BPIFA2	bA49G10.1, C20orf70, PSP, SPLUNC2	ENSG00000131050	BPI fold containing family A member 2	20	33161768-33181412	Predicted secreted proteins	Evidence at protein level	HPA044006	Enhanced					Tissue enhanced	Tissue enriched	520	salivary gland: 2662.8	epididymis: 5.1	Not detected		
BPIFA3	bA49G10.4, C20orf71, SPLUNC3	ENSG00000131059	BPI fold containing family A member 3	20	33217310-33227758	Predicted secreted proteins	Evidence at protein level	HPA062708	Enhanced					Not detected	Tissue enriched	534	testis: 53.4	all non-specific tissues: 0.0	Not detected		
BPIFB1	bA49G10.6, C20orf114, dJ1187J4.1, LPLUNC1, MGC14597, VEMSGP	ENSG00000125999	BPI fold containing family B member 1	20	33273480-33309878	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA024256	Supported					Tissue enhanced	Tissue enhanced		cervix, uterine: 839.4;stomach: 443.3	lung: 157.3	Cell line enhanced		CAPAN-2: 2.2;RT4: 1.6;SK-BR-3: 3.1
BPIFB2	BPIL1, C20orf184, dJ726C3.2, LPLUNC2	ENSG00000078898	BPI fold containing family B member 2	20	33007600-33023709	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049491, HPA060121	Enhanced		Approved	Vesicles	Endometrial cancer:1.97e-5 (favourable)	Group enriched	Group enriched	23	esophagus: 98.5;salivary gland: 90.5	cervix, uterine: 4.0	Cell line enriched	418	Hep G2: 146.8
BPIFB3	C20orf185, dJ726C3.4, LPLUNC3, RYA3	ENSG00000186190	BPI fold containing family B member 3	20	33055424-33073628	Plasma proteins, Predicted secreted proteins	Evidence at transcript level	HPA045741	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.0	salivary gland: 0.2	Group enriched	28	HEL: 3.3;HMC-1: 2.3
BPIFB4	C20orf186, dJ726C3.5, LPLUNC4	ENSG00000186191	BPI fold containing family B member 4	20	33079644-33111751	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		parathyroid gland: 1.3	testis: 0.7	Cell line enhanced		HSkMC: 1.7;U-2 OS: 4.0
BPIFB6	BPIL3, LPLUNC6	ENSG00000167104	BPI fold containing family B member 6	20	33031648-33044047	Predicted secreted proteins	Evidence at protein level	HPA043057	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BPIFC	BPIL2, dJ149A16.7	ENSG00000184459	BPI fold containing family C	22	32413847-32464484	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA037665, HPA043306	Uncertain					Group enriched	Tissue enriched	18	skin: 75.6	breast: 4.1	Cell line enhanced		SCLC-21H: 1.5
BRINP1	DBC1, DBCCR1, FAM5A	ENSG00000078725	BMP/retinoic acid inducible neural specific 1	9	119153458-119369467	Predicted secreted proteins, Transporters	Evidence at protein level	HPA038828	Approved		Approved	Microtubules		Mixed	Tissue enriched	8	cerebral cortex: 59.6	seminal vesicle: 7.2	Cell line enhanced		HSkMC: 6.2;NTERA-2: 16.8;SCLC-21H: 8.7
BRINP2	DBCCR1L2, FAM5B	ENSG00000198797	BMP/retinoic acid inducible neural specific 2	1	177171497-177282422	Predicted secreted proteins, Transporters	Evidence at transcript level	HPA050681, HPA061920	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enriched	Group enriched	10	adrenal gland: 11.5;cerebral cortex: 35.4	testis: 2.3	Group enriched	5	HDLM-2: 6.7;PC-3: 1.6;REH: 1.8;SCLC-21H: 7.3;SH-SY5Y: 1.4
BRINP3	DBCCR1L, DBCCR1L1, FAM5C	ENSG00000162670	BMP/retinoic acid inducible neural specific 3	1	190097662-190478404	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054693	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 44.5;small intestine: 19.6	prostate: 10.9	Cell line enriched	6	SCLC-21H: 17.0
BSG	CD147, EMMPRIN, OK	ENSG00000172270	Basigin (Ok blood group)	19	571277-583493	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002427, HPA036048, HPA074870	Enhanced		Approved	Vesicles	Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 593.5	Expressed in all		
BST1	CD157	ENSG00000109743	Bone marrow stromal cell antigen 1	4	15702950-15738313	CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050121	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 105.5	duodenum: 54.8	Cell line enhanced		THP-1: 60.3;TIME: 39.6;U-937: 45.8;WM-115: 51.6
BTBD17	BTBD17A, LGALS3BPL, TANGO10A	ENSG00000204347	BTB domain containing 17	17	74356416-74361946	Predicted secreted proteins	Evidence at protein level	HPA025022	Approved					Group enriched	Tissue enriched	19	cerebral cortex: 12.9	adrenal gland: 0.6	Group enriched	24	AF22: 2.7;NTERA-2: 3.6;SCLC-21H: 12.8
BTD		ENSG00000169814	Biotinidase	3	15601341-15645822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052275	Uncertain				Renal cancer:2.60e-9 (favourable)	Expressed in all	Expressed in all			epididymis: 53.0	Mixed		
BTN2A2	BT2.2, BTF2, BTN2.2	ENSG00000124508	Butyrophilin subfamily 2 member A2	6	26383096-26394874	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051504	Uncertain		Supported	Mitochondria	Breast cancer:1.01e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.6	Mixed		
BTN3A1	BT3.1, BTF5, BTN3.1, CD277	ENSG00000026950	Butyrophilin subfamily 3 member A1	6	26402237-26415216	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012565	Approved		Uncertain	Vesicles	Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 112.6	Mixed		
BTN3A2	BTN3.2	ENSG00000186470	Butyrophilin subfamily 3 member A2	6	26365159-26378320	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB019392	Uncertain				Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.4	Mixed		
BTN3A3	BTF3, BTN3.3	ENSG00000111801	Butyrophilin subfamily 3 member A3	6	26440472-26453415	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007904, HPA011871	Enhanced				Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9
C10orf99	AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833	ENSG00000188373	Chromosome 10 open reading frame 99	10	84173738-84185294	Predicted secreted proteins	Evidence at protein level	HPA050920	Enhanced				Renal cancer:1.20e-5 (unfavourable)	Mixed	Group enriched	11	colon: 239.2;esophagus: 185.4;rectum: 264.2	urinary bladder: 20.8	Cell line enriched	6	RT4: 37.2
C11orf1	FLJ23499	ENSG00000137720	Chromosome 11 open reading frame 1	11	111878935-111885975	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038410, HPA057519	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.39e-4 (favourable), Endometrial cancer:9.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 104.9	Expressed in all		
C11orf24	DM4E3	ENSG00000171067	Chromosome 11 open reading frame 24	11	68261335-68272001	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012748	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 65.9	Expressed in all		
C11orf94		ENSG00000234776	Chromosome 11 open reading frame 94	11	45906513-45907282	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	55	testis: 20.7	esophagus,thyroid gland: 0.3	Cell line enhanced		HEK 293: 1.1
C12orf10	Gamm1, MYG, MYG1	ENSG00000139637	Chromosome 12 open reading frame 10	12	53299686-53307177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038626, HPA038627	Approved	Supported	Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 114.3	Expressed in all		
C12orf73	DKFZp547P055, FLJ13975	ENSG00000204954	Chromosome 12 open reading frame 73	12	103950202-103965708	Predicted secreted proteins	Evidence at protein level	HPA038883	Uncertain		Approved	Plasma membrane<br>Centrosome<br>Mitochondria	Urothelial cancer:1.61e-4 (favourable), Liver cancer:6.98e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 17.8	Expressed in all		
C12orf76	FLJ40142	ENSG00000174456	Chromosome 12 open reading frame 76	12	110027028-110073686	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA039713, HPA042013	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
C14orf80		ENSG00000185347	Chromosome 14 open reading frame 80	14	105489855-105499575	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039049, HPA039050	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:3.54e-4 (unfavourable)	Expressed in all	Mixed			appendix,skin: 6.6	Mixed		
C15orf41	FLJ22851, HH114, MGC11326	ENSG00000186073	Chromosome 15 open reading frame 41	15	36579611-36810248	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061023	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		heart muscle: 63.4	smooth muscle: 14.3	Expressed in all		
C16orf89	MGC45438	ENSG00000153446	Chromosome 16 open reading frame 89	16	5044122-5066110	Predicted secreted proteins	Evidence at protein level	HPA013613, HPA016934	Enhanced					Group enriched	Tissue enhanced		lung: 145.4;thyroid gland: 352.5	epididymis: 94.3	Cell line enhanced		ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0
C16orf90	LOC646174	ENSG00000215131	Chromosome 16 open reading frame 90	16	3493484-3495480	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	214	testis: 21.4	all non-specific tissues: 0.0	Not detected		
C17orf58		ENSG00000186665	Chromosome 17 open reading frame 58	17	67991101-67996431	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA023036	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 50.5	cervix, uterine: 42.4	Expressed in all		
C17orf67		ENSG00000214226	Chromosome 17 open reading frame 67	17	56791913-56838773	Predicted secreted proteins	Evidence at protein level	HPA043479	Uncertain	Approved				Mixed	Mixed			spleen: 3.7	Cell line enhanced		MOLT-4: 11.9
C17orf75	NJMU-R1, SRI2	ENSG00000108666	Chromosome 17 open reading frame 75	17	32324565-32350023	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004061	Approved	Approved	Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.33e-4 (favourable), Ovarian cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.6	Expressed in all		
C17orf99	GLPG464, UNQ464	ENSG00000187997	Chromosome 17 open reading frame 99	17	78146353-78166177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029655	Uncertain					Not detected	Tissue enriched	6	bone marrow: 5.5	fallopian tube,lymph node: 0.9	Group enriched	14	HaCaT: 3.1;HMC-1: 6.2;K-562: 3.8
C19orf47	FLJ36888	ENSG00000160392	Chromosome 19 open reading frame 47	19	40319536-40348527	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041843, HPA046309	Uncertain		Enhanced	Nucleoplasm	Endometrial cancer:7.10e-5 (unfavourable), Liver cancer:1.41e-4 (unfavourable), Breast cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.7	Expressed in all		
C19orf70	MIC13, P117, QIL1	ENSG00000174917	Chromosome 19 open reading frame 70	19	5678421-5680896	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042672	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:7.60e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 79.9	Expressed in all		
C1orf127	FLJ37118	ENSG00000175262	Chromosome 1 open reading frame 127	1	10946471-10982037	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA027654	Uncertain					Tissue enriched	Tissue enhanced		skeletal muscle: 5.7	stomach: 2.1	Cell line enhanced		THP-1: 1.7
C1orf159	FLJ20584	ENSG00000131591	Chromosome 1 open reading frame 159	1	1081818-1116361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010019	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 15.3	Expressed in all		
C1orf54	FLJ23221	ENSG00000118292	Chromosome 1 open reading frame 54	1	150268200-150280916	Predicted secreted proteins	Evidence at transcript level	HPA026518, HPA043874	Approved		Approved	Plasma membrane	Renal cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 76.0	Cell line enhanced		AF22: 61.4;AN3-CA: 87.4;ASC TERT1: 75.6;HSkMC: 63.9;HUVEC TERT2: 73.1
C1orf56	FLJ20519, MENT	ENSG00000143443	Chromosome 1 open reading frame 56	1	151047740-151051986	Predicted secreted proteins	Evidence at protein level	HPA037429, HPA037430	Enhanced					Expressed in all	Tissue enriched	7	testis: 48.5	thyroid gland: 6.8	Mixed		
C1QA		ENSG00000173372	Complement C1q A chain	1	22636506-22639608	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002350, CAB009823	Supported		Uncertain	Golgi apparatus<br>Cytosol	Renal cancer:1.58e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 1166.4	Cell line enhanced		HMC-1: 2.0;RPMI-8226: 4.9;SCLC-21H: 3.5
C1QB		ENSG00000173369	Complement C1q B chain	1	22652762-22661538	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052116	Approved				Renal cancer:9.58e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 1435.2	Not detected		
C1QC	C1QG	ENSG00000159189	Complement C1q C chain	1	22643630-22648110	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001471, CAB009828	Supported		Uncertain	Vesicles	Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 1285.6	Cell line enhanced		RPMI-8226: 1.7
C1QL1	C1QRF, C1QTNF14, CRF	ENSG00000131094	Complement C1q like 1	17	44959693-44968071	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.31e-8 (unfavourable)	Tissue enriched	Tissue enriched	14	cerebral cortex: 38.4	prostate: 2.6	Cell line enhanced		SCLC-21H: 49.2;SH-SY5Y: 31.5;U-2 OS: 108.2;U-87 MG: 32.8
C1QL2	C1QTNF10, CTRP10	ENSG00000144119	Complement C1q like 2	2	119156243-119158889	Predicted secreted proteins	Evidence at protein level	HPA057934	Uncertain					Mixed	Tissue enriched	17	cerebral cortex: 2.5	lymph node,testis: 0.1	Cell line enhanced		SCLC-21H: 2.8
C1QL3	C1ql, C1QTNF13, CTRP13, K100	ENSG00000165985	Complement C1q like 3	10	16513743-16522005	Predicted secreted proteins	Evidence at protein level						Renal cancer:6.29e-5 (favourable)	Mixed	Tissue enriched	24	cerebral cortex: 43.3	duodenum: 1.8	Group enriched	10	HDLM-2: 29.9;SCLC-21H: 22.4
C1QL4	C1QTNF11, CTRP11	ENSG00000186897	Complement C1q like 4	12	49332411-49337188	Predicted secreted proteins	Evidence at transcript level						Renal cancer:3.03e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 2.1;thyroid gland: 1.2	cerebral cortex: 0.7	Cell line enhanced		AN3-CA: 32.7;U-2 OS: 9.6
C1QTNF1	CTRP1, FLJ90694, GIP, ZSIG37	ENSG00000173918	C1q and tumor necrosis factor related protein 1	17	79022814-79049788	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025429	Approved				Renal cancer:9.09e-9 (unfavourable), Cervical cancer:2.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 155.0	seminal vesicle: 65.5	Cell line enhanced		ASC diff: 229.1;BJ hTERT+: 66.0;HHSteC: 105.8;U-87 MG: 78.1
C1QTNF12	ADIPOLIN, C1QDC2, CTRP12, FAM132A, MGC105127	ENSG00000184163	C1q and tumor necrosis factor related protein 12	1	1242446-1246722	Predicted secreted proteins	Evidence at protein level	HPA024107	Approved		Approved	Vesicles		Mixed	Tissue enhanced		duodenum: 6.9;small intestine: 7.3	colon: 2.1	Group enriched	5	EFO-21: 3.9;U-2 OS: 4.3
C1QTNF3	2310005P21Rik, Corcs, Cors, Cors-26, CTRP3	ENSG00000082196	C1q and tumor necrosis factor related protein 3	5	34019448-34043832	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064996, HPA066011	Uncertain		Approved	Golgi apparatus	Renal cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 38.8	smooth muscle: 33.0	Cell line enriched	195	U-266/84: 563.8
C1QTNF4	CTRP4, ZACRP4	ENSG00000172247	C1q and tumor necrosis factor related protein 4	11	47589664-47594659	Predicted secreted proteins	Evidence at protein level	HPA041032	Approved					Mixed	Tissue enriched	5	cerebral cortex: 28.2	parathyroid gland: 5.2	Cell line enriched	6	REH: 10.4
C1QTNF5	CTRP5, DKFZp586B0621, LORD	ENSG00000223953	C1q and tumor necrosis factor related protein 5	11	119338939-119340940	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025607, HPA038604	Uncertain					Not detected	Mixed			gallbladder: 71.5	Cell line enhanced		HHSteC: 30.0;HUVEC TERT2: 45.5;TIME: 41.0
C1QTNF7	CTRP7	ENSG00000163145	C1q and tumor necrosis factor related protein 7	4	15339818-15446166	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB007055, HPA051797, HPA055392	Uncertain		Approved	Vesicles		Mixed	Mixed			cervix, uterine: 36.4	Cell line enhanced		ASC diff: 3.0;ASC TERT1: 2.1;HSkMC: 1.2
C1QTNF8	CTRP8, UNQ5829	ENSG00000184471	C1q and tumor necrosis factor related protein 8	16	1090005-1096244	Predicted secreted proteins	Evidence at protein level	HPA056438	Uncertain					Not detected	Not detected			fallopian tube: 0.7	Not detected		
C1QTNF9	AQL1, C1QTNF9A, CTRP9, MGC48915	ENSG00000240654	C1q and tumor necrosis factor related protein 9	13	24307166-24322535	Predicted secreted proteins	Evidence at protein level	HPA056632	Uncertain					Not detected	Tissue enhanced		skeletal muscle: 2.9	adipose tissue: 2.1	Not detected		
C1QTNF9B	CTRP9B	ENSG00000205863	C1q and tumor necrosis factor related protein 9B	13	23890525-23902655	Predicted secreted proteins	Evidence at protein level	HPA056632	Uncertain					Tissue enhanced	Tissue enhanced		skin: 9.4	testis: 3.3	Not detected		
C1R		ENSG00000159403	Complement C1r	12	7080209-7092607	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001251, HPA001551	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:1.94e-14 (unfavourable)	Expressed in all	Expressed in all			liver: 1226.4	Cell line enhanced		ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4
C1RL	C1r-LP, C1RL1	ENSG00000139178	Complement C1r subcomponent like	12	7089587-7109273	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011338, CAB026172	Supported		Approved	Microtubules<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Breast cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			liver: 83.7	Cell line enhanced		HSkMC: 60.9
C1S		ENSG00000182326	Complement C1s	12	6988259-7071032	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016722, HPA018852	Supported		Approved	Nucleus<br>Cytosol	Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable)	Expressed in all	Expressed in all			liver: 1326.7	Cell line enhanced		ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5
C2		ENSG00000166278	Complement C2	6	31897785-31945672	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016775	Supported				Renal cancer:2.64e-7 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 86.3;lung: 42.6	placenta: 21.9	Group enriched	5	Hep G2: 30.0;Karpas-707: 94.7
C20orf173	dJ477O4.4	ENSG00000125975	Chromosome 20 open reading frame 173	20	35523186-35529652	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	137	testis: 34.3	skin: 0.2	Not detected		
C21orf33	D21S2048E, ES1, GT335, HES1, KNP-I, KNP-Ia, KNPH, KNPI	ENSG00000160221	Chromosome 21 open reading frame 33	21	44133605-44145723	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018517	Supported		Approved	Centrosome<br>Mitochondria		Mixed	Expressed in all			kidney: 35.4	Cell line enhanced		Daudi: 101.9
C21orf62	B37, C21orf120, PRED81	ENSG00000205929	Chromosome 21 open reading frame 62	21	32793564-32813743	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016899	Enhanced				Renal cancer:1.14e-4 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 6.4;kidney: 5.1;ovary: 12.6	prostate: 4.2	Group enriched	13	AF22: 2.5;RPTEC TERT1: 1.1
C2orf40	augurin, ECRG4	ENSG00000119147	Chromosome 2 open reading frame 40	2	106063246-106078159	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA008546	Uncertain				Breast cancer:4.58e-4 (favourable)	Tissue enriched	Tissue enhanced		seminal vesicle: 116.4;thyroid gland: 128.1	prostate: 61.6	Not detected		
C2orf66	UNQ6411	ENSG00000187944	Chromosome 2 open reading frame 66	2	196805002-196810276	Predicted secreted proteins	Evidence at transcript level	HPA020869	Uncertain					Mixed	Tissue enhanced		adipose tissue: 2.8;adrenal gland: 1.7;testis: 1.7	skin: 1.1	Cell line enhanced		HEL: 4.0;RT4: 1.3;TIME: 1.5
C2orf69	FLJ38973	ENSG00000178074	Chromosome 2 open reading frame 69	2	199911256-199955935	Predicted secreted proteins	Evidence at protein level	HPA045225	Uncertain					Expressed in all	Expressed in all			testis: 26.6	Expressed in all		
C3	ARMD9, C3a, C3b, CPAMD1	ENSG00000125730	Complement C3	19	6677704-6730562	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003563, CAB004209, HPA020432	Enhanced				Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			liver: 2486.8	Group enriched	6	BJ hTERT+: 287.5;EFO-21: 689.2;Hep G2: 539.6;HSkMC: 386.3;SiHa: 220.2
C3orf33	AC3-33, FLJ31139	ENSG00000174928	Chromosome 3 open reading frame 33	3	155762617-155806351	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037663	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.48e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 14.4	Mixed		
C4A	C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG	ENSG00000244731	Complement C4A (Rodgers blood group)	6	31982024-32002681	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009811, CAB032603, HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		liver: 46.1	thyroid gland: 28.2	Group enriched	8	HDLM-2: 49.4;HSkMC: 51.4;U-266/70: 12.8;U-266/84: 23.9
C4B	C4B1, C4B3, C4F, CH, CO4, CPAMD3	ENSG00000224389	Complement C4B (Chido blood group)	6	32014762-32035418	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		adrenal gland: 59.4;liver: 65.5	fallopian tube,kidney: 18.3	Cell line enriched	5	Karpas-707: 92.1
C4BPB	C4BP	ENSG00000123843	Complement component 4 binding protein beta	1	207088842-207099993	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051620	Approved					Tissue enriched	Group enriched	16	liver: 241.3;ovary: 52.0	placenta: 8.9	Group enriched	15	CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7
C4orf26	AI2A4, FLJ23657	ENSG00000174792	Chromosome 4 open reading frame 26	4	75556048-75565885	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	12	placenta: 5.9	cerebral cortex: 0.5	Cell line enriched	7	HDLM-2: 40.8
C4orf48		ENSG00000243449	Chromosome 4 open reading frame 48	4	2041993-2043970	Predicted secreted proteins	Evidence at protein level	HPA052447	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 22.1	testis: 11.2	Cell line enhanced		HEK 293: 145.6;PC-3: 318.4
C5	C5a, C5b, CPAMD4	ENSG00000106804	Complement C5	9	120952335-121050276	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA029339	Uncertain				Liver cancer:9.43e-4 (favourable)	Tissue enriched	Tissue enriched	21	liver: 225.6	lung: 10.5	Cell line enhanced		A549: 25.6;Hep G2: 20.6
C5orf46	MGC23985, SSSP1	ENSG00000178776	Chromosome 5 open reading frame 46	5	147880726-147906538	Predicted secreted proteins	Evidence at transcript level	HPA058999			Approved	Nuclear speckles<br>Mitochondria	Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)	Tissue enhanced	Group enriched	8	breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9	heart muscle: 5.8	Cell line enhanced		PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3
C6		ENSG00000039537	Complement C6	5	41142234-41261438	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA043823, CAB069427	Enhanced				Renal cancer:4.31e-4 (favourable)	Group enriched	Group enriched	9	fallopian tube: 73.5;liver: 358.3	heart muscle: 23.4	Group enriched	11	ASC diff: 3.2;ASC TERT1: 4.5;HSkMC: 12.3
C6orf120	bA160E12.4	ENSG00000185127	Chromosome 6 open reading frame 120	6	169702190-169704856	Predicted secreted proteins	Evidence at protein level	HPA039626	Uncertain				Liver cancer:9.52e-5 (unfavourable), Cervical cancer:2.26e-4 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 28.7	Expressed in all		
C6orf15	STG	ENSG00000204542	Chromosome 6 open reading frame 15	6	31111223-31112559	Predicted secreted proteins	Evidence at transcript level	HPA001436	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 2.0	tonsil: 0.8	Group enriched	12	RH-30: 3.1;U-2 OS: 1.4
C6orf58	LEG1	ENSG00000184530	Chromosome 6 open reading frame 58	6	127519455-127591817	Predicted secreted proteins	Evidence at protein level	HPA036263, HPA041449	Enhanced					Group enriched	Group enriched	21	duodenum: 603.5;salivary gland: 163.4;stomach: 314.9	esophagus: 17.1	Cell line enhanced		RPMI-8226: 1.8;WM-115: 1.8
C7		ENSG00000112936	Complement C7	5	40909252-40982939	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001465	Approved				Liver cancer:5.89e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 1115.3	placenta: 718.4	Group enriched	11	ASC diff: 115.0;HHSteC: 185.4;HSkMC: 221.4;SH-SY5Y: 223.2
C7orf57		ENSG00000164746	Chromosome 7 open reading frame 57	7	48035511-48061304	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021286	Enhanced					Mixed	Tissue enhanced		fallopian tube: 22.0;testis: 6.8	lung: 3.4	Cell line enhanced		hTERT-HME1: 4.2;U-266/70: 2.4
C7orf73	PL-5283	ENSG00000243317	Chromosome 7 open reading frame 73	7	135662496-135693418	Predicted secreted proteins	Evidence at protein level	HPA065565			Approved	Mitochondria	Ovarian cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.3	Expressed in all		
C8A		ENSG00000157131	Complement C8 alpha chain	1	56854806-56918221	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	63	liver: 328.8	gallbladder: 5.2	Not detected		
C8B		ENSG00000021852	Complement C8 beta chain	1	56929210-56966140	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023694	Supported				Liver cancer:9.31e-5 (favourable)	Tissue enriched	Tissue enriched	54	liver: 435.5	lung: 8.1	Cell line enhanced		Hep G2: 1.0
C8G		ENSG00000176919	Complement C8 gamma chain	9	136945246-136946974	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046269	Approved		Uncertain	Endoplasmic reticulum	Colorectal cancer:2.99e-4 (unfavourable)	Tissue enriched	Group enriched	6	duodenum: 49.8;liver: 106.5;small intestine: 34.5	gallbladder: 9.8	Cell line enriched	16	HMC-1: 139.2
C9		ENSG00000113600	Complement C9	5	39284262-39424868	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002151, HPA029577	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	120	liver: 728.9	epididymis: 6.0	Cell line enhanced		U-698: 1.4
C9orf47	bA791O21.3, C9orf108, FLJ37523	ENSG00000186354	Chromosome 9 open reading frame 47	9	88990863-88996140	Predicted secreted proteins	Evidence at transcript level	CAB009902	Approved					Not detected	Mixed			adrenal gland: 2.1	Cell line enhanced		AF22: 2.7;HeLa: 1.6
CA10	CA-RPX, CARPX, HUCEP-15	ENSG00000154975	Carbonic anhydrase 10	17	51630313-52160017	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054825, HPA057837	Supported		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 56.7;cervix, uterine: 32.1	testis: 10.7	Cell line enhanced		RT4: 1.6;SCLC-21H: 7.3
CA11	CARP2, CARPX1	ENSG00000063180	Carbonic anhydrase 11	19	48637942-48646312	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041778			Approved	Vesicles<br>Microtubules	Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 244.1	ovary: 49.5	Cell line enhanced		AN3-CA: 39.9;SCLC-21H: 35.8
CA6		ENSG00000131686	Carbonic anhydrase 6	1	8945867-8975092	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA028550, HPA028692	Enhanced					Mixed	Tissue enriched	154	salivary gland: 3805.4	breast: 24.7	Mixed		
CA9	CAIX, MN	ENSG00000107159	Carbonic anhydrase 9	9	35673856-35681159	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005100, CAB017107, HPA055207	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 36.0;stomach: 93.6	small intestine: 14.5	Group enriched	11	A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
CACNA2D1	CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3	ENSG00000153956	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	7	81946444-82443798	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008213, HPA008621	Enhanced				Renal cancer:1.16e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 35.4	Cell line enhanced		HUVEC TERT2: 45.6;SH-SY5Y: 66.1
CADM3	BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1	ENSG00000162706	Cell adhesion molecule 3	1	159171609-159203313	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002981, CAB025746	Enhanced				Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 278.5;placenta: 113.9	cervix, uterine: 44.7	Group enriched	7	HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
CALCA	CALC1	ENSG00000110680	Calcitonin related polypeptide alpha	11	14966668-14972354	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059886		Supported			Endometrial cancer:4.49e-5 (unfavourable)	Tissue enriched	Group enriched	78	parathyroid gland: 849.6;thyroid gland: 183.4	kidney: 6.6	Not detected		
CALCB	CALC2, CGRP-II, FLJ30166	ENSG00000175868	Calcitonin related polypeptide beta	11	14904997-15082342	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059886		Supported			Endometrial cancer:3.42e-5 (unfavourable)	Tissue enhanced	Tissue enriched	46	thyroid gland: 32.6	testis: 0.7	Cell line enhanced		HEK 293: 5.4;Karpas-707: 7.5;SH-SY5Y: 3.8;U-266/70: 11.8
CALCR	CTR	ENSG00000004948	Calcitonin receptor	7	93424487-93574730	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028962, HPA061428	Enhanced					Tissue enriched	Tissue enhanced		kidney: 2.1;testis: 1.4	placenta: 1.0	Cell line enhanced		RPTEC TERT1: 1.5;T-47d: 3.6
CALCRL	CGRPR, CRLR	ENSG00000064989	Calcitonin receptor like receptor	2	187343129-187448460	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008070, HPA046515	Uncertain		Supported	Plasma membrane		Expressed in all	Tissue enhanced		lung: 114.3	adipose tissue: 76.8	Cell line enhanced		HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
CALR	cC1qR, CRT, FLJ26680, RO, SSA	ENSG00000179218	Calreticulin	19	12938578-12944489	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001513, HPA002242, CAB019952	Enhanced				Renal cancer:1.11e-16 (unfavourable), Ovarian cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1652.0	Expressed in all		
CALR3	CRT2, CT93, FLJ25355, MGC26577	ENSG00000269058	Calreticulin 3	19	16479057-16496192	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025749, HPA043355, HPA048460	Enhanced					Not detected	Tissue enriched	93	testis: 98.8	epididymis: 1.0	Not detected		
CALU		ENSG00000128595	Calumenin	7	128739292-128771807	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006018	Supported		Supported	Endoplasmic reticulum	Renal cancer:1.30e-11 (unfavourable), Urothelial cancer:4.60e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 444.9	Expressed in all		
CANX	CNX, IP90, P90	ENSG00000127022	Calnexin	5	179678628-179730925	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004738, HPA009433, HPA009696	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 294.4	Expressed in all		
CARTPT	CART	ENSG00000164326	CART prepropeptide	5	71719163-71721048	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB025515, HPA046278	Enhanced				Stomach cancer:4.36e-4 (unfavourable)	Tissue enriched	Tissue enriched	8	adrenal gland: 132.5	cerebral cortex: 17.4	Not detected		
CASQ1	CASQ, PDIB1	ENSG00000143318	Calsequestrin 1	1	160190556-160201886	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA007845, CAB015170, HPA026823	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria	Urothelial cancer:8.93e-5 (favourable)	Mixed	Tissue enriched	33	skeletal muscle: 1514.0	esophagus: 45.3	Group enriched	9	BEWO: 18.6;HDLM-2: 35.6;RT4: 53.5
CASQ2	PDIB2	ENSG00000118729	Calsequestrin 2	1	115700007-115768781	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027285, HPA055298	Enhanced				Urothelial cancer:2.25e-5 (unfavourable), Head and neck cancer:2.30e-4 (unfavourable)	Mixed	Tissue enriched	11	heart muscle: 679.4	skeletal muscle: 62.3	Cell line enriched	14	HSkMC: 9.6
CATSPERB	C14orf161, FLJ14298	ENSG00000133962	Cation channel sperm associated auxiliary subunit beta	14	91580696-91780707	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035134	Uncertain		Uncertain	Vesicles		Mixed	Mixed			skin: 2.7	Cell line enhanced		CAPAN-2: 1.1
CBLN1		ENSG00000102924	Cerebellin 1 precursor	16	49277917-49281831	Predicted secreted proteins	Evidence at protein level						Thyroid cancer:7.10e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 32.4	adipose tissue: 12.3	Group enriched	30	NTERA-2: 40.0;SCLC-21H: 148.4
CBLN2		ENSG00000141668	Cerebellin 2 precursor	18	72536680-72638521	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	7	cerebral cortex: 30.2;seminal vesicle: 7.3	small intestine: 2.8	Cell line enriched	8	SH-SY5Y: 57.5
CBLN3		ENSG00000139899	Cerebellin 3 precursor	14	24426532-24430954	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041266	Supported	Supported	Approved	Nucleus	Renal cancer:6.20e-6 (unfavourable), Endometrial cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.4	Cell line enhanced		HDLM-2: 16.0;HSkMC: 17.3;Karpas-707: 13.3
CBLN4	CBLNL1, dJ885A10.1	ENSG00000054803	Cerebellin 4 precursor	20	55997440-56005472	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051496, HPA074497		Supported	Approved	Midbody ring		Mixed	Tissue enhanced		adrenal gland: 24.5;cerebral cortex: 15.6;epididymis: 11.2	fallopian tube: 6.8	Cell line enriched	51	SH-SY5Y: 10.2
CCBE1	FLJ30681, KIAA1983	ENSG00000183287	Collagen and calcium binding EGF domains 1	18	59430940-59697380	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041361, HPA041374	Uncertain		Enhanced	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		ovary: 40.6	cervix, uterine: 16.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 91.8;HBF TERT88: 109.2;hTERT-HME1: 117.8;LHCN-M2: 146.3
CCDC112	MGC39633	ENSG00000164221	Coiled-coil domain containing 112	5	115267188-115296831	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045120, HPA050621	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.51e-6 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 73.7	cerebral cortex: 13.1	Expressed in all		
CCDC129	FLJ38344	ENSG00000180347	Coiled-coil domain containing 129	7	31514071-31658720	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024103	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		cervix, uterine: 2.6;salivary gland: 2.4	testis: 2.1	Cell line enhanced		U-2 OS: 1.6
CCDC134	FLJ22349	ENSG00000100147	Coiled-coil domain containing 134	22	41800679-41826299	Predicted secreted proteins	Evidence at protein level	HPA003936	Approved				Liver cancer:7.42e-7 (unfavourable), Renal cancer:1.36e-5 (favourable), Endometrial cancer:4.09e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.1	Mixed		
CCDC149	DKFZp761B107	ENSG00000181982	Coiled-coil domain containing 149	4	24806117-24980204	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044158, HPA047913	Uncertain		Approved	Nucleoli	Endometrial cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.1	Cell line enhanced		U-87 MG: 30.1
CCDC3	DKFZp761F241	ENSG00000151468	Coiled-coil domain containing 3	10	12896625-13099652	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA062425			Approved	Nucleus<br>Cytosol	Renal cancer:1.38e-5 (unfavourable)	Expressed in all	Mixed			skin: 158.4	Cell line enhanced		HAP1: 19.8;HDLM-2: 30.2;U-2 OS: 21.3
CCDC80	DRO1, SSG1, URB	ENSG00000091986	Coiled-coil domain containing 80	3	112596794-112649530	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002266	Approved				Renal cancer:2.86e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 526.0	Cell line enhanced		fHDF/TERT166: 992.9
CCDC88B	BRLZ, CCDC88, FLJ00354, FLJ37970, GIPIE, HkRP3	ENSG00000168071	Coiled-coil domain containing 88B	11	64340223-64357534	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026652	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:7.65e-5 (unfavourable), Head and neck cancer:1.48e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 36.2	bone marrow: 31.3	Cell line enhanced		HMC-1: 73.4;THP-1: 23.2
CCER2		ENSG00000262484	Coiled-coil glutamate rich protein 2	19	38908980-38912158	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069716	Uncertain				Urothelial cancer:2.32e-4 (favourable)	Mixed	Tissue enhanced		skin: 3.3	testis: 1.2	Mixed		
CCK		ENSG00000187094	Cholecystokinin	3	42257825-42266207	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045039, HPA069515	Enhanced	Supported				Group enriched	Group enriched	5	cerebral cortex: 133.7;duodenum: 116.2;prostate: 31.6	small intestine: 17.7	Group enriched	6	CAPAN-2: 8.5;RPTEC TERT1: 18.9
CCL1	I-309, P500, SCYA1, SISe, TCA3	ENSG00000108702	C-C motif chemokine ligand 1	17	34360328-34363231	Predicted secreted proteins	Evidence at protein level	HPA049861	Uncertain					Not detected	Tissue enriched	5	rectum: 2.6	cerebral cortex,testis: 0.4	Cell line enriched	50	HMC-1: 622.2
CCL11	eotaxin, MGC22554, SCYA11	ENSG00000172156	C-C motif chemokine ligand 11	17	34285668-34288334	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable)	Mixed	Tissue enhanced		appendix: 39.3;small intestine: 37.3	duodenum: 30.8	Cell line enriched	18	BJ hTERT+: 7.2
CCL13	CKb10, MCP-4, MGC17134, NCC-1, SCYA13, SCYL1	ENSG00000181374	C-C motif chemokine ligand 13	17	34356452-34358610	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			lung: 31.6	Cell line enhanced		ASC diff: 1.2;BJ hTERT+: 1.3;BJ hTERT+ SV40 Large T+ RasG12V: 1.0;HMC-1: 1.1;HSkMC: 1.1
CCL14	CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2	ENSG00000276409	C-C motif chemokine ligand 14	17	35983291-35987004	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004423, HPA030268	Uncertain					Mixed	Tissue enhanced		spleen: 271.8	adipose tissue: 123.7	Cell line enriched	53	HUVEC TERT2: 46.6
CCL15	HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3	ENSG00000275718	C-C motif chemokine ligand 15	17	35996440-36002038	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058608			Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:3.02e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 21.5;rectum: 30.6;small intestine: 26.6	colon: 18.9	Cell line enriched	12	Hep G2: 22.7
CCL16	CKb12, HCC-4, LCC-1, LEC, LMC, Mtn-1, NCC-4, SCYA16, SCYL4	ENSG00000275152	C-C motif chemokine ligand 16	17	35976493-35981496	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	91	liver: 60.8	spleen: 0.6	Cell line enriched	19	Hep G2: 6.8
CCL17	ABCD-2, SCYA17, TARC	ENSG00000102970	C-C motif chemokine ligand 17	16	57404767-57416062	Predicted secreted proteins	Evidence at protein level	CAB002583	Approved				Cervical cancer:1.91e-5 (favourable), Urothelial cancer:5.80e-4 (favourable)	Mixed	Tissue enhanced		appendix: 11.1;lymph node: 9.9	tonsil: 5.4	Cell line enriched	725	HDLM-2: 2231.6
CCL18	AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18	ENSG00000275385	C-C motif chemokine ligand 18	17	36064280-36072032	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		adipose tissue: 20.9;lung: 13.0;tonsil: 10.5	lymph node: 6.2	Not detected		
CCL19	CKb11, ELC, exodus-3, MIP-3b, SCYA19	ENSG00000172724	C-C motif chemokine ligand 19	9	34689567-34691277	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA067758	Enhanced				Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)	Expressed in all	Group enriched	5	adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0	gallbladder: 107.9	Cell line enhanced		HDLM-2: 2.9;TIME: 1.2
CCL2	GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF	ENSG00000108691	C-C motif chemokine ligand 2	17	34255218-34257203	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB013676, HPA019163	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 411.3	Group enriched	5	BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8
CCL20	CKb4, exodus-1, LARC, MIP-3a, SCYA20, ST38	ENSG00000115009	C-C motif chemokine ligand 20	2	227813842-227817564	Predicted secreted proteins	Evidence at protein level						Renal cancer:9.19e-8 (unfavourable), Pancreatic cancer:2.73e-4 (unfavourable), Liver cancer:9.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 269.7;tonsil: 155.2	urinary bladder: 83.4	Cell line enhanced		Hep G2: 23.9;NB-4: 12.7;RT4: 12.0
CCL21	6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4	ENSG00000137077	C-C motif chemokine ligand 21	9	34709005-34710124	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005067, HPA051210	Enhanced					Mixed	Tissue enhanced		lymph node: 3155.9	tonsil: 946.7	Cell line enhanced		K-562: 1.0
CCL22	A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1	ENSG00000102962	C-C motif chemokine ligand 22	16	57358772-57366190	Predicted secreted proteins	Evidence at protein level						Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable)	Mixed	Tissue enhanced		appendix: 18.6;tonsil: 13.5	skin: 7.9	Cell line enriched	21	HDLM-2: 45.9
CCL23	Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23	ENSG00000274736	C-C motif chemokine ligand 23	17	36013056-36017968	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042015	Uncertain					Mixed	Tissue enhanced		smooth muscle: 15.4	lung: 11.1	Group enriched	5	HEL: 15.9;THP-1: 25.4;U-937: 5.1
CCL24	Ckb-6, eotaxin-2, MPIF-2, MPIF2, SCYA24	ENSG00000106178	C-C motif chemokine ligand 24	7	75811665-75823356	Predicted secreted proteins	Evidence at protein level						Colorectal cancer:5.41e-4 (favourable)	Tissue enhanced	Tissue enhanced		rectum: 111.7;small intestine: 96.2	urinary bladder: 51.4	Cell line enhanced		CAPAN-2: 4.8;RH-30: 2.0;U-2 OS: 5.9
CCL25	Ckb15, SCYA25, TECK	ENSG00000131142	C-C motif chemokine ligand 25	19	8052767-8062650	Predicted secreted proteins	Evidence at protein level	HPA055883	Uncertain					Group enriched	Group enriched	317	duodenum: 529.5;small intestine: 653.7	lymph node: 1.8	Cell line enhanced		BEWO: 2.7;HEL: 2.7;REH: 5.6;SH-SY5Y: 2.0
CCL26	eotaxin-3, IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1	ENSG00000006606	C-C motif chemokine ligand 26	7	75769533-75789896	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		ovary: 12.0	rectum: 7.6	Cell line enhanced		hTEC/SVTERT24-B: 15.8;PC-3: 42.0;U-2 OS: 13.1
CCL27	ALP, CTACK, CTAK, ESkine, ILC, PESKY, SCYA27, skinkine	ENSG00000213927	C-C motif chemokine ligand 27	9	34661880-34664048	Predicted secreted proteins	Evidence at protein level	HPA073848	Enhanced					Not detected	Tissue enriched	16	skin: 504.4	breast: 32.2	Cell line enhanced		AN3-CA: 2.0
CCL28	CCK1, MEC, SCYA28	ENSG00000151882	C-C motif chemokine ligand 28	5	43376645-43412391	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077434	Supported				Pancreatic cancer:1.43e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 71.1;salivary gland: 126.0	thyroid gland: 38.0	Cell line enhanced		EFO-21: 12.1;SiHa: 31.8;SK-MEL-30: 12.9;T-47d: 37.8
CCL3	G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3	ENSG00000277632	C-C motif chemokine ligand 3	17	36088256-36090169	Cancer-related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		bone marrow: 50.2	adipose tissue: 12.5	Group enriched	14	Karpas-707: 110.0;U-266/70: 198.4;U-266/84: 494.6
CCL3L3	CCL3L1, D17S1718, G0S19-2, LD78BETA, MGC12815, SCYA3L, SCYA3L1	ENSG00000276085	C-C motif chemokine ligand 3 like 3	17	36194869-36196758	Predicted secreted proteins	Evidence at protein level							Expressed in all	Group enriched	8	bone marrow: 7.4;gallbladder: 1.5	lymph node,urinary bladder: 0.5	Group enriched	33	U-266/70: 37.7;U-266/84: 73.6
CCL4	Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4	ENSG00000275302	C-C motif chemokine ligand 4	17	36103590-36105621	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB007805	Approved				Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 24.8	lymph node: 17.6	Group enriched	22	Karpas-707: 2.2;U-266/70: 5.1;U-266/84: 2.4
CCL4L2		ENSG00000276070	C-C motif chemokine ligand 4 like 2	17	36210924-36212878	Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		bone marrow: 19.4	gallbladder: 10.9	Cell line enhanced		Daudi: 2.9;HMC-1: 5.0;U-266/70: 6.7
CCL5	D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228	ENSG00000271503	C-C motif chemokine ligand 5	17	35871491-35880793	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 80.5	lymph node: 68.5	Group enriched	7	HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8
CCL7	FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7	ENSG00000108688	C-C motif chemokine ligand 7	17	34270221-34272242	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 3.6;bone marrow: 15.2	gallbladder,rectum: 1.1	Cell line enhanced		BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4
CCL8	HC14, MCP-2, SCYA8	ENSG00000108700	C-C motif chemokine ligand 8	17	34319036-34321402	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.05e-7 (unfavourable)	Mixed	Mixed			adipose tissue: 13.1	Cell line enhanced		EFO-21: 1.3;HSkMC: 1.4
CCNB1IP1	C14orf18, HEI10	ENSG00000100814	Cyclin B1 interacting protein 1	14	20311368-20333312	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.18e-6 (favourable)	Expressed in all	Expressed in all			ovary: 120.9	Expressed in all		
CD14		ENSG00000170458	CD14 molecule	5	140631728-140633701	Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001887, HPA002127, CAB033631, CAB072865, CAB072866	Enhanced		Supported	Vesicles	Renal cancer:6.80e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 267.3	Cell line enhanced		A549: 8.6;CACO-2: 12.0;SiHa: 18.3
CD160	BY55, NK1, NK28	ENSG00000117281	CD160 molecule	1	145719471-145739288	CD markers, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 19.6	small intestine: 5.1	Mixed		
CD164	DFNA66, MGC-24, MUC-24	ENSG00000135535	CD164 molecule	6	109366514-109382457	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010636	Uncertain					Expressed in all	Expressed in all			thyroid gland: 613.1	Expressed in all		
CD177	HNA2A, NB1, PRV1	ENSG00000204936	CD177 molecule	19	43353659-43363172	Predicted secreted proteins	Evidence at protein level	HPA041820, HPA046601	Enhanced				Cervical cancer:3.66e-4 (favourable)	Tissue enhanced	Group enriched	16	bone marrow: 193.1;colon: 155.7;prostate: 105.4;rectum: 181.9	appendix: 9.7	Cell line enriched	23	RPMI-8226: 65.6
CD1E		ENSG00000158488	CD1e molecule	1	158353696-158357553	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057769	Uncertain					Mixed	Tissue enhanced		skin: 18.3	tonsil: 10.4	Cell line enriched	980	MOLT-4: 1075.1
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
CD200	MOX1, MOX2, MRC, OX-2	ENSG00000091972	CD200 molecule	3	112332347-112362812	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031149	Approved					Expressed in all	Mixed			cerebral cortex: 78.6	Cell line enhanced		AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4
CD200R1	CD200R, HCRTR2, MOX2R, OX2R	ENSG00000163606	CD200 receptor 1	3	112921209-112975122	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA068512			Supported	Plasma membrane		Mixed	Tissue enhanced		spleen: 14.5	placenta: 10.2	Cell line enriched	8	HEL: 26.4
CD22	SIGLEC-2, SIGLEC2	ENSG00000012124	CD22 molecule	19	35319261-35347355	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002418, HPA024353	Enhanced					Mixed	Tissue enhanced		lymph node: 264.4;ovary: 162.2;spleen: 151.7;tonsil: 210.1	appendix: 98.1	Group enriched	11	Daudi: 201.6;REH: 76.6;U-698: 153.7;WM-115: 49.6
CD226	DNAM-1, DNAM1, PTA1, TLiSA1	ENSG00000150637	CD226 molecule	18	69831158-69961803	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015715, HPA050348	Supported		Approved	Midbody		Not detected	Tissue enriched	11	parathyroid gland: 318.5	spleen: 28.4	Group enriched	7	HEL: 89.9;HMC-1: 37.6
CD24	CD24A	ENSG00000272398	CD24 molecule	6	106969831-106975627	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045879, CAB078471			Supported	Vesicles	Breast cancer:2.44e-5 (unfavourable), Colorectal cancer:3.29e-4 (favourable), Liver cancer:7.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 2706.1	esophagus: 1402.0	Cell line enhanced		NTERA-2: 984.0;RPTEC TERT1: 3501.8;SK-BR-3: 1014.5
CD276	B7-H3, B7H3, B7RP-2	ENSG00000103855	CD276 molecule	15	73683966-73714518	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009285, HPA017139, CAB017826	Enhanced		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable)	Expressed in all	Mixed			placenta: 30.2	Cell line enhanced		U-2197: 176.1
CD300A	CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60	ENSG00000167851	CD300a molecule	17	74466416-74484796	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011645	Approved				Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 85.8	appendix: 40.0	Cell line enhanced		HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9
CD300LB	CLM7, TREM5	ENSG00000178789	CD300 molecule like family member b	17	74521174-74531474	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 11.4	spleen: 5.2	Cell line enhanced		HL-60: 1.5;NB-4: 1.5;THP-1: 1.3
CD300LF	CD300f, CLM1, IGSF13, IREM1, NKIR	ENSG00000186074	CD300 molecule like family member f	17	74694311-74712978	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013712	Supported					Expressed in all	Tissue enhanced		lung: 25.6;spleen: 28.0	appendix: 18.2	Group enriched	7	THP-1: 16.6;U-937: 37.2
CD300LG	CLM9, Trem4	ENSG00000161649	CD300 molecule like family member g	17	43847148-43863629	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	adipose tissue: 143.0;placenta: 86.4;testis: 33.9	lung: 17.3	Not detected		
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
CD4		ENSG00000010610	CD4 molecule	12	6786858-6820808	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000011, HPA004252, HPA004472, CAB068180	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 549.0	spleen: 220.5	Group enriched	5	HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD40	Bp50, p50, TNFRSF5	ENSG00000101017	CD40 molecule	20	46118272-46129863	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002495, HPA031567, HPA031568, CAB072868	Enhanced				Renal cancer:4.48e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 64.7	Cell line enhanced		CAPAN-2: 63.4;EFO-21: 116.6
CD44	CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1	ENSG00000026508	CD44 molecule (Indian blood group)	11	35138870-35232402	Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000112, CAB000316, HPA005785	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane	Renal cancer:1.78e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 530.1	Mixed		
CD48	BCM1, BLAST, hCD48, mCD48, SLAMF2	ENSG00000117091	CD48 molecule	1	160678746-160711851	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002497, HPA055146	Enhanced		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 311.4;spleen: 213.1;tonsil: 226.0	appendix: 148.5	Cell line enhanced		Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
CD5	LEU1, T1	ENSG00000110448	CD5 molecule	11	61102395-61127852	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015392, CAB020308, HPA043416, HPA060839	Enhanced				Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)	Mixed	Tissue enhanced		appendix: 29.8;lymph node: 43.0	tonsil: 20.2	Cell line enriched	71	MOLT-4: 56.4
CD55	CR, CROM, DAF, TC	ENSG00000196352	CD55 molecule (Cromer blood group)	1	207321508-207386804	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002190, CAB010454, HPA024386	Enhanced		Uncertain	Vesicles<br>Midbody ring	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 324.4	Cell line enhanced		HMC-1: 495.0;U-2197: 364.6
CD59	16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20	ENSG00000085063	CD59 molecule	11	33698261-33736445	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001448, HPA026494	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 923.3	Cell line enhanced		TIME: 2367.1;U-2197: 2401.2
CD5L	API6, Spalpha	ENSG00000073754	CD5 molecule like	1	157830914-157898256	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065686, HPA068384	Enhanced				Liver cancer:8.88e-5 (favourable)	Tissue enriched	Tissue enriched	14	spleen: 787.1	liver: 54.4	Not detected		
CD6	Tp120	ENSG00000013725	CD6 molecule	11	60971680-61020377	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002489, CAB016252	Enhanced				Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)	Mixed	Tissue enhanced		appendix: 28.5;lymph node: 49.2	tonsil: 26.8	Cell line enriched	17	MOLT-4: 31.3
CD68	DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1	ENSG00000129226	CD68 molecule	17	7579467-7582113	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000051, CAB000066, HPA048982, CAB072861, CAB072862	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (unfavourable)	Mixed	Expressed in all			lung: 532.4	Expressed in all		
CD7	GP40, LEU-9, Tp40, TP41	ENSG00000173762	CD7 molecule	17	82314868-82317602	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002594, HPA039079	Enhanced				Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 43.1;lymph node: 41.5;spleen: 43.1	small intestine: 17.0	Group enriched	5	Hep G2: 35.2;MOLT-4: 95.7
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
CD80	B7-1, B7.1, CD28LG, CD28LG1	ENSG00000121594	CD80 molecule	3	119524293-119559602	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025368, HPA050092	Enhanced					Mixed	Tissue enhanced		appendix: 7.2;lymph node: 6.7;tonsil: 6.3	spleen: 4.7	Cell line enhanced		Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
CD86	B7-2, B7.2, CD28LG2	ENSG00000114013	CD86 molecule	3	122055366-122121139	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004319	Uncertain				Renal cancer:9.83e-5 (unfavourable)	Expressed in all	Mixed			appendix: 47.8	Cell line enriched	10	HDLM-2: 275.8
CD8A	CD8	ENSG00000153563	CD8a molecule	2	86784610-86808396	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000012, HPA037756, CAB075722	Enhanced				Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 161.9	lymph node: 46.9	Cell line enriched	5	MOLT-4: 11.7
CD8B	CD8B1	ENSG00000172116	CD8b molecule	2	86815339-86861924	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004353, HPA029164	Enhanced		Supported	Plasma membrane	Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 60.8;lymph node: 39.6	parathyroid gland: 22.7	Cell line enriched	50	RPMI-8226: 837.8
CD99	MIC2	ENSG00000002586	CD99 molecule	X	2691179-2741309	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000020, HPA035304	Supported		Approved	Golgi apparatus	Renal cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 375.1	Mixed		
CDC45	CDC45L, CDC45L2	ENSG00000093009	Cell division cycle 45	22	19479459-19520612	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000614, CAB009459	Enhanced		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:6.95e-6 (unfavourable), Pancreatic cancer:8.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 37.5	bone marrow: 15.3	Expressed in all		
CDCP1	CD318, SIMA135	ENSG00000163814	CUB domain containing protein 1	3	45082278-45146422	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010978, HPA010979, CAB025637	Enhanced				Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable)	Expressed in all	Mixed			skin: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 263.4;hTERT-HME1: 135.9
CDCP2		ENSG00000157211	CUB domain containing protein 2	1	54132968-54153770	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA031143	Uncertain					Not detected	Not detected			breast,cervix, uterine,spleen: 0.1	Not detected		
CDH1	CD324, UVO, uvomorulin	ENSG00000039068	Cadherin 1	16	68737225-68835548	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 475.1	thyroid gland: 266.2	Cell line enhanced		BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
CDH11	CAD11, OB	ENSG00000140937	Cadherin 11	16	64943753-65126112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013072	Enhanced				Renal cancer:2.48e-9 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 223.4	placenta: 173.7	Cell line enhanced		BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5
CDH13	CDHH	ENSG00000140945	Cadherin 13	16	82626803-83800640	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001380, CAB025863	Enhanced		Supported	Plasma membrane	Renal cancer:1.73e-6 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 70.0	cervix, uterine: 66.4	Cell line enhanced		LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced		Supported	Cell Junctions		Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0
CDH18	CDH14, EY-CADHERIN	ENSG00000145526	Cadherin 18	5	19472951-20575873	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014416	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 19.0	testis: 3.2	Cell line enhanced		EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6
CDH19	CDH7	ENSG00000071991	Cadherin 19	18	66501083-66604138	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056332	Uncertain					Tissue enriched	Mixed			heart muscle: 8.4	Group enriched	15	SK-MEL-30: 28.3;WM-115: 63.0
CDH23	CDHR23, DFNB12, USH1D	ENSG00000107736	Cadherin related 23	10	71396934-71815947	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017232	Approved				Urothelial cancer:3.40e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 30.2	ovary: 19.4	Cell line enhanced		RT4: 11.9;SCLC-21H: 6.6
CDH5	7B4, CD144	ENSG00000179776	Cadherin 5	16	66366622-66404786	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028366	Approved				Renal cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 335.1	lung: 120.5	Group enriched	5	HUVEC TERT2: 616.7;TIME: 522.0
CDHR1	CORD15, KIAA1775, PCDH21, RP65	ENSG00000148600	Cadherin related family member 1	10	84194635-84219621	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036819	Supported					Tissue enhanced	Group enriched	5	rectum: 57.9;skin: 252.1	colon: 29.2	Cell line enhanced		HAP1: 10.5;HEK 293: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
CDHR4	CDH29, VLLR9392	ENSG00000187492	Cadherin related family member 4	3	49790732-49799835	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA076277	Enhanced					Tissue enriched	Tissue enriched	9	fallopian tube: 105.0	lung: 11.4	Cell line enhanced		ASC TERT1: 1.0
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced					Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced		CACO-2: 2.1
CDNF	ARMETL1	ENSG00000185267	Cerebral dopamine neurotrophic factor	10	14819250-14838575	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044587	Uncertain					Mixed	Tissue enhanced		testis: 20.1	skeletal muscle: 12.5	Cell line enhanced		RPMI-8226: 8.5
CDON	CDO, CDON1, ORCAM	ENSG00000064309	Cell adhesion associated, oncogene regulated	11	125955796-126063335	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB012422, HPA017377	Uncertain				Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 75.5	ovary: 53.5	Cell line enhanced		AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
CDSN	D6S586E	ENSG00000204539	Corneodesmosin	6	31115090-31120446	Predicted secreted proteins	Evidence at protein level	HPA044730, HPA054184	Enhanced					Group enriched	Tissue enriched	20	skin: 77.0	epididymis: 3.7	Cell line enriched	7	A-431: 1.4
CEACAM16	DFNA4B	ENSG00000213892	Carcinoembryonic antigen related cell adhesion molecule 16	19	44699151-44710714	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045075	Uncertain					Not detected	Not detected			tonsil: 0.5	Cell line enhanced		U-266/70: 1.1
CEACAM18		ENSG00000213822	Carcinoembryonic antigen related cell adhesion molecule 18	19	51478622-51490952	Predicted secreted proteins	Evidence at protein level	HPA059487	Uncertain		Approved	Midbody		Tissue enhanced	Group enriched	14	duodenum: 10.5;small intestine: 7.2	gallbladder: 0.6	Group enriched	12	CACO-2: 3.6;RT4: 1.1
CEACAM19	CEAL1	ENSG00000186567	Carcinoembryonic antigen related cell adhesion molecule 19	19	44662278-44684359	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA014462, HPA052865	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Mixed			skin: 12.7	Cell line enhanced		RPTEC TERT1: 11.9;TIME: 16.9
CEACAM5	CD66e, CEA	ENSG00000105388	Carcinoembryonic antigen related cell adhesion molecule 5	19	41708585-41729798	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000021, CAB000022, HPA011041, HPA019758	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 1012.7;rectum: 1086.0	appendix: 257.7	Cell line enriched	6	HaCaT: 11.8
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported					Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected		
CEACAM8	CD66b, CGM6	ENSG00000124469	Carcinoembryonic antigen related cell adhesion molecule 8	19	42580241-42595055	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033676	Approved					Not detected	Tissue enriched	86	bone marrow: 142.1	lung: 1.6	Not detected		
CECR1	ADGF, IDGFL	ENSG00000093072	Cat eye syndrome chromosome region, candidate 1	22	17178790-17221989	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007888	Approved				Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)	Expressed in all	Expressed in all			spleen: 161.4	Cell line enhanced		CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1
CEL	BSSL, MODY8	ENSG00000170835	Carboxyl ester lipase	9	133061978-133071861	Predicted secreted proteins	Evidence at protein level	HPA008023, HPA052701	Enhanced				Breast cancer:4.14e-4 (unfavourable)	Tissue enriched	Tissue enriched	95	pancreas: 23233.0	epididymis: 244.0	Mixed		
CELA2A	ELA2A	ENSG00000142615	Chymotrypsin like elastase family member 2A	1	15456728-15472091	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	371	pancreas: 34335.1	ovary: 92.5	Cell line enhanced		HMC-1: 1.1
CELA2B	ELA2B, RP11-265F14.2	ENSG00000215704	Chymotrypsin like elastase family member 2B	1	15465909-15491400	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	262	pancreas: 4261.7	ovary: 16.2	Cell line enriched	5	U-138 MG: 3.8
CELA3A	ELA3, ELA3A	ENSG00000142789	Chymotrypsin like elastase family member 3A	1	22001656-22012539	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028086, HPA045650	Supported		Approved	Cytosol		Tissue enriched	Tissue enriched	352	pancreas: 56987.6	ovary: 161.9	Cell line enriched	24	MOLT-4: 20.6
CELA3B	CBPP, ELA3B	ENSG00000219073	Chymotrypsin like elastase family member 3B	1	21977021-21998642	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028086, HPA045650	Supported		Approved	Cytosol		Tissue enriched	Tissue enriched	296	pancreas: 10568.2	ovary: 35.6	Mixed		
CEMIP	HYBID, IR2155535, KIAA1199, TMEM2L	ENSG00000103888	Cell migration inducing hyaluronan binding protein	15	80779343-80951776	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.65e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 53.2	appendix: 15.8	Cell line enhanced		BJ: 172.4;BJ hTERT+: 260.3;fHDF/TERT166: 200.3;HSkMC: 122.9;U-138 MG: 89.3
CER1	DAND4	ENSG00000147869	Cerberus 1, DAN family BMP antagonist	9	14719724-14722717	Predicted secreted proteins	Evidence at protein level	HPA019917	Uncertain					Tissue enriched	Tissue enriched	6	epididymis: 1.3	endometrium: 0.2	Group enriched	10	HEL: 3.6;NTERA-2: 7.1;SCLC-21H: 3.2
CERCAM	CEECAM1, CerCAM, GLT25D3	ENSG00000167123	Cerebral endothelial cell adhesion molecule	9	128411751-128437351	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021657, HPA051595	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 155.6	Mixed		
CERS1	LAG1, LASS1, UOG1	ENSG00000223802	Ceramide synthase 1	19	18868545-18896727	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045724	Approved		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	13	cerebral cortex: 136.3;testis: 28.0	skeletal muscle: 6.5	Cell line enhanced		AN3-CA: 28.0;HEK 293: 28.4
CES1	CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1	ENSG00000198848	Carboxylesterase 1	16	55802851-55833337	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012023, HPA046717	Enhanced		Enhanced	Endoplasmic reticulum	Urothelial cancer:9.92e-4 (unfavourable)	Tissue enriched	Group enriched	7	gallbladder: 399.2;liver: 1099.9;lung: 229.9	adipose tissue: 79.7	Group enriched	5	Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
CES3	ES31, FLJ21736	ENSG00000172828	Carboxylesterase 3	16	66961237-66975148	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041008, HPA041307	Approved		Approved	Nuclear membrane<br>Endoplasmic reticulum	Liver cancer:7.26e-5 (favourable)	Mixed	Tissue enhanced		colon: 37.2;duodenum: 30.5;rectum: 34.1	small intestine: 26.6	Cell line enhanced		AN3-CA: 7.1
CES4A	CES8, FLJ37464	ENSG00000172824	Carboxylesterase 4A	16	66988589-67009758	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035701	Approved		Approved	Cytosol	Renal cancer:2.35e-6 (unfavourable)	Mixed	Group enriched	7	fallopian tube: 28.9;skin: 9.2	epididymis: 2.7	Cell line enhanced		HDLM-2: 17.6;SiHa: 4.2
CES5A	CAUXIN, CES4C1, CES5, CES7, FLJ31547	ENSG00000159398	Carboxylesterase 5A	16	55846154-55956031	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047635	Uncertain					Tissue enhanced	Tissue enriched	40	epididymis: 79.9	liver: 1.9	Cell line enriched	29	U-266/70: 5.8
CETP	BPIFF	ENSG00000087237	Cholesteryl ester transfer protein	16	56961850-56983845	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Mixed	Group enriched	6	adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7	thyroid gland: 8.4	Cell line enhanced		HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1
CFB	BF, BFD, H2-Bf	ENSG00000243649	Complement factor B	6	31945650-31952084	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832, CAB016381	Supported		Approved	Endoplasmic reticulum<br>Vesicles<br>Cell Junctions	Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)	Expressed in all	Tissue enriched	21	liver: 285.9	stomach: 13.8	Cell line enhanced		CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
CFC1	CRYPTIC, HTX2	ENSG00000136698	Cripto, FRL-1, cryptic family 1	2	130592168-130599575	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA041773	Uncertain					Tissue enriched	Tissue enhanced		pancreas: 4.1;prostate: 10.4;stomach: 8.0	fallopian tube: 1.6	Group enriched	18	RPMI-8226: 13.6;SCLC-21H: 12.6
CFC1B		ENSG00000152093	Cripto, FRL-1, cryptic family 1B	2	130521197-130528604	Predicted secreted proteins	No evidence	HPA041773	Uncertain					Not detected	Not detected			pancreas,prostate,rectum: 0.1	Not detected		
CFD	ADN, DF, PFD	ENSG00000197766	Complement factor D	19	859643-863630	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA052799			Uncertain	Plasma membrane	Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)	Expressed in all	Tissue enriched	7	adipose tissue: 378.5	breast: 52.5	Group enriched	6	ASC diff: 82.6;THP-1: 121.6
CFH	ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS	ENSG00000000971	Complement factor H	1	196651878-196747504	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016385, CAB016769, HPA038922, HPA049176, HPA053326	Supported		Approved	Vesicles	Renal cancer:1.92e-6 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 839.5	gallbladder: 205.3	Cell line enhanced		HHSteC: 100.0;RT4: 176.9
CFHR1	CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2	ENSG00000244414	Complement factor H related 1	1	196819757-196832189	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA038922, HPA040726	Supported		Approved	Vesicles	Liver cancer:8.71e-6 (favourable)	Tissue enriched	Tissue enriched	147	liver: 1057.6	lymph node: 7.1	Cell line enhanced		HL-60: 1.5;U-266/70: 1.9
CFHR2	CFHL2, FHR2, HFL3	ENSG00000080910	Complement factor H related 2	1	196943772-196959226	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726, HPA049813	Supported					Tissue enriched	Tissue enriched	4661	liver: 466.1	all non-specific tissues: 0.0	Not detected		
CFHR3	CFHL3, DOWN16, FHR-3, FHR3, HLF4	ENSG00000116785	Complement factor H related 3	1	196774795-196795406	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:2.86e-5 (favourable)	Tissue enriched	Tissue enriched	244	liver: 314.2	adipose tissue: 1.2	Cell line enhanced		NTERA-2: 2.1;T-47d: 4.2;U-266/70: 6.1
CFHR4	CFHL4, FHR-4, FHR4	ENSG00000134365	Complement factor H related 4	1	196850241-196918972	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.57e-6 (favourable)	Tissue enriched	Tissue enriched	373	liver: 78.3	testis: 0.2	Cell line enhanced		U-266/70: 1.1
CFHR5	CFHL5, FHR-5, FHR5	ENSG00000134389	Complement factor H related 5	1	196977556-197009674	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726	Supported					Tissue enriched	Tissue enriched	500	liver: 88.0	testis: 0.1	Not detected		
CFI	C3b-INA, FI, IF, KAF	ENSG00000205403	Complement factor I	4	109740694-109802179	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA001143, CAB016777, HPA024061	Supported				Urothelial cancer:6.06e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 524.7	kidney: 221.8	Cell line enhanced		CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4
CFP	PFC	ENSG00000126759	Complement factor properdin	X	47623172-47630305	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 58.1;spleen: 76.6	appendix: 29.9	Cell line enhanced		EFO-21: 21.2;HEL: 4.6;HMC-1: 4.9;NB-4: 7.2;U-937: 6.1
CGA	FSHA, GPHa, GPHA1, HCG, LHA, TSHA	ENSG00000135346	Glycoprotein hormones, alpha polypeptide	6	87085498-87095406	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023350, HPA029698	Enhanced					Tissue enhanced	Tissue enriched	22	placenta: 654.5	stomach: 29.1	Cell line enriched	26	BEWO: 481.2
CGB1		ENSG00000267631	Chorionic gonadotropin beta subunit 1	19	49035610-49036895	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Not detected			pancreas: 0.6	Cell line enriched	5	HMC-1: 16.3
CGB2		ENSG00000104818	Chorionic gonadotropin beta subunit 2	19	49031912-49033238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Not detected			testis: 0.7	Cell line enhanced		HMC-1: 28.4;U-266/70: 9.9;U-266/84: 11.8
CGB3	CGB	ENSG00000104827	Chorionic gonadotropin beta subunit 3	19	49022869-49024333	Predicted secreted proteins	Evidence at protein level	CAB000042, CAB010884, HPA038925, HPA038934	Enhanced		Approved	Cytosol		Tissue enhanced	Tissue enriched	21	placenta: 14.9	testis: 0.7	Cell line enriched	23	BEWO: 65.1
CGB5	HCG	ENSG00000189052	Chorionic gonadotropin beta subunit 5	19	49043884-49045311	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol	Stomach cancer:1.18e-5 (unfavourable), Urothelial cancer:9.47e-4 (unfavourable)	Tissue enhanced	Tissue enriched	68	placenta: 31.7	pancreas,skin,testis: 0.4	Group enriched	24	BEWO: 99.4;U-251 MG: 40.1
CGB7	CG-beta-a	ENSG00000196337	Chorionic gonadotropin beta subunit 7	19	49054275-49058860	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Tissue enhanced		skin: 3.8	placenta,seminal vesicle,skeletal muscle: 1.0	Cell line enhanced		BEWO: 4.7;HaCaT: 3.5;hTCEpi: 3.4;U-251 MG: 6.1
CGB8		ENSG00000213030	Chorionic gonadotropin beta subunit 8	19	49047638-49049106	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Tissue enhanced	Tissue enriched	90	placenta: 29.2	parathyroid gland: 0.3	Group enriched	8	BEWO: 167.1;U-251 MG: 51.5
CGREF1	CGR11	ENSG00000138028	Cell growth regulator with EF-hand domain 1	2	27098889-27119115	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008241	Uncertain				Endometrial cancer:3.18e-4 (unfavourable), Liver cancer:7.57e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 44.7	stomach: 11.5	Cell line enhanced		SK-BR-3: 58.9
CH17-296N19.1		ENSG00000283378		9	61330717-61453030	Predicted secreted proteins	Evidence at transcript level								Tissue enriched	7	bone marrow: 7.3	testis: 0.9	Group enriched	6	A549: 24.8;SiHa: 6.4;TIME: 7.0;WM-115: 23.6
CH507-9B2.3		ENSG00000280071		21	5079294-5128425	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018517	Uncertain		Approved	Centrosome<br>Mitochondria		Mixed	Expressed in all			kidney: 148.3	Mixed		
CHAD	SLRR4A	ENSG00000136457	Chondroadherin	17	50464496-50468966	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018241	Enhanced				Liver cancer:1.59e-4 (favourable), Breast cancer:7.68e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 31.8	adrenal gland: 13.4	Cell line enhanced		RT4: 3.4;SCLC-21H: 10.1
CHADL	SLRR4B	ENSG00000100399	Chondroadherin like	22	41229510-41240934	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005696, HPA024654	Uncertain				Lung cancer:1.56e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 28.4	skin: 6.7	Cell line enhanced		BEWO: 11.4
CHGA		ENSG00000100604	Chromogranin A	14	92923080-92935293	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000023, HPA017369, CAB040544, CAB055506, CAB058688	Enhanced		Supported	Vesicles	Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable)	Tissue enhanced	Tissue enriched	9	parathyroid gland: 7061.6	adrenal gland: 818.1	Group enriched	156	SCLC-21H: 285.4;SH-SY5Y: 700.4
CHGB	SCG1, SgI	ENSG00000089199	Chromogranin B	20	5911430-5925361	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008759, CAB009403, HPA012602	Enhanced	Supported	Enhanced	Vesicles	Head and neck cancer:1.89e-4 (unfavourable), Pancreatic cancer:9.96e-4 (favourable)	Tissue enriched	Tissue enriched	26	adrenal gland: 4382.4	cerebral cortex: 168.3	Group enriched	25	SCLC-21H: 405.5;SH-SY5Y: 559.4
CHI3L1	GP39, YKL40	ENSG00000133048	Chitinase 3 like 1	1	203178931-203186749	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4	bone marrow: 146.9	Group enriched	7	ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1
CHI3L2	YKL-39, YKL39	ENSG00000064886	Chitinase 3 like 2	1	111200771-111243440	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005443	Uncertain				Renal cancer:8.59e-7 (unfavourable), Glioma:1.55e-4 (unfavourable), Head and neck cancer:2.19e-4 (favourable)	Tissue enriched	Tissue enhanced		appendix: 152.3	tonsil: 103.1	Cell line enhanced		ASC diff: 62.1;MOLT-4: 277.3;U-698: 51.9
CHIA	AMCase, CHIT2, TSA1902	ENSG00000134216	Chitinase, acidic	1	111290862-111320566	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059193	Approved					Tissue enhanced	Group enriched	11	lung: 15.6;stomach: 8.2	endometrium: 1.1	Cell line enhanced		ASC diff: 1.1
CHID1	FLJ42707, MGC3234	ENSG00000177830	Chitinase domain containing 1	11	867860-915058	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039374	Uncertain		Uncertain	Nucleoplasm<br>Intermediate filaments	Endometrial cancer:6.76e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 109.0	Expressed in all		
CHIT1	CHI3, CHIT	ENSG00000133063	Chitinase 1	1	203212827-203273641	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010575	Approved				Cervical cancer:2.02e-4 (favourable)	Tissue enhanced	Group enriched	14	bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0	prostate,thyroid gland: 1.8	Not detected		
CHL1	CALL, FLJ44930, L1CAM2, MGC132578	ENSG00000134121	Cell adhesion molecule L1 like	3	196596-409417	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003345, CAB026120	Enhanced				Renal cancer:1.21e-6 (favourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 111.8	ovary: 20.9	Group enriched	6	SK-MEL-30: 73.7;WM-115: 29.2
CHN1	ARHGAP2, CHN, DURS2, n-chimerin, RhoGAP2	ENSG00000128656	Chimerin 1	2	174799363-175005369	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036111			Approved	Cytosol	Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Group enriched	7	cerebral cortex: 639.0;parathyroid gland: 133.3	placenta: 56.0	Cell line enhanced		BJ hTERT+: 172.5
CHPF2	ChSy-3, CSGlcA-T, KIAA1402	ENSG00000033100	Chondroitin polymerizing factor 2	7	151232489-151238827	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020992	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.51e-4 (favourable), Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder,spleen: 23.5	Expressed in all		
CHRD		ENSG00000090539	Chordin	3	184380073-184390736	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035827	Approved				Renal cancer:6.09e-7 (unfavourable)	Mixed	Mixed			endometrium: 16.8	Cell line enhanced		Hep G2: 7.9;U-2 OS: 4.0
CHRDL1	CHL, MGC1, NRLN1	ENSG00000101938	Chordin like 1	X	110673856-110795819	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA000226, HPA000250	Approved				Urothelial cancer:2.23e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 386.7	parathyroid gland: 315.6	Group enriched	8	ASC diff: 446.8;ASC TERT1: 622.4
CHRDL2	BNF1	ENSG00000054938	Chordin like 2	11	74696429-74731385	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021771	Uncertain		Uncertain	Mitochondria	Urothelial cancer:6.08e-4 (unfavourable)	Tissue enhanced	Group enriched	9	appendix: 157.7;endometrium: 128.3;gallbladder: 168.5;smooth muscle: 183.1;urinary bladder: 43.5	cervix, uterine: 14.6	Cell line enhanced		HeLa: 1.6;PC-3: 1.2;SiHa: 2.6
CHRNA2		ENSG00000120903	Cholinergic receptor nicotinic alpha 2 subunit	8	27459761-27479883	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	24	prostate: 46.8	breast: 1.9	Not detected		
CHRNA5		ENSG00000169684	Cholinergic receptor nicotinic alpha 5 subunit	15	78565520-78595269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054381	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:3.64e-5 (unfavourable)	Mixed	Mixed			gallbladder: 6.9	Mixed		
CHRNB1	CHRNB	ENSG00000170175	Cholinergic receptor nicotinic beta 1 subunit	17	7445061-7457707	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005822, CAB011200	Approved					Expressed in all	Expressed in all			skeletal muscle: 21.9	Cell line enhanced		LHCN-M2: 28.7;RH-30: 68.7
CHRND	ACHRD	ENSG00000135902	Cholinergic receptor nicotinic delta subunit	2	232525993-232536667	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA056404, HPA065404			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	12	skeletal muscle: 9.6	prostate: 0.8	Cell line enriched	76	RH-30: 79.9
CHST1	C6ST, KSGal6ST	ENSG00000175264	Carbohydrate sulfotransferase 1	11	45648877-45665622	Enzymes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.64e-7 (unfavourable), Liver cancer:3.95e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 49.0;parathyroid gland: 19.1	thyroid gland: 9.9	Cell line enhanced		HUVEC TERT2: 11.4;TIME: 10.8;WM-115: 35.6
CHST10	HNK-1ST	ENSG00000115526	Carbohydrate sulfotransferase 10	2	100391860-100417656	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012884, HPA051545	Approved		Approved	Cytosol	Pancreatic cancer:4.05e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 46.4	endometrium: 19.4	Mixed		
CHST13	C4ST3	ENSG00000180767	Carbohydrate sulfotransferase 13	3	126524283-126543291	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		liver: 5.9;testis: 6.3	spleen: 2.9	Group enriched	6	CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9
CHST6	MCDC1	ENSG00000183196	Carbohydrate sulfotransferase 6	16	75472052-75495384	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cervix, uterine: 16.3;duodenum: 10.6;small intestine: 10.9	cerebral cortex: 7.9	Cell line enhanced		AN3-CA: 10.8;CAPAN-2: 11.4;NTERA-2: 6.2;U-2 OS: 8.0;WM-115: 6.7
CHST7	C6ST-2, C6ST2	ENSG00000147119	Carbohydrate sulfotransferase 7	X	46573784-46598408	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA003919	Approved				Cervical cancer:7.20e-4 (favourable)	Expressed in all	Mixed			spleen: 12.8	Cell line enhanced		EFO-21: 22.4;NTERA-2: 21.4
CHSY1	CSS1, KIAA0990	ENSG00000131873	Chondroitin sulfate synthase 1	15	101175723-101251932	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048902	Uncertain				Renal cancer:6.33e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 64.8	Expressed in all		
CILP	HsT18872	ENSG00000138615	Cartilage intermediate layer protein	15	65194758-65211488	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003195	Uncertain				Thyroid cancer:2.24e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 67.0;smooth muscle: 70.8	gallbladder: 54.9	Cell line enhanced		ASC diff: 2.9;ASC TERT1: 1.7;EFO-21: 1.0;HSkMC: 4.7
CILP2	MGC45771	ENSG00000160161	Cartilage intermediate layer protein 2	19	19538248-19546659	Predicted secreted proteins	Evidence at protein level	HPA041847	Uncertain				Endometrial cancer:3.22e-6 (unfavourable), Ovarian cancer:2.50e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 2.5;testis: 4.2	adipose tissue: 0.8	Cell line enhanced		ASC diff: 3.2;HEK 293: 2.6
CLCA1	CaCC, CLCRG1	ENSG00000016490	Chloride channel accessory 1	1	86468368-86500289	Predicted secreted proteins, Transporters	Evidence at protein level	HPA052787, HPA059301	Enhanced				Colorectal cancer:2.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 699.6;duodenum: 882.2;rectum: 1126.3;small intestine: 1522.4	appendix: 133.7	Cell line enhanced		BEWO: 1.9;NB-4: 1.5;RPMI-8226: 1.8;SH-SY5Y: 1.9;U-2197: 1.3
CLCF1	BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6	ENSG00000175505	Cardiotrophin-like cytokine factor 1	11	67364168-67374177	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA042444	Uncertain		Approved	Nuclear bodies<br>Vesicles		Expressed in all	Tissue enhanced		gallbladder: 26.3	endometrium: 21.4	Cell line enhanced		SiHa: 56.8
CLDN7	CEPTRL2, CPETRL2, Hs.84359	ENSG00000181885	Claudin 7	17	7259903-7263983	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013063, HPA014703, HPA073662	Enhanced		Approved	Vesicles<br>Cell Junctions	Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)	Expressed in all	Mixed			small intestine: 350.1	Cell line enhanced		BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1
CLEC11A	CLECSF3, LSLCL, P47, SCGF	ENSG00000105472	C-type lectin domain family 11 member A	19	50723329-50725718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042690	Approved		Approved	Centrosome	Renal cancer:1.02e-5 (unfavourable), Endometrial cancer:6.91e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 81.5	cervix, uterine: 18.6	Cell line enhanced		HEL: 313.4;HMC-1: 544.7;NB-4: 546.3;THP-1: 465.7;U-937: 280.7
CLEC18A	MRCL	ENSG00000157322	C-type lectin domain family 18 member A	16	69950705-69964452	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048976	Uncertain					Tissue enriched	Group enriched	7	kidney: 15.7;testis: 3.7	adrenal gland: 1.3	Not detected		
CLEC18B		ENSG00000140839	C-type lectin domain family 18 member B	16	74408270-74421953	Predicted secreted proteins	Evidence at transcript level	HPA048976	Uncertain				Glioma:1.55e-4 (unfavourable)	Group enriched	Group enriched	10	kidney: 30.9;testis: 8.1	cerebral cortex: 2.0	Cell line enhanced		AF22: 1.1;K-562: 2.7
CLEC18C	MGC34761	ENSG00000157335	C-type lectin domain family 18 member C	16	70173322-70187361	Predicted secreted proteins	Evidence at transcript level	HPA048976	Uncertain					Tissue enriched	Group enriched	23	kidney: 11.4;testis: 3.6	duodenum: 0.3	Not detected		
CLEC19A		ENSG00000261210	C-type lectin domain family 19 member A	16	19285739-19322145	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	8	cerebral cortex: 3.2	skin: 0.4	Not detected		
CLEC20A	FLJ44005, LINC00083, NCRNA00083, RP4-593C16.2	ENSG00000188585	C-type lectin domain family 20 member A	1	178479247-178499634	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	6	testis: 3.3	lymph node: 0.5	Not detected		
CLEC3A	CLECSF1	ENSG00000166509	C-type lectin domain family 3 member A	16	78022515-78066761	Predicted secreted proteins	Evidence at protein level	HPA051511	Uncertain				Breast cancer:1.61e-4 (unfavourable)	Tissue enriched	Tissue enhanced		breast: 12.4;urinary bladder: 8.3	prostate: 3.3	Cell line enhanced		MCF7: 2.5;SK-BR-3: 5.5;T-47d: 19.7
CLEC3B	TN, TNA	ENSG00000163815	C-type lectin domain family 3 member B	3	45001548-45036071	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002582, HPA034794	Approved				Liver cancer:9.99e-9 (favourable), Head and neck cancer:1.53e-4 (favourable), Pancreatic cancer:5.68e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 303.3	adipose tissue: 203.9	Cell line enhanced		ASC diff: 169.4;ASC TERT1: 341.9;U-2197: 94.5
CLGN		ENSG00000153132	Calmegin	4	140388455-140427968	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB020709, HPA048761, HPA058627	Enhanced		Enhanced	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	5	testis: 186.4	heart muscle: 35.6	Cell line enhanced		U-251 MG: 54.9
CLN5		ENSG00000102805	Ceroid-lipofuscinosis, neuronal 5	13	76990660-77019143	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041788	Approved				Renal cancer:1.52e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.1	Expressed in all		
CLPS		ENSG00000137392	Colipase	6	35794982-35797344	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010512	Enhanced					Tissue enriched	Tissue enriched	264	pancreas: 56632.1	ovary: 214.3	Not detected		
CLPSL1	C6orf127, dJ510O8.6	ENSG00000204140	Colipase like 1	6	35781017-35793675	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA073155	Enhanced					Group enriched	Tissue enriched	38	epididymis: 733.4	pancreas: 19.3	Cell line enriched	25	T-47d: 7.9
CLPSL2	C6orf126, dJ510O8.5, UNQ3045	ENSG00000196748	Colipase like 2	6	35776594-35779552	Predicted secreted proteins	Evidence at protein level	HPA043460, HPA051655	Approved		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	703	epididymis: 713.1	seminal vesicle: 1.0	Cell line enriched	6	T-47d: 6.6
CLSTN3	CDHR14, CSTN3, KIAA0726	ENSG00000139182	Calsyntenin 3	12	7129698-7158945	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.6	parathyroid gland: 40.3	Mixed		
CLU	APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2	ENSG00000120885	Clusterin	8	27596917-27615031	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000572, CAB016253	Enhanced				Thyroid cancer:7.66e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 11170.2	Expressed in all		
CLUL1		ENSG00000079101	Clusterin like 1	18	596988-650334	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025264, HPA075240	Supported		Approved	Endoplasmic reticulum<br>Plasma membrane		Mixed	Tissue enhanced		prostate: 13.9	thyroid gland: 11.5	Cell line enhanced		Hep G2: 23.4
CMA1		ENSG00000092009	Chymase 1	14	24505353-24508265	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000363, HPA052634	Enhanced					Mixed	Tissue enhanced		breast: 23.8	esophagus: 11.4	Not detected		
CMPK1	CMPK, UMP-CMPK	ENSG00000162368	Cytidine/uridine monophosphate kinase 1	1	47333797-47378839	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA053730, HPA058604	Approved		Supported	Nucleus	Glioma:8.67e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 169.1	Expressed in all		
CNDP1	CN1, CPGL2, HsT2308, MGC10825	ENSG00000150656	Carnosine dipeptidase 1	18	74534440-74587212	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008933	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 101.7;liver: 23.0	duodenum: 5.1	Cell line enriched	68	U-266/84: 57.1
CNGA4	CNCA2, CNG5, CNGB2, OCNC2, OCNCb	ENSG00000132259	Cyclic nucleotide gated channel alpha 4	11	6234765-6244429	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:1.48e-4 (favourable)	Tissue enriched	Group enriched	9	fallopian tube: 27.9;testis: 10.5	lung: 2.1	Not detected		
CNPY2	Cnpy2, HP10390, TMEM4, ZSIG9	ENSG00000257727	Canopy FGF signaling regulator 2	12	56309842-56316336	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038465, HPA038466	Supported		Supported	Cytosol	Renal cancer:2.32e-8 (unfavourable), Pancreatic cancer:8.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 87.4	Expressed in all		
CNPY3	CAG4A, TNRC5	ENSG00000137161	Canopy FGF signaling regulator 3	6	42929192-42939287	Predicted secreted proteins	Evidence at protein level	HPA016560	Uncertain				Renal cancer:9.85e-6 (unfavourable), Colorectal cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 103.1	Expressed in all		
CNPY4	MGC40499, PRAT4B	ENSG00000166997	Canopy FGF signaling regulator 4	7	100119613-100125511	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014166, HPA025240	Uncertain		Approved	Vesicles	Renal cancer:3.59e-5 (unfavourable), Liver cancer:3.99e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 34.8	Expressed in all		
CNTFR		ENSG00000122756	Ciliary neurotrophic factor receptor	9	34551432-34590140	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025310	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 62.6;cerebral cortex: 53.4	spleen: 27.5	Group enriched	9	AF22: 107.8;SH-SY5Y: 55.3
CNTN1	F3, GP135	ENSG00000018236	Contactin 1	12	40692442-41072418	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025200, HPA070467	Enhanced				Urothelial cancer:3.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 225.5	ovary: 65.6	Cell line enhanced		A549: 218.0;HaCaT: 38.4;SCLC-21H: 85.1;SH-SY5Y: 46.5
CNTN2	AXT, TAG-1, TAX, TAX1	ENSG00000184144	Contactin 2	1	205042937-205078284	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001397, HPA012497	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 81.7	testis: 11.2	Group enriched	7	NTERA-2: 3.8;SCLC-21H: 11.1
CNTN3	BIG-1, PANG	ENSG00000113805	Contactin 3	3	74262568-74521140	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003341	Approved					Mixed	Tissue enhanced		cerebral cortex: 12.4	fallopian tube: 12.0	Cell line enhanced		BJ: 6.0;fHDF/TERT166: 15.2
CNTN4	BIG-2	ENSG00000144619	Contactin 4	3	2098813-3057956	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 48.7	testis: 24.3	Group enriched	6	BEWO: 8.1;CACO-2: 7.6;HEK 293: 5.1;SH-SY5Y: 18.0;WM-115: 5.6
CNTN5	hNB-2, NB-2	ENSG00000149972	Contactin 5	11	99020953-100358885	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039492, HPA041223	Approved		Supported	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 2.6;placenta: 3.4;thyroid gland: 3.0	fallopian tube: 1.8	Not detected		
CNTNAP2	Caspr2, KIAA0868, NRXN4	ENSG00000174469	Contactin associated protein-like 2	7	146116002-148420998	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002739	Enhanced					Tissue enhanced	Group enriched	11	cerebral cortex: 17.9;prostate: 6.0	fallopian tube: 1.0	Cell line enhanced		AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5
CNTNAP3	CASPR3, CNTNAP3A, FLJ14195, KIAA1714	ENSG00000106714	Contactin associated protein-like 3	9	39072767-39288315	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Mixed	Mixed			esophagus: 8.2	Cell line enhanced		A549: 17.0;AF22: 22.2;WM-115: 37.4
CNTNAP3B		ENSG00000154529	Contactin associated protein-like 3B	9	41890314-42129510	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Not detected	Mixed			esophagus,skin: 10.4	Cell line enhanced		A549: 27.0;AF22: 41.2;WM-115: 28.0
COASY	CoASY, DPCK, NBP, PPAT	ENSG00000068120	Coenzyme A synthase	17	42561467-42566277	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022875, HPA022912, HPA023273	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.1	Expressed in all		
COCH	COCH-5B2, DFNA31, DFNA9	ENSG00000100473	Cochlin	14	30874514-30895065	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065086			Approved	Vesicles		Mixed	Group enriched	6	pancreas: 94.8;prostate: 79.0;seminal vesicle: 99.1	cervix, uterine: 15.4	Cell line enhanced		HEK 293: 92.9;K-562: 114.9;NB-4: 71.8;SCLC-21H: 130.1
COL10A1		ENSG00000123500	Collagen type X alpha 1 chain	6	116118923-116158747	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA053268			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		gallbladder: 14.5	ovary: 4.9	Cell line enriched	6	hTEC/SVTERT24-B: 39.7
COL11A2	DFNA13, DFNB53, HKE5	ENSG00000204248	Collagen type XI alpha 2 chain	6	33162681-33192499	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		testis: 1.2	cerebral cortex: 0.7	Not detected		
COL12A1	COL12A1L	ENSG00000111799	Collagen type XII alpha 1 chain	6	75084326-75206051	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009143, HPA070695	Uncertain		Approved	Nucleus	Renal cancer:1.69e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 113.7	Cell line enhanced		fHDF/TERT166: 1109.7;SiHa: 894.9
COL15A1		ENSG00000204291	Collagen type XV alpha 1 chain	9	98943179-99070792	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017913, HPA017915	Enhanced		Approved	Endoplasmic reticulum	Urothelial cancer:3.08e-4 (unfavourable), Liver cancer:5.47e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 312.1	smooth muscle: 146.2	Cell line enhanced		BJ: 21.5;BJ hTERT+: 42.8;HDLM-2: 21.5;U-2197: 40.3;WM-115: 29.2
COL16A1		ENSG00000084636	Collagen type XVI alpha 1 chain	1	31652247-31704319	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027235, HPA027237			Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:4.00e-9 (unfavourable), Glioma:7.08e-4 (unfavourable)	Expressed in all	Mixed			ovary: 181.5	Cell line enhanced		ASC diff: 88.5;BJ hTERT+: 91.9;fHDF/TERT166: 81.2;U-2197: 87.0
COL18A1	KNO, KNO1, KS	ENSG00000182871	Collagen type XVIII alpha 1 chain	21	45405137-45513720	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001961, HPA011025, HPA036104	Approved		Approved	Golgi apparatus	Liver cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 144.0	Cell line enhanced		EFO-21: 290.7;NTERA-2: 173.6;TIME: 152.4
COL19A1		ENSG00000082293	Collagen type XIX alpha 1 chain	6	69866571-70209976	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042422	Uncertain					Tissue enhanced	Tissue enhanced		lymph node: 3.2;tonsil: 2.9	spleen: 2.1	Cell line enhanced		HDLM-2: 5.2;RH-30: 13.4;SCLC-21H: 4.6;SK-MEL-30: 9.3;WM-115: 9.7
COL1A1	OI4	ENSG00000108821	Collagen type I alpha 1 chain	17	50183289-50201632	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008405, HPA011795	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 1872.5	Cell line enhanced		BJ: 2487.8;fHDF/TERT166: 3474.4;HSkMC: 1569.1;U-138 MG: 2286.9
COL1A2	OI4	ENSG00000164692	Collagen type I alpha 2 chain	7	94394561-94431232	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB032650, HPA059738	Approved		Supported	Endoplasmic reticulum	Renal cancer:1.51e-9 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 2950.1	Cell line enhanced		ASC diff: 2673.1;ASC TERT1: 3247.5;BJ: 3371.1;fHDF/TERT166: 10547.5;HSkMC: 2949.4
COL20A1	KIAA1510	ENSG00000101203	Collagen type XX alpha 1 chain	20	63293186-63334851	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051962	Uncertain					Tissue enriched	Tissue enriched	7	cerebral cortex: 16.2	testis: 2.3	Not detected		
COL21A1		ENSG00000124749	Collagen type XXI alpha 1 chain	6	56056590-56394094	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031212			Supported	Cytosol		Mixed	Tissue enhanced		cervix, uterine: 36.7;placenta: 39.0	endometrium: 19.6	Cell line enhanced		ASC TERT1: 15.7;BEWO: 7.2;HSkMC: 16.7
COL22A1		ENSG00000169436	Collagen type XXII alpha 1 chain	8	138588235-138914006	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024830	Supported		Supported	Endoplasmic reticulum<br>Vesicles	Lung cancer:2.13e-6 (unfavourable), Glioma:3.62e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 9.7	prostate: 4.8	Group enriched	5	HDLM-2: 27.1;RT4: 9.7;SCLC-21H: 9.4;U-2 OS: 6.9
COL24A1		ENSG00000171502	Collagen type XXIV alpha 1 chain	1	85729233-86156943	Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			cervix, uterine: 3.5	Cell line enhanced		Karpas-707: 2.7;NTERA-2: 1.9;RH-30: 2.6;U-266/70: 5.3
COL26A1	EMI6, EMID2, Emu2	ENSG00000160963	Collagen type XXVI alpha 1 chain	7	101362820-101559024	Predicted secreted proteins	Evidence at protein level	HPA027059	Approved		Approved	Vesicles	Liver cancer:2.32e-5 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 10.2;parathyroid gland: 5.4	prostate: 3.1	Cell line enhanced		AF22: 29.3;BEWO: 22.8;HAP1: 10.9;NTERA-2: 25.1
COL27A1	FLJ11895, KIAA1870, MGC11337	ENSG00000196739	Collagen type XXVII alpha 1 chain	9	114155560-114312511	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021884, HPA048471	Uncertain					Expressed in all	Mixed			endometrium: 39.8	Cell line enhanced		BEWO: 53.2;Hep G2: 33.0
COL28A1		ENSG00000215018	Collagen type XXVIII alpha 1 chain	7	7356203-7535853	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043844, HPA060468	Uncertain		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 18.2	fallopian tube: 8.0	Cell line enhanced		U-266/70: 7.6;WM-115: 4.8
COL2A1	AOM, SEDC, STL1	ENSG00000139219	Collagen type II alpha 1 chain	12	47972965-48004486	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002214, HPA055753	Supported		Approved	Nucleoplasm		Mixed	Group enriched	9	epididymis: 23.0;stomach: 6.2	prostate: 1.6	Group enriched	23	AF22: 154.1;HAP1: 101.9;HEK 293: 33.7
COL3A1	EDS4A	ENSG00000168542	Collagen type III alpha 1 chain	2	188974320-189012746	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007583, CAB016766, CAB059993	Approved				Renal cancer:3.59e-10 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8	placenta: 2768.0	Cell line enhanced		AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4
COL4A1		ENSG00000187498	Collagen type IV alpha 1 chain	13	110148963-110307149	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001695, HPA054039	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:1.30e-7 (unfavourable), Cervical cancer:4.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 1237.0	smooth muscle: 436.3	Cell line enhanced		ASC diff: 355.1;EFO-21: 845.9
COL4A2	DKFZp686I14213, FLJ22259	ENSG00000134871	Collagen type IV alpha 2 chain	13	110305812-110513027	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010751, HPA029118	Enhanced		Supported	Vesicles	Renal cancer:3.49e-5 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 829.9	smooth muscle: 401.0	Cell line enhanced		EFO-21: 1032.9;WM-115: 470.6
COL4A3		ENSG00000169031	Collagen type IV alpha 3 chain	2	227164565-227314792	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042064	Approved		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:2.51e-7 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 26.8	lung: 22.4	Cell line enhanced		HeLa: 10.8;Karpas-707: 7.1;RPTEC TERT1: 8.3;U-266/70: 6.7
COL4A5	ASLN, ATS	ENSG00000188153	Collagen type IV alpha 5 chain	X	108439844-108697545	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA065449			Uncertain	Lipid droplets	Renal cancer:2.41e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 76.4	Cell line enhanced		HHSteC: 80.3;HUVEC TERT2: 76.9;SiHa: 73.2;TIME: 73.5
COL4A6		ENSG00000197565	Collagen type IV alpha 6 chain	X	108155607-108439497	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA065393			Approved	Endoplasmic reticulum		Mixed	Mixed			smooth muscle: 36.9	Cell line enhanced		HBEC3-KT: 32.9;HHSteC: 49.7;hTERT-HME1: 33.8;HUVEC TERT2: 34.7;TIME: 76.5
COL5A1		ENSG00000130635	Collagen type V alpha 1 chain	9	134641774-134844843	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030769	Approved		Approved	Vesicles	Renal cancer:2.07e-12 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 157.8	Cell line enhanced		BJ: 370.0;fHDF/TERT166: 317.6;SiHa: 305.8
COL5A2		ENSG00000204262	Collagen type V alpha 2 chain	2	189031896-189179879	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.53e-10 (unfavourable), Urothelial cancer:3.58e-4 (unfavourable), Lung cancer:5.37e-4 (unfavourable)	Expressed in all	Mixed			placenta: 154.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 407.0;BJ hTERT+ SV40 Large T+ RasG12V: 363.2;fHDF/TERT166: 325.7
COL5A3		ENSG00000080573	Collagen type V alpha 3 chain	19	9959561-10010471	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA048256	Approved				Renal cancer:7.17e-8 (unfavourable), Urothelial cancer:6.87e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 47.7	adipose tissue: 30.9	Cell line enhanced		ASC TERT1: 27.4;BJ: 20.0;BJ hTERT+: 21.4;HSkMC: 20.6;WM-115: 25.9
COL6A1		ENSG00000142156	Collagen type VI alpha 1 chain	21	45981737-46005050	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019142, HPA029401	Enhanced		Approved	Cytosol	Renal cancer:1.07e-8 (unfavourable), Urothelial cancer:4.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 401.2	Cell line enhanced		ASC TERT1: 1614.9;HHSteC: 849.5;HSkMC: 1234.5;U-138 MG: 1268.9
COL6A2		ENSG00000142173	Collagen type VI alpha 2 chain	21	46098097-46132849	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007029, HPA030920, HPA038799	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.72e-14 (unfavourable)	Expressed in all	Expressed in all			placenta: 472.0	Cell line enhanced		ASC TERT1: 1480.1;BJ: 903.2;HHSteC: 946.3;HSkMC: 1105.7;U-138 MG: 1108.3
COL6A3		ENSG00000163359	Collagen type VI alpha 3 chain	2	237324003-237414375	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010080	Supported				Renal cancer:5.57e-11 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 557.1	gallbladder: 375.3	Cell line enhanced		ASC diff: 2271.2;ASC TERT1: 2960.3;BJ hTERT+: 1039.3;HSkMC: 1966.4
COL6A5	COL29A1, FLJ35880, VWA4	ENSG00000172752	Collagen type VI alpha 5 chain	3	130345516-130484844	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA043138	Uncertain					Not detected	Group enriched	6	lung: 3.8;skin: 7.4	duodenum,stomach: 0.9	Cell line enriched	73	HDLM-2: 14.7
COL6A6		ENSG00000206384	Collagen type VI alpha 6 chain	3	130560334-130678155	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045239	Uncertain					Tissue enhanced	Tissue enhanced		lung: 11.2	breast: 2.9	Not detected		
COL7A1	EBD1, EBDCT, EBR1	ENSG00000114270	Collagen type VII alpha 1 chain	3	48564073-48595267	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016357, HPA042420	Enhanced				Pancreatic cancer:3.86e-4 (unfavourable), Head and neck cancer:6.31e-4 (favourable)	Expressed in all	Tissue enriched	6	skin: 114.5	endometrium,prostate: 20.1	Cell line enhanced		HBEC3-KT: 71.5;HDLM-2: 89.9;HeLa: 81.8;SiHa: 86.9
COL8A1	C3orf7, MGC9568	ENSG00000144810	Collagen type VIII alpha 1 chain	3	99638475-99799226	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA053107	Enhanced		Supported	Vesicles	Renal cancer:9.39e-8 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 87.4	lung: 56.9	Cell line enhanced		fHDF/TERT166: 930.0;LHCN-M2: 289.1;TIME: 423.8
COL8A2	FECD, FECD1, PPCD, PPCD2	ENSG00000171812	Collagen type VIII alpha 2 chain	1	36095236-36125220	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049788	Uncertain		Uncertain	Golgi apparatus	Renal cancer:9.35e-5 (unfavourable), Ovarian cancer:7.26e-4 (unfavourable), Head and neck cancer:9.44e-4 (favourable)	Expressed in all	Mixed			placenta: 18.2	Cell line enhanced		BJ: 4.9;fHDF/TERT166: 3.3;HHSteC: 11.8
COL9A1		ENSG00000112280	Collagen type IX alpha 1 chain	6	70215061-70303083	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA074749	Supported					Mixed	Tissue enriched	6	prostate: 31.4	testis: 5.1	Group enriched	6	AF22: 27.0;NTERA-2: 9.9
COL9A2	EDM2, MED	ENSG00000049089	Collagen type IX alpha 2 chain	1	40300487-40317816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056316, HPA075286	Approved		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 53.4	seminal vesicle: 32.4	Cell line enhanced		HDLM-2: 91.5;HMC-1: 79.4;THP-1: 69.5
COL9A3	DJ885L7.4.1, EDM3, FLJ90759, IDD, MED	ENSG00000092758	Collagen type IX alpha 3 chain	20	62816244-62841159	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040125, HPA058323	Supported		Approved	Nucleoplasm<br>Intermediate filaments		Mixed	Group enriched	6	cerebral cortex: 7.5;salivary gland: 10.5;testis: 6.3;thyroid gland: 19.1	seminal vesicle: 1.8	Group enriched	6	BEWO: 139.2;Hep G2: 40.1;SK-MEL-30: 37.9;WM-115: 57.3
COLEC10	CL-L1	ENSG00000184374	Collectin subfamily member 10	8	118995452-119106582	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:5.79e-4 (favourable)	Mixed	Group enriched	8	liver: 51.2;placenta: 26.0	thyroid gland: 5.0	Group enriched	6	BJ hTERT+: 5.2;HHSteC: 2.1;SK-BR-3: 8.4
COLEC11	CL-K1, MGC3279	ENSG00000118004	Collectin subfamily member 11	2	3594832-3644644	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035241	Approved					Tissue enhanced	Tissue enhanced		gallbladder: 102.0	adrenal gland: 36.2	Group enriched	8	HHSteC: 135.6;SH-SY5Y: 158.1
COLGALT1	FLJ22329, GLT25D1	ENSG00000130309	Collagen beta(1-O)galactosyltransferase 1	19	17555594-17583162	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047821	Approved		Approved	Vesicles	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.65e-5 (unfavourable), Pancreatic cancer:1.92e-4 (unfavourable), Urothelial cancer:3.83e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 58.0	Expressed in all		
COLGALT2	C1orf17, GLT25D2, KIAA0584	ENSG00000198756	Collagen beta(1-O)galactosyltransferase 2	1	183929854-184037729	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031749, HPA031750	Approved		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	5	cerebral cortex: 46.4	prostate: 8.8	Cell line enhanced		Hep G2: 11.7;SK-MEL-30: 14.3;U-251 MG: 14.6;WM-115: 22.1
COLQ	EAD	ENSG00000206561	Collagen like tail subunit of asymmetric acetylcholinesterase	3	15450133-15521751	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045876			Approved	Plasma membrane<br>Cell Junctions		Mixed	Tissue enhanced		parathyroid gland: 19.4	fallopian tube: 17.6	Cell line enhanced		BEWO: 13.9;HDLM-2: 4.5;U-937: 5.9
COMP	EDM1, EPD1, MED, PSACH, THBS5	ENSG00000105664	Cartilage oligomeric matrix protein	19	18782773-18791314	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077555			Approved	Golgi apparatus	Renal cancer:1.52e-6 (unfavourable), Colorectal cancer:9.08e-5 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable), Urothelial cancer:6.95e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 24.5	smooth muscle: 18.2	Cell line enriched	5	fHDF/TERT166: 666.2
CORT	MGC32686	ENSG00000241563	Cortistatin	1	10449719-10451902	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	24	cerebral cortex: 24.8	placenta: 1.0	Mixed		
CP		ENSG00000047457	Ceruloplasmin	3	149162410-149222055	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001834, CAB008591	Supported				Renal cancer:1.14e-7 (unfavourable)	Tissue enhanced	Tissue enriched	9	liver: 916.0	cervix, uterine: 99.1	Cell line enriched	12	EFO-21: 273.0
CPA1	CPA	ENSG00000091704	Carboxypeptidase A1	7	130380339-130388114	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021836, CAB025197, HPA052215	Enhanced					Tissue enriched	Tissue enriched	367	pancreas: 48856.8	ovary: 133.1	Cell line enhanced		AN3-CA: 10.9;SCLC-21H: 2.5;U-2 OS: 1.7
CPA2		ENSG00000158516	Carboxypeptidase A2	7	130266827-130289798	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA020342, HPA021317	Enhanced					Tissue enriched	Tissue enriched	104	pancreas: 9283.9	stomach: 89.6	Cell line enhanced		AN3-CA: 2.0;CACO-2: 3.0;RH-30: 2.8;SCLC-21H: 1.9
CPA3		ENSG00000163751	Carboxypeptidase A3	3	148865256-148897196	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA006479, HPA008689, CAB020712	Enhanced					Mixed	Tissue enhanced		gallbladder: 173.9	lung: 126.9	Cell line enriched	46	HEL: 265.9
CPA4	CPA3	ENSG00000128510	Carboxypeptidase A4	7	130293134-130324180	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021030	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Urothelial cancer:1.31e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	skin: 67.8	esophagus: 10.0	Cell line enhanced		LHCN-M2: 238.0;U-2 OS: 159.5;U-87 MG: 268.2
CPA6	CPAH	ENSG00000165078	Carboxypeptidase A6	8	67422038-67746385	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		prostate: 4.9;rectum: 2.9	colon: 1.7	Cell line enhanced		CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6
CPAMD8	K-CAP, KIAA1283, VIP	ENSG00000160111	C3 and PZP like, alpha-2-macroglobulin domain containing 8	19	16892947-17026815	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031327, HPA031328, HPA031330	Uncertain					Mixed	Tissue enhanced		prostate: 25.1;seminal vesicle: 52.1	lung: 22.8	Group enriched	10	BEWO: 18.7;EFO-21: 11.7;T-47d: 32.2
CPB1		ENSG00000153002	Carboxypeptidase B1	3	148791102-148860187	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026158, HPA038069, HPA046340	Enhanced					Group enriched	Tissue enriched	312	pancreas: 47292.1	ovary: 151.6	Cell line enhanced		HDLM-2: 1.0;U-2 OS: 1.7
CPB2	CPU, PCPB, TAFI	ENSG00000080618	Carboxypeptidase B2	13	46053186-46105076	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004146	Approved				Liver cancer:2.06e-4 (favourable)	Tissue enriched	Tissue enriched	28	liver: 755.5	lung: 26.5	Cell line enriched	66	Hep G2: 117.8
CPE		ENSG00000109472	Carboxypeptidase E	4	165361194-165498320	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003819, CAB024907	Supported		Approved	Nucleoplasm<br>Vesicles<br>Centrosome	Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1560.8	Group enriched	5	Hep G2: 211.8;SCLC-21H: 493.5;SH-SY5Y: 147.0;SiHa: 668.1
CPM		ENSG00000135678	Carboxypeptidase M	12	68842197-68971570	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002657, HPA077243	Uncertain		Uncertain	Vesicles	Endometrial cancer:1.00e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 164.0	placenta: 101.2	Cell line enhanced		ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
CPN1		ENSG00000120054	Carboxypeptidase N subunit 1	10	100042193-100081877	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040323			Approved	Nucleus<br>Nucleoli		Group enriched	Tissue enriched	22	liver: 37.1	testis: 1.7	Cell line enriched	16	SK-MEL-30: 110.4
CPN2	ACBP	ENSG00000178772	Carboxypeptidase N subunit 2	3	194339765-194351328	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004732	Uncertain				Liver cancer:2.05e-4 (favourable), Renal cancer:4.59e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	liver: 113.6	kidney: 15.6	Cell line enriched	17	Hep G2: 41.9
CPO		ENSG00000144410	Carboxypeptidase O	2	206939554-206969474	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	14	small intestine: 131.5	epididymis: 9.3	Not detected		
CPQ	LDP, PGCP	ENSG00000104324	Carboxypeptidase Q	8	96645227-97149654	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023235, HPA024490	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 382.5	Cell line enhanced		ASC TERT1: 92.2
CPVL		ENSG00000106066	Carboxypeptidase, vitellogenic like	7	28995231-29195451	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003697, HPA045715, HPA056466	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:8.56e-6 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 301.8	Cell line enhanced		BEWO: 183.9;RPTEC TERT1: 604.1
CPXM1	CPX-1, CPX1, CPXM	ENSG00000088882	Carboxypeptidase X, M14 family member 1	20	2794069-2800637	Enzymes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.62e-10 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 130.4;gallbladder: 132.2	urinary bladder: 75.0	Group enriched	5	AF22: 158.5;HSkMC: 62.0;NB-4: 92.9;NTERA-2: 34.2;REH: 136.3;SH-SY5Y: 113.9
CPXM2	CPX2, UNQ676	ENSG00000121898	Carboxypeptidase X, M14 family member 2	10	123706207-123940267	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048375	Uncertain				Renal cancer:9.02e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 72.6;smooth muscle: 80.7	urinary bladder: 34.4	Group enriched	15	BJ: 15.4;fHDF/TERT166: 55.4
CPZ		ENSG00000109625	Carboxypeptidase Z	4	8592660-8619759	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 121.5	placenta: 58.0	Cell line enhanced		BEWO: 63.6;BJ: 32.8;BJ hTERT+: 42.2;RH-30: 54.5;U-2197: 38.2
CR1L		ENSG00000197721	Complement C3b/C4b receptor 1 like	1	207645113-207738416	Predicted secreted proteins	Evidence at protein level	HPA049348	Approved					Tissue enhanced	Not detected			bone marrow: 0.8	Group enriched	8	HEL: 1.1;HMC-1: 2.6;K-562: 1.4
CRB1	LCA8, RP12	ENSG00000134376	Crumbs 1, cell polarity complex component	1	197268204-197478455	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA061250, HPA063127	Approved		Uncertain	Vesicles		Tissue enriched	Group enriched	10	cerebral cortex: 12.2;testis: 5.0	ovary: 0.8	Cell line enriched	5	HeLa: 9.0
CRB2	FLJ16786, FLJ38464	ENSG00000148204	Crumbs 2, cell polarity complex component	9	123356170-123380324	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043674	Supported					Group enriched	Tissue enhanced		cerebral cortex: 9.4	kidney: 2.0	Cell line enriched	7	AF22: 32.2
CREG1	CREG	ENSG00000143162	Cellular repressor of E1A stimulated genes 1	1	167529677-167553767	Predicted secreted proteins	Evidence at protein level	HPA056390			Approved	Vesicles<br>Microtubules		Expressed in all	Expressed in all			thyroid gland: 209.5	Expressed in all		
CREG2		ENSG00000175874	Cellular repressor of E1A stimulated genes 2	2	101345551-101387595	Predicted secreted proteins	Evidence at protein level	HPA038224	Enhanced					Mixed	Tissue enriched	164	cerebral cortex: 90.9	fallopian tube: 0.5	Cell line enhanced		CACO-2: 2.0;HaCaT: 5.6;HeLa: 1.6;PC-3: 2.3
CRELD1	AVSD2	ENSG00000163703	Cysteine rich with EGF like domains 1	3	9933822-9945413	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026964	Uncertain		Approved	Nucleoli<br>Cytosol	Glioma:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
CRELD2	MGC11256	ENSG00000184164	Cysteine rich with EGF like domains 2	22	49918167-49927540	Predicted secreted proteins	Evidence at protein level	HPA000603, CAB025604	Approved				Renal cancer:1.34e-9 (unfavourable), Endometrial cancer:2.42e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 94.2	Expressed in all		
CRH	CRF, CRH1	ENSG00000147571	Corticotropin releasing hormone	8	66176382-66178725	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046846, HPA062111	Uncertain	Supported				Tissue enriched	Tissue enhanced		cerebral cortex: 2.1;placenta: 8.0	adipose tissue: 1.2	Not detected		
CRHBP	CRF-BP, CRFBP	ENSG00000145708	Corticotropin releasing hormone binding protein	5	76952713-76981158	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046120	Approved					Tissue enhanced	Tissue enhanced		liver: 69.9;spleen: 42.2	kidney: 30.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.3;HBF TERT88: 6.0;U-698: 4.8;U-87 MG: 3.6;WM-115: 3.2
CRHR1	CRF-R, CRF1, CRHR	ENSG00000120088	Corticotropin releasing hormone receptor 1	17	45784280-45835828	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025251	Approved					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 0.8	Cell line enhanced		RT4: 2.7;SH-SY5Y: 2.2
CRHR2	CRF-RB, CRF2, HM-CRF	ENSG00000106113	Corticotropin releasing hormone receptor 2	7	30651943-30700129	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046683	Uncertain					Not detected	Tissue enhanced		seminal vesicle: 1.7	cerebral cortex: 1.2	Not detected		
CRISP1	AEGL1, ARP, CRISP-1, HSCRISP1D, HSCRISP1G, HUMARP	ENSG00000124812	Cysteine rich secretory protein 1	6	49834257-49877096	Predicted secreted proteins	Evidence at protein level	HPA028445, HPA030534	Enhanced					Not detected	Tissue enriched	20	epididymis: 1915.6	seminal vesicle: 96.7	Cell line enhanced		NB-4: 1.7
CRISP2	CRISP-2, CT36, GAPDL5, TPX1	ENSG00000124490	Cysteine rich secretory protein 2	6	49692358-49713590	Predicted secreted proteins	Evidence at protein level	HPA031248	Enhanced					Mixed	Tissue enriched	43	testis: 853.2	fallopian tube: 19.7	Not detected		
CRISP3	Aeg2, CRISP-3, CRS3, dJ442L6.3, SGP28	ENSG00000096006	Cysteine rich secretory protein 3	6	49727384-49744437	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054392	Supported					Group enriched	Tissue enhanced		fallopian tube: 1885.2;salivary gland: 915.8	esophagus: 288.4	Group enriched	59	HEL: 11.2;RT4: 3.3;SK-BR-3: 6.9;T-47d: 4.2
CRISPLD2	DKFZP434B044, LCRISP2, LGL1	ENSG00000103196	Cysteine rich secretory protein LCCL domain containing 2	16	84819984-84920768	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030054, HPA030055	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.97e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 174.3	Cell line enhanced		BEWO: 66.9;HHSteC: 135.7;HSkMC: 49.5
CRLF1	CISS, CISS1, CLF, CLF-1	ENSG00000006016	Cytokine receptor like factor 1	19	18572220-18607741	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041493, HPA041793	Approved				Renal cancer:3.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 17.2;placenta: 16.8	adipose tissue: 10.1	Group enriched	8	ASC diff: 706.3;Hep G2: 309.6
CRP	PTX1	ENSG00000132693	C-reactive protein	1	159712289-159714589	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB005036, HPA027367, HPA027396	Supported				Renal cancer:4.17e-10 (unfavourable)	Tissue enriched	Group enriched	67	gallbladder: 172.9;liver: 532.1	endometrium: 5.2	Cell line enhanced		EFO-21: 5.9;HDLM-2: 5.8;U-2 OS: 4.4;U-266/84: 7.5
CRTAC1	ASPIC1, CEP-68, FLJ10320	ENSG00000095713	Cartilage acidic protein 1	10	97865000-98030828	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008175	Enhanced				Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1	urinary bladder: 12.8	Cell line enhanced		HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0
CRTAP	CASP, LEPREL3, P3H5	ENSG00000170275	Cartilage associated protein	3	33113979-33147773	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA043598, HPA044150	Approved		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cervix, uterine: 197.9	Expressed in all		
CRY2		ENSG00000121671	Cryptochrome circadian clock 2	11	45847118-45883248	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037577	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.44e-15 (favourable), Liver cancer:6.82e-5 (favourable), Colorectal cancer:1.67e-4 (unfavourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.2	Expressed in all		
CSAD	CSD, PCAP	ENSG00000139631	Cysteine sulfinic acid decarboxylase	12	53157663-53180909	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039487	Approved				Renal cancer:1.93e-6 (unfavourable), Urothelial cancer:6.81e-6 (favourable), Liver cancer:1.37e-4 (favourable), Pancreatic cancer:3.39e-4 (favourable), Head and neck cancer:6.33e-4 (favourable), Colorectal cancer:9.50e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 70.7	Cell line enhanced		ASC diff: 57.9;T-47d: 49.5
CSF1	M-CSF, MCSF, MGC31930	ENSG00000184371	Colony stimulating factor 1	1	109910242-109930992	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 66.6	Cell line enhanced		ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5
CSF1R	C-FMS, CD115, CSFR, FMS	ENSG00000182578	Colony stimulating factor 1 receptor	5	150053291-150113372	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB008970, HPA012323	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 147.7	Group enriched	6	BEWO: 118.6;SK-BR-3: 35.4
CSF2	GM-CSF, GMCSF	ENSG00000164400	Colony stimulating factor 2	5	132073790-132076170	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA057404, HPA062006			Enhanced	Vesicles		Mixed	Tissue enhanced		lung: 3.0	urinary bladder: 0.9	Cell line enhanced		BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9
CSF2RA	CD116, CSF2R	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	X	1268800-1310381	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016148	Uncertain				Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 93.3	appendix: 34.6	Group enriched	8	BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
CSF3	C17orf33, G-CSF, GCSF, MGC45931	ENSG00000108342	Colony stimulating factor 3	17	40015361-40017813	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:8.45e-4 (favourable)	Mixed	Tissue enhanced		appendix: 19.1;cervix, uterine: 38.2	adipose tissue: 10.3	Cell line enhanced		BJ hTERT+: 57.2;hTEC/SVTERT24-B: 34.2;U-87 MG: 265.0
CSH1	CSA, CSMT, FLJ75407, hCS-A, PL	ENSG00000136488	Chorionic somatomammotropin hormone 1	17	63894909-63896661	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026374, HPA043715	Enhanced					Tissue enriched	Tissue enriched	211	placenta: 13487.0	smooth muscle: 63.9	Cell line enriched	6	BEWO: 11.1
CSH2	CS-2, CSB, hCS-B	ENSG00000213218	Chorionic somatomammotropin hormone 2	17	63872012-63873766	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Tissue enhanced	Tissue enriched	193	placenta: 3932.3	smooth muscle: 20.4	Cell line enriched	27	BEWO: 7.7
CSHL1	CS-5, CSHP1, CSL, hCS-L, MGC149868	ENSG00000204414	Chorionic somatomammotropin hormone like 1	17	63909597-63918838	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025646, HPA043715	Enhanced					Not detected	Tissue enriched	352	placenta: 216.7	smooth muscle: 0.6	Not detected		
CSN1S1	CASA, CSN1	ENSG00000126545	Casein alpha s1	4	69931081-69946574	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035659, HPA057031	Enhanced					Tissue enriched	Tissue enriched	85	breast: 1600.9	adipose tissue: 18.9	Not detected		
CSN2	CASB	ENSG00000135222	Casein beta	4	69955256-69961007	Predicted secreted proteins	Evidence at protein level	HPA041036	Supported					Tissue enriched	Tissue enriched	348	breast: 347.6	salivary gland: 0.9	Not detected		
CSN3	CSN10	ENSG00000171209	Casein kappa	4	70242588-70251428	Predicted secreted proteins	Evidence at protein level	HPA035953, HPA035954	Enhanced					Group enriched	Tissue enriched	13	breast: 428.0	salivary gland: 32.0	Not detected		
CST1		ENSG00000170373	Cystatin SN	20	23747553-23751268	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026769, HPA043706, HPA044763	Enhanced				Breast cancer:4.00e-4 (favourable)	Mixed	Tissue enriched	27	salivary gland: 9590.6	gallbladder: 352.0	Cell line enhanced		CACO-2: 139.8;RT4: 891.2;TIME: 178.3
CST11	CST8L, CTES2, dJ322G13.6	ENSG00000125831	Cystatin 11	20	23450403-23452857	Predicted secreted proteins	Evidence at protein level	HPA053399	Enhanced					Not detected	Tissue enriched	299	epididymis: 266.6	testis: 0.8	Not detected		
CST2		ENSG00000170369	Cystatin SA	20	23823769-23826731	Predicted secreted proteins	Evidence at protein level	CAB024963, HPA043706, HPA044763	Enhanced					Mixed	Tissue enriched	281	salivary gland: 2052.3	gallbladder: 7.3	Cell line enriched	13	RT4: 53.8
CST3		ENSG00000101439	Cystatin C	20	23626706-23638473	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000118, HPA013143	Enhanced		Supported	Golgi apparatus<br>Vesicles	Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1265.8	Cell line enhanced		ASC diff: 1105.8
CST4		ENSG00000101441	Cystatin S	20	23685640-23689040	Predicted secreted proteins	Evidence at protein level	HPA043706, HPA044763	Supported				Ovarian cancer:4.98e-5 (unfavourable), Urothelial cancer:2.88e-4 (favourable)	Mixed	Tissue enriched	113	salivary gland: 9926.9	gallbladder: 87.6	Cell line enhanced		CACO-2: 4.5;hTEC/SVTERT24-B: 2.1;RT4: 10.7;TIME: 1.8
CST5		ENSG00000170367	Cystatin D	20	23875935-23879750	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB024944, HPA061449	Enhanced					Tissue enriched	Tissue enriched	363	salivary gland: 756.2	lung,smooth muscle: 2.0	Not detected		
CST6		ENSG00000175315	Cystatin E/M	11	66011841-66013505	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019316, HPA044963	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	9	skin: 213.2	breast: 24.9	Group enriched	6	A-431: 83.9;CAPAN-2: 228.1
CST7		ENSG00000077984	Cystatin F	20	24949230-24959928	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040442	Enhanced				Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable)	Expressed in all	Tissue enriched	9	bone marrow: 642.9	spleen: 74.1	Group enriched	19	HL-60: 58.5;HMC-1: 170.9;NB-4: 126.6;U-937: 278.1
CST8	CRES, CTES5	ENSG00000125815	Cystatin 8	20	23491101-23496018	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	208	testis: 20.7	all non-specific tissues: 0.0	Not detected		
CST9	CLM, CTES7A	ENSG00000173335	Cystatin 9	20	23602410-23605876	Predicted secreted proteins	Evidence at transcript level	HPA029190	Uncertain					Tissue enriched	Tissue enriched	12	breast: 2.1	kidney: 0.1	Not detected		
CST9L	bA218C14.1, CTES7B	ENSG00000101435	Cystatin 9-like	20	23564732-23568749	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	testis: 108.4	epididymis: 19.6	Cell line enriched	13	HEL: 1.2
CSTL1	CTES1, dJ322G13.4	ENSG00000125823	Cystatin like 1	20	23439685-23444930	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	37	testis: 4.6	placenta,seminal vesicle,skin,small intestine,stomach: 0.1	Not detected		
CT55	CXorf48, FLJ20527	ENSG00000169551	Cancer/testis antigen 55	X	135156536-135171398	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	31	testis: 6.5	cerebral cortex: 0.2	Cell line enriched	18	K-562: 6.7
CTB-16J4.1		ENSG00000283267		7	90316503-90321308	Predicted secreted proteins	No evidence								Not detected			testis: 0.4	Not detected		
CTB-60B18.6		ENSG00000267335		19	49022953-49036895	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA038925	Uncertain		Approved	Cytosol		Not detected	Not detected			duodenum,testis: 0.7	Cell line enhanced		HMC-1: 3.7;U-251 MG: 5.2
CTBS	CTB	ENSG00000117151	Chitobiase	1	84549606-84574480	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017043, HPA023594, HPA048810	Approved		Uncertain	Cytosol		Expressed in all	Mixed			epididymis: 3.8	Mixed		
CTC-295J13.3		ENSG00000248109		5	148221650-148243580	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.2	seminal vesicle: 0.9	Cell line enriched	5	HeLa: 479.6
CTC1	AAF132, C17orf68, FLJ22170	ENSG00000178971	CST telomere replication complex component 1	17	8224821-8248044	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:6.49e-5 (favourable)	Expressed in all	Expressed in all			spleen: 30.9	Expressed in all		
CTD-2265O21.8		ENSG00000284491		19	12802072-12804303	Predicted secreted proteins	No evidence								Not detected			testis: 0.6	Not detected		
CTD-2313N18.7		ENSG00000225805		11	71878453-71884561	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	13	epididymis: 86.1	thyroid gland: 6.4	Cell line enhanced		RH-30: 16.4
CTGF	CCN2, IGFBP8	ENSG00000118523	Connective tissue growth factor	6	131948176-131951373	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005123, HPA031075	Approved				Stomach cancer:5.04e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 845.3	Cell line enhanced		EFO-21: 1511.7;HUVEC TERT2: 1148.6;TIME: 2338.5
CTHRC1		ENSG00000164932	Collagen triple helix repeat containing 1	8	103371515-103382997	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059806, HPA061896	Approved		Approved	Nucleoplasm	Renal cancer:1.22e-14 (unfavourable), Liver cancer:1.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 137.8;placenta: 125.5;urinary bladder: 100.0	breast: 49.2	Cell line enhanced		ASC TERT1: 202.9;HHSteC: 162.6;HSkMC: 291.0;WM-115: 375.8
CTNS	CTNS-LSB, PQLC4	ENSG00000040531	Cystinosin, lysosomal cystine transporter	17	3636468-3661542	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA046947			Supported	Vesicles<br>Intermediate filaments	Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
CTRB1	CTRB	ENSG00000168925	Chymotrypsinogen B1	16	75219000-75224924	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	376	pancreas: 48923.8	ovary: 130.0	Cell line enhanced		EFO-21: 2.9;HDLM-2: 2.3;U-2 OS: 2.4;U-266/84: 1.0
CTRB2		ENSG00000168928	Chymotrypsinogen B2	16	75204096-75207185	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	392	pancreas: 29060.0	ovary: 74.0	Cell line enhanced		EFO-21: 3.0;U-2 OS: 6.8;U-251 MG: 1.5;U-266/84: 1.9
CTRC	CLCR, ELA4	ENSG00000162438	Chymotrypsin C	1	15438439-15449242	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046920	Enhanced					Tissue enriched	Tissue enriched	361	pancreas: 18186.4	ovary: 50.3	Not detected		
CTRL		ENSG00000141086	Chymotrypsin like	16	67927640-67932414	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA034504, HPA034505	Enhanced		Uncertain	Nucleoplasm		Not detected	Tissue enriched	209	pancreas: 1629.9	ovary: 7.8	Mixed		
CTSA	GSL, PPGB	ENSG00000064601	Cathepsin A	20	45890144-45898820	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024930, HPA031068	Enhanced		Enhanced	Vesicles	Liver cancer:1.95e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 243.4	Expressed in all		
CTSB		ENSG00000164733	Cathepsin B	8	11842524-11869448	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000457, HPA018156	Uncertain		Supported	Nucleoli<br>Vesicles	Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 2894.5	Expressed in all		
CTSC	DPP1, PALS, PLS	ENSG00000109861	Cathepsin C	11	88293592-88337787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025364, HPA066610, HPA068434	Enhanced		Supported	Vesicles	Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			lung: 390.4	Expressed in all		
CTSD	CLN10, CPSD	ENSG00000117984	Cathepsin D	11	1752752-1764573	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000109, HPA003001	Enhanced				Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 1026.9	Expressed in all		
CTSE		ENSG00000196188	Cathepsin E	1	206009264-206023909	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA012940, CAB032687	Enhanced				Urothelial cancer:5.26e-5 (favourable)	Group enriched	Group enriched	9	duodenum: 229.1;stomach: 1121.8	lung: 74.6	Group enriched	7	BEWO: 20.3;RT4: 32.6
CTSF	CATSF, CLN13	ENSG00000174080	Cathepsin F	11	66563463-66568841	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002141, HPA031431, HPA055610	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:8.92e-7 (favourable)	Expressed in all	Expressed in all			ovary: 140.6	Cell line enhanced		SK-MEL-30: 123.6
CTSG	CG	ENSG00000100448	Cathepsin G	14	24573522-24576260	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000110, HPA047737	Enhanced				Head and neck cancer:1.57e-4 (favourable), Urothelial cancer:8.91e-4 (unfavourable)	Mixed	Tissue enriched	84	bone marrow: 3457.0	gallbladder: 41.2	Cell line enriched	6	THP-1: 6055.4
CTSH	ACC-4, ACC-5, ACC4, ACC5, CPSB	ENSG00000103811	Cathepsin H	15	78921058-78949574	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000458, HPA003524	Enhanced		Supported	Vesicles<br>Cytosol<br>Cytoplasmic bodies	Endometrial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			lung: 570.6	Cell line enhanced		CAPAN-2: 219.5;HaCaT: 161.7;RT4: 558.6
CTSK	CTSO, CTSO2, PKND, PYCD	ENSG00000143387	Cathepsin K	1	150796208-150808323	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050346			Supported	Vesicles	Renal cancer:7.12e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 575.0	Group enriched	6	ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CTSL	CTSL1, FLJ31037	ENSG00000135047	Cathepsin L	9	87725519-87731393	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000459	Enhanced				Lung cancer:5.15e-5 (unfavourable), Renal cancer:4.34e-4 (favourable), Glioma:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 748.5	Cell line enhanced		ASC TERT1: 1401.5
CTSO	CTSO1	ENSG00000256043	Cathepsin O	4	155924118-155953917	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA002041	Approved					Expressed in all	Expressed in all			gallbladder: 32.4	Cell line enhanced		HSkMC: 15.9;Karpas-707: 30.6
CTSS		ENSG00000163131	Cathepsin S	1	150730196-150765957	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000460, HPA002988	Supported		Approved	Vesicles		Expressed in all	Expressed in all			spleen: 374.8	Cell line enhanced		HMC-1: 238.0;U-698: 410.8
CTSV	CTSL2, CTSU	ENSG00000136943	Cathepsin V	9	97029679-97039643	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB017112	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 69.3;skin: 64.2;testis: 131.8	placenta: 25.9	Cell line enriched	7	BEWO: 563.7
CTSW		ENSG00000172543	Cathepsin W	11	65879809-65883741	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016345	Enhanced				Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 70.6;spleen: 60.4	lung: 36.5	Group enriched	20	HEL: 149.5;NB-4: 242.5
CTSZ	CTSX	ENSG00000101160	Cathepsin Z	20	58995185-59007247	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025114, HPA049876, HPA053504	Supported		Supported	Vesicles	Renal cancer:5.72e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 476.8	Cell line enhanced		fHDF/TERT166: 693.2
CUBN	gp280, IFCR, MGA1	ENSG00000107611	Cubilin	10	16823964-17129831	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004133, HPA043854	Enhanced				Renal cancer:1.12e-4 (favourable)	Tissue enriched	Group enriched	22	kidney: 153.7;small intestine: 54.4	thyroid gland: 4.7	Cell line enhanced		AN3-CA: 14.6;WM-115: 5.9
CUTA	ACHAP, C6orf82	ENSG00000112514	CutA divalent cation tolerance homolog	6	33416442-33418317	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016787, HPA064369	Uncertain		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:8.50e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 293.5	Expressed in all		
CX3CL1	ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1	ENSG00000006210	C-X3-C motif chemokine ligand 1	16	57372458-57385048	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026192, HPA040361	Approved		Supported	Plasma membrane	Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 100.1	lung: 69.3	Cell line enhanced		EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
CXADR	CAR	ENSG00000154639	Coxsackie virus and adenovirus receptor	21	17512382-17593579	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003342, CAB005103, HPA030411, HPA030412	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Head and neck cancer:3.50e-4 (favourable)	Expressed in all	Mixed			skin: 59.1	Cell line enhanced		CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7
CXCL1	FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1	ENSG00000163739	C-X-C motif chemokine ligand 1	4	73869393-73871242	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 178.6;spleen: 112.8	urinary bladder: 92.0	Group enriched	7	BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0
CXCL10	C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10	ENSG00000169245	C-X-C motif chemokine ligand 10	4	76021117-76023497	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.16e-6 (unfavourable), Ovarian cancer:1.12e-5 (favourable), Pancreatic cancer:4.61e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 129.4	lymph node: 72.5	Cell line enhanced		BJ hTERT+: 4.9;BJ hTERT+ SV40 Large T+: 2.0;BJ hTERT+ SV40 Large T+ RasG12V: 2.1;RPMI-8226: 2.9;THP-1: 2.0
CXCL11	b-R1, H174, I-TAC, IP-9, SCYB11, SCYB9B	ENSG00000169248	C-X-C motif chemokine ligand 11	4	76033682-76041415	Predicted secreted proteins	Evidence at protein level	CAB009921	Uncertain				Ovarian cancer:4.31e-7 (favourable), Renal cancer:3.29e-6 (unfavourable), Pancreatic cancer:8.18e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.5	lymph node: 11.5	Group enriched	6	BJ hTERT+: 2.4;BJ hTERT+ SV40 Large T+: 4.3;BJ hTERT+ SV40 Large T+ RasG12V: 4.7
CXCL12	PBSF, SCYB12, SDF-1a, SDF-1b, SDF1, SDF1A, SDF1B, TLSF-a, TLSF-b, TPAR1	ENSG00000107562	C-X-C motif chemokine ligand 12	10	44370165-44386493	Predicted secreted proteins	Evidence at protein level	CAB017564	Approved					Expressed in all	Expressed in all			endometrium: 618.3	Cell line enhanced		ASC diff: 349.6;BJ hTERT+ SV40 Large T+ RasG12V: 429.9;fHDF/TERT166: 388.7;HSkMC: 941.2
CXCL13	ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13	ENSG00000156234	C-X-C motif chemokine ligand 13	4	77511753-77611834	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA052613	Uncertain				Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable)	Expressed in all	Group enriched	7	appendix: 163.3;lymph node: 599.9;spleen: 423.8;tonsil: 395.7	urinary bladder: 57.9	Cell line enhanced		U-266/70: 1.0
CXCL14	BMAC, bolekine, BRAK, Kec, KS1, MIP-2g, NJAC, SCYB14	ENSG00000145824	C-X-C motif chemokine ligand 14	5	135570679-135579279	Predicted secreted proteins	Evidence at protein level	CAB029996	Uncertain				Cervical cancer:1.71e-4 (favourable), Colorectal cancer:4.52e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 874.5	kidney: 335.8	Group enriched	12	HAP1: 60.3;hTCEpi: 55.4;RPTEC TERT1: 157.5;U-2 OS: 88.6
CXCL17	Dcip1, DMC, UNQ473, VCC1	ENSG00000189377	C-X-C motif chemokine ligand 17	19	42428288-42443048	Predicted secreted proteins	Evidence at protein level						Lung cancer:4.92e-5 (favourable), Pancreatic cancer:4.63e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 193.5;stomach: 289.7	esophagus: 83.1	Cell line enhanced		RT4: 1.8
CXCL2	CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2	ENSG00000081041	C-X-C motif chemokine ligand 2	4	74097035-74099293	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 110.2	lung: 95.2	Cell line enhanced		BJ hTERT+: 38.3;HHSteC: 26.8;hTCEpi: 24.9;hTEC/SVTERT24-B: 24.7;hTERT-HME1: 25.6;U-87 MG: 27.5
CXCL3	CINC-2b, GRO3, GROg, MIP-2b, SCYB3	ENSG00000163734	C-X-C motif chemokine ligand 3	4	74036589-74038807	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Cervical cancer:2.33e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 26.9;cervix, uterine: 33.6	appendix: 20.3	Cell line enhanced		BJ hTERT+: 39.2;hTEC/SVTERT24-B: 75.0;RPTEC TERT1: 32.7
CXCL5	ENA-78, SCYB5	ENSG00000163735	C-X-C motif chemokine ligand 5	4	73995642-73998779	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065474	Approved				Renal cancer:2.45e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable), Pancreatic cancer:2.23e-4 (unfavourable), Cervical cancer:3.43e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 47.7	urinary bladder: 15.5	Cell line enhanced		A549: 165.3;EFO-21: 141.1;HSkMC: 77.3;hTEC/SVTERT24-B: 78.0;RPTEC TERT1: 436.4
CXCL6	CKA-3, GCP-2, SCYB6	ENSG00000124875	C-X-C motif chemokine ligand 6	4	73836497-73849064	Predicted secreted proteins	Evidence at protein level						Renal cancer:4.82e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 50.3;spleen: 112.9	urinary bladder: 32.4	Group enriched	6	BJ hTERT+: 36.7;EFO-21: 100.3;hTEC/SVTERT24-B: 22.6;HUVEC TERT2: 59.0;RPTEC TERT1: 62.9
CXCL8	3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1	ENSG00000169429	C-X-C motif chemokine ligand 8	4	73740506-73743716	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA057179	Supported				Renal cancer:3.13e-6 (unfavourable), Cervical cancer:1.18e-5 (unfavourable), Liver cancer:1.19e-5 (unfavourable)	Expressed in all	Tissue enriched	7	bone marrow: 2076.0	appendix: 293.4	Cell line enriched	6	BJ hTERT+: 3127.1
CXCL9	CMK, crg-10, Humig, MIG, SCYB9	ENSG00000138755	C-X-C motif chemokine ligand 9	4	76001275-76007488	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 327.4	appendix: 86.2	Not detected		
CXorf36	DIA1R, FLJ14103	ENSG00000147113	Chromosome X open reading frame 36	X	45148374-45200901	Disease related genes, Predicted secreted proteins	Evidence at transcript level	HPA002806	Uncertain					Expressed in all	Tissue enhanced		placenta: 58.4	adipose tissue: 36.3	Cell line enriched	145	HUVEC TERT2: 67.8
CYHR1	CHRP, KIAA0496, MGC13010	ENSG00000187954	Cysteine and histidine rich 1	8	144449582-144465677	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053653, HPA059543	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.4	Expressed in all		
CYP17A1	CPT7, CYP17, P450C17, S17AH	ENSG00000148795	Cytochrome P450 family 17 subfamily A member 1	10	102830531-102837533	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA048533	Enhanced				Renal cancer:5.43e-7 (favourable)	Tissue enriched	Tissue enriched	25	adrenal gland: 3751.4	testis: 152.4	Cell line enhanced		HMC-1: 2.6;SCLC-21H: 1.3
CYP20A1	CYP-M	ENSG00000119004	Cytochrome P450 family 20 subfamily A member 1	2	203238940-203305611	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055872, HPA058461	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Mixed			thyroid gland: 16.4	Mixed		
CYP2A6	CPA6, CYP2A, CYP2A3	ENSG00000255974	Cytochrome P450 family 2 subfamily A member 6	19	40843538-40850447	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046713, HPA047262	Supported				Liver cancer:5.38e-5 (favourable)	Tissue enriched	Tissue enriched	67	liver: 839.4	breast: 12.4	Cell line enhanced		RH-30: 1.1
CYP2A7	CYP2A	ENSG00000198077	Cytochrome P450 family 2 subfamily A member 7	19	40875439-40882752	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB033510, HPA046713, HPA047262	Enhanced					Group enriched	Tissue enriched	123	liver: 60.9	breast: 0.4	Not detected		
CYP2B6	CPB6, CYP2B, CYPIIB6	ENSG00000197408	Cytochrome P450 family 2 subfamily B member 6	19	40991299-41018398	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033866, HPA048124, HPA062973	Supported		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Tissue enhanced	Tissue enriched	18	liver: 283.3	kidney: 15.7	Cell line enhanced		HaCaT: 2.3
CYP2C18	CPCI, CYP2C, CYP2C17, P450IIC17	ENSG00000108242	Cytochrome P450 family 2 subfamily C member 18	10	94683621-94736190	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2	tonsil: 6.2	Cell line enhanced		BEWO: 3.0
CYP2C19	CPCJ, CYP2C, P450IIC19	ENSG00000165841	Cytochrome P450 family 2 subfamily C member 19	10	94762624-94853260	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015066	Supported					Not detected	Tissue enhanced		duodenum: 48.3;liver: 125.6	small intestine: 20.7	Not detected		
CYP2C8	CPC8	ENSG00000138115	Cytochrome P450 family 2 subfamily C member 8	10	95036772-95069497	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013547, HPA013970, HPA015066	Enhanced				Pancreatic cancer:9.82e-4 (favourable)	Tissue enriched	Tissue enriched	154	liver: 1124.1	gallbladder: 7.3	Not detected		
CYP2C9	CYP2C10, P450IIC9	ENSG00000138109	Cytochrome P450 family 2 subfamily C member 9	10	94938658-94989390	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA015066, CAB016123	Enhanced				Liver cancer:2.83e-6 (favourable)	Tissue enriched	Tissue enriched	7	liver: 963.1	duodenum: 136.8	Not detected		
CYP2E1	CYP2E	ENSG00000130649	Cytochrome P450 family 2 subfamily E member 1	10	133520406-133561220	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009128, HPA029564	Enhanced					Tissue enriched	Tissue enriched	177	liver: 5332.2	tonsil: 30.1	Cell line enhanced		HaCaT: 9.7;NB-4: 15.1
CYP2F1	CYP2F	ENSG00000197446	Cytochrome P450 family 2 subfamily F member 1	19	41114432-41128366	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	8	lung: 2.4;testis: 1.9	bone marrow,esophagus,tonsil: 0.2	Group enriched	16	HMC-1: 4.7;K-562: 4.5
CYP2S1		ENSG00000167600	Cytochrome P450 family 2 subfamily S member 1	19	41193049-41207539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049227, HPA069248	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 96.7;small intestine: 68.6;stomach: 111.7	colon: 25.9	Cell line enhanced		A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
CYP2W1	FLJ20359, MGC34287	ENSG00000073067	Cytochrome P450 family 2 subfamily W member 1	7	983199-989640	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012753	Uncertain				Urothelial cancer:5.85e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 5.5;duodenum: 6.2;skin: 9.7	placenta: 1.4	Group enriched	7	CACO-2: 11.2;Hep G2: 33.8
CYP46A1	CYP46	ENSG00000036530	Cytochrome P450 family 46 subfamily A member 1	14	99684304-99727301	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040702	Uncertain					Tissue enriched	Tissue enriched	21	cerebral cortex: 64.1	heart muscle: 3.0	Group enriched	5	AF22: 2.4;U-937: 5.4
CYP4F11		ENSG00000171903	Cytochrome P450 family 4 subfamily F member 11	19	15912367-15934867	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017265, CAB033648, HPA058960	Enhanced				Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 29.5;liver: 32.7;small intestine: 26.3	epididymis: 20.0	Cell line enhanced		A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
CYP4F2		ENSG00000186115	Cytochrome P450 family 4 subfamily F member 2	19	15878023-15898120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014048, HPA017265, HPA058960	Supported					Tissue enriched	Group enriched	6	duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3	prostate: 10.4	Cell line enhanced		Hep G2: 2.5
CYR61	CCN1, GIG1, IGFBP10	ENSG00000142871	Cysteine rich angiogenic inducer 61	1	85580761-85583962	Predicted secreted proteins	Evidence at protein level	HPA029853	Uncertain				Renal cancer:1.39e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 1095.9	Mixed		
CYTL1	C17, C4orf4	ENSG00000170891	Cytokine like 1	4	5014586-5019472	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA067201			Supported	Nuclear membrane<br>Endoplasmic reticulum	Stomach cancer:3.00e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable), Renal cancer:7.43e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		placenta: 64.9	seminal vesicle: 19.1	Cell line enhanced		HEL: 171.3;HUVEC TERT2: 124.6;NB-4: 237.3;WM-115: 86.9
D2HGDH	D2HGD, FLJ42195, MGC25181	ENSG00000180902	D-2-hydroxyglutarate dehydrogenase	2	241734579-241768816	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056216, HPA060548	Uncertain		Approved	Mitochondria	Head and neck cancer:9.11e-4 (favourable)	Expressed in all	Expressed in all			skin: 46.5	Expressed in all		
DAG1	156DAG, A3a, AGRNR, DAG	ENSG00000173402	Dystroglycan 1	3	49468703-49535618	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001960, CAB016353	Enhanced		Supported	Vesicles	Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			placenta: 109.3	Expressed in all		
DAND5	CER2, CKTSF1B3, Coco, DANTE, DTE, FLJ38607, GREM3	ENSG00000179284	DAN domain BMP antagonist family member 5	19	12965159-12974762	Predicted secreted proteins	Evidence at transcript level	HPA043493, HPA049472	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		heart muscle: 5.2	bone marrow,cerebral cortex: 1.3	Cell line enriched	16	SH-SY5Y: 19.9
DBH	DBM	ENSG00000123454	Dopamine beta-hydroxylase	9	133636360-133659344	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002130, HPA005960, HPA070789	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	28	adrenal gland: 356.8	liver: 12.6	Cell line enriched	370	SH-SY5Y: 1924.2
DCD	AIDD, DCD-1, DSEP, HCAP, PIF	ENSG00000161634	Dermcidin	12	54644591-54648493	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063967	Supported					Tissue enriched	Tissue enriched	96	breast: 336.4	skeletal muscle: 3.5	Not detected		
DCN	DSPG2, SLRR1B	ENSG00000011465	Decorin	12	91140484-91183123	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003315, CAB017118, HPA064736, CAB068930	Enhanced				Renal cancer:1.46e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 3807.0	Cell line enhanced		ASC diff: 2514.0;ASC TERT1: 1962.9;BJ hTERT+: 2379.1;HSkMC: 1868.4
DDIAS	C11orf82, FLJ25416, FLJ38838, noxin	ENSG00000165490	DNA damage induced apoptosis suppressor	11	82899975-82958277	Predicted secreted proteins	Evidence at protein level	HPA038540, HPA038541	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		testis: 20.0	skeletal muscle: 6.4	Mixed		
DDOST	KIAA0115, OST, OST48, WBP1	ENSG00000244038	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	1	20651767-20661544	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009746, HPA046841, HPA052867	Supported		Supported	Endoplasmic reticulum	Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 308.3	Expressed in all		
DDR1	CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6	ENSG00000204580	Discoidin domain receptor tyrosine kinase 1	6	30876421-30900156	CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010162, CAB025656, HPA057194	Approved		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.31e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Cell line enhanced		HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DDT	DDCT	ENSG00000099977	D-dopachrome tautomerase	22	23971365-23980469	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049871	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			liver: 109.9	Expressed in all		
DDX17	P72	ENSG00000100201	DEAD-box helicase 17	22	38483440-38507660	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB024908, HPA063142	Enhanced		Enhanced	Nuclear speckles	Lung cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 336.0	Expressed in all		
DDX20	DP103, GEMIN3	ENSG00000064703	DEAD-box helicase 20	1	111755245-111768016	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA005516, CAB015427	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)	Expressed in all	Tissue enriched	10	testis: 130.7	parathyroid gland: 12.6	Expressed in all		
DDX28	FLJ11282, MDDX28	ENSG00000182810	DEAD-box helicase 28	16	68021274-68023442	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA041911, HPA053585	Approved		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:2.07e-10 (favourable)	Expressed in all	Expressed in all			bone marrow: 11.2	Expressed in all		
DEFA1	DEF1, DEFA2, HNP-1, MRS	ENSG00000206047	Defensin alpha 1	8	6977649-6980080	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB032548, HPA052517	Enhanced					Not detected	Tissue enriched	269	bone marrow: 30312.0	skin: 112.6	Cell line enriched	9	NB-4: 2.6
DEFA1B		ENSG00000240247	Defensin alpha 1B	8	6996766-6999195	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052517	Supported					Not detected	Tissue enriched	463	bone marrow: 46364.0	spleen: 100.2	Not detected		
DEFA3	DEF3, HNP-3	ENSG00000239839	Defensin alpha 3	8	7015869-7018301	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA052517	Supported					Not detected	Tissue enriched	246	bone marrow: 23273.5	spleen: 94.7	Not detected		
DEFA4	DEF4, HP-4	ENSG00000164821	Defensin alpha 4	8	6935822-6938338	Predicted secreted proteins	Evidence at protein level	HPA051266	Enhanced					Not detected	Tissue enriched	640	bone marrow: 3105.2	spleen: 4.8	Cell line enriched	8	THP-1: 8.6
DEFA5	DEF5, HD-5	ENSG00000164816	Defensin alpha 5	8	7055304-7056734	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015775, CAB069919	Enhanced				Colorectal cancer:9.44e-5 (favourable)	Tissue enhanced	Group enriched	480	duodenum: 10677.9;small intestine: 19102.0	appendix: 31.0	Group enriched	6	BEWO: 55.6;NB-4: 31.4;RPMI-8226: 35.9;SH-SY5Y: 42.9;U-2197: 16.2
DEFA6	DEF6, HD-6	ENSG00000164822	Defensin alpha 6	8	6924693-6926076	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019462	Enhanced					Tissue enhanced	Group enriched	525	duodenum: 5743.0;small intestine: 10524.2	colon: 15.4	Group enriched	9	BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6
DEFB1	BD1, DEFB-1, DEFB101, HBD-1, HBD1, MGC51822	ENSG00000164825	Defensin beta 1	8	6870575-6878022	Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:1.90e-5 (favourable), Lung cancer:5.62e-4 (unfavourable), Pancreatic cancer:5.94e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 618.9;kidney: 1500.2	salivary gland: 232.3	Cell line enhanced		NB-4: 34.9;SCLC-21H: 45.7;THP-1: 129.4
DEFB103A	DEFB-3, DEFB103, DEFB3, HBD-3, HBD3, HBP-3, HBP3	ENSG00000176797	Defensin beta 103A	8	7881204-7882664	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 2.1	skin: 0.8	Not detected		
DEFB103B		ENSG00000177243	Defensin beta 103B	8	7428888-7430348	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 2.1	skin: 0.8	Not detected		
DEFB104A	DEFB-4, DEFB104, DEFB4	ENSG00000176782	Defensin beta 104A	8	7836471-7841242	Predicted secreted proteins	Evidence at protein level	HPA045292	Supported					Not detected	Tissue enriched	609	epididymis: 581.5	esophagus: 0.9	Not detected		
DEFB104B		ENSG00000177023	Defensin beta 104B	8	7470308-7475082	Predicted secreted proteins	Evidence at protein level	HPA045292	Supported					Not detected	Tissue enriched	609	epididymis: 581.5	esophagus: 0.9	Not detected		
DEFB105A	DEFB-5, DEFB105	ENSG00000186562	Defensin beta 105A	8	7821966-7823889	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	5851	epididymis: 2275.4	esophagus: 0.3	Cell line enhanced		BEWO: 1.9;NB-4: 5.1;SH-SY5Y: 1.6
DEFB105B		ENSG00000186599	Defensin beta 105B	8	7487669-7489593	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	18505	epididymis: 1850.5	all non-specific tissues: 0.0	Not detected		
DEFB106A	DEFB-6, DEFB106	ENSG00000186579	Defensin beta 106A	8	7825172-7829053	Predicted secreted proteins	Evidence at protein level	HPA045592	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SH-SY5Y: 1.2
DEFB106B		ENSG00000187082	Defensin beta 106B	8	7482504-7486400	Predicted secreted proteins	Evidence at protein level	HPA045592	Supported					Not detected	Tissue enriched	18221	epididymis: 2094.6	esophagus: 0.1	Cell line enriched	13	NB-4: 1.3
DEFB107A	DEFB-7, DEFB107	ENSG00000186572	Defensin beta 107A	8	7811720-7815716	Predicted secreted proteins	Evidence at transcript level	HPA045626	Approved					Not detected	Tissue enriched	2828	epididymis: 488.6	endometrium: 0.1	Not detected		
DEFB107B	HsT21816	ENSG00000198129	Defensin beta 107B	8	7495846-7509311	Predicted secreted proteins	Evidence at transcript level	HPA045626	Approved					Not detected	Tissue enriched	2828	epididymis: 488.6	endometrium: 0.1	Not detected		
DEFB108B		ENSG00000184276	Defensin beta 108B	11	71833200-71837710	Predicted secreted proteins	Evidence at transcript level	HPA042588	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DEFB110	DEFB-10, DEFB-11, DEFB111	ENSG00000203970	Defensin beta 110	6	50009138-50021981	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	3627	epididymis: 1094.2	seminal vesicle: 0.3	Not detected		
DEFB113	DEFB-13	ENSG00000214642	Defensin beta 113	6	49968677-49969625	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	568	epididymis: 56.8	all non-specific tissues: 0.0	Not detected		
DEFB114	DEFB-14	ENSG00000177684	Defensin beta 114	6	49960249-49964105	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	734	epididymis: 73.3	all non-specific tissues: 0.0	Not detected		
DEFB115	DEFB-15	ENSG00000215547	Defensin beta 115	20	31257664-31259632	Predicted secreted proteins	Evidence at transcript level	HPA053160	Uncertain					Not detected	Tissue enriched	14	epididymis: 1.3	all non-specific tissues: 0.0	Cell line enriched	16	U-2 OS: 1.6
DEFB116	DEFB-16	ENSG00000215545	Defensin beta 116	20	31303212-31308585	Predicted secreted proteins	No evidence	HPA047430	Uncertain					Not detected	Not detected			epididymis: 0.6	Not detected		
DEFB118	C20orf63, DEFB-18, dJ1018D12.3, ESC42	ENSG00000131068	Defensin beta 118	20	31368618-31373923	Predicted secreted proteins	Evidence at protein level	HPA042634	Enhanced					Not detected	Tissue enriched	12295	epididymis: 1229.5	all non-specific tissues: 0.0	Not detected		
DEFB119	DEFB-19, DEFB-20, DEFB120	ENSG00000180483	Defensin beta 119	20	31377164-31390603	Predicted secreted proteins	Evidence at protein level	HPA043059	Supported					Tissue enriched	Group enriched	3499	epididymis: 2335.6;testis: 472.8	duodenum: 0.4	Not detected		
DEFB121	DEFB-21	ENSG00000204548	Defensin beta 121	20	31404845-31412838	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	6458	epididymis: 2005.4	testis: 0.3	Cell line enriched	19	NB-4: 1.8
DEFB123	DEFB-23	ENSG00000180424	Defensin beta 123	20	31440519-31450257	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	438	epididymis: 108.1;testis: 178.0	small intestine: 0.3	Not detected		
DEFB124	DEFB-24	ENSG00000180383	Defensin beta 124	20	31465506-31476757	Predicted secreted proteins	Evidence at transcript level	HPA051046	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 8.9;testis: 5.7	endometrium: 5.4	Group enriched	6	HEL: 2.4;HMC-1: 1.3;U-2 OS: 1.1;WM-115: 5.7
DEFB125	DEFB-25	ENSG00000178591	Defensin beta 125	20	87250-97094	Predicted secreted proteins	Evidence at transcript level	HPA043095	Uncertain					Not detected	Group enriched	11	epididymis: 1.3;seminal vesicle: 1.5	testis: 0.1	Not detected		
DEFB126	bA530N10.1, C20orf8, DEFB-26	ENSG00000125788	Defensin beta 126	20	142369-145751	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	234	epididymis: 663.6	seminal vesicle: 2.8	Not detected		
DEFB127	bA530N10.2, C20orf73, DEF-27	ENSG00000088782	Defensin beta 127	20	157470-159163	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1015	epididymis: 1399.7	seminal vesicle: 1.3	Not detected		
DEFB128	DEFB-28	ENSG00000185982	Defensin beta 128	20	187853-189681	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	17134	epididymis: 1713.4	all non-specific tissues: 0.0	Not detected		
DEFB129	bA530N10.3, C20orf87, DEFB-29	ENSG00000125903	Defensin beta 129	20	227258-229886	Predicted secreted proteins	Evidence at protein level	HPA014581	Supported					Not detected	Tissue enriched	494	epididymis: 2368.3	seminal vesicle: 4.7	Cell line enhanced		NB-4: 1.7;SH-SY5Y: 1.3
DEFB130	DEFB-30, DEFB30	ENSG00000232948	Defensin beta 130	8	12310962-12318316	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	47	epididymis: 4.7	all non-specific tissues: 0.0	Not detected		
DEFB131	DEFB-31	ENSG00000186146	Defensin beta 131	4	9444534-9450514	Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	epididymis: 207.2	seminal vesicle: 21.0	Cell line enriched	6	TIME: 1.7
DEFB132	DEFB32, RP5-1103G7.6	ENSG00000186458	Defensin beta 132	20	257736-261096	Predicted secreted proteins	Evidence at transcript level	HPA046399	Approved					Tissue enhanced	Tissue enriched	11	epididymis: 332.3	seminal vesicle: 29.0	Not detected		
DEFB133		ENSG00000214643	Defensin beta 133	6	49946021-49950265	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	158	epididymis: 15.7	all non-specific tissues: 0.0	Not detected		
DEFB134		ENSG00000205882	Defensin beta 134	8	11993174-11996312	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	8	epididymis: 36.9	testis: 4.6	Not detected		
DEFB135		ENSG00000205883	Defensin beta 135	8	11982321-11984590	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	189	epididymis: 84.8	gallbladder,testis: 0.4	Cell line enhanced		HEK 293: 1.1;MCF7: 3.5
DEFB136	DEFB137	ENSG00000205884	Defensin beta 136	8	11973937-11974599	Predicted secreted proteins	Evidence at protein level	HPA068255	Enhanced					Not detected	Tissue enriched	9	epididymis: 3.8	seminal vesicle: 0.4	Cell line enhanced		HEK 293: 1.0
DEFB4A	DEFB-2, DEFB102, DEFB2, DEFB4, HBD-2, SAP1	ENSG00000171711	Defensin beta 4A	8	7894629-7896711	Predicted secreted proteins, Transporters	Evidence at protein level							Group enriched	Group enriched	8	esophagus: 6.0;gallbladder: 10.4;tonsil: 12.3	cervix, uterine: 1.2	Cell line enhanced		EFO-21: 2.4
DEFB4B	DEFB4P	ENSG00000177257	Defensin beta 4B	8	7414860-7416863	Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	19	tonsil: 2.7	lung,skin: 0.1	Not detected		
DFNA5	ICERE-1	ENSG00000105928	DFNA5, deafness associated tumor suppressor	7	24698353-24758113	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA011326, CAB019306	Approved		Enhanced	Cytosol	Liver cancer:2.49e-5 (unfavourable)	Mixed	Mixed			placenta: 58.7	Mixed		
DHH	HHG-3, MGC35145	ENSG00000139549	Desert hedgehog	12	49089421-49094819	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	21	testis: 20.7	appendix,placenta: 0.9	Group enriched	8	AN3-CA: 2.1;EFO-21: 4.6;HUVEC TERT2: 1.7;K-562: 7.8;TIME: 3.7
DHRS7	retDSR4, SDR34C1	ENSG00000100612	Dehydrogenase/reductase 7	14	60144120-60169856	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031121	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.92e-10 (favourable), Head and neck cancer:2.51e-4 (unfavourable), Breast cancer:6.42e-4 (favourable), Ovarian cancer:7.99e-4 (unfavourable)	Tissue enriched	Expressed in all			prostate: 650.0	Expressed in all		
DHRS7C	SDR32C2	ENSG00000184544	Dehydrogenase/reductase 7C	17	9771434-9791297	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	16	heart muscle: 62.4;skeletal muscle: 122.7	esophagus: 5.9	Not detected		
DHRS9	3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4	ENSG00000073737	Dehydrogenase/reductase 9	2	169064789-169096167	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036491, HPA036667	Approved				Pancreatic cancer:2.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 66.5;rectum: 48.1	esophagus: 30.1	Cell line enhanced		NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3
DIO2	SelY, TXDI2	ENSG00000211448	Iodothyronine deiodinase 2	14	80197527-80387757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029544, HPA048002			Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 269.4;thyroid gland: 601.2	esophagus: 70.3	Cell line enhanced		BJ: 70.1;HeLa: 63.5;SiHa: 184.0
DKK1	DKK-1, SK	ENSG00000107984	Dickkopf WNT signaling pathway inhibitor 1	10	52314296-52318042	Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.35e-8 (unfavourable), Lung cancer:7.80e-6 (unfavourable), Pancreatic cancer:1.27e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 56.5;placenta: 71.9	urinary bladder: 14.5	Cell line enhanced		BJ: 975.2;CACO-2: 841.6;fHDF/TERT166: 1247.0
DKK2		ENSG00000155011	Dickkopf WNT signaling pathway inhibitor 2	4	106921802-107283806	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009727, HPA052611	Uncertain		Supported	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 24.1	lung: 8.2	Cell line enriched	7	SH-SY5Y: 23.5
DKK3	REIC, RIG	ENSG00000050165	Dickkopf WNT signaling pathway inhibitor 3	11	11963106-12009769	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011868, CAB024949	Approved		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 373.5;heart muscle: 805.5	cervix, uterine: 138.8	Cell line enhanced		BJ: 355.1;BJ hTERT+: 524.6;fHDF/TERT166: 475.8;TIME: 285.3
DKK4		ENSG00000104371	Dickkopf WNT signaling pathway inhibitor 4	8	42374068-42377232	Predicted secreted proteins	Evidence at protein level	HPA052916	Approved					Tissue enriched	Tissue enhanced		duodenum: 2.4;esophagus: 5.4;testis: 2.7	urinary bladder: 1.4	Cell line enriched	9	Hep G2: 1.4
DKKL1	CT34, SGY-1	ENSG00000104901	Dickkopf like acrosomal protein 1	19	49361783-49375116	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025410, HPA047194	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	149	testis: 265.5	endometrium,fallopian tube: 1.7	Cell line enhanced		AF22: 5.0;AN3-CA: 8.9
DLG4	PSD-95, PSD95, SAP-90, SAP90	ENSG00000132535	Discs large MAGUK scaffold protein 4	17	7189890-7219702	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001999, CAB002000, HPA010122	Enhanced		Approved	Vesicles	Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 178.6	endometrium: 28.9	Cell line enhanced		HMC-1: 57.4
DLK1	Delta1, FA1, pG2, Pref-1, ZOG	ENSG00000185559	Delta like non-canonical Notch ligand 1	14	100725705-100738224	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005872, HPA053879, HPA062262	Supported		Approved	Golgi apparatus	Endometrial cancer:2.31e-4 (unfavourable)	Tissue enhanced	Group enriched	20	adrenal gland: 1591.0;placenta: 2331.6	ovary: 100.3	Group enriched	6	AF22: 118.4;Hep G2: 282.9;SH-SY5Y: 501.8
DLL1		ENSG00000198719	Delta like canonical Notch ligand 1	6	170282206-170306565	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA078298			Uncertain	Nucleoplasm		Expressed in all	Mixed			spleen: 20.0	Cell line enhanced		HaCaT: 7.0;HBEC3-KT: 8.8;NB-4: 13.1;THP-1: 11.4
DLL3	SCDO1	ENSG00000090932	Delta like canonical Notch ligand 3	19	39498895-39508481	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056533			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.94e-4 (unfavourable)	Group enriched	Tissue enriched	49	cerebral cortex: 51.3	testis: 1.0	Group enriched	6	SCLC-21H: 16.1;SH-SY5Y: 14.9;SK-MEL-30: 62.1
DMBT1	GP340, muclin, SALSA	ENSG00000187908	Deleted in malignant brain tumors 1	10	122560665-122643736	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA040778	Enhanced		Approved	Microtubule organizing center	Endometrial cancer:1.43e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 816.7;small intestine: 277.6	salivary gland: 136.1	Cell line enhanced		hTERT-HME1: 3.5;LHCN-M2: 7.8;RH-30: 20.9
DMKN	ZD52F10	ENSG00000161249	Dermokine	19	35497220-35513658	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029406	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.37e-6 (favourable)	Mixed	Tissue enriched	15	skin: 3991.5	breast: 259.8	Cell line enhanced		CACO-2: 150.9;HBEC3-KT: 169.4;RPTEC TERT1: 173.1
DMP1		ENSG00000152592	Dentin matrix acidic phosphoprotein 1	4	87650307-87664361	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA037465	Approved					Not detected	Not detected			testis: 0.8	Not detected		
DNAH14	C1orf67, DKFZp781B1548, Dnahc14, HL-18, HL18, MGC27277	ENSG00000185842	Dynein axonemal heavy chain 14	1	224896262-225399292	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027718, HPA028545, HPA031379	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		testis: 21.9	thyroid gland: 7.4	Mixed		
DNAJB11	EDJ, ERdj3, HEDJ	ENSG00000090520	DnaJ heat shock protein family (Hsp40) member B11	3	186567403-186585800	Predicted secreted proteins	Evidence at protein level	HPA010814, HPA017051	Supported		Supported	Endoplasmic reticulum	Renal cancer:3.44e-9 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 88.4	Expressed in all		
DNAJB9	MDG1	ENSG00000128590	DnaJ heat shock protein family (Hsp40) member B9	7	108569568-108574850	Predicted secreted proteins	Evidence at protein level	HPA040967, HPA041553	Supported		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 113.5	Expressed in all		
DNAJC25-GNG10		ENSG00000244115	DNAJC25-GNG10 readthrough	9	111631386-111670229	Predicted secreted proteins	Evidence at transcript level							Not detected	Mixed			prostate: 25.3	Expressed in all		
DNAJC3	ERdj6, HP58, P58, P58IPK, PRKRI	ENSG00000102580	DnaJ heat shock protein family (Hsp40) member C3	13	95677139-95794989	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039336, HPA041326	Uncertain		Approved	Endoplasmic reticulum	Endometrial cancer:3.47e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 88.4	Mixed		
DNASE1	DNL1	ENSG00000213918	Deoxyribonuclease 1	16	3611728-3680143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010703	Enhanced		Supported	Vesicles	Urothelial cancer:1.14e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 37.8	duodenum: 29.9	Mixed		
DNASE1L1	DNAS1L1, DNASEX, DNL1L, XIB	ENSG00000013563	Deoxyribonuclease 1 like 1	X	154401238-154412112	Predicted secreted proteins	Evidence at protein level	HPA072635	Approved				Renal cancer:2.19e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 56.6	Expressed in all		
DNASE1L2	DNAS1L2	ENSG00000167968	Deoxyribonuclease 1 like 2	16	2235816-2238711	Predicted secreted proteins	Evidence at protein level	HPA044714			Approved	Mitochondria		Mixed	Tissue enriched	6	skin: 11.9	cerebral cortex: 1.9	Mixed		
DNASE1L3	DNAS1L3, LSD	ENSG00000163687	Deoxyribonuclease 1 like 3	3	58192257-58214697	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019955	Approved				Renal cancer:1.06e-7 (favourable), Liver cancer:1.20e-6 (favourable)	Mixed	Tissue enhanced		liver: 136.7;spleen: 316.5	tonsil: 51.2	Cell line enhanced		BEWO: 1.8;RPMI-8226: 1.4
DNASE2	DNL, DNL2	ENSG00000105612	Deoxyribonuclease 2, lysosomal	19	12875211-12881468	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA066185	Enhanced					Expressed in all	Expressed in all			thyroid gland: 59.0	Expressed in all		
DNASE2B	DLAD	ENSG00000137976	Deoxyribonuclease 2 beta	1	84398532-84415018	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	salivary gland: 73.0	prostate: 10.5	Not detected		
DPEP1		ENSG00000015413	Dipeptidase 1 (renal)	16	89613308-89638456	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA009426, HPA012783	Enhanced		Approved	Nucleus<br>Cell Junctions	Renal cancer:6.84e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 262.6;small intestine: 418.9	pancreas: 92.8	Cell line enhanced		Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DPEP2		ENSG00000167261	Dipeptidase 2	16	67987394-68000586	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035644	Approved				Testis cancer:8.47e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 38.7	lung: 27.9	Cell line enhanced		HEL: 3.7;HMC-1: 16.1;U-937: 4.9
DPEP3		ENSG00000141096	Dipeptidase 3	16	67975663-67980829	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA031870, HPA058607	Enhanced					Group enriched	Tissue enriched	25	testis: 56.9	spleen: 2.3	Not detected		
DPH1	DPH2L, DPH2L1, OVCA1	ENSG00000108963	Diphthamide biosynthesis 1	17	2030110-2043430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069750			Approved	Nucleoplasm<br>Cell Junctions	Pancreatic cancer:1.78e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.5	Expressed in all		
DPP7	DPP2, DPPII	ENSG00000176978	Dipeptidyl peptidase 7	9	137110542-137115177	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021282, CAB025541, HPA059381	Supported		Enhanced	Golgi apparatus<br>Vesicles	Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 70.7	Mixed		
DPT		ENSG00000143196	Dermatopontin	1	168695459-168729264	Predicted secreted proteins	Evidence at protein level	HPA065548			Approved	Vesicles	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 330.3	Group enriched	10	ASC diff: 94.1;fHDF/TERT166: 44.4
DRAXIN	C1orf187, Draxin, FLJ34999, Neucrin	ENSG00000162490	Dorsal inhibitory axon guidance protein	1	11691729-11725857	Predicted secreted proteins	Evidence at protein level	HPA014302	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 1.5	testis: 0.6	Group enriched	5	NTERA-2: 28.2;REH: 5.8
DSE	DSEPI, SART2	ENSG00000111817	Dermatan sulfate epimerase	6	116254173-116444860	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014764, HPA052151	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)	Mixed	Mixed			appendix: 36.2	Mixed		
DSG2	CDHF5	ENSG00000046604	Desmoglein 2	18	31498043-31549008	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004896, CAB025122	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 251.3	rectum: 106.9	Cell line enhanced		HaCaT: 233.0;hTERT-HME1: 159.3
DSPP	DFNA39, DGI1, DMP3	ENSG00000152591	Dentin sialophosphoprotein	4	87608529-87616910	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA036230	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DUOX1	LNOX1, NOXEF1, THOX1	ENSG00000137857	Dual oxidase 1	15	45129933-45165576	Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA023544	Approved				Cervical cancer:4.31e-6 (favourable)	Tissue enhanced	Tissue enhanced		skin: 96.9;thyroid gland: 92.6	esophagus: 73.2	Cell line enhanced		HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
DYNLT3	TCTE1L, TCTEX1L	ENSG00000165169	Dynein light chain Tctex-type 3	X	37836757-37847637	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003938	Approved				Glioma:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 77.2	Mixed		
E2F5		ENSG00000133740	E2F transcription factor 5	8	85177225-85217158	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA055723			Supported	Nucleus<br>Nucleoli	Renal cancer:1.89e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 30.9	Cell line enhanced		AF22: 76.4;Daudi: 112.8
EBAG9	EB9, RCAS1	ENSG00000147654	Estrogen receptor binding site associated, antigen, 9	8	109539711-109565996	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021153, HPA021154, CAB072810, CAB072811, CAB072812	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 96.5	Expressed in all		
EBF4	COE4, KIAA1442, O/E-4, RP5-860F19.3	ENSG00000088881	Early B-cell factor 4	20	2692878-2760108	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:2.47e-5 (favourable), Colorectal cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Cell line enhanced		SH-SY5Y: 15.8
EBI3	IL27B, IL35B	ENSG00000105246	Epstein-Barr virus induced 3	19	4229498-4237531	Predicted secreted proteins	Evidence at protein level	HPA046635	Enhanced				Renal cancer:1.04e-8 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 209.2	spleen: 26.1	Cell line enriched	13	HDLM-2: 197.3
ECM1		ENSG00000143369	Extracellular matrix protein 1	1	150508062-150513789	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA027241	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.51e-9 (unfavourable), Urothelial cancer:1.20e-5 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable)	Expressed in all	Group enriched	6	epididymis: 581.9;esophagus: 989.7	tonsil: 122.7	Cell line enhanced		ASC TERT1: 277.2;BJ hTERT+: 233.5;fHDF/TERT166: 213.1;hTEC/SVTERT24-B: 192.3
ECM2		ENSG00000106823	Extracellular matrix protein 2	9	92493554-92536655	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035347	Approved				Renal cancer:4.09e-6 (unfavourable), Liver cancer:4.50e-5 (favourable)	Expressed in all	Mixed			adipose tissue: 128.6	Cell line enhanced		ASC diff: 13.1;ASC TERT1: 24.2;HSkMC: 26.7;hTCEpi: 30.9
ECSIT	SITPEC	ENSG00000130159	ECSIT signalling integrator	19	11505916-11529174	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042979	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.48e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 54.2	Expressed in all		
EDDM3B	FAM12B, HE3-BETA	ENSG00000181552	Epididymal protein 3B	14	20768427-20770948	Predicted secreted proteins	Evidence at protein level	HPA001323	Supported					Not detected	Tissue enriched	234	epididymis: 3239.8	seminal vesicle: 13.8	Cell line enhanced		BEWO: 1.3;NB-4: 1.7
EDEM2	bA4204.1, C20orf31, C20orf49, FLJ10783	ENSG00000088298	ER degradation enhancing alpha-mannosidase like protein 2	20	35115357-35147364	Predicted secreted proteins	Evidence at protein level	CAB037238, HPA048353	Approved				Renal cancer:4.76e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 54.7	Expressed in all		
EDIL3	DEL1	ENSG00000164176	EGF like repeats and discoidin domains 3	5	83940554-84384793	Predicted secreted proteins	Evidence at protein level	HPA020415	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 131.5	epididymis: 54.6	Cell line enhanced		LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4
EDN1	ET1	ENSG00000078401	Endothelin 1	6	12290363-12297194	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA031976, CAB032500, CAB037291	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Expressed in all	Mixed			lung: 43.5	Group enriched	6	EFO-21: 622.7;HUVEC TERT2: 372.8;T-47d: 129.1;TIME: 272.4
EDN2	ET2	ENSG00000127129	Endothelin 2	1	41478775-41484673	Predicted secreted proteins	Evidence at protein level	HPA028459	Uncertain		Approved	Cytosol	Endometrial cancer:2.85e-4 (unfavourable), Pancreatic cancer:5.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 10.6;small intestine: 18.1	epididymis: 5.5	Cell line enhanced		CAPAN-2: 12.3;EFO-21: 32.7;SCLC-21H: 19.7;SK-BR-3: 31.2;U-2 OS: 16.7
EDN3	ET3	ENSG00000124205	Endothelin 3	20	59300427-59325992	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA036618		Supported			Glioma:2.38e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 39.3	duodenum: 38.3	Not detected		
EDNRB	ETB, HSCR, HSCR2	ENSG00000136160	Endothelin receptor type B	13	77895481-77919768	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB017842, HPA027546	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.20e-5 (favourable)	Group enriched	Tissue enhanced		placenta: 180.2	cerebral cortex: 88.8	Cell line enhanced		AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EFEMP1	DHRD, FBLN3, FBNL, MTLV, S1-5	ENSG00000115380	EGF containing fibulin like extracellular matrix protein 1	2	55865967-55924139	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016368, HPA049806, HPA070841, HPA071588	Supported		Uncertain	Mitochondria	Renal cancer:3.89e-8 (unfavourable), Urothelial cancer:6.68e-5 (unfavourable), Endometrial cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			placenta: 488.7	Group enriched	5	HHSteC: 719.8;HSkMC: 733.9;HUVEC TERT2: 3552.1;TIME: 3104.2
EFEMP2	FBLN4, UPH1	ENSG00000172638	EGF containing fibulin like extracellular matrix protein 2	11	65866441-65873592	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023270	Approved				Renal cancer:3.94e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 50.3	Cell line enhanced		BJ hTERT+: 106.7;fHDF/TERT166: 149.3;LHCN-M2: 95.3
EFNA1	ECKLG, EPLG1, LERK1, TNFAIP4	ENSG00000169242	Ephrin A1	1	155127460-155134857	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB032498	Uncertain					Expressed in all	Mixed			placenta: 123.9	Cell line enhanced		BEWO: 211.4;SiHa: 136.8;SK-BR-3: 146.1
EFNA2	ELF-1, EPLG6, LERK6	ENSG00000099617	Ephrin A2	19	1286154-1300237	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005178, HPA067567	Uncertain		Approved	Mitochondria<br>Cytosol		Tissue enhanced	Group enriched	6	colon: 7.0;duodenum: 7.9;small intestine: 10.6	rectum: 1.5	Cell line enhanced		Hep G2: 6.6;NTERA-2: 5.4;REH: 6.8;SH-SY5Y: 17.8;U-2 OS: 5.8
EFNA4	EPLG4, LERK4	ENSG00000243364	Ephrin A4	1	155063731-155069553	Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB021350, HPA064952	Approved		Uncertain	Nucleus<br>Vesicles	Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			skin: 24.5	Expressed in all		
EGFL6	MAEG	ENSG00000198759	EGF like domain multiple 6	X	13569605-13633575	Predicted secreted proteins	Evidence at protein level	HPA001838	Enhanced				Ovarian cancer:4.95e-4 (favourable), Head and neck cancer:9.73e-4 (favourable)	Mixed	Tissue enriched	34	placenta: 921.8	lung: 26.8	Group enriched	5	BJ hTERT+: 3.5;NTERA-2: 1.7
EGFL7	ZNEU1	ENSG00000172889	EGF like domain multiple 7	9	136658856-136672678	Predicted secreted proteins	Evidence at protein level	HPA050716	Approved				Colorectal cancer:4.22e-6 (unfavourable), Renal cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 263.7	Cell line enhanced		EFO-21: 172.9;HUVEC TERT2: 276.0;TIME: 254.4
EGFL8	C6orf8, NG3	ENSG00000241404	EGF like domain multiple 8	6	32164583-32168281	Predicted secreted proteins	Evidence at protein level	HPA061173	Uncertain		Approved	Nuclear speckles<br>Vesicles		Mixed	Mixed			skin: 2.7	Mixed		
EGFLAM	AGRINL, AGRNL, FLJ39155, PIKA	ENSG00000164318	EGF like, fibronectin type III and laminin G domains	5	38258409-38465021	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 73.4	adipose tissue: 43.0	Cell line enhanced		hTERT-HME1: 12.6;HUVEC TERT2: 13.4;LHCN-M2: 30.8;U-2 OS: 16.5
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
EHF	ESE3, ESEJ	ENSG00000135373	ETS homologous factor	11	34621093-34661057	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA050923, HPA060734	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Colorectal cancer:5.81e-4 (favourable), Pancreatic cancer:6.94e-4 (unfavourable)	Mixed	Mixed			esophagus: 228.3	Cell line enhanced		CAPAN-2: 122.7;HaCaT: 85.2;HBEC3-KT: 76.2;RT4: 172.3;T-47d: 201.8
EIF2AK1	HRI, KIAA1369	ENSG00000086232	Eukaryotic translation initiation factor 2 alpha kinase 1	7	6022244-6059230	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016496, CAB022082, HPA061675	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.4	Expressed in all		
ELANE	ELA2, HLE, HNE, NE	ENSG00000197561	Elastase, neutrophil expressed	19	851014-856247	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB015409, HPA066836	Enhanced					Group enriched	Tissue enriched	320	bone marrow: 1199.6	skin: 3.7	Cell line enriched	56	THP-1: 1171.3
ELN	SVAS, WBS, WS	ENSG00000049540	Elastin	7	74027789-74069907	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010750, HPA018111, HPA056941	Supported		Approved	Plasma membrane	Thyroid cancer:6.29e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 125.8	Cell line enhanced		BJ: 121.3;fHDF/TERT166: 160.9;U-2197: 748.2
ELP2	FLJ10879, STATIP1, StIP	ENSG00000134759	Elongator acetyltransferase complex subunit 2	18	36129444-36180556	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002996, CAB020835	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Colorectal cancer:5.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 59.6	Expressed in all		
ELSPBP1	E12, EDDM12, HE12	ENSG00000169393	Epididymal sperm binding protein 1	19	47994651-48025153	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044256, HPA050341	Enhanced					Tissue enhanced	Tissue enriched	2038	epididymis: 3638.2	testis: 1.7	Cell line enhanced		BEWO: 1.5;HMC-1: 9.1;NB-4: 3.7
EMC1	KIAA0090	ENSG00000127463	ER membrane protein complex subunit 1	1	19215664-19251552	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048904	Approved		Approved	Microtubules<br>Cytokinetic bridge	Liver cancer:8.56e-6 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.4	Expressed in all		
EMC10	C19orf63, HSM1, HSS1, INM02	ENSG00000161671	ER membrane protein complex subunit 10	19	50476400-50490870	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053905	Uncertain				Renal cancer:6.64e-6 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.8	Cell line enhanced		HEK 293: 176.7
EMC9	C14orf122, CGI-112, FAM158A	ENSG00000100908	ER membrane protein complex subunit 9	14	24138959-24141588	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054715			Approved	Golgi apparatus	Ovarian cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 21.3	Expressed in all		
EMCN	MUC14	ENSG00000164035	Endomucin	4	100395341-100880126	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005928	Approved				Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Mixed			kidney: 83.7	Cell line enriched	6	HUVEC TERT2: 25.7
EMID1	EMI5, EMU1, hEmu1	ENSG00000186998	EMI domain containing 1	22	29205851-29259597	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA000592	Uncertain					Expressed in all	Mixed			spleen: 30.6	Cell line enhanced		HEL: 25.7;NB-4: 63.2
EMILIN1	DKFZp586M121, gp115	ENSG00000138080	Elastin microfibril interfacer 1	2	27078567-27086408	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002822	Supported				Renal cancer:8.13e-9 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 73.7	Cell line enhanced		BJ: 81.8;HHSteC: 82.2;HSkMC: 78.7;SH-SY5Y: 135.3
EMILIN2	FLJ33200, FOAP-10	ENSG00000132205	Elastin microfibril interfacer 2	18	2847030-2915993	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064576	Supported				Renal cancer:1.62e-4 (unfavourable), Liver cancer:6.30e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 269.3	placenta: 31.4	Cell line enhanced		ASC diff: 33.3;BEWO: 36.7;HL-60: 30.1;HMC-1: 53.5;U-2197: 43.7
EMILIN3	C20orf130, dJ620E11.4, EMILIN5	ENSG00000183798	Elastin microfibril interfacer 3	20	41359966-41366827	Predicted secreted proteins	Evidence at protein level	HPA044034, HPA059912	Approved					Tissue enhanced	Tissue enhanced		epididymis: 65.0	seminal vesicle: 14.0	Group enriched	7	AF22: 6.2;HAP1: 11.4;NTERA-2: 7.0;SCLC-21H: 15.2
ENDOU	P11, PP11, PRSS26	ENSG00000111405	Endonuclease, poly(U) specific	12	47709734-47725567	Predicted secreted proteins	Evidence at protein level	HPA012388, HPA067448	Enhanced				Head and neck cancer:6.29e-4 (favourable)	Tissue enhanced	Group enriched	6	esophagus: 70.3;skin: 24.9	tonsil: 7.7	Cell line enhanced		Daudi: 1.6;SK-BR-3: 3.6
ENHO	C9orf165, UNQ470	ENSG00000168913	Energy homeostasis associated	9	34521040-34523041	Predicted secreted proteins	Evidence at transcript level	HPA042575	Approved				Endometrial cancer:3.71e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	cerebral cortex: 140.3	testis: 11.5	Cell line enhanced		AN3-CA: 14.6;NTERA-2: 21.5;SCLC-21H: 12.8;SH-SY5Y: 10.9
ENPP6	MGC33971	ENSG00000164303	Ectonucleotide pyrophosphatase/phosphodiesterase 6	4	184088706-184221230	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042740	Approved		Approved	Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 30.6;ovary: 15.0	cerebral cortex: 8.6	Cell line enhanced		Karpas-707: 2.3;SH-SY5Y: 3.8;U-266/70: 2.2;U-266/84: 1.1
ENPP7	alk-SMase, NPP7	ENSG00000182156	Ectonucleotide pyrophosphatase/phosphodiesterase 7	17	79730919-79742222	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024603	Approved					Tissue enriched	Group enriched	22	duodenum: 45.7;small intestine: 110.2	kidney: 3.5	Cell line enhanced		Karpas-707: 1.4;U-266/70: 2.1
ENTPD5	CD39L4, NTPDase-5, PCPH	ENSG00000187097	Ectonucleoside triphosphate diphosphohydrolase 5	14	73958010-74019399	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002927	Enhanced		Approved	Cytosol	Renal cancer:3.95e-5 (favourable)	Expressed in all	Tissue enhanced		liver: 130.4	rectum: 111.3	Expressed in all		
ENTPD8	NTPDase-8, UNQ2492	ENSG00000188833	Ectonucleoside triphosphate diphosphohydrolase 8	9	137434364-137441816	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021509	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:7.17e-4 (favourable)	Mixed	Tissue enhanced		colon: 21.7;duodenum: 28.7;small intestine: 31.6	rectum: 12.5	Cell line enhanced		CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
EOGT	AER61, C3orf64, FLJ33770	ENSG00000163378	EGF domain specific O-linked N-acetylglucosamine transferase	3	68975214-69013961	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019460	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.97e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 50.3	Mixed		
EPCAM	17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1	ENSG00000119888	Epithelial cell adhesion molecule	2	47345158-47387601	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003809, HPA026761, CAB030012, CAB055098, HPA067463	Enhanced		Supported	Plasma membrane	Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		rectum: 680.5;small intestine: 714.7	colon: 659.9	Cell line enhanced		A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
EPGN	ALGV3072, EPG, epigen, PRO9904	ENSG00000182585	Epithelial mitogen	4	74308473-74315307	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014369			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Urothelial cancer:2.40e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 63.6	seminal vesicle: 5.4	Group enriched	7	hTCEpi: 132.6;U-2197: 76.6
EPHA10	FLJ16103, FLJ33655	ENSG00000183317	EPH receptor A10	1	37713880-37765133	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027497	Uncertain					Mixed	Tissue enhanced		testis: 20.4	colon: 7.9	Cell line enhanced		BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
EPHA3	ETK, ETK1, HEK, HEK4, TYRO4	ENSG00000044524	EPH receptor A3	3	89107524-89482134	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010462	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.28e-7 (unfavourable)	Mixed	Tissue enhanced		prostate: 51.9	gallbladder: 29.8	Cell line enriched	7	AF22: 192.5
EPHA4	Hek8, TYRO1	ENSG00000116106	EPH receptor A4	2	221418027-221574202	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028368	Enhanced				Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 41.6	testis: 22.2	Cell line enhanced		AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
EPHA7	Hek11	ENSG00000135333	EPH receptor A7	6	93240020-93419547	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010496	Approved					Tissue enhanced	Tissue enriched	13	parathyroid gland: 253.5	prostate: 20.2	Cell line enhanced		AF22: 15.6;HEK 293: 41.9;RH-30: 41.8;THP-1: 25.7
EPHA8	EEK, Hek3	ENSG00000070886	EPH receptor A8	1	22563564-22603594	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009660, HPA031433	Uncertain					Mixed	Tissue enhanced		adrenal gland: 4.7;spleen: 2.6;testis: 1.9	cerebral cortex: 1.3	Cell line enriched	14	SCLC-21H: 70.4
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
EPHB4	HTK, Tyro11	ENSG00000196411	EPH receptor B4	7	100802565-100827521	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013537	Uncertain				Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 50.6	Mixed		
EPHX1	EPHX	ENSG00000143819	Epoxide hydrolase 1	1	225810092-225845563	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020593, HPA048847	Enhanced				Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)	Tissue enriched	Expressed in all			adrenal gland: 1085.6	Cell line enhanced		ASC diff: 821.1;SiHa: 629.7
EPO	EP	ENSG00000130427	Erythropoietin	7	100720800-100723700	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB010336	Supported				Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable)	Group enriched	Tissue enhanced		cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7	prostate: 1.1	Group enriched	6	BEWO: 2.0;Hep G2: 5.5
EPPIN	CT71, dJ461P17.2, EPPIN1, EPPIN2, EPPIN3, SPINLW1, WAP7, WFDC7	ENSG00000101448	Epididymal peptidase inhibitor	20	45540626-45547752	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	117	epididymis: 414.2;testis: 128.4	fallopian tube: 2.3	Cell line enhanced		U-87 MG: 2.6
EPPIN-WFDC6	SPINLW1-WFDC6	ENSG00000249139	EPPIN-WFDC6 readthrough	20	45536986-45547426	Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	78	epididymis: 41.7;testis: 58.2	fallopian tube: 0.6	Not detected		
EPS8L1	DRC3, FLJ20258, MGC23164, MGC4642	ENSG00000131037	EPS8 like 1	19	55072020-55087923	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041851, HPA043545	Uncertain		Supported	Cytosol	Colorectal cancer:4.44e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 18.4;stomach: 23.5	esophagus: 9.0	Cell line enhanced		BEWO: 51.9;T-47d: 24.8
EPX	EPO, EPP, EPX-PEN	ENSG00000121053	Eosinophil peroxidase	17	58192737-58205174	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA050507	Approved					Not detected	Tissue enriched	24	bone marrow: 20.5	cerebral cortex: 0.8	Cell line enriched	55	NB-4: 157.0
EPYC	DSPG3, Pg-Lb, SLRR3B	ENSG00000083782	Epiphycan	12	90963679-91005026	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038212, HPA045455	Approved				Pancreatic cancer:1.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	placenta: 8.9	endometrium: 1.5	Not detected		
EQTN	AFAF, C9orf11, equatorin, SPACA8	ENSG00000120160	Equatorin	9	27284659-27297139	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015089, HPA015504	Enhanced					Not detected	Tissue enriched	94	testis: 67.7	ovary: 0.7	Not detected		
ERAP1	A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP	ENSG00000164307	Endoplasmic reticulum aminopeptidase 1	5	96760810-96808100	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025095, HPA042317	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			placenta: 68.0	Expressed in all		
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERFE	C1QTNF15, CTRP15, FAM132B, FLJ37034	ENSG00000178752	Erythroferrone	2	238158982-238168900	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA077259			Approved	Endoplasmic reticulum<br>Microtubule organizing center	Renal cancer:2.46e-4 (unfavourable), Endometrial cancer:3.75e-4 (unfavourable)	Tissue enhanced	Group enriched	8	testis: 17.2;thyroid gland: 40.6	appendix: 3.4	Cell line enhanced		RH-30: 25.5
ERLEC1	C2orf30, CL25084, ERLECTIN, XTP3-B, XTP3TPB	ENSG00000068912	Endoplasmic reticulum lectin 1	2	53787044-53818819	Predicted secreted proteins, Transporters	Evidence at protein level	HPA031501, HPA031502, HPA031503	Enhanced					Expressed in all	Expressed in all			thyroid gland: 121.9	Expressed in all		
ERLIN2	C8orf2, Erlin-2, NET32, SPFH2, SPG18	ENSG00000147475	ER lipid raft associated 2	8	37736599-37759101	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA002025, CAB014894	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:6.67e-6 (favourable), Glioma:1.96e-4 (unfavourable), Colorectal cancer:5.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 80.9	Expressed in all		
ERN1	IRE1, IRE1P	ENSG00000178607	Endoplasmic reticulum to nucleus signaling 1	17	64039142-64130819	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009495, HPA027730	Supported				Renal cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 53.4	Cell line enhanced		Karpas-707: 74.5;U-266/70: 74.0
ERN2	IRE1b	ENSG00000134398	Endoplasmic reticulum to nucleus signaling 2	16	23690326-23713500	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016558	Uncertain					Mixed	Group enriched	7	cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1	appendix: 3.8	Cell line enriched	8	CAPAN-2: 5.9
ERO1A	ERO1-alpha, Ero1alpha, ERO1L	ENSG00000197930	Endoplasmic reticulum oxidoreductase 1 alpha	14	52639916-52695900	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026653, HPA030053, CAB034294	Enhanced				Renal cancer:6.54e-9 (unfavourable), Lung cancer:1.10e-5 (unfavourable), Pancreatic cancer:2.27e-4 (unfavourable), Liver cancer:7.59e-4 (unfavourable), Cervical cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 181.5	Expressed in all		
ERO1B	ERO1-L(beta), Ero1beta, ERO1LB	ENSG00000086619	Endoplasmic reticulum oxidoreductase 1 beta	1	236215555-236281985	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028085	Approved				Lung cancer:7.53e-5 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
ERP27	C12orf46, ERp27, FLJ32115, PDIA8	ENSG00000139055	Endoplasmic reticulum protein 27	12	14914035-14939082	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039636, HPA052851	Enhanced					Expressed in all	Group enriched	10	fallopian tube: 104.4;pancreas: 282.3	kidney: 20.0	Cell line enhanced		CAPAN-2: 16.3;RT4: 74.3
ERP29	C12orf8, ERp28, ERp29, ERp31, PDI-DB, PDIA9	ENSG00000089248	Endoplasmic reticulum protein 29	12	112013316-112023451	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039363, HPA039456	Enhanced		Uncertain	Nucleoplasm<br>Microtubules	Endometrial cancer:7.43e-5 (favourable), Liver cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 150.9	Expressed in all		
ERP44	KIAA0573, PDIA10, TXNDC4	ENSG00000023318	Endoplasmic reticulum protein 44	9	99979179-100099040	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001318	Supported				Head and neck cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.4	Expressed in all		
ERV3-1	envR, ERV-R, ERV3, H-PLK, HERV-R	ENSG00000213462	Endogenous retrovirus group 3 member 1	7	64990809-65006743	Predicted secreted proteins	Evidence at protein level	HPA017209, HPA046508	Enhanced		Approved	Vesicles		Expressed in all	Mixed			adrenal gland: 39.8	Mixed		
ESM1		ENSG00000164283	Endothelial cell specific molecule 1	5	54977864-55022671	Predicted secreted proteins	Evidence at protein level						Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)	Tissue enriched	Tissue enhanced		kidney: 19.2;thyroid gland: 27.2	endometrium: 5.8	Group enriched	5	HUVEC TERT2: 236.2;TIME: 434.9
ETNK2	EKI2, FLJ10761	ENSG00000143845	Ethanolamine kinase 2	1	204131062-204152003	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057167	Enhanced				Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 110.6;liver: 120.7;testis: 143.1	ovary: 43.4	Mixed		
EXTL2		ENSG00000162694	Exostosin like glycosyltransferase 2	1	100872372-100895998	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020716, HPA068921	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:1.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.1	Expressed in all		
F10		ENSG00000126218	Coagulation factor X	13	113122814-113149529	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 67.5	cervix, uterine: 51.6	Cell line enhanced		BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
F11	FXI	ENSG00000088926	Coagulation factor XI	4	186265945-186288806	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039808			Approved	Vesicles	Liver cancer:3.29e-5 (favourable)	Tissue enriched	Tissue enhanced		liver: 180.1	kidney: 44.7	Cell line enriched	8	Hep G2: 6.0
F12		ENSG00000131187	Coagulation factor XII	5	177402140-177409576	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003825	Approved				Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable)	Tissue enriched	Tissue enriched	78	liver: 141.6	bone marrow: 1.8	Cell line enhanced		HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5
F13B	FXIIIB	ENSG00000143278	Coagulation factor XIII B chain	1	197039191-197067267	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003827, HPA052139	Supported				Liver cancer:6.78e-5 (favourable)	Tissue enriched	Tissue enriched	111	liver: 122.1	duodenum: 1.1	Not detected		
F2		ENSG00000180210	Coagulation factor II, thrombin	11	46719180-46739506	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016780, CAB018650, HPA051476, HPA054698	Enhanced				Renal cancer:6.75e-12 (unfavourable)	Tissue enriched	Tissue enriched	1472	liver: 627.3	testis: 0.4	Cell line enriched	18	Hep G2: 186.7
F2R	CF2R, PAR-1, PAR1, TR	ENSG00000181104	Coagulation factor II thrombin receptor	5	76716043-76735781	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB008973, CAB012962	Approved				Renal cancer:2.21e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 94.1	Cell line enhanced		HUVEC TERT2: 297.4;WM-115: 331.7
F2RL3	PAR4	ENSG00000127533	F2R like thrombin/trypsin receptor 3	19	16888860-16892606	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:6.25e-4 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Group enriched	8	HEL: 26.3;HMC-1: 10.0
F5		ENSG00000198734	Coagulation factor V	1	169514166-169586588	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002036	Uncertain		Approved	Golgi apparatus	Stomach cancer:3.39e-4 (unfavourable)	Tissue enriched	Group enriched	11	gallbladder: 28.4;liver: 93.7;placenta: 68.2	fallopian tube: 5.9	Cell line enriched	7	Hep G2: 22.8
F7		ENSG00000057593	Coagulation factor VII	13	113105788-113120681	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004826			Approved	Mitochondria		Tissue enriched	Tissue enriched	44	liver: 65.0	testis: 1.4	Group enriched	7	CACO-2: 11.8;Hep G2: 6.1
F8	DXS1253E, F8C, FVIII, HEMA	ENSG00000185010	Coagulation factor VIII	X	154835788-155026940	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018777	Enhanced					Expressed in all	Expressed in all			lung: 23.4	Mixed		
F9	FIX	ENSG00000101981	Coagulation factor IX	X	139530758-139563458	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:6.69e-4 (favourable)	Tissue enriched	Tissue enriched	2258	liver: 365.0	kidney: 0.1	Not detected		
FAM131A	C3orf40, MGC21688	ENSG00000175182	Family with sequence similarity 131 member A	3	184335926-184348421	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042800	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 100.5	Mixed		
FAM134A	C2orf17, MAG-2, MGC3035	ENSG00000144567	Family with sequence similarity 134 member A	2	219176225-219185479	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011170, HPA011844	Approved		Approved	Cytosol	Liver cancer:1.49e-4 (unfavourable), Colorectal cancer:7.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 143.4	Expressed in all		
FAM171A1	C10orf38, FLJ12884	ENSG00000148468	Family with sequence similarity 171 member A1	10	15211643-15371062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051345	Approved		Approved	Nucleoplasm<br>Plasma membrane	Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 73.2	Cell line enhanced		TIME: 95.9
FAM171B	FLJ34104, KIAA1946	ENSG00000144369	Family with sequence similarity 171 member B	2	186693971-186765965	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010639, HPA013434	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 114.5	parathyroid gland: 19.3	Mixed		
FAM172A	C5orf21, DKFZP564D172	ENSG00000113391	Family with sequence similarity 172 member A	5	93618069-94111699	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012299, HPA045505	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.0	Expressed in all		
FAM177A1	C14orf24	ENSG00000151327	Family with sequence similarity 177 member A1	14	35044907-35113130	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053222, HPA055440	Uncertain		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:8.51e-5 (favourable), Head and neck cancer:9.70e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 103.2	Expressed in all		
FAM180A	HWKM1940, UNQ1940	ENSG00000189320	Family with sequence similarity 180 member A	7	135728348-135748846	Predicted secreted proteins	Evidence at protein level	HPA021224	Uncertain					Mixed	Tissue enhanced		gallbladder: 25.5	heart muscle: 10.4	Cell line enhanced		BJ hTERT+: 45.6;fHDF/TERT166: 44.5;U-138 MG: 55.9;U-2197: 239.9
FAM189A1	KIAA0574, TMEM228	ENSG00000104059	Family with sequence similarity 189 member A1	15	29120254-29570723	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA009410, HPA010637	Uncertain		Supported	Nucleus		Mixed	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 2.0	colon,testis: 0.8	Cell line enhanced		EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
FAM198A	C3orf41, DKFZP434B172	ENSG00000144649	Family with sequence similarity 198 member A	3	42979267-43060211	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047726	Approved		Supported	Vesicles		Mixed	Mixed			fallopian tube: 15.7	Cell line enhanced		AN3-CA: 3.7;RPMI-8226: 3.0;T-47d: 7.5
FAM19A1	TAFA-1, TAFA1	ENSG00000183662	Family with sequence similarity 19 member A1, C-C motif chemokine like	3	68004216-68545625	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013407	Approved					Tissue enhanced	Tissue enriched	6	cerebral cortex: 30.8	seminal vesicle: 5.3	Cell line enriched	9	REH: 1.5
FAM19A3	TAFA-3, TAFA3	ENSG00000184599	Family with sequence similarity 19 member A3, C-C motif chemokine like	1	112720419-112727235	Predicted secreted proteins	Evidence at transcript level	HPA055927	Approved				Glioma:8.24e-4 (unfavourable)	Mixed	Group enriched	15	adrenal gland: 19.9;testis: 8.7	epididymis: 0.9	Cell line enhanced		BJ hTERT+: 3.7;HEL: 1.6;U-87 MG: 1.7
FAM19A4	TAFA-4	ENSG00000163377	Family with sequence similarity 19 member A4, C-C motif chemokine like	3	68731766-68953297	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	10	adrenal gland: 18.5	gallbladder: 1.9	Cell line enhanced		HAP1: 1.8;NTERA-2: 8.8;SCLC-21H: 1.1
FAM19A5	TAFA-5	ENSG00000219438	Family with sequence similarity 19 member A5, C-C motif chemokine like	22	48489460-48850912	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	CAB025629	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 49.9	cervix, uterine: 12.9	Cell line enhanced		fHDF/TERT166: 15.8;HEK 293: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8
FAM26D	C6orf78, FLJ32239	ENSG00000164451	Family with sequence similarity 26 member D	6	116529013-116558868	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	46	placenta: 33.8	testis: 0.7	Not detected		
FAM78A	C9orf59, FLJ00024	ENSG00000126882	Family with sequence similarity 78 member A	9	131258076-131276547	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021472, HPA023914	Uncertain		Uncertain	Nucleus<br>Vesicles	Head and neck cancer:2.00e-4 (favourable), Cervical cancer:3.67e-4 (favourable)	Expressed in all	Mixed			lymph node: 27.4	Cell line enhanced		BEWO: 37.7;HEL: 34.3;HL-60: 30.4;NB-4: 37.9;THP-1: 35.7;U-937: 27.8
FAM96A	CIA2A, FLJ22875	ENSG00000166797	Family with sequence similarity 96 member A	15	64072559-64094018	Predicted secreted proteins	Evidence at protein level	HPA040459, HPA063729	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 106.1	Expressed in all		
FAS	APO-1, APT1, CD95, FAS1, TNFRSF6	ENSG00000026103	Fas cell surface death receptor	10	88990582-89015785	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027444	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			rectum: 32.9	Cell line enhanced		Karpas-707: 104.1
FAT1	CDHF7, CDHR8, FAT	ENSG00000083857	FAT atypical cadherin 1	4	186587783-186726722	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001869, HPA023882	Approved				Lung cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 37.6	Cell line enhanced		fHDF/TERT166: 221.3
FBLN1	FBLN	ENSG00000077942	Fibulin 1	22	45502238-45601135	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001612, HPA001613, CAB004393, CAB068187	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:3.02e-10 (unfavourable), Endometrial cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 1324.4	Cell line enhanced		ASC diff: 1263.9;BJ: 870.2;BJ hTERT+: 1319.9;HSkMC: 979.4;RT4: 1182.4
FBLN2		ENSG00000163520	Fibulin 2	3	13549131-13638422	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001934, CAB018622	Enhanced		Supported	Plasma membrane	Liver cancer:3.17e-4 (favourable), Endometrial cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 142.2	Cell line enhanced		ASC diff: 262.8;fHDF/TERT166: 204.8;HMC-1: 273.5;HSkMC: 161.5
FBLN5	ARMD3, DANCE, EVEC, UP50	ENSG00000140092	Fibulin 5	14	91869412-91947987	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000848, HPA000868, CAB025843	Supported		Supported	Plasma membrane	Liver cancer:6.75e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 221.0	Group enriched	6	ASC diff: 345.3;ASC TERT1: 182.9;BJ: 207.7;BJ hTERT+: 185.8;fHDF/TERT166: 343.2;HHSteC: 70.5;HSkMC: 175.5
FBLN7	FLJ37440, TM14	ENSG00000144152	Fibulin 7	2	112138385-112188216	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034992			Approved	Plasma membrane<br>Cell Junctions		Mixed	Mixed			parathyroid gland: 18.7	Cell line enhanced		AF22: 24.3;BJ hTERT+: 14.4;SCLC-21H: 18.6;SH-SY5Y: 13.4;U-2197: 23.6
FBN1	FBN, MASS, MFS1, OCTD, SGS, WMS	ENSG00000166147	Fibrillin 1	15	48408306-48645849	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002670, HPA017759, HPA021057, CAB058696, CAB068188	Enhanced		Approved	Cytosol	Renal cancer:7.44e-5 (unfavourable), Urothelial cancer:5.11e-4 (unfavourable), Stomach cancer:6.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 107.5	adipose tissue: 70.8	Cell line enhanced		ASC TERT1: 315.9;fHDF/TERT166: 318.3;U-138 MG: 199.6;U-2197: 276.9
FBN2	CCA, DA9	ENSG00000138829	Fibrillin 2	5	128257909-128659185	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012853, CAB026401	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:7.41e-5 (unfavourable)	Mixed	Tissue enriched	9	placenta: 118.4	testis: 13.8	Cell line enhanced		HHSteC: 116.8;hTERT-HME1: 171.2;HUVEC TERT2: 107.0
FBN3		ENSG00000142449	Fibrillin 3	19	8065402-8149846	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049482	Uncertain				Endometrial cancer:5.15e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 2.1;thyroid gland: 1.8	cerebral cortex,salivary gland: 1.1	Cell line enhanced		CACO-2: 3.1;NTERA-2: 12.3;REH: 16.9
FBXW7	AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10	ENSG00000109670	F-box and WD repeat domain containing 7	4	152321259-152536101	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB013793, CAB029987	Supported		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 87.4	Expressed in all		
FCAR	CD89	ENSG00000186431	Fc fragment of IgA receptor	19	54874248-54890472	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014050	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	15	bone marrow: 12.3	appendix: 0.8	Not detected		
FCGBP	FC(GAMMA)BP	ENSG00000275395	Fc fragment of IgG binding protein	19	39863323-39934626	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003517, HPA003564	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytokinetic bridge	Ovarian cancer:9.70e-6 (unfavourable), Head and neck cancer:1.28e-5 (favourable), Liver cancer:4.74e-5 (unfavourable), Thyroid cancer:4.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		colon: 166.7	cervix, uterine: 83.5	Cell line enhanced		A549: 2.7;RH-30: 6.8
FCGR1B	CD64b	ENSG00000198019	Fc fragment of IgG receptor Ib	1	121087345-121096310	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		appendix: 27.5;epididymis: 61.7	placenta: 17.0	Cell line enhanced		HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
FCGR3A	CD16, CD16a, FCG3, FCGR3	ENSG00000203747	Fc fragment of IgG receptor IIIa	1	161541759-161550737	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032435, HPA055431	Supported				Renal cancer:3.22e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 419.4	Not detected		
FCGRT	alpha-chain, FCRN	ENSG00000104870	Fc fragment of IgG receptor and transporter	19	49506816-49526333	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012122, HPA015130	Approved					Expressed in all	Expressed in all			small intestine: 312.0	Mixed		
FCMR	FAIM3, TOSO	ENSG00000162894	Fc fragment of IgM receptor	1	206904386-206923247	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003910	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Breast cancer:4.23e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 175.8;spleen: 148.0;tonsil: 146.7	appendix: 88.1	Group enriched	5	RPMI-8226: 97.7;U-266/70: 51.8
FCN1	FCNM	ENSG00000085265	Ficolin 1	9	134905890-134917963	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000685, HPA001295, CAB016760	Enhanced				Renal cancer:3.98e-4 (unfavourable)	Mixed	Group enriched	5	appendix: 323.4;bone marrow: 634.5	spleen: 94.6	Group enriched	7	NB-4: 12.4;U-937: 22.6
FCN2	EBP-37, FCNL, ficolin-2, P35	ENSG00000160339	Ficolin 2	9	134880812-134887520	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	5	liver: 55.0	breast: 10.4	Not detected		
FCN3	FCNH, HAKA1	ENSG00000142748	Ficolin 3	1	27369112-27374824	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025945	Approved					Mixed	Group enriched	6	liver: 144.1;lung: 266.5	placenta: 33.0	Not detected		
FCRL1	CD307a, FCRH1, IFGP1, IRTA5	ENSG00000163534	Fc receptor like 1	1	157794403-157820105	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013323	Enhanced					Mixed	Tissue enhanced		lymph node: 30.3;spleen: 23.5;tonsil: 20.0	appendix: 12.5	Group enriched	31	Daudi: 3.7;U-698: 11.9
FCRL3	CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e	ENSG00000160856	Fc receptor like 3	1	157674321-157700857	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048022	Enhanced					Mixed	Group enriched	13	appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3	urinary bladder: 2.8	Cell line enriched	7	Daudi: 6.9
FCRL5	BXMAS1, CD307e, FCRH5, IRTA2	ENSG00000143297	Fc receptor like 5	1	157513377-157552520	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 20.5;tonsil: 32.8	appendix: 17.9	Cell line enhanced		U-266/70: 2.5;U-698: 5.1
FCRLA	FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595	ENSG00000132185	Fc receptor like A	1	161706972-161714352	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016545	Enhanced					Tissue enriched	Group enriched	10	appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7	urinary bladder: 6.2	Cell line enhanced		Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
FCRLB	FCRL2, FCRLM2, FCRLY, FLJ31052, FREB-2	ENSG00000162746	Fc receptor like B	1	161721563-161728143	Predicted secreted proteins	Evidence at protein level	CAB026139	Uncertain		Supported	Cytosol		Tissue enhanced	Tissue enhanced		tonsil: 1.6	seminal vesicle: 1.2	Cell line enhanced		fHDF/TERT166: 6.8;HMC-1: 6.5
FDCSP	C4orf7, FDC-SP	ENSG00000181617	Follicular dendritic cell secreted protein	4	70226071-70235252	Predicted secreted proteins	Evidence at protein level	HPA014326, CAB014890	Enhanced				Lung cancer:1.32e-4 (favourable), Head and neck cancer:2.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		lymph node: 1014.2;salivary gland: 1371.2;tonsil: 2458.1	appendix: 359.2	Cell line enhanced		HL-60: 1.0;K-562: 1.0;RH-30: 1.7;U-87 MG: 4.6
FETUB		ENSG00000090512	Fetuin B	3	186635969-186653141	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035132	Supported					Tissue enriched	Tissue enriched	16	liver: 123.3	esophagus: 7.6	Not detected		
FGA		ENSG00000171560	Fibrinogen alpha chain	4	154583126-154590766	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016776, HPA051370, HPA064755	Supported				Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable)	Tissue enriched	Tissue enriched	237	liver: 9265.4	stomach: 39.0	Cell line enriched	11	Hep G2: 285.6
FGB		ENSG00000171564	Fibrinogen beta chain	4	154562956-154571086	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001900, HPA001901, CAB008624	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:5.72e-5 (unfavourable)	Tissue enriched	Tissue enriched	556	liver: 10006.0	kidney: 17.9	Cell line enriched	9	Hep G2: 184.1
FGF10		ENSG00000070193	Fibroblast growth factor 10	5	44303544-44389706	Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010315	Uncertain					Tissue enriched	Tissue enhanced		ovary: 41.4	adipose tissue: 16.9	Cell line enriched	9	AF22: 51.3
FGF17	FGF-13	ENSG00000158815	Fibroblast growth factor 17	8	22042398-22048809	Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA052600	Approved					Tissue enhanced	Mixed			cerebral cortex: 1.8	Not detected		
FGF18	FGF-18, ZFGF5	ENSG00000156427	Fibroblast growth factor 18	5	171419656-171457623	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA018795	Uncertain					Group enriched	Tissue enhanced		heart muscle: 6.6	adipose tissue: 1.9	Cell line enriched	61	EFO-21: 178.4
FGF19		ENSG00000162344	Fibroblast growth factor 19	11	69698232-69704642	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA036082	Approved					Mixed	Tissue enriched	28	gallbladder: 262.2	small intestine: 9.4	Cell line enriched	14	CAPAN-2: 87.6
FGF21		ENSG00000105550	Fibroblast growth factor 21	19	48755559-48758330	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA061286	Supported					Tissue enriched	Tissue enriched	38	liver: 6.6	thyroid gland: 0.1	Group enriched	8	HHSteC: 1.2;U-2 OS: 5.2
FGF22		ENSG00000070388	Fibroblast growth factor 22	19	639879-644371	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enhanced		skin: 8.5	cerebral cortex: 2.0	Cell line enhanced		AN3-CA: 1.8
FGF23		ENSG00000118972	Fibroblast growth factor 23	12	4368227-4379728	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Mixed			epididymis: 1.5	Cell line enhanced		AF22: 1.9
FGF3	HBGF-3, INT2	ENSG00000186895	Fibroblast growth factor 3	11	69810224-69819024	Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA012692	Approved	Approved				Group enriched	Not detected			all non-specific tissues: 0.0	Cell line enriched	89	CAPAN-2: 8.8
FGF4	HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF	ENSG00000075388	Fibroblast growth factor 4	11	69771016-69775403	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011209	Uncertain					Tissue enriched	Not detected			testis: 0.4	Cell line enriched	90	NTERA-2: 15.7
FGF5		ENSG00000138675	Fibroblast growth factor 5	4	80266599-80336680	Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010313, HPA042442			Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Not detected	Tissue enhanced		gallbladder: 5.6	smooth muscle: 1.4	Cell line enhanced		BJ hTERT+: 97.8;fHDF/TERT166: 68.3;HBF TERT88: 85.6;LHCN-M2: 67.6;U-138 MG: 108.3
FGF7	KGF	ENSG00000140285	Fibroblast growth factor 7	15	49423096-49488775	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA043605	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		gallbladder: 55.0	endometrium: 31.1	Cell line enhanced		ASC diff: 31.5;ASC TERT1: 29.3;HSkMC: 31.1;RH-30: 33.7;U-138 MG: 23.1
FGF8	AIGF	ENSG00000107831	Fibroblast growth factor 8	10	101770130-101780369	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Group enriched	Tissue enriched	7	skeletal muscle: 15.7	testis: 2.2	Cell line enriched	29	RH-30: 40.4
FGFBP1	FGFBP, HBP17	ENSG00000137440	Fibroblast growth factor binding protein 1	4	15935569-15938740	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA004332	Enhanced				Pancreatic cancer:5.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 297.8	skin: 40.2	Cell line enhanced		CAPAN-2: 164.8;HaCaT: 489.2;HBEC3-KT: 688.5
FGFBP2	KSP37	ENSG00000137441	Fibroblast growth factor binding protein 2	4	15960243-15969309	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA039180	Uncertain					Group enriched	Tissue enhanced		bone marrow: 29.0	spleen: 18.0	Cell line enhanced		SK-MEL-30: 4.8;T-47d: 2.8;WM-115: 1.2
FGFBP3	C10orf13, MGC39320	ENSG00000174721	Fibroblast growth factor binding protein 3	10	91906589-91909483	Predicted secreted proteins	Evidence at protein level	HPA053943	Uncertain					Mixed	Tissue enriched	8	cerebral cortex: 19.5	thyroid gland: 2.5	Cell line enriched	11	AF22: 312.7
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FGFRL1		ENSG00000127418	Fibroblast growth factor receptor-like 1	4	1009936-1026897	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB026019, HPA068828	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 67.6	Mixed		
FGG		ENSG00000171557	Fibrinogen gamma chain	4	154604134-154612967	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027529, CAB033120	Supported				Renal cancer:1.00e-6 (unfavourable)	Tissue enriched	Tissue enriched	115	liver: 8699.0	lung: 75.7	Cell line enriched	42	Hep G2: 503.3
FGL1	HFREP-1	ENSG00000104760	Fibrinogen like 1	8	17864380-17910365	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Stomach cancer:5.38e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	liver: 1005.3	pancreas: 137.8	Group enriched	12	A549: 49.7;Hep G2: 89.4
FGL2	pT49, T49	ENSG00000127951	Fibrinogen like 2	7	77193371-77199848	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA021011, HPA026682	Enhanced					Expressed in all	Expressed in all			spleen: 232.5	Cell line enhanced		RPTEC TERT1: 4.2;U-937: 4.7;WM-115: 6.3
FHL1	bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA	ENSG00000022267	Four and a half LIM domains 1	X	136146702-136211359	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001040, HPA001391, CAB020817	Enhanced		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 3804.7	Cell line enhanced		BJ hTERT+: 219.3
FHOD3	FHOS2, FLJ22297, FLJ22717, KIAA1695	ENSG00000134775	Formin homology 2 domain containing 3	18	36297714-36780055	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021827, HPA024696	Uncertain				Renal cancer:1.19e-5 (favourable)	Mixed	Tissue enhanced		heart muscle: 96.5;seminal vesicle: 88.0	epididymis: 51.4	Cell line enhanced		BJ hTERT+: 58.7;HDLM-2: 74.2
FIBIN	MGC24932	ENSG00000176971	Fin bud initiation factor homolog (zebrafish)	11	26994184-26996121	Predicted secreted proteins	Evidence at protein level	HPA040120	Uncertain				Thyroid cancer:1.85e-6 (unfavourable), Renal cancer:1.93e-5 (favourable), Stomach cancer:6.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 124.4	lung: 37.5	Group enriched	9	ASC diff: 67.5;ASC TERT1: 43.5;fHDF/TERT166: 24.9;HHSteC: 106.9;HSkMC: 96.0;hTCEpi: 25.5
FJX1	FLJ22416, FLJ25593	ENSG00000179431	Four jointed box 1	11	35618419-35620868	Predicted secreted proteins	Evidence at protein level	HPA059220	Uncertain		Approved	Vesicles	Renal cancer:9.24e-9 (unfavourable), Urothelial cancer:6.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.4	endometrium: 8.8	Mixed		
FKBP10	FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65	ENSG00000141756	FK506 binding protein 10	17	41812680-41823217	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051171, HPA057021	Enhanced		Approved	Vesicles	Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)	Expressed in all	Mixed			placenta: 84.7	Mixed		
FKBP11	FKBP19	ENSG00000134285	FK506 binding protein 11	12	48921518-48926474	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041709	Enhanced		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)	Expressed in all	Mixed			pancreas: 60.7	Mixed		
FKBP14	FKBP22, FLJ20731	ENSG00000106080	FK506 binding protein 14	7	30010587-30026684	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA013329, HPA026829	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 20.3	Mixed		
FKBP2	FKBP-13, PPIase	ENSG00000173486	FK506 binding protein 2	11	64241003-64244132	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB025561, HPA049405	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			epididymis: 399.2	Expressed in all		
FKBP7	FKBP23	ENSG00000079150	FK506 binding protein 7	2	178463664-178478600	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA008707	Approved	Supported	Supported	Endoplasmic reticulum	Renal cancer:4.61e-6 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 60.2	endometrium: 44.1	Cell line enhanced		ASC diff: 104.3;ASC TERT1: 65.6
FKBP9	FKBP60, FKBP63	ENSG00000122642	FK506 binding protein 9	7	32957404-33006931	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012595, HPA055256	Approved		Supported	Golgi apparatus<br>Vesicles<br>Mitochondria	Urothelial cancer:7.02e-6 (unfavourable), Head and neck cancer:2.02e-4 (unfavourable), Cervical cancer:4.22e-4 (unfavourable), Glioma:8.06e-4 (unfavourable), Liver cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 110.4	Mixed		
FLJ22763		ENSG00000241224	Uncharacterized LOC401081	3	109118252-109150514	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		duodenum: 97.6;small intestine: 94.5	kidney: 19.5	Cell line enhanced		CACO-2: 1.0
FLT1	FLT, VEGFR1	ENSG00000102755	Fms related tyrosine kinase 1	13	28300344-28495145	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011740, HPA014290, CAB068189, CAB068190	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 622.5	thyroid gland: 81.9	Cell line enhanced		BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK 293: 14.1;T-47d: 13.7;TIME: 12.7
FMOD	SLRR2E	ENSG00000122176	Fibromodulin	1	203340628-203351489	Predicted secreted proteins	Evidence at protein level						Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 171.7	Cell line enhanced		CACO-2: 28.0;HHSteC: 8.7;HSkMC: 14.1
FN1	CIG, FINC, GFND2, LETS, MSF	ENSG00000115414	Fibronectin 1	2	215360440-215436172	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000126, HPA027066	Enhanced				Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 4284.3	lung: 1167.5	Cell line enhanced		ASC TERT1: 24376.9;HSkMC: 11926.5;hTERT-HME1: 7509.7
FNDC1	bA243O10.1, dJ322A24.1, FNDC2, KIAA1866	ENSG00000164694	Fibronectin type III domain containing 1	6	159169397-159272109	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030962, HPA030963	Approved		Supported	Nuclear speckles	Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable)	Tissue enhanced	Tissue enhanced		gallbladder: 22.9;thyroid gland: 34.1	smooth muscle: 16.5	Cell line enhanced		fHDF/TERT166: 2.3
FNDC7	FLJ35838	ENSG00000143107	Fibronectin type III domain containing 7	1	108712657-108742740	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028079, HPA054297	Enhanced		Approved	Nucleoplasm<br>Actin filaments		Not detected	Tissue enriched	12	testis: 2.0	bone marrow,cerebral cortex: 0.1	Not detected		
FOLR2		ENSG00000165457	Folate receptor beta	11	72216601-72221950	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:8.41e-4 (favourable), Colorectal cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 235.4	Group enriched	6	Daudi: 2.6;U-698: 12.5
FOLR3	FR-G	ENSG00000110203	Folate receptor 3	11	72114869-72139892	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		bone marrow: 56.7	appendix: 12.4	Group enriched	5	hTERT-HME1: 55.6;U-2197: 60.1
FOXRED2	ERFAD, FLJ23322	ENSG00000100350	FAD dependent oxidoreductase domain containing 2	22	36487190-36507101	Predicted secreted proteins	Evidence at protein level	HPA031611, HPA031612	Approved				Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		SiHa: 155.2
FPGS		ENSG00000136877	Folylpolyglutamate synthase	9	127794597-127814327	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050488	Approved				Endometrial cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube,ovary: 26.1	Expressed in all		
FRAS1	FLJ14927, FLJ22031, KIAA1500	ENSG00000138759	Fraser extracellular matrix complex subunit 1	4	78057570-78544269	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011281, HPA051601	Approved		Approved	Nucleoli fibrillar center	Renal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 20.2	kidney,placenta: 8.2	Cell line enhanced		fHDF/TERT166: 28.1;RH-30: 19.7;SiHa: 23.0
FREM1	C9orf143, C9orf145, C9orf154, DKFZp686M16108, FLJ25461, TILRR	ENSG00000164946	FRAS1 related extracellular matrix 1	9	14734666-14910995	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 34.0;epididymis: 44.5	smooth muscle: 23.2	Cell line enriched	8	HEL: 162.3
FREM3		ENSG00000183090	FRAS1 related extracellular matrix 3	4	143577302-143700675	Predicted secreted proteins	Evidence at protein level	HPA041641	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.6	lung: 0.6	Not detected		
FRMPD2	MGC35285, PDZD5C, PDZK5C	ENSG00000170324	FERM and PDZ domain containing 2	10	48153088-48274870	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.6;fallopian tube: 4.6	thyroid gland: 0.8	Cell line enhanced		BEWO: 2.3;SCLC-21H: 1.2
FRZB	FRE, FRITZ, FRP-3, FRZB-1, FRZB-PEN, FRZB1, FZRB, hFIZ, SFRP3, SRFP3	ENSG00000162998	Frizzled-related protein	2	182833275-182867162	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:8.97e-6 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 101.2	gallbladder: 50.3	Cell line enhanced		AF22: 16.2;ASC diff: 5.3;NTERA-2: 6.7;SH-SY5Y: 6.0
FSHB		ENSG00000131808	Follicle stimulating hormone beta subunit	11	30231016-30235261	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB023410, HPA069703	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FSHR	FSHRO, LGR1, ODG1	ENSG00000170820	Follicle stimulating hormone receptor	2	48962157-49154537	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Group enriched	9	ovary: 2.5;testis: 4.3	gallbladder: 0.3	Not detected		
FST	FS	ENSG00000134363	Follistatin	5	53480409-53487134	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026025	Approved				Renal cancer:4.44e-5 (unfavourable)	Expressed in all	Mixed			liver: 33.0	Cell line enhanced		BJ hTERT+: 272.8;HaCaT: 253.0;PC-3: 509.0
FSTL1	FRP, FSL1, OCC-1, OCC1, tsc36	ENSG00000163430	Follistatin like 1	3	120392293-120451253	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035251, HPA040815	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 656.3	Cell line enhanced		BJ: 1888.8;fHDF/TERT166: 2153.3;HBF TERT88: 1729.6
FSTL3	FLRG, FSRP	ENSG00000070404	Follistatin like 3	19	676365-683399	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024899, HPA045378	Approved		Approved	Nucleoplasm	Lung cancer:4.61e-7 (unfavourable), Ovarian cancer:1.65e-4 (unfavourable), Colorectal cancer:3.01e-4 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 260.8	Expressed in all		
FSTL4	KIAA1061	ENSG00000053108	Follistatin like 4	5	133196455-133612564	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045920	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 9.5	urinary bladder: 7.3	Cell line enhanced		SCLC-21H: 66.8
FSTL5	DKFZp566D234, KIAA1263	ENSG00000168843	Follistatin like 5	4	161383897-162164035	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	11	adrenal gland: 7.8;cerebral cortex: 16.2	testis: 1.1	Cell line enhanced		HL-60: 9.8;HUVEC TERT2: 9.0;Karpas-707: 53.8;SH-SY5Y: 11.3;U-2197: 15.1
FUCA1		ENSG00000179163	Fucosidase, alpha-L- 1, tissue	1	23845077-23868294	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046542, HPA056371	Enhanced				Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 185.6	Cell line enhanced		CAPAN-2: 144.5
FUCA2	dJ20N2.5, MGC1314	ENSG00000001036	Fucosidase, alpha-L- 2, plasma	6	143494811-143511690	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031659, HPA031660, HPA031661	Uncertain				Liver cancer:2.70e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 154.2	Mixed		
FURIN	FUR, PACE, PCSK3, SPC1	ENSG00000140564	Furin, paired basic amino acid cleaving enzyme	15	90868592-90883458	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009499	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 92.8	Expressed in all		
FUT11	MGC33202	ENSG00000196968	Fucosyltransferase 11	10	73772291-73780251	Predicted secreted proteins	Evidence at protein level	HPA014033	Approved		Approved	Nuclear membrane<br>Golgi apparatus	Cervical cancer:2.39e-6 (unfavourable), Renal cancer:3.67e-4 (unfavourable), Breast cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			placenta: 25.0	Mixed		
FXR1		ENSG00000114416	FMR1 autosomal homolog 1	3	180868141-180982753	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018246, HPA055475	Approved		Enhanced	Cytosol	Renal cancer:2.19e-5 (unfavourable), Liver cancer:2.70e-4 (unfavourable), Endometrial cancer:5.96e-4 (unfavourable), Pancreatic cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 276.6	Expressed in all		
FXYD3	MAT-8, PLML	ENSG00000089356	FXYD domain containing ion transport regulator 3	19	35115879-35124324	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010856	Enhanced				Renal cancer:1.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 1455.6;rectum: 1952.1	stomach: 557.3	Cell line enhanced		HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3
GAA		ENSG00000171298	Glucosidase alpha, acid	17	80101556-80119879	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026970, HPA029126	Enhanced				Colorectal cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 69.7	Mixed		
GABBR1	GPRC3A, hGB1a	ENSG00000204681	Gamma-aminobutyric acid type B receptor subunit 1	6	29555629-29633976	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050483, HPA058459	Uncertain		Approved	Centrosome	Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.8	spleen: 13.1	Cell line enhanced		U-2 OS: 6.7
GABRA1	EJM5	ENSG00000022355	Gamma-aminobutyric acid type A receptor alpha1 subunit	5	161847063-161899981	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022502, HPA055746	Enhanced					Tissue enriched	Tissue enriched	46	cerebral cortex: 85.0	adrenal gland: 1.8	Not detected		
GABRA2		ENSG00000151834	Gamma-aminobutyric acid type A receptor alpha2 subunit	4	46248427-46475230	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB079061		Supported				Tissue enhanced	Tissue enriched	7	cerebral cortex: 74.3	epididymis: 11.3	Cell line enhanced		U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
GABRA5		ENSG00000186297	Gamma-aminobutyric acid type A receptor alpha5 subunit	15	26866363-26949207	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077031, CAB079022		Supported	Supported	Plasma membrane		Mixed	Tissue enriched	43	cerebral cortex: 81.6	esophagus: 1.8	Group enriched	10	A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GABRD		ENSG00000187730	Gamma-aminobutyric acid type A receptor delta subunit	1	2019298-2030758	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044371	Enhanced		Uncertain	Golgi apparatus<br>Vesicles	Renal cancer:4.12e-8 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 34.0	testis: 2.7	Cell line enhanced		EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GABRG3		ENSG00000182256	Gamma-aminobutyric acid type A receptor gamma3 subunit	15	26971282-27541991	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054010	Supported					Tissue enhanced	Tissue enhanced		prostate: 10.6;testis: 16.5	cerebral cortex: 4.2	Cell line enhanced		K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
GABRP		ENSG00000094755	Gamma-aminobutyric acid type A receptor pi subunit	5	170763350-170814047	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB014883	Uncertain				Cervical cancer:3.37e-4 (favourable)	Mixed	Expressed in all			breast: 177.0	Cell line enhanced		A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
GAL	GAL-GMAP, GALN, GLNN, GMAP	ENSG00000069482	Galanin and GMAP prepropeptide	11	68683779-68691175	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049864	Enhanced	Supported	Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 18.1;smooth muscle: 12.1	colon: 5.2	Cell line enhanced		CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1
GALC		ENSG00000054983	Galactosylceramidase	14	87837820-87993665	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB022196	Approved					Expressed in all	Expressed in all			testis: 44.0	Cell line enhanced		CAPAN-2: 72.3;HMC-1: 67.2
GALNS	GALNAC6S, GAS	ENSG00000141012	Galactosamine (N-acetyl)-6-sulfatase	16	88813734-88856970	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026404, HPA042433	Enhanced		Approved	Cytosol	Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.7	Expressed in all		
GALNT15	GALNT7, GALNTL2, pp-GalNAc-T15	ENSG00000131386	Polypeptide N-acetylgalactosaminyltransferase 15	3	16174649-16231992	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017076	Uncertain		Approved	Golgi apparatus<br>Cytosol		Tissue enriched	Tissue enhanced		adipose tissue: 36.3;cerebral cortex: 41.2;placenta: 43.0	breast: 18.3	Group enriched	11	ASC diff: 91.0;ASC TERT1: 90.9;HSkMC: 72.4;U-2197: 22.3
GALNT2	GalNAc-T2	ENSG00000143641	Polypeptide N-acetylgalactosaminyltransferase 2	1	230057990-230282124	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011222	Supported		Enhanced	Golgi apparatus	Renal cancer:2.79e-13 (unfavourable), Lung cancer:8.48e-8 (unfavourable), Cervical cancer:1.22e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 48.5	Expressed in all		
GALP		ENSG00000197487	Galanin like peptide	19	56176020-56185775	Predicted secreted proteins	Evidence at transcript level	HPA053938	Uncertain					Tissue enhanced	Not detected			liver: 0.3	Not detected		
GANAB	G2AN, GIIA, GluII, KIAA0088	ENSG00000089597	Glucosidase II alpha subunit	11	62624826-62646726	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026874, HPA061426	Enhanced		Approved	Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 295.2	Expressed in all		
GAPVD1	DKFZP434C212, KIAA1521	ENSG00000165219	GTPase activating protein and VPS9 domains 1	9	125261794-125367207	Predicted intracellular proteins	Evidence at protein level	HPA029386, HPA029387	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
GARS	CMT2D, DSMAV, GlyRS, SMAD1	ENSG00000106105	Glycyl-tRNA synthetase	7	30594681-30634033	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA017896, HPA019097	Enhanced		Supported	Cytosol	Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.0	Expressed in all		
GAS1		ENSG00000180447	Growth arrest specific 1	9	86944363-86947189	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB024164, HPA036085, HPA066902	Approved		Approved	Nuclear speckles	Thyroid cancer:1.13e-5 (unfavourable), Renal cancer:1.96e-5 (unfavourable), Colorectal cancer:1.55e-4 (unfavourable), Stomach cancer:8.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 110.8	smooth muscle: 74.4	Cell line enhanced		AN3-CA: 44.7;BJ hTERT+: 53.4;RH-30: 95.7
GAS6	AXLLG, AXSF, DKFZp666G247, FLJ34709	ENSG00000183087	Growth arrest specific 6	13	113820549-113864067	Predicted secreted proteins	Evidence at protein level	HPA008275, HPA056080	Approved		Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:8.93e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 193.7	Cell line enhanced		BJ: 295.0;BJ hTERT+: 407.1;RPMI-8226: 339.8
GAST	GAS	ENSG00000184502	Gastrin	17	41712326-41715969	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB000038	Supported					Group enriched	Tissue enriched	200	stomach: 11203.5	duodenum: 55.9	Group enriched	6	BEWO: 2.6;HaCaT: 4.7;hTCEpi: 2.3
GC	DBP, hDBP, VDBP	ENSG00000145321	GC, vitamin D binding protein	4	71741693-71804041	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001526, CAB008596, HPA019855	Supported				Renal cancer:5.81e-5 (unfavourable), Liver cancer:8.08e-4 (favourable)	Tissue enriched	Tissue enriched	5	liver: 3875.6	gallbladder: 712.5	Cell line enhanced		HL-60: 1.4;RH-30: 2.5;SiHa: 1.3
GCG	GLP1, GLP2, GRPP	ENSG00000115263	Glucagon	2	162142873-162152404	Predicted secreted proteins	Evidence at protein level	CAB000040, HPA036760, HPA036761	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles		Tissue enriched	Tissue enhanced		pancreas: 346.3;rectum: 137.2;small intestine: 123.9	colon: 69.4	Group enriched	7	EFO-21: 100.6;U-2 OS: 158.1
GCGR	GGR	ENSG00000215644	Glucagon receptor	17	81804132-81814013	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071228			Approved	Golgi apparatus		Tissue enhanced	Group enriched	7	adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0	skin: 1.6	Cell line enhanced		HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
GCSH		ENSG00000140905	Glycine cleavage system protein H	16	81081938-81096425	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041368	Approved		Approved	Vesicles	Renal cancer:6.26e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 157.3	Expressed in all		
GDF1		ENSG00000130283	Growth differentiation factor 1	19	18868545-18896096	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	7	cerebral cortex: 12.2	testis: 1.7	Cell line enhanced		EFO-21: 2.8;HEK 293: 3.3;NB-4: 3.1;NTERA-2: 2.4;SCLC-21H: 2.4
GDF10	BMP-3b	ENSG00000266524	Growth differentiation factor 10	10	47300386-47313547	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015498	Uncertain					Mixed	Tissue enhanced		lung: 19.6	testis: 9.0	Cell line enhanced		AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4
GDF11	BMP-11	ENSG00000135414	Growth differentiation factor 11	12	55743280-55757278	Predicted secreted proteins	Evidence at protein level	HPA060985, HPA069609	Enhanced		Approved	Vesicles	Pancreatic cancer:1.08e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,seminal vesicle: 13.3	Cell line enhanced		HMC-1: 112.3
GDF15	MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB	ENSG00000130513	Growth differentiation factor 15	19	18374731-18389176	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011191, CAB062554, HPA070957	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Tissue enhanced		placenta: 122.1;prostate: 74.5	kidney: 41.6	Cell line enhanced		BEWO: 401.5;HHSteC: 474.6
GDF2	BMP-9, BMP9	ENSG00000263761	Growth differentiation factor 2	10	47322490-47326270	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023357	Uncertain					Not detected	Tissue enriched	61	liver: 11.3	placenta,testis: 0.1	Not detected		
GDF3		ENSG00000184344	Growth differentiation factor 3	12	7689782-7695776	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA018468	Uncertain					Tissue enriched	Tissue enhanced		kidney: 1.1;spleen: 1.1	testis: 0.8	Cell line enriched	14	NTERA-2: 450.4
GDF5	BMP14, CDMP1	ENSG00000125965	Growth differentiation factor 5	20	35433347-35454746	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015648	Uncertain					Tissue enriched	Tissue enhanced		salivary gland: 4.1	seminal vesicle: 1.7	Cell line enhanced		ASC TERT1: 12.2;BJ hTERT+: 4.4;HHSteC: 4.8;HSkMC: 10.3;U-87 MG: 6.5
GDF6	BMP13, KFS, KFS1, SGM1	ENSG00000156466	Growth differentiation factor 6	8	96142330-96160792	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045206	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Renal cancer:2.17e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		placenta: 15.1	gallbladder: 3.8	Cell line enriched	7	LHCN-M2: 27.7
GDF7	BMP12	ENSG00000143869	Growth differentiation factor 7	2	20666664-20679245	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		seminal vesicle: 29.5	endometrium: 11.5	Cell line enhanced		HAP1: 1.7;Hep G2: 2.8;RT4: 6.2;SH-SY5Y: 3.3
GDF9		ENSG00000164404	Growth differentiation factor 9	5	132861181-132866884	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069146	Supported					Tissue enriched	Group enriched	5	epididymis: 5.0;testis: 14.1	thyroid gland: 1.8	Mixed		
GDNF	ATF1, ATF2, HFB1-GDNF	ENSG00000168621	Glial cell derived neurotrophic factor	5	37812677-37839686	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB005210, HPA070283	Supported		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			placenta: 7.0	Cell line enhanced		hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1
GFPT2	GFAT2	ENSG00000131459	Glutamine-fructose-6-phosphate transaminase 2	5	180300690-180353387	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056892, HPA059910	Uncertain		Supported	Vesicles	Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 90.9	appendix: 25.7	Cell line enhanced		ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
GFRA2	GDNFRB, NTNRA, RETL2, TRNR2	ENSG00000168546	GDNF family receptor alpha 2	8	21690403-21812357	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024704, CAB032791	Uncertain		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		thyroid gland: 13.4	spleen: 9.5	Group enriched	12	HEL: 8.1;HMC-1: 17.5;WM-115: 3.6
GFRA4		ENSG00000125861	GDNF family receptor alpha 4	20	3659292-3663399	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 1.4	testis: 0.3	Not detected		
GGH		ENSG00000137563	Gamma-glutamyl hydrolase	8	63015079-63039171	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019296, HPA025226	Approved				Endometrial cancer:3.99e-7 (unfavourable), Lung cancer:1.65e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 90.0	liver: 63.2	Mixed		
GH1	GH, GH-N, GHN, hGH-N	ENSG00000259384	Growth hormone 1	17	63917200-63918838	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Not detected	Tissue enhanced		placenta: 1.2	duodenum: 0.6	Cell line enhanced		U-698: 1.8
GH2	GH-V, GHL, GHV, hGH-V	ENSG00000136487	Growth hormone 2	17	63880215-63881935	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Not detected	Tissue enriched	199	placenta: 189.1	smooth muscle: 0.9	Cell line enriched	21	BEWO: 7.8
GHDC	LGP1	ENSG00000167925	GH3 domain containing	17	42188799-42194532	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA031650	Uncertain				Renal cancer:2.00e-6 (favourable), Glioma:5.91e-5 (unfavourable), Endometrial cancer:3.21e-4 (favourable), Ovarian cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.2	Mixed		
GHRH	GHRF	ENSG00000118702	Growth hormone releasing hormone	20	37251082-37261835	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		adrenal gland: 1.4;duodenum: 3.4	small intestine: 1.2	Cell line enhanced		NTERA-2: 2.0;U-266/84: 5.4
GHRL	ghrelin, MTLRP, obestatin	ENSG00000157017	Ghrelin and obestatin prepropeptide	3	10285675-10292947	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014246, CAB022731	Enhanced					Mixed	Tissue enriched	8	stomach: 156.2	duodenum: 19.0	Cell line enhanced		Karpas-707: 10.4
GIF	IF, IFMH, INF, TCN3	ENSG00000134812	Gastric intrinsic factor	11	59829268-59845501	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039908, HPA040774	Enhanced					Tissue enriched	Tissue enriched	1701	stomach: 1311.7	cerebral cortex: 0.7	Not detected		
GIP		ENSG00000159224	Gastric inhibitory polypeptide	17	48958554-48968596	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016729, HPA021612	Enhanced					Tissue enriched	Group enriched	156	duodenum: 261.3;small intestine: 93.9	stomach: 1.1	Cell line enhanced		A549: 6.0;BEWO: 5.7;Hep G2: 6.5
GKN2	blottin, BRICD1B, GDDR, PRO813, TFIZ1, VLTI465	ENSG00000183607	Gastrokine 2	2	68945232-68952970	Predicted secreted proteins	Evidence at protein level	HPA057765	Enhanced					Tissue enriched	Tissue enriched	37	stomach: 3843.6	lung: 103.7	Cell line enhanced		A549: 1.6;HMC-1: 1.5;NTERA-2: 2.1;PC-3: 3.6;U-2 OS: 1.5;U-266/70: 1.3
GLA	GALA	ENSG00000102393	Galactosidase alpha	X	101397803-101407925	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000237, HPA000966	Enhanced				Liver cancer:5.62e-5 (unfavourable), Stomach cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 59.2	Expressed in all		
GLB1	EBP, ELNR1	ENSG00000170266	Galactosidase beta 1	3	32996608-33097230	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008382, HPA040610, HPA069503	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 122.5	Cell line enriched	5	BEWO: 804.9
GLB1L	MGC10771	ENSG00000163521	Galactosidase beta 1 like	2	219236606-219245478	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043058	Enhanced					Expressed in all	Tissue enhanced		testis: 95.4	fallopian tube: 37.3	Mixed		
GLG1	CFR-1, ESL-1, MG-160	ENSG00000090863	Golgi glycoprotein 1	16	74447427-74607144	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010815	Supported		Enhanced	Golgi apparatus	Renal cancer:1.56e-7 (favourable), Cervical cancer:1.99e-4 (unfavourable), Urothelial cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
GLIPR1	GliPR, RTVP1	ENSG00000139278	GLI pathogenesis related 1	12	75480680-75503853	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011014	Approved				Renal cancer:8.69e-9 (unfavourable)	Expressed in all	Mixed			appendix: 64.9	Cell line enhanced		hTEC/SVTERT24-B: 189.5;U-138 MG: 359.6
GLIPR1L1	MGC26856	ENSG00000173401	GLI pathogenesis related 1 like 1	12	75334639-75370560	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042095	Enhanced					Not detected	Tissue enriched	45	testis: 78.3	skin: 1.7	Cell line enriched	100	NTERA-2: 109.3
GLMP	C1orf85, MGC31963, NCU-G1	ENSG00000198715	Glycosylated lysosomal membrane protein	1	156290089-156295689	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029121	Uncertain				Liver cancer:6.35e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 96.6	Mixed		
GLRB		ENSG00000109738	Glycine receptor beta	4	157076057-157172090	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052363	Approved				Renal cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 62.0;parathyroid gland: 63.1	cervix, uterine: 14.1	Mixed		
GLS	GLS1, KIAA0838	ENSG00000115419	Glutaminase	2	190880827-190965552	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036223	Enhanced		Supported	Mitochondria	Endometrial cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 333.2	Expressed in all		
GLT6D1	GLTDC1	ENSG00000204007	Glycosyltransferase 6 domain containing 1	9	135623656-135639540	Predicted secreted proteins	Evidence at transcript level	HPA023424	Uncertain					Not detected	Tissue enriched	42	testis: 8.3	epididymis: 0.1	Not detected		
GLT8D2	FLJ31494	ENSG00000120820	Glycosyltransferase 8 domain containing 2	12	103988984-104064183	Predicted intracellular proteins	Evidence at protein level	HPA026904	Approved		Approved	Cytosol	Renal cancer:1.58e-6 (unfavourable), Cervical cancer:7.37e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 57.1	Cell line enhanced		ASC TERT1: 48.9;BJ hTERT+: 73.1;HSkMC: 47.3
GLTPD2		ENSG00000182327	Glycolipid transfer protein domain containing 2	17	4788959-4790390	Predicted secreted proteins	Evidence at protein level	HPA058295, HPA065267	Uncertain		Approved	Vesicles		Tissue enriched	Tissue enhanced		duodenum: 11.0;kidney: 12.8;liver: 13.8	small intestine: 7.2	Cell line enhanced		CACO-2: 8.6;Hep G2: 9.4
GM2A	SAP-3	ENSG00000196743	GM2 ganglioside activator	5	151212150-151270440	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008063	Enhanced				Liver cancer:1.77e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 89.5	Expressed in all		
GML	LY6DL	ENSG00000104499	Glycosylphosphatidylinositol anchored molecule like	8	142834247-142916506	Predicted secreted proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	39	adrenal gland: 251.3	testis: 6.4	Not detected		
GNLY	D2S69E, LAG-2, LAG2, NKG5, TLA519	ENSG00000115523	Granulysin	2	85685175-85698854	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025186, HPA058021	Enhanced				Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 152.4;endometrium: 113.5;spleen: 112.9	lung: 51.0	Not detected		
GNPTG	C16orf27, c316G12.3, CAB56184, GNPTAG	ENSG00000090581	N-acetylglucosamine-1-phosphate transferase gamma subunit	16	1351923-1364113	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004055	Approved		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 66.2	Expressed in all		
GNRH1	GNRH, GRH, LHRH	ENSG00000147437	Gonadotropin releasing hormone 1	8	25419260-25424654	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027532	Supported				Renal cancer:8.08e-9 (unfavourable)	Mixed	Mixed			skin: 10.4	Cell line enriched	5	SCLC-21H: 23.9
GNRH2		ENSG00000125787	Gonadotropin releasing hormone 2	20	3043622-3045747	Predicted secreted proteins	Evidence at transcript level	HPA004338	Uncertain					Tissue enhanced	Mixed			ovary: 2.7	Mixed		
GORAB	FLJ11752, GO, NTKL-BP1, SCYL1BP1	ENSG00000120370	Golgin, RAB6 interacting	1	170532129-170553446	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027208, HPA027250	Approved		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:7.83e-12 (unfavourable), Head and neck cancer:1.39e-4 (favourable), Liver cancer:5.26e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 7.9	Mixed		
GP2	ZAP75	ENSG00000169347	Glycoprotein 2	16	20309572-20327808	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015739, HPA016668	Enhanced					Tissue enriched	Tissue enriched	206	pancreas: 7530.3	duodenum: 36.5	Not detected		
GP6	GPVI	ENSG00000088053	Glycoprotein VI platelet	19	55013705-55038264	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA066482	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 1.2	skin: 0.7	Group enriched	12	HEL: 8.5;K-562: 3.7;U-2 OS: 2.7
GPC2	cerebroglycan, DKFZp547M109, FLJ38962	ENSG00000213420	Glypican 2	7	100169606-100177372	Predicted secreted proteins	Evidence at protein level	CAB025423, HPA053945	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:9.94e-4 (favourable)	Mixed	Tissue enhanced		skin: 5.7;testis: 10.1	cerebral cortex: 3.4	Cell line enhanced		AF22: 39.1;SH-SY5Y: 46.0
GPC5		ENSG00000179399	Glypican 5	13	91398607-92873682	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040152, HPA044081	Enhanced		Approved	Nucleus<br>Cytosol	Glioma:5.67e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 15.8;kidney: 8.1;testis: 11.5	lung: 4.9	Group enriched	9	CACO-2: 41.2;HeLa: 18.9
GPC6		ENSG00000183098	Glypican 6	13	93226842-94407401	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017671	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			gallbladder: 27.3	Cell line enhanced		ASC diff: 42.9;HSkMC: 51.5;U-87 MG: 51.7
GPER1	CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR	ENSG00000164850	G protein-coupled estrogen receptor 1	7	1082208-1093815	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027052	Approved				Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			placenta: 9.1	Cell line enhanced		AN3-CA: 10.6;Hep G2: 15.3
GPHA2	A2, GPA2, MGC126572, ZSIG51	ENSG00000149735	Glycoprotein hormone alpha 2	11	64934471-64935888	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	6	gallbladder: 26.3;pancreas: 76.9	testis: 7.9	Cell line enriched	6	Hep G2: 14.4
GPHB5	GPB5, ZLUT1	ENSG00000179600	Glycoprotein hormone beta 5	14	63312835-63318879	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
GPIHBP1	GPI-HBP1, LOC338328	ENSG00000277494	Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1	8	143213193-143217170	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA066302	Enhanced					Mixed	Group enriched	6	adipose tissue: 94.2;lung: 33.0	skeletal muscle: 10.5	Cell line enhanced		Karpas-707: 2.3
GPLD1		ENSG00000112293	Glycosylphosphatidylinositol specific phospholipase D1	6	24424565-24495205	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008625, HPA012500	Uncertain				Liver cancer:1.12e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 23.6	skin: 9.0	Cell line enhanced		Daudi: 5.7;U-698: 5.6
GPNMB	HGFIN, NMB	ENSG00000136235	Glycoprotein nmb	7	23235967-23275108	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 654.6	Cell line enriched	5	ASC diff: 3230.9
GPR162	A-2, GRCA	ENSG00000250510	G protein-coupled receptor 162	12	6821545-6829972	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055135	Enhanced		Approved	Microtubule organizing center	Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)	Tissue enriched	Group enriched	6	cerebral cortex: 84.3;fallopian tube: 29.4	lung: 9.5	Cell line enhanced		AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2
GPX3		ENSG00000211445	Glutathione peroxidase 3	5	151020438-151028993	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB069456	Uncertain				Stomach cancer:1.65e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 11674.4	Cell line enriched	11	ASC diff: 5265.2
GPX4	MCSP, PHGPx	ENSG00000167468	Glutathione peroxidase 4	19	1103926-1106791	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008630, HPA047224, HPA058546	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 1140.7	Expressed in all		
GPX5		ENSG00000224586	Glutathione peroxidase 5	6	28525925-28534952	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	30	epididymis: 12.2	seminal vesicle: 0.4	Not detected		
GPX6	GPXP3	ENSG00000198704	Glutathione peroxidase 6	6	28503296-28528215	Enzymes, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	12	epididymis: 4.0	testis: 0.3	Not detected		
GPX7	FLJ14777, GPX6, NPGPx	ENSG00000116157	Glutathione peroxidase 7	1	52602372-52609051	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA025829			Approved	Nucleoli	Renal cancer:2.26e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 42.1	Cell line enhanced		REH: 69.6;RPMI-8226: 89.3;THP-1: 68.1
GREM1	CKTSF1B1, CRAC1, DAND2, DRM, gremlin, HMPS	ENSG00000166923	Gremlin 1, DAN family BMP antagonist	15	32717974-32745107	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA007526	Uncertain				Lung cancer:4.46e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 92.4;smooth muscle: 67.3	urinary bladder: 22.4	Cell line enhanced		BJ: 150.1;BJ hTERT+: 219.5;BJ hTERT+ SV40 Large T+ RasG12V: 161.4;fHDF/TERT166: 426.8;hTEC/SVTERT24-B: 168.1
GREM2	CKTSF1B2, DAND3, FLJ21195, Prdc	ENSG00000180875	Gremlin 2, DAN family BMP antagonist	1	240489573-240612149	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB009920	Uncertain					Mixed	Tissue enhanced		gallbladder: 48.8;parathyroid gland: 78.3	rectum: 22.6	Cell line enhanced		BJ: 5.1;BJ hTERT+: 5.2;fHDF/TERT166: 25.0
GRHL3	SOM, TFCP2L4	ENSG00000158055	Grainyhead like transcription factor 3	1	24319322-24364482	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA059960	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Group enriched	11	esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1	testis: 4.3	Cell line enhanced		BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5
GRIA2	GluA2, GLUR2, GLURB	ENSG00000120251	Glutamate ionotropic receptor AMPA type subunit 2	4	157204182-157366075	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007812, HPA008441	Enhanced					Group enriched	Tissue enriched	7	cerebral cortex: 206.6	endometrium: 27.5	Cell line enriched	8	SCLC-21H: 19.9
GRIA3	GluA3, GLUR3, GLURC, MRX94	ENSG00000125675	Glutamate ionotropic receptor AMPA type subunit 3	X	123184153-123490915	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA058659	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 56.6	adrenal gland: 11.3	Cell line enhanced		BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
GRIA4	GluA4, GLUR4, GLURD	ENSG00000152578	Glutamate ionotropic receptor AMPA type subunit 4	11	105609994-105982092	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	10	cerebral cortex: 73.2	adrenal gland: 7.3	Cell line enhanced		AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1
GRM2	GPRC1B, mGlu2, MGLUR2	ENSG00000164082	Glutamate metabotropic receptor 2	3	51707070-51718613	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027868, HPA065166	Approved	Supported				Tissue enhanced	Tissue enriched	10	cerebral cortex: 4.4	testis: 0.4	Cell line enriched	7	SCLC-21H: 7.3
GRM3	GPRC1C, mGlu3, MGLUR3	ENSG00000198822	Glutamate metabotropic receptor 3	7	86643914-86864884	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	43	cerebral cortex: 62.3	testis: 1.4	Cell line enriched	8	AF22: 35.5
GRM5	GPRC1E, mGlu5, MGLUR5, PPP1R86	ENSG00000168959	Glutamate metabotropic receptor 5	11	88504576-89065945	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	8	cerebral cortex: 27.2	testis: 3.2	Not detected		
GRN	CLN11, PCDGF, PGRN	ENSG00000030582	Granulin precursor	17	44345086-44353102	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008763, CAB019394, HPA028747	Approved		Enhanced	Endoplasmic reticulum<br>Endosomes<br>Lysosomes	Glioma:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 439.4	Expressed in all		
GRP		ENSG00000134443	Gastrin releasing peptide	18	59220168-59230774	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lung: 13.4;thyroid gland: 10.4	parathyroid gland: 3.9	Group enriched	8	BJ hTERT+: 4.2;fHDF/TERT166: 5.1
GSN	DKFZp313L0718	ENSG00000148180	Gelsolin	9	121207794-121332843	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010823, CAB016728, CAB036009, HPA054026	Supported		Supported	Actin filaments	Urothelial cancer:1.79e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1354.2	Cell line enhanced		ASC diff: 964.0;HaCaT: 513.8
GTDC1	FLJ11753, Hmat-Xa	ENSG00000121964	Glycosyltransferase like domain containing 1	2	143938068-144332568	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036694	Uncertain		Approved	Cytosol	Renal cancer:6.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.4	Mixed		
GUCA2A	GUCA2, STARA	ENSG00000197273	Guanylate cyclase activator 2A	1	42162691-42164718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018215	Enhanced					Group enriched	Group enriched	15	colon: 768.8;rectum: 859.2;small intestine: 1127.0	duodenum: 61.5	Cell line enhanced		BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5
GUCA2B		ENSG00000044012	Guanylate cyclase activator 2B	1	42153421-42155824	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 87.6;small intestine: 148.3	duodenum: 37.5	Group enriched	6	A549: 1.3;CACO-2: 3.2
GUSB		ENSG00000169919	Glucuronidase beta	7	65960684-65982314	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA036322, HPA036323	Approved		Supported	Vesicles		Expressed in all	Expressed in all			breast: 95.9	Expressed in all		
GXYLT2	GLT8D4	ENSG00000172986	Glucoside xylosyltransferase 2	3	72888073-72998138	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA068429	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Midbody ring	Renal cancer:1.46e-7 (unfavourable), Urothelial cancer:2.42e-5 (unfavourable)	Mixed	Mixed			ovary: 20.6	Cell line enhanced		MOLT-4: 29.2
GYPB	CD235b, GPB, MNS, SS	ENSG00000250361	Glycophorin B (MNS blood group)	4	143996104-144019345	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	5	bone marrow: 37.2	placenta: 7.3	Cell line enriched	5	HEL: 225.3
GZMA	CTLA3, HFSP	ENSG00000145649	Granzyme A	5	55102648-55110252	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA054134	Uncertain				Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Mixed			spleen: 70.9	Cell line enhanced		HL-60: 3.2
GZMB	CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT	ENSG00000100453	Granzyme B	14	24630954-24634267	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000376, HPA003418	Enhanced				Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 40.1	bone marrow,spleen: 36.2	Cell line enriched	6	HMC-1: 17.4
GZMH	CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2	ENSG00000100450	Granzyme H	14	24606480-24609699	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA029200	Enhanced				Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable)	Expressed in all	Tissue enhanced		spleen: 35.3	lymph node: 25.3	Not detected		
GZMK	PRSS, TRYP2	ENSG00000113088	Granzyme K	5	55024253-55034570	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA063181	Enhanced				Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 103.9	spleen: 41.9	Not detected		
GZMM	LMET1, MET1	ENSG00000197540	Granzyme M	19	544034-549924	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA015624	Enhanced				Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 20.9;spleen: 19.7	appendix: 13.0	Cell line enhanced		EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1
H6PD	GDH	ENSG00000049239	Hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	1	9234775-9271337	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA004824, HPA005440	Approved		Uncertain	Cytosol		Expressed in all	Expressed in all			ovary: 42.8	Mixed		
HABP2	FSAP, HABP, HGFAL, PHBP	ENSG00000148702	Hyaluronan binding protein 2	10	113550837-113589602	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019518	Approved					Tissue enriched	Group enriched	12	gallbladder: 55.8;liver: 225.6	stomach: 11.3	Cell line enriched	5	RPTEC TERT1: 38.3
HADHB	MTPB	ENSG00000138029	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit	2	26243170-26290468	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037539, HPA037540, HPA066099	Enhanced		Supported	Mitochondria	Renal cancer:1.37e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 300.8	Expressed in all		
HAMP	HEPC, HFE2B, LEAP-1, LEAP1	ENSG00000105697	Hepcidin antimicrobial peptide	19	35280716-35285143	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Group enriched	Tissue enriched	12	liver: 259.1	heart muscle: 21.9	Cell line enriched	127	Hep G2: 135.7
HAPLN1	CRTL1	ENSG00000145681	Hyaluronan and proteoglycan link protein 1	5	83637805-83721613	Predicted secreted proteins	Evidence at protein level	HPA019105, HPA019482, HPA025238	Enhanced	Approved	Supported	Vesicles	Renal cancer:4.81e-9 (unfavourable)	Mixed	Tissue enriched	8	placenta: 103.4	cerebral cortex: 12.8	Group enriched	35	PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3
HAPLN2	BRAL1	ENSG00000132702	Hyaluronan and proteoglycan link protein 2	1	156619294-156625725	Predicted secreted proteins	Evidence at protein level	HPA045765	Enhanced					Tissue enriched	Tissue enriched	47	cerebral cortex: 42.1	duodenum: 0.8	Not detected		
HAPLN3	EXLD1, HsT19883	ENSG00000140511	Hyaluronan and proteoglycan link protein 3	15	88877288-88895626	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039237	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.18e-13 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.8;lymph node: 10.8	spleen: 4.0	Cell line enhanced		HDLM-2: 29.8;U-2 OS: 31.7
HAPLN4	BRAL2, KIAA1926	ENSG00000187664	Hyaluronan and proteoglycan link protein 4	19	19255641-19262796	Predicted secreted proteins	Evidence at protein level	HPA055856	Approved					Not detected	Group enriched	7	cerebral cortex: 8.4;duodenum: 15.3;small intestine: 21.2	cervix, uterine: 2.1	Cell line enhanced		NB-4: 2.6;NTERA-2: 10.4;SCLC-21H: 2.6
HARS2	HARSL, HARSR, HO3	ENSG00000112855	Histidyl-tRNA synthetase 2, mitochondrial	5	140691426-140699291	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035941	Approved		Approved	Cytosol	Liver cancer:2.92e-4 (unfavourable), Colorectal cancer:6.19e-4 (favourable), Breast cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.5	Expressed in all		
HAVCR1	CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1	ENSG00000113249	Hepatitis A virus cellular receptor 1	5	157029413-157059119	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007173, CAB075697	Approved		Approved	Vesicles	Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)	Tissue enriched	Group enriched	6	colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7	gallbladder: 0.8	Group enriched	5	A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
HBS1L	DKFZp434g247, EF-1a, eRF3c, ERFS, HBS1, HSPC276, KIAA1038	ENSG00000112339	HBS1 like translational GTPase	6	134960378-135103056	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029728, HPA029729	Approved		Approved	Nuclear bodies<br>Cytosol	Colorectal cancer:6.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.2	Expressed in all		
HCRT	OX, PPOX	ENSG00000161610	Hypocretin neuropeptide precursor	17	42184060-42185452	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB004758	Uncertain					Tissue enhanced	Not detected			adipose tissue,appendix,cerebral cortex,duodenum: 0.1	Not detected		
HDHD5	CECR5	ENSG00000069998	Haloacid dehalogenase like hydrolase domain containing 5	22	17137511-17165287	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005548	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			duodenum: 26.7	Mixed		
HEATR5A	C14orf125, DKFZP434I1735	ENSG00000129493	HEAT repeat containing 5A	14	31291791-31420582	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049539	Uncertain				Renal cancer:1.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
HEPH	CPL, KIAA0698	ENSG00000089472	Hephaestin	X	66162549-66268867	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005824	Approved				Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 119.0	Cell line enhanced		AF22: 28.1;HEL: 22.8;HSkMC: 26.1;K-562: 64.5;LHCN-M2: 23.8
HEXA		ENSG00000213614	Hexosaminidase subunit alpha	15	72340919-72376476	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054583	Supported				Endometrial cancer:5.63e-8 (favourable)	Expressed in all	Expressed in all			epididymis: 200.6	Mixed		
HFE2	haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC	ENSG00000168509	Hemochromatosis type 2 (juvenile)	1	146017468-146036746	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	15	heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6	esophagus: 8.6	Cell line enhanced		HSkMC: 1.1;K-562: 1.4
HGF	DFNB39, F-TCF, HGFB, HPTA, SF	ENSG00000019991	Hepatocyte growth factor	7	81699006-81770438	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010333, HPA040360, HPA044088	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 438.8	gallbladder: 27.5	Cell line enhanced		ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7
HGFAC	HGFA, HGFAP	ENSG00000109758	HGF activator	4	3441887-3449495	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA058279, HPA059076	Enhanced				Renal cancer:9.31e-4 (unfavourable)	Tissue enriched	Tissue enriched	14	liver: 28.6	testis: 2.0	Cell line enriched	6	Hep G2: 3.6
HHIP	FLJ20992, HIP	ENSG00000164161	Hedgehog interacting protein	4	144646021-144745271	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012616	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		lung: 24.2	cerebral cortex: 10.8	Group enriched	6	HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5
HHIPL1	KIAA1822	ENSG00000182218	HHIP like 1	14	99645110-99680569	Predicted secreted proteins	Evidence at transcript level	HPA052767	Approved					Mixed	Tissue enhanced		cerebral cortex: 6.6	smooth muscle: 2.6	Cell line enhanced		EFO-21: 2.9;fHDF/TERT166: 4.3;SiHa: 3.9;THP-1: 2.6
HHIPL2	FLJ13840, KIAA1822L	ENSG00000143512	HHIP like 2	1	222522258-222548103	Predicted secreted proteins	Evidence at protein level	HPA059673	Enhanced		Uncertain	Mitochondria<br>Cytosol	Lung cancer:4.64e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 9.0;thyroid gland: 3.4	prostate: 1.4	Cell line enhanced		A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5
HHLA1	PLA2L	ENSG00000132297	HERV-H LTR-associating 1	8	132061486-132111159	Predicted secreted proteins	Evidence at transcript level	HPA059051	Uncertain					Not detected	Not detected			placenta: 0.1	Cell line enriched	12	NTERA-2: 1.1
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced					Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced		HDLM-2: 3.7;Karpas-707: 2.0
HIBADH	NS5ATP1	ENSG00000106049	3-hydroxyisobutyrate dehydrogenase	7	27525442-27662995	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019522, HPA021002	Enhanced				Renal cancer:5.56e-11 (favourable)	Expressed in all	Expressed in all			kidney: 113.0	Expressed in all		
HIPK1	KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2	ENSG00000163349	Homeodomain interacting protein kinase 1	1	113929192-113977869	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016664	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 89.7	Expressed in all		
HLA-A		ENSG00000206503	Major histocompatibility complex, class I, A	6	29941260-29945884	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB078470			Supported	Golgi apparatus<br>Plasma membrane	Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)	Expressed in all	Mixed			gallbladder: 340.9	Cell line enhanced		A-431: 1127.9
HLA-C	D6S204, HLA-JY3, PSORS1	ENSG00000204525	Major histocompatibility complex, class I, C	6	31268749-31272130	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		lung: 744.7	small intestine: 396.9	Cell line enhanced		A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2
HLA-DOA	HLA-D0-alpha, HLA-DNA, HLA-DZA	ENSG00000204252	Major histocompatibility complex, class II, DO alpha	6	33004178-33009612	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045038	Enhanced					Expressed in all	Tissue enhanced		spleen: 14.4	tonsil: 8.9	Cell line enhanced		Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4
HLA-DPA1	HLA-DP1A	ENSG00000231389	Major histocompatibility complex, class II, DP alpha 1	6	33064569-33080775	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017967	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			lung: 120.6	Cell line enhanced		Daudi: 26.7;HDLM-2: 107.3;REH: 26.8
HLA-DQA1	CELIAC1, HLA-DQA	ENSG00000196735	Major histocompatibility complex, class II, DQ alpha 1	6	32628179-32647062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012315	Enhanced					Expressed in all	Tissue enhanced		lung: 504.8	lymph node: 338.6	Cell line enriched	9	HDLM-2: 1315.9
HLA-DQB1	CELIAC1, HLA-DQB, IDDM1	ENSG00000179344	Major histocompatibility complex, class II, DQ beta 1	6	32659467-32668383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013667	Uncertain		Supported	Golgi apparatus<br>Rods & Rings		Expressed in all	Tissue enhanced		lymph node: 287.3	lung: 268.5	Cell line enriched	8	HDLM-2: 555.8
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected		
HMCN1	ARMD1, FBLN6, FIBL-6, FIBL6	ENSG00000143341	Hemicentin 1	1	185734551-186190949	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051677	Uncertain				Renal cancer:3.59e-7 (unfavourable)	Tissue enriched	Tissue enhanced		lung: 22.3	prostate: 12.6	Group enriched	6	fHDF/TERT166: 17.3;MCF7: 58.7;SK-MEL-30: 38.8;U-138 MG: 13.5;WM-115: 43.4
HMCN2	DKFZp434P0216, FLJ23816	ENSG00000148357	Hemicentin 2	9	130265882-130434123	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053903, HPA070647	Enhanced		Approved	Vesicles		Mixed	Mixed			small intestine: 11.4	Cell line enhanced		HaCaT: 6.9;RH-30: 17.3;SH-SY5Y: 4.4;U-87 MG: 4.0
HP		ENSG00000257017	Haptoglobin	16	72054592-72061055	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003787, HPA047750	Enhanced		Approved	Vesicles	Renal cancer:6.94e-13 (unfavourable)	Tissue enriched	Tissue enriched	182	liver: 28407.0	bone marrow: 155.8	Cell line enhanced		Hep G2: 153.5;HSkMC: 88.2
HPR		ENSG00000261701	Haptoglobin-related protein	16	72063224-72077246	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047750	Supported		Approved	Vesicles		Tissue enriched	Tissue enriched	24	liver: 444.1	heart muscle: 18.7	Cell line enriched	14	Hep G2: 34.3
HPSE	HPA, HPSE1, HSE1	ENSG00000173083	Heparanase	4	83292461-83335153	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB009813, HPA055344			Enhanced	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		parathyroid gland: 20.0	testis: 10.0	Cell line enhanced		Karpas-707: 27.7
HPSE2	HPA2, HPR2, UFS	ENSG00000172987	Heparanase 2 (inactive)	10	98457077-99235862	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044603	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 53.4	prostate: 22.8	Group enriched	24	BJ hTERT+: 11.3;HEL: 23.9
HPX		ENSG00000110169	Hemopexin	11	6431049-6442617	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016725	Supported				Liver cancer:2.26e-4 (favourable)	Tissue enriched	Tissue enriched	506	liver: 2617.9	breast: 5.1	Cell line enriched	6	Hep G2: 13.9
HRC	MGC133236	ENSG00000130528	Histidine rich calcium binding protein	19	49151198-49155424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004833	Enhanced					Mixed	Group enriched	39	heart muscle: 351.8;skeletal muscle: 155.5	epididymis,prostate: 6.5	Group enriched	6	Hep G2: 3.9;HSkMC: 4.0;K-562: 7.1;THP-1: 9.3;U-266/84: 3.0
HRG	HPRG, HRGP	ENSG00000113905	Histidine rich glycoprotein	3	186660216-186678240	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050269, HPA054598	Supported		Uncertain	Nucleoli fibrillar center	Liver cancer:9.64e-5 (favourable)	Tissue enriched	Tissue enriched	83	liver: 2689.0	kidney: 32.2	Cell line enhanced		HL-60: 2.0;RH-30: 2.8;SiHa: 1.1
HS3ST1	3OST1	ENSG00000002587	Heparan sulfate-glucosamine 3-sulfotransferase 1	4	11393150-11429765	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA002237	Approved		Approved	Vesicles	Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 13.9;ovary: 23.2	urinary bladder: 5.6	Cell line enhanced		CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3
HS6ST2		ENSG00000171004	Heparan sulfate 6-O-sulfotransferase 2	X	132626016-132961395	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034625, HPA034626	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.03e-4 (favourable)	Mixed	Tissue enhanced		kidney: 15.0;ovary: 17.6	placenta: 11.9	Cell line enhanced		HEK 293: 42.3;RH-30: 63.9;SH-SY5Y: 87.0
HS6ST3		ENSG00000185352	Heparan sulfate 6-O-sulfotransferase 3	13	96090839-96839562	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA078257			Approved	Nucleoplasm<br>Nuclear membrane<br>Actin filaments	Renal cancer:6.12e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 27.7	urinary bladder: 6.0	Group enriched	8	HAP1: 2.9;RT4: 13.7
HSD11B1L	SCDR10, SDR26C2	ENSG00000167733	Hydroxysteroid 11-beta dehydrogenase 1 like	19	5680604-5688523	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049078			Approved	Vesicles	Head and neck cancer:4.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.6	fallopian tube: 7.9	Cell line enhanced		SH-SY5Y: 20.1
HSD17B11	17-BETA-HSD11, 17-BETA-HSDXI, DHRS8, PAN1B, RetSDR2, SDR16C2	ENSG00000198189	Hydroxysteroid 17-beta dehydrogenase 11	4	87336610-87391386	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021608	Approved		Supported	Lipid droplets		Expressed in all	Expressed in all			small intestine: 295.2	Cell line enhanced		CAPAN-2: 236.8
HSP90B1	GP96, GRP94, TRA1	ENSG00000166598	Heat shock protein 90 beta family member 1	12	103930107-103953645	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003901, CAB005224, HPA008424	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.03e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 2386.1	Expressed in all		
HSPA13	STCH	ENSG00000155304	Heat shock protein family A (Hsp70) member 13	21	14371115-14383484	Predicted secreted proteins	Evidence at protein level	HPA014797	Approved					Expressed in all	Expressed in all			cerebral cortex: 55.7	Expressed in all		
HSPA5	BiP, GRP78	ENSG00000044574	Heat shock protein family A (Hsp70) member 5	9	125234853-125241330	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005221, HPA038845, HPA038846	Enhanced		Approved	Cytosol	Renal cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 968.4	Expressed in all		
HSPG2	perlecan, PRCAN, SJS1	ENSG00000142798	Heparan sulfate proteoglycan 2	1	21822245-21937297	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009820, HPA018892, CAB020718	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 135.6	Cell line enhanced		EFO-21: 257.0;HUVEC TERT2: 511.1;TIME: 402.8
HTATIP2	CC3, FLJ26963, SDR44U1, TIP30	ENSG00000109854	HIV-1 Tat interactive protein 2	11	20363685-20383783	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006417, HPA024321	Approved		Supported	Cytosol	Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 135.2	Mixed		
HTN1	HIS1	ENSG00000126550	Histatin 1	4	70050402-70058845	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1777	salivary gland: 24297.5	ovary: 13.6	Not detected		
HTN3	HIS2	ENSG00000205649	Histatin 3	4	70028413-70036538	Predicted secreted proteins, Transporters	Evidence at protein level	CAB073541	Enhanced		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	1666	salivary gland: 47614.6	ovary: 28.5	Mixed		
HTRA1	ARMD7, HtrA, IGFBP5-protease, PRSS11	ENSG00000166033	HtrA serine peptidase 1	10	122461525-122514908	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036655	Enhanced		Supported	Plasma membrane	Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable)	Expressed in all	Mixed			ovary: 503.4	Cell line enhanced		ASC diff: 1649.0;HSkMC: 1139.5;LHCN-M2: 1027.1;U-87 MG: 974.2
HTRA3	Prsp, Tasp	ENSG00000170801	HtrA serine peptidase 3	4	8269765-8307111	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021187, HPA063810	Approved		Approved	Vesicles	Renal cancer:1.61e-9 (unfavourable), Thyroid cancer:1.29e-4 (unfavourable)	Expressed in all	Mixed			ovary: 60.9	Cell line enriched	6	U-2197: 168.9
HTRA4	FLJ90724	ENSG00000169495	HtrA serine peptidase 4	8	38974164-38988662	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045402	Enhanced					Tissue enhanced	Tissue enriched	20	placenta: 94.9	bone marrow: 4.7	Cell line enriched	160	BEWO: 219.1
HYAL1	FUS2, HYAL-1, LUCA1, NAT6	ENSG00000114378	Hyaluronoglucosaminidase 1	3	50299889-50312381	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002112	Uncertain				Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 71.1;spleen: 69.3	kidney: 43.5	Cell line enhanced		Hep G2: 66.6;SK-BR-3: 20.5
HYAL2	LuCa-2, LUCA2	ENSG00000068001	Hyaluronoglucosaminidase 2	3	50317790-50322906	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036436	Uncertain					Expressed in all	Expressed in all			spleen: 214.2	Expressed in all		
HYAL3	LUCA-3, LUCA14, Minna14	ENSG00000186792	Hyaluronoglucosaminidase 3	3	50292831-50299468	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049402	Uncertain				Urothelial cancer:2.12e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.7	testis: 14.0	Expressed in all		
HYOU1	Grp170, HSP12A, ORP150	ENSG00000149428	Hypoxia up-regulated 1	11	119044189-119057202	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049296	Approved				Renal cancer:5.10e-5 (unfavourable), Endometrial cancer:2.58e-4 (favourable), Thyroid cancer:5.00e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 111.7	Expressed in all		
IAPP	AMYLIN, DAP, IAP	ENSG00000121351	Islet amyloid polypeptide	12	21354959-21379978	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000352, HPA053194	Enhanced					Tissue enriched	Tissue enriched	7	pancreas: 35.0	testis: 5.3	Cell line enhanced		U-2 OS: 1.3
IBSP	BSP, BSP-II, SP-II	ENSG00000029559	Integrin binding sialoprotein	4	87799581-87812435	Cancer-related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 1.6;cervix, uterine: 1.3	gallbladder,placenta: 0.3	Cell line enriched	6	U-138 MG: 7.3
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
ICAM2	CD102	ENSG00000108622	Intercellular adhesion molecule 2	17	64002594-64020634	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071155			Uncertain	Cytosol		Expressed in all	Expressed in all			spleen: 200.5	Group enriched	7	HUVEC TERT2: 1043.9;TIME: 259.9
ICAM4	CD242, LW	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	19	10286967-10288522	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 8.7;lung: 14.5	epididymis: 2.9	Cell line enhanced		HEL: 67.4;K-562: 35.3;NB-4: 20.5
IDS	SIDS	ENSG00000010404	Iduronate 2-sulfatase	X	149476990-149521096	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enriched	5	cerebral cortex: 435.8	epididymis: 86.8	Expressed in all		
IDUA	MPS1	ENSG00000127415	Iduronidase, alpha-L-	4	986997-1004506	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025901, HPA046979, HPA054254	Enhanced		Supported	Vesicles	Renal cancer:7.87e-5 (unfavourable), Urothelial cancer:8.04e-5 (favourable), Colorectal cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.5	Cell line enhanced		U-266/70: 43.1
IER3IP1		ENSG00000134049	Immediate early response 3 interacting protein 1	18	47152834-47176374	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010027	Supported		Supported	Endoplasmic reticulum	Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.8	Expressed in all		
IFFO2		ENSG00000169991	Intermediate filament family orphan 2	1	18904281-18956686	Predicted intracellular proteins	Evidence at transcript level	HPA015987, HPA064603	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			skin: 72.4	Cell line enhanced		HDLM-2: 129.1
IFI30	GILT, IFI-30, IP-30, IP30, MGC32056	ENSG00000216490	IFI30, lysosomal thiol reductase	19	18173162-18178117	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026650	Approved		Supported	Vesicles<br>Cytosol		Mixed	Expressed in all			appendix: 828.7	Cell line enhanced		Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0
IFNA1	IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA@, IFNA13	ENSG00000197919	Interferon alpha 1	9	21440454-21441316	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			urinary bladder: 0.2	Cell line enhanced		HeLa: 1.4
IFNA10	IFN-alphaC	ENSG00000186803	Interferon alpha 10	9	21206181-21207143	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA13		ENSG00000233816	Interferon alpha 13	9	21367424-21368962	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			epididymis: 0.5	Not detected		
IFNA14	IFN-alphaH, LEIF2H	ENSG00000228083	Interferon alpha 14	9	21239002-21239991	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA16	IFN-alphaO	ENSG00000147885	Interferon alpha 16	9	21216373-21217311	Predicted secreted proteins	Evidence at transcript level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA17	IFN-alphaI, LEIF2C1	ENSG00000234829	Interferon alpha 17	9	21227243-21228222	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA2	IFN-alphaA, IFNA	ENSG00000188379	Interferon alpha 2	9	21384254-21385388	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA21	IFN-alphaI	ENSG00000137080	Interferon alpha 21	9	21165637-21166660	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			lymph node: 0.1	Not detected		
IFNA4	IFN-alpha4a, MGC142200	ENSG00000236637	Interferon alpha 4	9	21186694-21187671	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA5	IFN-alphaG	ENSG00000147873	Interferon alpha 5	9	21304326-21305312	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			epididymis: 0.2	Not detected		
IFNA6	IFN-alphaK	ENSG00000120235	Interferon alpha 6	9	21349835-21351378	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA7	IFN-alphaJ, IFNA-J	ENSG00000214042	Interferon alpha 7	9	21201469-21202205	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA8	IFN-alphaB	ENSG00000120242	Interferon alpha 8	9	21409147-21410185	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNAR1	IFNAR, IFRC	ENSG00000142166	Interferon alpha and beta receptor subunit 1	21	33324477-33359862	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018015, HPA029226	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
IFNB1	IFB, IFF, IFNB	ENSG00000171855	Interferon beta 1	9	21077105-21077963	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB009386	Uncertain					Not detected	Not detected			bone marrow: 0.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 1.1
IFNG		ENSG00000111537	Interferon gamma	12	68154768-68159747	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010344	Approved					Mixed	Tissue enhanced		appendix: 4.7;bone marrow: 7.6;lymph node: 7.9	lung: 2.5	Not detected		
IFNGR1	CD119, IFNGR	ENSG00000027697	Interferon gamma receptor 1	6	137197484-137219449	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025889, HPA063871	Approved				Renal cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 221.9	Expressed in all		
IFNL1	IL-29, IL29	ENSG00000182393	Interferon lambda 1	19	39296325-39298673	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			appendix,duodenum,lung,spleen,testis: 0.1	Not detected		
IFNL3	IL-28B, IL28B, IL28C	ENSG00000197110	Interferon lambda 3	19	39243553-39245129	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
IFNW1		ENSG00000177047	Interferon omega 1	9	21140214-21142145	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			bone marrow,lymph node,skin,testis,thyroid gland: 0.1	Not detected		
IGF1	IGF-I, IGF1A, IGFI	ENSG00000017427	Insulin like growth factor 1	12	102395867-102480645	Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA048946	Approved				Endometrial cancer:1.04e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 126.8	smooth muscle: 98.2	Cell line enhanced		ASC diff: 21.1;HDLM-2: 45.4;K-562: 19.8;U-266/70: 10.2
IGF2	C11orf43, FLJ44734, IGF-II	ENSG00000167244	Insulin like growth factor 2	11	2129112-2141238	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007556, HPA007993	Enhanced		Approved	Nucleoplasm<br>Vesicles	Liver cancer:7.12e-4 (favourable)	Group enriched	Tissue enriched	18	placenta: 3962.9	fallopian tube: 217.6	Cell line enhanced		CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
IGFALS	ALS	ENSG00000099769	Insulin like growth factor binding protein acid labile subunit	16	1790413-1794971	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040692, HPA040948	Approved		Supported	Nucleoplasm	Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)	Tissue enhanced	Group enriched	6	liver: 25.0;stomach: 6.6	gallbladder: 2.5	Cell line enhanced		Hep G2: 1.2;U-266/70: 1.3
IGFBP1	AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12	ENSG00000146678	Insulin like growth factor binding protein 1	7	45888357-45893668	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004445, HPA046972, HPA050640	Enhanced		Approved	Golgi apparatus	Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable)	Tissue enriched	Group enriched	52	endometrium: 120.4;liver: 563.0;placenta: 265.8	fallopian tube: 6.0	Group enriched	8	Hep G2: 33.4;U-2197: 71.7;U-87 MG: 128.8
IGFBP2	IBP2	ENSG00000115457	Insulin like growth factor binding protein 2	2	216632828-216664436	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077723			Approved	Endoplasmic reticulum	Renal cancer:2.22e-5 (unfavourable), Melanoma:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 279.9	Cell line enhanced		ASC diff: 1479.2;HMC-1: 4500.9
IGFBP3	BP-53, IBP3	ENSG00000146674	Insulin like growth factor binding protein 3	7	45912245-45921874	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010360			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 2671.0	endometrium: 886.0	Cell line enhanced		fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3
IGFBP4	BP-4, HT29-IGFBP, IBP4, IGFBP-4	ENSG00000141753	Insulin like growth factor binding protein 4	17	40443461-40457731	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA066240	Supported				Renal cancer:2.72e-5 (unfavourable), Endometrial cancer:3.54e-4 (favourable), Liver cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 932.6	Cell line enhanced		A549: 1206.8;HSkMC: 1458.4
IGFBP5		ENSG00000115461	Insulin like growth factor binding protein 5	2	216672105-216695525	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059827			Approved	Nuclear bodies<br>Golgi apparatus<br>Vesicles	Endometrial cancer:1.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 2374.4;ovary: 1646.3	fallopian tube: 949.1	Cell line enhanced		BJ: 704.3;BJ hTERT+: 1787.5;T-47d: 500.8;U-138 MG: 702.9
IGFBP6		ENSG00000167779	Insulin like growth factor binding protein 6	12	53097436-53102345	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008005	Uncertain				Glioma:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 72.2	cervix, uterine: 47.7	Cell line enhanced		BJ: 290.6;HaCaT: 180.1;U-87 MG: 136.0
IGFBP7	FSTL2, IGFBP-7, MAC25, PSF	ENSG00000163453	Insulin like growth factor binding protein 7	4	57030773-57110385	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002196, CAB020668	Approved		Uncertain	Golgi apparatus		Expressed in all	Expressed in all			seminal vesicle: 916.3	Cell line enhanced		BJ: 585.7;BJ hTERT+: 522.8;EFO-21: 407.8;RPTEC TERT1: 516.3;TIME: 821.5
IGFBPL1	bA113O24.1	ENSG00000137142	Insulin like growth factor binding protein like 1	9	38408994-38424447	Predicted secreted proteins	Evidence at protein level	HPA051354	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	8	thyroid gland: 31.5	cerebral cortex: 3.9	Group enriched	6	AF22: 359.4;NTERA-2: 100.5;RH-30: 101.1;SCLC-21H: 438.6;SH-SY5Y: 383.3
IGFL1	UNQ644	ENSG00000188293	IGF like family member 1	19	46229752-46231243	Predicted secreted proteins	Evidence at protein level	HPA014001	Uncertain					Group enriched	Tissue enriched	22	esophagus: 97.7	tonsil: 4.4	Group enriched	8	HaCaT: 6.2;RT4: 20.8;SK-BR-3: 6.6
IGFL2	UNQ645	ENSG00000204866	IGF like family member 2	19	46143106-46161299	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA059137	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	6	skin: 35.5	parathyroid gland: 6.1	Cell line enriched	33	CACO-2: 68.3
IGFL3	UNQ483	ENSG00000188624	IGF like family member 3	19	46120071-46124674	Predicted secreted proteins	Evidence at protein level	HPA062776	Uncertain					Tissue enhanced	Tissue enriched	7	skin: 16.9	parathyroid gland: 2.5	Cell line enhanced		BJ hTERT+: 3.1;hTEC/SVTERT24-B: 1.3;U-2 OS: 1.4;U-87 MG: 2.5
IGFLR1	FLJ22573, TMEM149, U2AF1L4	ENSG00000126246	IGF like family receptor 1	19	35738801-35742453	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012369	Uncertain		Approved	Focal adhesion sites	Ovarian cancer:1.59e-5 (favourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.8	Cell line enhanced		HMC-1: 29.7;U-266/70: 26.0
IGLON5	LOC402665	ENSG00000142549	IgLON family member 5	19	51311848-51330354	Predicted secreted proteins	Evidence at protein level	HPA041994	Approved		Uncertain	Nucleus	Renal cancer:5.62e-7 (unfavourable)	Tissue enhanced	Group enriched	7	adrenal gland: 2.3;cerebral cortex: 11.1;testis: 9.5	esophagus,seminal vesicle: 1.0	Group enriched	8	HMC-1: 30.8;NTERA-2: 16.0;SH-SY5Y: 24.3;U-2 OS: 6.9
IGSF1	IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2	ENSG00000147255	Immunoglobulin superfamily member 1	X	131273506-131578899	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012732, HPA035582	Enhanced		Approved	Cytosol	Endometrial cancer:4.25e-8 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 20.0	adrenal gland: 13.1	Cell line enhanced		Hep G2: 22.7;SH-SY5Y: 30.6
IGSF10	CMF608, FLJ25972	ENSG00000152580	Immunoglobulin superfamily member 10	3	151425384-151458709	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012921	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Mixed	Tissue enhanced		ovary: 18.1	gallbladder: 14.7	Cell line enhanced		HeLa: 31.1;HL-60: 18.4;REH: 15.7;RPMI-8226: 38.1
IGSF11	BT-IgSF, CT119, Igsf13, MGC35227, VSIG3	ENSG00000144847	Immunoglobulin superfamily member 11	3	118900557-119146068	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046377	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 31.0;testis: 64.9	ovary: 20.1	Cell line enhanced		A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
IGSF21	MGC15730, RP11-121A23.1	ENSG00000117154	Immunoglobin superfamily member 21	1	18107746-18378483	Predicted secreted proteins	Evidence at protein level	HPA044535	Approved					Group enriched	Tissue enhanced		cerebral cortex: 28.9;spleen: 13.2	adrenal gland: 5.9	Cell line enriched	6	SCLC-21H: 21.2
IGSF8	CD316, CD81P3, EWI2, PGRL	ENSG00000162729	Immunoglobulin superfamily member 8	1	160091340-160098943	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011917	Uncertain				Cervical cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.8	Expressed in all		
IGSF9	IGSF9A, KIAA1355, Nrt1	ENSG00000085552	Immunoglobulin superfamily member 9	1	159927039-159945604	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037753	Uncertain				Endometrial cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 28.1	stomach: 13.2	Cell line enhanced		BEWO: 25.2;HaCaT: 34.4;SCLC-21H: 40.2
IHH	BDA1, HHG2	ENSG00000163501	Indian hedgehog	2	219054420-219060467	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.67e-6 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3	prostate: 3.2	Cell line enriched	11	CACO-2: 16.8
IL10	CSIF, IL-10, IL10A, TGIF	ENSG00000136634	Interleukin 10	1	206767602-206772494	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB013120	Uncertain					Mixed	Tissue enhanced		appendix: 8.7	adipose tissue: 7.4	Group enriched	7	HMC-1: 5.2;U-266/70: 6.5
IL11	AGIF, IL-11	ENSG00000095752	Interleukin 11	19	55364389-55370463	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044955			Uncertain	Mitochondria	Pancreatic cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 5.7;endometrium: 5.2;gallbladder: 4.9	placenta: 1.7	Cell line enhanced		BJ: 50.3;BJ hTERT+: 54.5;hTEC/SVTERT24-B: 54.2;U-251 MG: 179.7
IL11RA		ENSG00000137070	Interleukin 11 receptor subunit alpha	9	34650702-34661892	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013162, CAB032830, HPA036652	Supported				Renal cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Mixed		
IL12B	CLMF, CLMF2, IL-12B, NKSF, NKSF2	ENSG00000113302	Interleukin 12B	5	159314783-159330887	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040970	Approved					Tissue enriched	Not detected			spleen: 0.6	Cell line enhanced		SCLC-21H: 1.0
IL12RB1	CD212, IL12RB	ENSG00000096996	Interleukin 12 receptor subunit beta 1	19	18058995-18098944	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074414			Approved	Plasma membrane	Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 25.9	spleen: 20.6	Cell line enhanced		Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8
IL12RB2		ENSG00000081985	Interleukin 12 receptor subunit beta 2	1	67307364-67396900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024168	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 11.8	cerebral cortex: 4.4	Cell line enhanced		HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
IL13	ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600	ENSG00000169194	Interleukin 13	5	132656263-132661110	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042421			Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	10	testis: 19.9	gallbladder: 2.0	Cell line enriched	226	HDLM-2: 38.1
IL13RA1	CD213a1, IL-13Ra, NR4	ENSG00000131724	Interleukin 13 receptor subunit alpha 1	X	118727572-118794539	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000293			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.19e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 72.0	Mixed		
IL15RA	CD215, IL-15RA	ENSG00000134470	Interleukin 15 receptor subunit alpha	10	5943639-5978187	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026215	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.5	Cell line enhanced		CAPAN-2: 59.4;HDLM-2: 70.4
IL17A	CTLA8, IL-17, IL-17A, IL17	ENSG00000112115	Interleukin 17A	6	52186387-52190638	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052258	Uncertain					Not detected	Tissue enhanced		appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5	gallbladder: 0.3	Group enriched	16	Karpas-707: 1.9;U-266/84: 1.2
IL17B	IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7	ENSG00000127743	Interleukin 17B	5	149371324-149404202	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA042441	Uncertain					Mixed	Tissue enhanced		breast: 4.0	smooth muscle: 3.3	Cell line enhanced		HEL: 1.2
IL17C	CX2, IL-17C, IL-21, MGC126884, MGC138401	ENSG00000124391	Interleukin 17C	16	88638591-88640473	Predicted secreted proteins	Evidence at protein level	HPA065051	Supported					Mixed	Tissue enriched	6	endometrium: 3.5	gallbladder: 0.6	Not detected		
IL17D	FLJ30846, IL-17D, IL-22, IL-27, IL27	ENSG00000172458	Interleukin 17D	13	20702127-20723098	Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	7	cerebral cortex: 100.2;skeletal muscle: 45.9	ovary: 10.2	Mixed		
IL17F	IL-17F, ML-1, ML1	ENSG00000112116	Interleukin 17F	6	52236681-52244537	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 1.8	urinary bladder: 0.9	Not detected		
IL17RA	CD217, CDw217, hIL-17R, IL-17RA, IL17R	ENSG00000177663	Interleukin 17 receptor A	22	17084954-17115694	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024996	Enhanced		Approved	Nucleoplasm<br>Cytosol	Stomach cancer:8.35e-4 (favourable)	Expressed in all	Mixed			bone marrow: 20.6	Cell line enhanced		HL-60: 47.4;THP-1: 50.1
IL17RC	IL17-RL	ENSG00000163702	Interleukin 17 receptor C	3	9917074-9933630	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019885, CAB026255	Approved				Endometrial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Mixed		
IL17RE	FLJ23658	ENSG00000163701	Interleukin 17 receptor E	3	9902612-9916402	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019011	Uncertain					Expressed in all	Mixed			small intestine: 22.6	Cell line enhanced		ASC TERT1: 27.7;BEWO: 14.7;T-47d: 18.4
IL18BP	IL18BPa	ENSG00000137496	Interleukin 18 binding protein	11	71998541-72005715	Predicted secreted proteins	Evidence at protein level	CAB025980, HPA041061	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:2.93e-6 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 56.2	appendix: 32.8	Mixed		
IL18R1	CD218a, IL-1Rrp, IL1RRP	ENSG00000115604	Interleukin 18 receptor 1	2	102311529-102398775	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007615	Approved		Approved	Mitochondria	Renal cancer:4.52e-4 (unfavourable)	Mixed	Mixed			placenta: 14.4	Cell line enhanced		HDLM-2: 28.1;HHSteC: 51.3;HMC-1: 36.8;U-937: 54.3
IL18RAP	AcPL, CD218b	ENSG00000115607	Interleukin 18 receptor accessory protein	2	102418689-102452565	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025270	Enhanced					Mixed	Tissue enhanced		bone marrow: 70.9	appendix: 16.9	Cell line enriched	10	U-937: 42.2
IL19	IL-10C, IL-19, MDA1, NG.1, ZMDA1	ENSG00000142224	Interleukin 19	1	206798870-206842981	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cervix, uterine: 21.0	salivary gland: 2.3	Cell line enriched	11	BJ hTERT+: 4.9
IL1R1	CD121A, D2S1473, IL1R, IL1RA	ENSG00000115594	Interleukin 1 receptor type 1	2	102064544-102179874	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005823, CAB007779, HPA029560	Approved				Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 246.0	Cell line enhanced		ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
IL1R2	CD121b, IL1RB	ENSG00000115590	Interleukin 1 receptor type 2	2	101991844-102028544	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027597, HPA027598	Uncertain				Renal cancer:5.58e-12 (unfavourable)	Mixed	Mixed			appendix: 50.3	Cell line enriched	24	HDLM-2: 436.8
IL1RAP	C3orf13, IL-1RAcP, IL1R3	ENSG00000196083	Interleukin 1 receptor accessory protein	3	190514051-190659750	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035293	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 113.0;placenta: 53.7	gallbladder: 19.8	Cell line enhanced		SK-MEL-30: 193.6
IL1RL1	DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1	ENSG00000115602	Interleukin 1 receptor like 1	2	102311502-102352037	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007406, HPA007917	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	placenta: 289.6	gallbladder: 23.7	Group enriched	6	HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2
IL1RL2	IL1R-rp2, IL1RRP2	ENSG00000115598	Interleukin 1 receptor like 2	2	102186973-102240002	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015485	Uncertain					Mixed	Tissue enhanced		skin: 15.5	parathyroid gland: 8.5	Cell line enhanced		A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1
IL1RN	ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430	ENSG00000136689	Interleukin 1 receptor antagonist	2	113107214-113134016	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001482, CAB009633	Enhanced				Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1243.9	tonsil: 290.5	Cell line enhanced		A-431: 51.8;HaCaT: 100.6;RT4: 89.4
IL2	IL-2, TCGF	ENSG00000109471	Interleukin 2	4	122451470-122456725	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010310	Uncertain					Not detected	Not detected			rectum,small intestine,tonsil: 0.3	Not detected		
IL20	IL-20, IL10D, ZCYTO10	ENSG00000162891	Interleukin 20	1	206865354-206869223	Predicted secreted proteins	Evidence at protein level	CAB025802	Uncertain					Tissue enhanced	Tissue enhanced		smooth muscle: 1.0	seminal vesicle: 0.8	Cell line enhanced		SiHa: 1.9
IL20RA	IL-20R1, ZCYTOR7	ENSG00000016402	Interleukin 20 receptor subunit alpha	6	136999971-137045180	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024990, HPA042281	Approved		Approved	Cytosol	Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable)	Mixed	Tissue enhanced		skin: 45.0	breast: 33.5	Group enriched	7	CAPAN-2: 8.4;HaCaT: 6.1;RT4: 9.2;SH-SY5Y: 11.4;T-47d: 10.0
IL21	IL-21, Za11	ENSG00000138684	Interleukin 21	4	122612628-122621069	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 18.1;tonsil: 6.3	testis: 4.1	Not detected		
IL22	IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18	ENSG00000127318	Interleukin 22	12	68248242-68253607	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			appendix,urinary bladder: 0.8	Not detected		
IL22RA2	CRF2-S1, IL-22BP	ENSG00000164485	Interleukin 22 receptor subunit alpha 2	6	137143820-137173648	Predicted secreted proteins	Evidence at protein level	HPA030582, CAB034906	Uncertain					Mixed	Tissue enhanced		breast: 4.1;tonsil: 2.9	appendix: 1.9	Cell line enhanced		U-937: 1.0
IL23A	IL-23, IL-23A, IL23P19, P19, SGRF	ENSG00000110944	Interleukin 23 subunit alpha	12	56334174-56340410	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA001554	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		tonsil: 8.0	urinary bladder: 6.5	Cell line enhanced		A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0
IL25	IL-17E, IL-25, IL17E	ENSG00000166090	Interleukin 25	14	23372809-23376403	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024864	Approved					Not detected	Not detected			testis: 0.3	Not detected		
IL26	AK155, IL-26	ENSG00000111536	Interleukin 26	12	68201351-68225821	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		appendix: 1.2;urinary bladder: 1.4	tonsil: 0.9	Cell line enriched	19	HDLM-2: 12.4
IL27	IL-27, IL-27A, IL27A, IL27p28, IL30, MGC71873, p28	ENSG00000197272	Interleukin 27	16	28499362-28512051	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024722	Approved				Liver cancer:1.30e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 8.0	appendix: 1.6	Cell line enriched	15	BEWO: 17.2
IL2RB	CD122, IL15RB	ENSG00000100385	Interleukin 2 receptor subunit beta	22	37125838-37175054	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062657	Enhanced				Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 52.7;spleen: 67.1	lymph node: 39.8	Cell line enriched	10	HDLM-2: 476.9
IL3	IL-3, MCGF, MGC79398, MGC79399, MULTI-CSF	ENSG00000164399	Interleukin 3	5	132060529-132063204	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			bone marrow,epididymis,parathyroid gland,testis: 0.1	Cell line enriched	15	HMC-1: 2.2
IL31	IL-31	ENSG00000204671	Interleukin 31	12	122172030-122174199	Predicted secreted proteins	Evidence at transcript level	CAB025657	Approved					Not detected	Not detected			testis: 0.2	Not detected		
IL31RA	CRL, CRL3, GLM-R, Glmr, IL-31RA	ENSG00000164509	Interleukin 31 receptor A	5	55851379-55922853	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051532, HPA068114	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 3.6	bone marrow: 1.2	Cell line enhanced		hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
IL34	C16orf77, IL-34, MGC34647	ENSG00000157368	Interleukin 34	16	70579895-70660682	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.52e-8 (unfavourable), Cervical cancer:7.41e-4 (favourable), Head and neck cancer:9.69e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 58.0;spleen: 145.6	cerebral cortex: 20.8	Cell line enhanced		NTERA-2: 5.5;U-138 MG: 3.5
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
IL4	BCGF-1, BCGF1, BSF1, IL-4, MGC79402	ENSG00000113520	Interleukin 4	5	132673986-132682676	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA072995	Approved					Not detected	Tissue enhanced		parathyroid gland: 1.6	skin: 0.6	Group enriched	6	HMC-1: 3.4;MOLT-4: 17.0
IL4I1	FIG1	ENSG00000104951	Interleukin 4 induced 1	19	49889654-49929539	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045598	Enhanced				Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 24.5;testis: 32.0	lymph node: 10.5	Cell line enhanced		EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8
IL4R	CD124	ENSG00000077238	Interleukin 4 receptor	16	27313668-27364778	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004451, HPA050124	Enhanced				Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Mixed		
IL5	EDF, IL-5, TRF	ENSG00000113525	Interleukin 5	5	132541444-132556838	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010304	Approved					Not detected	Tissue enriched	9	testis: 9.6	small intestine: 1.0	Cell line enhanced		Hep G2: 1.9;TIME: 1.0
IL5RA	CD125, CDw125, IL5R	ENSG00000091181	Interleukin 5 receptor subunit alpha	3	3066326-3126613	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 22.7	lung: 4.9	Cell line enriched	28	HMC-1: 66.2
IL6	BSF2, HGF, HSF, IFNB2, IL-6	ENSG00000136244	Interleukin 6	7	22725884-22732002	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB023406, CAB072821	Supported		Approved	Vesicles	Renal cancer:1.10e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 136.4	urinary bladder: 73.6	Group enriched	7	BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	1	154405193-154469450	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.65e-4 (favourable)	Expressed in all	Mixed			appendix: 33.4	Cell line enhanced		THP-1: 147.4;U-266/84: 186.8
IL6ST	CD130, GP130	ENSG00000134352	Interleukin 6 signal transducer	5	55935095-55994993	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010558, CAB025784	Uncertain		Supported	Golgi apparatus<br>Plasma membrane	Renal cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.8	Expressed in all		
IL7	IL-7	ENSG00000104432	Interleukin 7	8	78675743-78805523	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019590	Approved				Renal cancer:2.69e-4 (unfavourable)	Mixed	Mixed			skin: 10.2	Cell line enhanced		HDLM-2: 15.6;HEL: 15.9;HMC-1: 22.1
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	5	35852695-35879603	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010215	Approved		Approved	Plasma membrane<br>Microtubule organizing center		Expressed in all	Tissue enhanced		appendix: 182.9;lymph node: 158.5	tonsil: 112.9	Cell line enhanced		fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
IL9	HP40, IL-9, P40	ENSG00000145839	Interleukin 9	5	135892246-135895827	Cancer-related genes, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.7	skin: 0.5	Cell line enriched	235	HDLM-2: 41.4
ILDR1	DFNB42, MGC50831	ENSG00000145103	Immunoglobulin like domain containing receptor 1	3	121987323-122022204	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018207	Approved				Renal cancer:5.79e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	cervix, uterine: 20.0	Cell line enhanced		CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6
ILDR2	C1orf32	ENSG00000143195	Immunoglobulin like domain containing receptor 2	1	166895711-166975482	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012545	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 11.3;testis: 17.4	kidney: 3.1	Cell line enhanced		AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
IMP4	BXDC4, MGC19606	ENSG00000136718	IMP4 homolog, U3 small nucleolar ribonucleoprotein	2	130342225-130347810	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066222, HPA066673			Enhanced	Nucleoli	Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 22.7	Expressed in all		
IMPG1	GP147, IPM150, SPACR	ENSG00000112706	Interphotoreceptor matrix proteoglycan 1	6	75921115-76072678	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027142, HPA030332, HPA030333	Enhanced					Not detected	Tissue enhanced		cerebral cortex: 1.5;skin: 1.6	duodenum,small intestine: 0.9	Cell line enhanced		HaCaT: 1.0
INHA		ENSG00000123999	Inhibin alpha subunit	2	219569162-219575713	Predicted secreted proteins	Evidence at protein level	CAB000047, HPA019141	Enhanced		Approved	Vesicles	Renal cancer:4.03e-5 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 51.5;ovary: 38.0;testis: 106.3	placenta: 14.9	Cell line enhanced		HEL: 3.7;SK-BR-3: 6.8
INHBA		ENSG00000122641	Inhibin beta A subunit	7	41667168-41705834	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 28.7;gallbladder: 35.1	lung: 16.4	Group enriched	6	HBEC3-KT: 54.3;hTEC/SVTERT24-B: 227.2;hTERT-HME1: 71.4;TIME: 97.6;U-138 MG: 172.4;U-2 OS: 52.9
INHBB		ENSG00000163083	Inhibin beta B subunit	2	120346143-120351808	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:1.02e-4 (favourable), Colorectal cancer:1.44e-4 (unfavourable), Renal cancer:3.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 27.1	adipose tissue: 24.9	Cell line enhanced		A549: 42.9;ASC diff: 43.3;MCF7: 44.4;PC-3: 85.1;SK-BR-3: 122.2
INHBC		ENSG00000175189	Inhibin beta C subunit	12	57434760-57450828	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	42	liver: 85.9	testis: 2.0	Cell line enhanced		Hep G2: 4.5;Karpas-707: 4.7;RH-30: 3.2;U-266/70: 2.6
INHBE	activin, MGC4638	ENSG00000139269	Inhibin beta E subunit	12	57452323-57459280	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016843, CAB034017	Enhanced		Approved	Vesicles	Renal cancer:5.66e-8 (unfavourable)	Tissue enriched	Tissue enriched	28	liver: 68.1	thyroid gland: 2.4	Cell line enhanced		HHSteC: 43.4;Karpas-707: 57.3;U-266/70: 203.5
INS	IDDM1, IDDM2	ENSG00000254647	Insulin	11	2159779-2161341	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000048, HPA004932, CAB012098, CAB053843	Enhanced					Tissue enriched	Tissue enriched	27	pancreas: 1850.7	skin: 68.2	Group enriched	10	EFO-21: 194.7;U-2 OS: 281.2;U-698: 61.2
INS-IGF2		ENSG00000129965	INS-IGF2 readthrough	11	2132538-2161209	Predicted secreted proteins	Evidence at protein level	CAB019430	Enhanced					Not detected	Tissue enhanced		pancreas: 1.6;placenta: 3.3	adrenal gland,endometrium: 0.5	Cell line enhanced		SH-SY5Y: 1.3
INSL3	MGC119818, MGC119819, RLF, RLNL	ENSG00000248099	Insulin like 3	19	17816512-17821574	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA028615	Enhanced					Tissue enriched	Tissue enriched	120	testis: 772.7	appendix: 6.4	Cell line enhanced		Karpas-707: 4.1;SCLC-21H: 6.1;SH-SY5Y: 5.0
INSL4	EPIL	ENSG00000120211	Insulin like 4	9	5231419-5235304	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	12	placenta: 22.2	epididymis: 1.8	Cell line enriched	10	A549: 22.2
INSL5		ENSG00000172410	Insulin like 5	1	66797741-66801256	Predicted secreted proteins	Evidence at protein level	HPA030100, CAB033849	Enhanced					Group enriched	Group enriched	228	colon: 77.7;rectum: 141.9	cerebral cortex: 0.4	Not detected		
INSL6	RIF1	ENSG00000120210	Insulin like 6	9	5131979-5185668	Predicted secreted proteins	Evidence at protein level	HPA021364	Enhanced					Not detected	Tissue enriched	40	testis: 21.6	placenta: 0.5	Not detected		
IPO11	RanBP11	ENSG00000086200	Importin 11	5	62403972-62628582	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067097	Approved		Enhanced	Nucleus<br>Nucleoli fibrillar center	Liver cancer:4.28e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 40.6	Expressed in all		
IQCF6		ENSG00000214686	IQ motif containing F6	3	51778561-51779187	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	125	testis: 17.6	kidney,skin,stomach: 0.1	Cell line enhanced		U-937: 1.1
IQGAP1	HUMORFA01, KIAA0051, p195, SAR1	ENSG00000140575	IQ motif containing GTPase activating protein 1	15	90388218-90502243	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013302, HPA014055	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Pancreatic cancer:5.67e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 120.4	Expressed in all		
IRAK3	IRAK-M	ENSG00000090376	Interleukin 1 receptor associated kinase 3	12	66188879-66254622	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043097	Approved		Approved	Vesicles	Renal cancer:6.23e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 51.0	adipose tissue: 19.3	Cell line enhanced		HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5
ISLR	HsT17563	ENSG00000129009	Immunoglobulin superfamily containing leucine rich repeat	15	74173671-74176872	Predicted secreted proteins	Evidence at protein level	HPA040326, HPA050811	Approved		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:4.89e-8 (unfavourable)	Expressed in all	Mixed			endometrium: 198.8	Cell line enhanced		ASC diff: 85.5;ASC TERT1: 46.5;fHDF/TERT166: 227.9;RPMI-8226: 63.5
ISLR2	KIAA1465	ENSG00000167178	Immunoglobulin superfamily containing leucine rich repeat 2	15	74100311-74138540	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012930, HPA067333	Uncertain					Mixed	Group enriched	5	cerebral cortex: 31.1;testis: 14.8	endometrium: 4.5	Group enriched	13	SCLC-21H: 68.2;SH-SY5Y: 91.6
ISM1	bA149I18.1, C20orf82	ENSG00000101230	Isthmin 1	20	13221771-13300651	Predicted secreted proteins	Evidence at protein level						Renal cancer:9.32e-6 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 74.7	placenta: 24.8	Cell line enhanced		ASC diff: 40.6;Hep G2: 16.4
ISM2	FLJ32147, TAIL1, THSD3	ENSG00000100593	Isthmin 2	14	77474394-77498850	Predicted secreted proteins	Evidence at protein level	HPA039314, HPA039742	Supported		Supported	Nucleoplasm		Mixed	Tissue enriched	112	placenta: 274.5	epididymis: 2.4	Cell line enriched	21	BEWO: 345.7
ITGA4	CD49D	ENSG00000115232	Integrin subunit alpha 4	2	181457202-181536187	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074961			Approved	Plasma membrane	Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Mixed	Tissue enhanced		spleen: 67.6	appendix: 49.6	Cell line enhanced		fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGA9	ALPHA-RLC, ITGA4L, RLC	ENSG00000144668	Integrin subunit alpha 9	3	37452115-37823514	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030609	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 34.7	Cell line enhanced		CACO-2: 8.3;HEL: 7.3;SH-SY5Y: 12.3;WM-115: 6.1
ITGAL	CD11A, LFA-1	ENSG00000005844	Integrin subunit alpha L	16	30472658-30523185	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025011	Enhanced				Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 79.0;spleen: 80.9	appendix: 52.5	Cell line enriched	5	HMC-1: 570.1
ITGAX	CD11C	ENSG00000140678	Integrin subunit alpha X	16	31355134-31382997	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004458, HPA004723, CAB072871	Enhanced				Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 58.3;spleen: 59.0	bone marrow: 30.4	Cell line enriched	5	HMC-1: 92.2
ITGB1	CD29, FNRB, GPIIA, MDF2, MSK12	ENSG00000150093	Integrin subunit beta 1	10	32900319-33005792	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB003434, HPA059297, HPA069003	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites	Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1069.5	Expressed in all		
ITGB2	CD18, LFA-1, MAC-1, MFI7	ENSG00000160255	Integrin subunit beta 2	21	44885953-44931989	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008877, HPA016894	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			appendix: 239.2	Cell line enhanced		EFO-21: 120.5;THP-1: 518.6;U-937: 447.2
ITGB3	CD61, GP3A, GPIIIa	ENSG00000259207	Integrin subunit beta 3	17	47253846-47311816	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027852	Supported					Group enriched	Tissue enhanced		thyroid gland: 95.6	smooth muscle: 36.8	Cell line enhanced		EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
ITGB7		ENSG00000139626	Integrin subunit beta 7	12	53191318-53207307	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042277			Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			spleen: 32.5	Group enriched	97	Karpas-707: 3399.5;RPMI-8226: 2658.1
ITGBL1	OSCP, TIED	ENSG00000198542	Integrin subunit beta like 1	13	101452593-101720856	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005676	Uncertain				Urothelial cancer:2.70e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 59.8	placenta: 47.2	Cell line enhanced		ASC diff: 142.9;fHDF/TERT166: 267.4;LHCN-M2: 259.5
ITIH1	H1P, IATIH, ITIH	ENSG00000055957	Inter-alpha-trypsin inhibitor heavy chain 1	3	52777592-52792068	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041639, HPA042049	Approved		Approved	Vesicles	Liver cancer:1.89e-5 (favourable)	Tissue enriched	Tissue enriched	458	liver: 786.3	spleen: 1.7	Cell line enhanced		ASC diff: 3.6;Hep G2: 1.1;HL-60: 1.0
ITIH2	H2P	ENSG00000151655	Inter-alpha-trypsin inhibitor heavy chain 2	10	7703269-7749520	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059150	Supported		Approved	Golgi apparatus	Liver cancer:1.48e-4 (favourable)	Tissue enriched	Tissue enriched	208	liver: 1093.4	cerebral cortex: 5.2	Cell line enriched	896	Hep G2: 735.5
ITIH3	H3P	ENSG00000162267	Inter-alpha-trypsin inhibitor heavy chain 3	3	52794768-52809009	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017373	Approved	Approved			Renal cancer:4.49e-8 (unfavourable)	Tissue enriched	Tissue enriched	51	liver: 413.6	spleen: 8.0	Cell line enriched	18	Hep G2: 11.7
ITIH4	H4P, IHRP, ITIHL1	ENSG00000055955	Inter-alpha-trypsin inhibitor heavy chain family member 4	3	52812975-52831479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001835, HPA003948, CAB072872	Enhanced		Approved	Vesicles		Tissue enriched	Tissue enriched	71	liver: 984.5	skeletal muscle: 13.8	Cell line enhanced		HDLM-2: 2.2;U-266/70: 2.1
ITIH5	MGC10848	ENSG00000123243	Inter-alpha-trypsin inhibitor heavy chain family member 5	10	7559270-7666998	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038305	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			placenta: 123.4	Cell line enriched	7	WM-115: 101.4
ITIH6	ITIH5L, UNQ6369	ENSG00000102313	Inter-alpha-trypsin inhibitor heavy chain family member 6	X	54748899-54798240	Predicted secreted proteins	Evidence at protein level	HPA000506	Uncertain					Tissue enriched	Not detected			prostate: 0.6	Cell line enriched	24	WM-115: 50.0
ITLN1	FLJ20022, hIntL, HL-1, ITLN, LFR	ENSG00000179914	Intelectin 1	1	160876539-160885170	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB012652, HPA063275, HPA067326	Enhanced					Tissue enhanced	Tissue enhanced		colon: 447.7;rectum: 1428.1;small intestine: 468.9	duodenum: 276.3	Cell line enhanced		HEL: 2.3;HL-60: 1.5;U-937: 5.7
ITLN2	HL-2	ENSG00000158764	Intelectin 2	1	160945025-160954799	Predicted secreted proteins	Evidence at protein level	HPA006683, HPA067326	Enhanced					Tissue enhanced	Group enriched	19	duodenum: 244.7;small intestine: 454.0	lung: 18.2	Cell line enhanced		HEL: 10.8;HMC-1: 3.0;SK-MEL-30: 3.0
IZUMO1R	Folbp3, FOLR4, JUNO	ENSG00000183560	IZUMO1 receptor, JUNO	11	94305592-94307721	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.8	Not detected		
IZUMO4	C19orf36	ENSG00000099840	IZUMO family member 4	19	2096429-2099593	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA045099, HPA048496	Enhanced		Uncertain	Nucleoplasm<br>Vesicles	Pancreatic cancer:1.69e-4 (favourable), Endometrial cancer:7.08e-4 (favourable)	Mixed	Tissue enriched	52	testis: 341.9	ovary: 6.5	Cell line enhanced		Karpas-707: 6.0;RPMI-8226: 7.2
JAM3	JAM-C, JAMC	ENSG00000166086	Junctional adhesion molecule 3	11	134068925-134152001	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003417, HPA050434	Uncertain		Enhanced	Golgi apparatus	Urothelial cancer:2.68e-4 (unfavourable), Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 144.4	Cell line enhanced		RH-30: 119.8
JAML	AMICA, AMICA1, Gm638	ENSG00000160593	Junction adhesion molecule like	11	118193740-118225094	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047919	Approved				Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		appendix: 82.3	spleen: 67.0	Cell line enhanced		CACO-2: 4.8;HMC-1: 24.2
JCHAIN	IGCJ, IGJ, JCH	ENSG00000132465	Joining chain of multimeric IgA and IgM	4	70655541-70681817	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB034436, HPA044132	Enhanced				Head and neck cancer:7.56e-7 (favourable), Breast cancer:1.81e-6 (favourable), Renal cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 6965.1	Group enriched	205	Daudi: 2569.0;Karpas-707: 1336.5;RPMI-8226: 2653.0;U-266/70: 5934.2;U-266/84: 2263.1;U-698: 3199.2
JMJD8	C16orf20	ENSG00000161999	Jumonji domain containing 8	16	681671-684528	Predicted secreted proteins	Evidence at transcript level							Expressed in all	Expressed in all			parathyroid gland: 59.8	Mixed		
KANSL2	C12orf41, FLJ20436, NSL2	ENSG00000139620	KAT8 regulatory NSL complex subunit 2	12	48653401-48682238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038497, HPA038498	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:4.32e-4 (favourable), Liver cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 31.9	Expressed in all		
KAZALD1	FKSG28, FKSG40	ENSG00000107821	Kazal type serine peptidase inhibitor domain 1	10	101061841-101068131	Predicted secreted proteins	Evidence at protein level	HPA011800	Uncertain				Thyroid cancer:5.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 26.8	cervix, uterine: 15.7	Cell line enhanced		AN3-CA: 35.1;T-47d: 45.4
KCNIP2	KCHIP2	ENSG00000120049	Potassium voltage-gated channel interacting protein 2	10	101825974-101843920	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2	breast: 16.6	Cell line enhanced		HEL: 13.8;HMC-1: 9.2
KCNIP3	CSEN, DREAM, KCHIP3	ENSG00000115041	Potassium voltage-gated channel interacting protein 3	2	95297304-95386083	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069797	Approved				Endometrial cancer:1.58e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 40.6;parathyroid gland: 44.0	thyroid gland: 28.0	Cell line enhanced		BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1
KCNK7	K2p7.1	ENSG00000173338	Potassium two pore domain channel subfamily K member 7	11	65592855-65595996	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels	Evidence at transcript level	HPA077577			Approved	Plasma membrane		Tissue enhanced	Tissue enriched	7	skin: 53.2	esophagus: 7.9	Cell line enhanced		SCLC-21H: 8.4
KCNU1	KCa5.1, Kcnma3, KCNMC1, Slo3	ENSG00000215262	Potassium calcium-activated channel subfamily U member 1	8	36784324-36936128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063317			Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	28	testis: 13.5	adipose tissue,epididymis: 0.4	Cell line enriched	6	HDLM-2: 7.3
KCP	CRIM2, FLJ33365, NET67	ENSG00000135253	Kielin/chordin-like protein	7	128862451-128910719	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		kidney: 2.7;seminal vesicle: 3.3	gallbladder: 1.5	Cell line enhanced		CAPAN-2: 8.4;HMC-1: 4.7;U-87 MG: 2.3
KDELC1	EP58, MGC5302	ENSG00000134901	KDEL motif containing 1	13	102784281-102799007	Predicted secreted proteins	Evidence at protein level	CAB020780, HPA043946, HPA064398	Approved		Supported	Nucleus	Head and neck cancer:2.24e-4 (unfavourable), Renal cancer:4.73e-4 (unfavourable), Lung cancer:4.81e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 17.7	Mixed		
KDELC2	MGC33424	ENSG00000178202	KDEL motif containing 2	11	108472105-108498432	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039315, HPA039817, HPA066134	Uncertain		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:6.27e-5 (unfavourable), Liver cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.2	Mixed		
KDM3B	C5orf7, JMJD1B, KIAA1082, NET22	ENSG00000120733	Lysine demethylase 3B	5	138352596-138437028	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016610, HPA057202	Supported		Enhanced	Nucleoplasm	Renal cancer:6.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.3	Expressed in all		
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
KERA	CNA2, SLRR2B	ENSG00000139330	Keratocan	12	91050491-91057983	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039321	Uncertain					Mixed	Tissue enhanced		gallbladder: 1.5	breast,fallopian tube: 0.8	Not detected		
KIAA0319	NMIG	ENSG00000137261	KIAA0319	6	24544104-24646155	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015607, HPA076313	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 15.8	fallopian tube: 2.8	Cell line enhanced		HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
KIAA1324	EIG121, maba1	ENSG00000116299	KIAA1324	1	109113679-109206781	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029869, HPA070749	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)	Mixed	Mixed			cervix, uterine: 129.0	Cell line enhanced		MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3
KIFC2		ENSG00000167702	Kinesin family member C2	8	144466043-144474202	Predicted secreted proteins	Evidence at protein level	HPA029264	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 73.1	Mixed		
KIR2DL4	103AS, 15.212, CD158D	ENSG00000189013	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	19	54803535-54814517	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Not detected			all non-specific tissues: 0.0	Not detected		
KIRREL2	DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1	ENSG00000126259	Kin of IRRE like 2 (Drosophila)	19	35855861-35867109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071587, HPA074326			Supported	Microtubule organizing center		Mixed	Tissue enriched	8	pancreas: 11.6	cerebral cortex: 1.4	Cell line enhanced		HDLM-2: 20.2;HMC-1: 29.3
KISS1		ENSG00000170498	KiSS-1 metastasis-suppressor	1	204190341-204196486	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB017775, HPA035542	Enhanced		Approved	Vesicles	Urothelial cancer:6.29e-6 (favourable)	Tissue enhanced	Tissue enriched	87	placenta: 328.1	stomach: 3.7	Group enriched	21	BJ: 123.9;U-2 OS: 60.5
KLHL22	FLJ14360, KELCHL	ENSG00000099910	Kelch like family member 22	22	20441519-20495883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040766			Supported	Golgi apparatus<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:1.34e-8 (favourable), Pancreatic cancer:3.85e-6 (favourable), Endometrial cancer:4.88e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.6	Mixed		
KLK1	Klk6	ENSG00000167748	Kallikrein 1	19	50819148-50823787	Enzymes, Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	36	pancreas: 1994.7;salivary gland: 2549.9	colon: 63.5	Cell line enriched	18	RPMI-8226: 26.9
KLK10	NES1, PRSSL1	ENSG00000129451	Kallikrein related peptidase 10	19	51012739-51020175	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA017195			Uncertain	Plasma membrane<br>Cytosol	Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 138.2;skin: 52.7	tonsil: 45.8	Group enriched	5	CAPAN-2: 200.9;HaCaT: 307.2
KLK11	PRSS20, TLSP	ENSG00000167757	Kallikrein related peptidase 11	19	51022216-51028039	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026340	Approved				Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 225.7;skin: 214.5	prostate: 104.9	Cell line enhanced		CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6
KLK12	KLK-L5	ENSG00000186474	Kallikrein related peptidase 12	19	51029092-51035230	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB025473	Uncertain				Thyroid cancer:8.01e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 32.4	tonsil: 8.1	Not detected		
KLK13	KLK-L4	ENSG00000167759	Kallikrein related peptidase 13	19	51056206-51065114	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA062136	Enhanced					Tissue enhanced	Tissue enriched	9	esophagus: 402.2	tonsil: 45.0	Cell line enriched	10	HaCaT: 16.8
KLK14	KLK-L6	ENSG00000129437	Kallikrein related peptidase 14	19	51077495-51084245	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026228	Uncertain					Tissue enhanced	Tissue enriched	5	skin: 10.4	breast: 2.0	Cell line enhanced		HaCaT: 8.7;U-266/84: 3.7
KLK15	ACO, HSRNASPH, prostinogen	ENSG00000174562	Kallikrein related peptidase 15	19	50825289-50837213	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019802	Uncertain					Tissue enhanced	Tissue enhanced		colon: 3.2;salivary gland: 2.4	adrenal gland: 1.8	Cell line enriched	5	RPMI-8226: 1.7
KLK2		ENSG00000167751	Kallikrein related peptidase 2	19	50861568-50880567	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000764	Supported					Tissue enriched	Tissue enriched	192	prostate: 867.2	testis: 4.5	Cell line enhanced		NB-4: 3.6
KLK3	APS, PSA	ENSG00000142515	Kallikrein related peptidase 3	19	50854915-50860764	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000070, HPA000764	Enhanced					Tissue enriched	Tissue enriched	365	prostate: 12913.0	seminal vesicle: 35.3	Group enriched	165	BEWO: 30.5;NB-4: 17.7;RPMI-8226: 12.8;SH-SY5Y: 11.1;U-2197: 10.1
KLK4	EMSP, EMSP1, KLK-L1, PRSS17, PSTS	ENSG00000167749	Kallikrein related peptidase 4	19	50906352-50910738	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051839	Enhanced					Tissue enriched	Tissue enriched	37	prostate: 406.5	skin: 10.8	Cell line enhanced		CAPAN-2: 5.7;HaCaT: 7.0
KLK5	KLK-L2, SCTE	ENSG00000167754	Kallikrein related peptidase 5	19	50943303-50953093	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA014343, CAB025503, CAB026341	Enhanced				Urothelial cancer:3.85e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable), Lung cancer:9.79e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	skin: 213.5	breast: 37.8	Group enriched	41	A-431: 414.4;HaCaT: 396.7
KLK6	Bssp, Klk7, neurosin, PRSS18, PRSS9	ENSG00000167755	Kallikrein related peptidase 6	19	50958631-50969673	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051837			Supported	Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge	Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3	kidney: 10.2	Group enriched	15	A-431: 496.5;CAPAN-2: 1158.9
KLK7	PRSS6, SCCE	ENSG00000169035	Kallikrein related peptidase 7	19	50976482-50984099	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018994, CAB026342, HPA062126	Enhanced		Supported	Nuclear membrane<br>Plasma membrane	Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)	Tissue enhanced	Group enriched	5	esophagus: 68.7;skin: 219.6	fallopian tube: 27.9	Group enriched	6	CAPAN-2: 7.1;HaCaT: 28.1
KLK8	HNP, neuropsin, ovasin, PRSS19, TADG14	ENSG00000129455	Kallikrein related peptidase 8	19	50996007-51002711	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB019393, HPA035761	Enhanced		Approved	Vesicles	Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 77.9;fallopian tube: 20.9;skin: 96.8	breast: 11.0	Group enriched	7	A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
KLK9	KLK-L3	ENSG00000213022	Kallikrein related peptidase 9	19	51003111-51009634	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at transcript level	CAB025049	Uncertain					Tissue enriched	Not detected			skin,tonsil: 0.8	Not detected		
KLKB1	KLK3	ENSG00000164344	Kallikrein B1	4	186208979-186258471	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	45	liver: 155.0	gallbladder,kidney: 3.4	Cell line enhanced		NTERA-2: 2.9;SCLC-21H: 2.3
KMT5A	PR-Set7, SET07, SET8, SETD8	ENSG00000183955	Lysine methyltransferase 5A	12	123383773-123409358	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA064495			Approved	Nucleus<br>Cytosol	Liver cancer:6.21e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 36.8	Expressed in all		
KNG1	BDK, BK, KNG	ENSG00000113889	Kininogen 1	3	186717276-186743954	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001616, HPA001645, CAB009809	Enhanced				Liver cancer:1.28e-6 (favourable)	Tissue enriched	Group enriched	994	kidney: 522.4;liver: 1864.6	rectum: 1.2	Cell line enhanced		CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3
KREMEN2	KRM2, MGC10791	ENSG00000131650	Kringle containing transmembrane protein 2	16	2963944-2968383	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA003223	Uncertain		Approved	Nucleoli	Lung cancer:8.98e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 6.9	cerebral cortex: 2.1	Cell line enhanced		HMC-1: 24.6;RPMI-8226: 19.1
KRTDAP	KDAP, UNQ467	ENSG00000188508	Keratinocyte differentiation associated protein	19	35487324-35495558	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA063474	Enhanced					Group enriched	Tissue enriched	11	skin: 4647.8	breast: 422.9	Cell line enriched	47	hTCEpi: 55.8
L1CAM	CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1	ENSG00000198910	L1 cell adhesion molecule	X	153861514-153909223	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010896	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 36.0;cerebral cortex: 66.9	seminal vesicle: 12.8	Cell line enhanced		BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
LA16c-380H5.3		ENSG00000270168		16	2988256-3002016	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	7	skin: 4.8	lung: 0.7	Cell line enhanced		HaCaT: 3.6;hTCEpi: 2.2;SCLC-21H: 3.6
LACRT	LACRITIN	ENSG00000135413	Lacritin	12	54630811-54634895	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	6	salivary gland: 4.6	breast: 0.7	Not detected		
LAG3	CD223	ENSG00000089692	Lymphocyte activating 3	12	6772512-6778455	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002301, HPA013967	Enhanced				Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 32.0	lymph node: 17.6	Cell line enriched	140	HDLM-2: 136.0
LAIR2	CD306	ENSG00000167618	Leukocyte associated immunoglobulin like receptor 2	19	54497879-54510687	CD markers, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 1.4	spleen: 0.8	Cell line enhanced		BEWO: 2.2
LALBA	LYZL7	ENSG00000167531	Lactalbumin alpha	12	48567684-48570066	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026343, HPA029855, HPA029856	Supported					Tissue enriched	Tissue enriched	566	breast: 2476.8	testis: 4.3	Not detected		
LAMA1	LAMA	ENSG00000101680	Laminin subunit alpha 1	18	6941744-7117814	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010179	Enhanced					Mixed	Tissue enhanced		testis: 11.2	thyroid gland: 4.3	Cell line enhanced		AF22: 55.1;BEWO: 192.1
LAMA2	LAMM	ENSG00000196569	Laminin subunit alpha 2	6	128883141-129516569	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB040310, CAB078182	Enhanced				Urothelial cancer:3.65e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 150.0	ovary: 49.5	Cell line enhanced		ASC diff: 174.0;ASC TERT1: 126.8;HSkMC: 113.6
LAMA3	BM600-150kDa, epiligrin, kalinin-165kDa, LAMNA, nicein-150kDa	ENSG00000053747	Laminin subunit alpha 3	18	23689443-23955066	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009309, CAB010757	Uncertain		Enhanced	Endoplasmic reticulum	Pancreatic cancer:3.58e-6 (unfavourable)	Mixed	Mixed			placenta: 30.7	Cell line enhanced		CAPAN-2: 122.4;HaCaT: 195.1;HBEC3-KT: 770.3
LAMA4	LAMA3	ENSG00000112769	Laminin subunit alpha 4	6	112108760-112254939	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA015693, CAB078156	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.00e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 146.3	Cell line enhanced		ASC diff: 216.1;ASC TERT1: 333.0;HSkMC: 271.2;HUVEC TERT2: 340.0;TIME: 306.5
LAMA5		ENSG00000130702	Laminin subunit alpha 5	20	62307955-62367312	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054609, CAB078157	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		skin: 42.1	placenta: 28.9	Cell line enhanced		CACO-2: 131.3
LAMB1	CLM	ENSG00000091136	Laminin subunit beta 1	7	107923799-108003255	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004056, HPA004132, CAB004256	Enhanced				Liver cancer:2.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 263.7	adipose tissue: 161.4	Cell line enhanced		HSkMC: 640.2
LAMB2	LAMS, NPHS5	ENSG00000172037	Laminin subunit beta 2	3	49121114-49133118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000053, HPA001895, HPA050033, CAB078160	Supported		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 207.4	Cell line enhanced		fHDF/TERT166: 231.7
LAMB3	BM600-125kDa, kalinin-140kDa, LAMNB1, nicein-125kDa	ENSG00000196878	Laminin subunit beta 3	1	209614870-209652466	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008069, CAB078183	Enhanced		Approved	Nucleoli<br>Mitochondria	Renal cancer:2.43e-5 (unfavourable), Lung cancer:9.62e-5 (unfavourable), Pancreatic cancer:2.55e-4 (unfavourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Mixed			stomach: 68.9	Cell line enhanced		CAPAN-2: 308.4;HaCaT: 470.9;HBEC3-KT: 935.2;hTCEpi: 295.3
LAMB4		ENSG00000091128	Laminin subunit beta 4	7	108023548-108130356	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020242, HPA024247	Approved		Uncertain	Cytosol		Tissue enhanced	Tissue enriched	12	skin: 46.5	placenta: 3.8	Cell line enhanced		BEWO: 1.8
LAMC1	LAMB2	ENSG00000135862	Laminin subunit gamma 1	1	183023460-183145592	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001908, HPA001909, CAB004486, CAB078163	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane	Urothelial cancer:8.85e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 332.9	smooth muscle: 147.5	Cell line enhanced		ASC diff: 1091.5;HSkMC: 716.3
LAMC2	BM600-100kDa, EBR2, EBR2A, kalinin-105kDa, LAMB2T, LAMNB2, nicein-100kDa	ENSG00000058085	Laminin subunit gamma 2	1	183186238-183244900	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004257, HPA024638, CAB078165	Enhanced		Approved	Cytosol	Lung cancer:4.20e-6 (unfavourable), Pancreatic cancer:7.11e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 57.8	lung: 38.9	Cell line enhanced		A-431: 521.5;CAPAN-2: 460.7;HBEC3-KT: 1872.4;hTERT-HME1: 1202.0;RPTEC TERT1: 464.3
LAMC3	DKFZp434E202	ENSG00000050555	Laminin subunit gamma 3	9	131009082-131094473	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022814	Enhanced					Mixed	Tissue enhanced		placenta: 88.7	testis: 26.1	Cell line enhanced		AF22: 5.3;EFO-21: 19.9;Hep G2: 5.5;SiHa: 8.5;U-2 OS: 6.9
LAMP3	CD208, DC-LAMP, DCLAMP, LAMP, TSC403	ENSG00000078081	Lysosomal associated membrane protein 3	3	183122213-183163839	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025133, HPA051467	Enhanced		Enhanced	Vesicles	Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)	Mixed	Tissue enriched	7	lung: 319.3	appendix: 44.9	Group enriched	8	EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3
LARGE2	FLJ35207, GYLTL1B, PP5656	ENSG00000165905	LARGE xylosyl- and glucuronyltransferase 2	11	45921621-45929096	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056621	Approved				Renal cancer:3.04e-12 (favourable)	Mixed	Tissue enhanced		placenta: 52.7	parathyroid gland: 21.6	Cell line enhanced		BEWO: 33.3;NTERA-2: 32.6;T-47d: 67.1
LAT2	HSPC046, LAB, NTAL, WBSCR15, WBSCR5, WSCR5	ENSG00000086730	Linker for activation of T-cells family member 2	7	74199652-74229834	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003462	Enhanced				Renal cancer:4.10e-4 (unfavourable), Testis cancer:6.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 70.0	tonsil: 58.3	Cell line enhanced		NB-4: 128.3;REH: 209.9;THP-1: 139.1;U-937: 157.8
LBP	BPIFD2	ENSG00000129988	Lipopolysaccharide binding protein	20	38346356-38377023	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001508, CAB025905	Approved				Renal cancer:3.62e-12 (unfavourable), Cervical cancer:5.56e-4 (unfavourable), Stomach cancer:5.76e-4 (unfavourable)	Tissue enriched	Group enriched	5	adipose tissue: 69.3;liver: 264.7	appendix: 31.3	Group enriched	7	ASC diff: 6.7;HSkMC: 8.5
LCAT		ENSG00000213398	Lecithin-cholesterol acyltransferase	16	67939750-67944131	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044767			Approved	Nucleoplasm	Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 105.7	Cell line enhanced		BEWO: 73.6
LCN1	MGC71975, PMFA, TLC, TP, VEGP	ENSG00000160349	Lipocalin 1	9	135521438-135526532	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	fallopian tube: 3.1;seminal vesicle: 12.2	testis: 0.6	Not detected		
LCN10		ENSG00000187922	Lipocalin 10	9	136738167-136743356	Predicted secreted proteins	Evidence at protein level	HPA055919	Approved					Tissue enriched	Tissue enriched	6	epididymis: 18.9	endometrium: 3.3	Not detected		
LCN12	MGC48935	ENSG00000184925	Lipocalin 12	9	136949551-136955497	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	31	epididymis: 45.4	thyroid gland: 1.4	Not detected		
LCN15	PRO6093, UNQ2541	ENSG00000177984	Lipocalin 15	9	136759634-136766255	Predicted secreted proteins	Evidence at protein level	HPA060584	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0	colon: 2.8	Group enriched	14	Hep G2: 11.9;SCLC-21H: 3.0
LCN2	24p3, NGAL	ENSG00000148346	Lipocalin 2	9	128149071-128153455	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002695, CAB016549, CAB016550	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:9.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 1852.1;gallbladder: 3419.4	cervix, uterine: 1163.5	Group enriched	11	CAPAN-2: 3169.5;EFO-21: 1362.3
LCN6		ENSG00000267206	Lipocalin 6	9	136744011-136748528	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	234	epididymis: 1881.6	smooth muscle: 8.0	Group enriched	5	NB-4: 2.1;REH: 9.6
LCN9		ENSG00000148386	Lipocalin 9	9	135663322-135666422	Predicted secreted proteins	Evidence at protein level	HPA060941	Enhanced					Not detected	Tissue enhanced		epididymis: 1.1	cerebral cortex: 0.6	Cell line enriched	19	BEWO: 16.2
LDLR	LDLCQ2	ENSG00000130164	Low density lipoprotein receptor	19	11089362-11133816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009647, HPA013159	Approved				Pancreatic cancer:6.60e-5 (unfavourable), Urothelial cancer:3.43e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 87.6	Expressed in all		
LDLRAD2		ENSG00000187942	Low density lipoprotein receptor class A domain containing 2	1	21812265-21825221	Predicted secreted proteins	Evidence at transcript level	HPA030478	Approved					Mixed	Mixed			adipose tissue: 2.1	Cell line enhanced		REH: 1.1;TIME: 1.8
LEAP2	LEAP-2	ENSG00000164406	Liver enriched antimicrobial peptide 2	5	132872322-132875046	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.68e-4 (favourable)	Tissue enriched	Tissue enriched	9	liver: 66.1	small intestine: 7.7	Mixed		
LECT2	chm-II, chm2	ENSG00000145826	Leukocyte cell derived chemotaxin 2	5	135922279-135955034	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043883	Enhanced				Liver cancer:4.16e-5 (favourable)	Tissue enriched	Tissue enriched	16	liver: 230.9	testis: 14.6	Mixed		
LEFTY1	LEFTB, LEFTYB	ENSG00000243709	Left-right determination factor 1	1	225886282-225911382	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA047883, HPA056210	Approved				Renal cancer:2.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 58.4;pancreas: 20.4;rectum: 35.2	appendix: 9.6	Cell line enriched	7	NTERA-2: 50.6
LEFTY2	EBAF, LEFTA, LEFTYA, TGFB4	ENSG00000143768	Left-right determination factor 2	1	225936598-225941489	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025801, HPA047883, HPA056210	Approved					Tissue enriched	Group enriched	6	endometrium: 264.3;smooth muscle: 57.0	ovary: 26.0	Group enriched	12	HDLM-2: 8.7;NTERA-2: 40.5;RPMI-8226: 31.4
LEP	OB, OBS	ENSG00000174697	Leptin	7	128241284-128257628	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010490, HPA030721	Approved	Approved				Tissue enhanced	Tissue enriched	11	adipose tissue: 322.5	breast: 29.6	Cell line enhanced		BEWO: 2.1
LFNG	SCDO3	ENSG00000106003	LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	7	2512529-2529177	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069130	Approved				Endometrial cancer:6.36e-4 (favourable)	Expressed in all	Expressed in all			skin: 68.5	Cell line enhanced		RH-30: 44.5;U-2 OS: 52.5
LGALS3BP	90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B	ENSG00000108679	Galectin 3 binding protein	17	78971238-78980109	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000554, CAB002158	Supported				Renal cancer:1.07e-6 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 323.2	Cell line enhanced		SK-BR-3: 1216.4
LGI1	EPITEMPIN, EPT, ETL1, IB1099	ENSG00000108231	Leucine rich glioma inactivated 1	10	93757809-93806272	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	11	cerebral cortex: 45.4	esophagus: 4.2	Group enriched	5	AF22: 9.4;NTERA-2: 6.4
LGI2	FLJ10675, KIAA1916	ENSG00000153012	Leucine rich repeat LGI family member 2	4	24998847-25030879	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017140	Approved		Approved	Centrosome		Mixed	Tissue enriched	19	parathyroid gland: 371.4	smooth muscle: 19.6	Cell line enhanced		AF22: 27.8;RPMI-8226: 9.3;SCLC-21H: 21.4
LGI3		ENSG00000168481	Leucine rich repeat LGI family member 3	8	22146825-22157084	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024826			Approved	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 76.0;lung: 23.9;skin: 17.3;thyroid gland: 21.6	esophagus: 5.2	Cell line enhanced		A549: 1.0;SCLC-21H: 1.9;SK-MEL-30: 1.3;WM-115: 1.0
LGI4		ENSG00000153902	Leucine rich repeat LGI family member 4	19	35124513-35142451	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042116, HPA043556	Approved		Approved	Golgi apparatus	Renal cancer:2.84e-7 (unfavourable)	Group enriched	Mixed			cerebral cortex: 26.2	Cell line enriched	36	WM-115: 29.6
LGMN	LGMN1, PRSC1	ENSG00000100600	Legumain	14	92703807-92748702	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001426	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.70e-4 (favourable)	Expressed in all	Expressed in all			placenta: 360.0	Cell line enhanced		RPMI-8226: 587.9;U-266/70: 339.8
LGR4	GPR48	ENSG00000205213	Leucine rich repeat containing G protein-coupled receptor 4	11	27365961-27472775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030267, HPA054350	Uncertain		Approved	Microtubule organizing center	Renal cancer:2.00e-7 (favourable)	Expressed in all	Expressed in all			kidney: 56.2	Cell line enhanced		HAP1: 86.6
LHB	CGB4, hLHB, LSH-B	ENSG00000104826	Luteinizing hormone beta polypeptide	19	49015980-49017081	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB022241, CAB022707, HPA038925	Supported		Approved	Cytosol	Pancreatic cancer:6.78e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 3.2;pancreas: 4.8;testis: 2.9	adrenal gland,skin,small intestine: 0.7	Mixed		
LHCGR	HHG, LCGR, LGR2, LHR, ULG5	ENSG00000138039	Luteinizing hormone/choriogonadotropin receptor	2	48686775-48755730	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009814	Uncertain					Not detected	Tissue enhanced		ovary: 1.6;testis: 4.3	adipose tissue: 1.3	Not detected		
LIF	CDF, DIA, HILDA	ENSG00000128342	Leukemia inhibitory factor	22	30240447-30246851	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018844, CAB025985	Approved		Enhanced	Cytosol	Renal cancer:6.78e-8 (unfavourable), Cervical cancer:9.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 75.6	urinary bladder: 42.0	Cell line enhanced		hTEC/SVTERT24-B: 111.9;U-138 MG: 121.7;U-251 MG: 77.3;U-87 MG: 95.4
LILRA2	CD85h, ILT1, LIR-7, LIR7	ENSG00000239998	Leukocyte immunoglobulin like receptor A2	19	54572920-54590287	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 9.9;spleen: 7.0	appendix: 4.0	Cell line enhanced		REH: 1.8;THP-1: 2.7;U-937: 7.1
LILRB3	CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	19	54216278-54223506	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Group enriched	5	adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8	placenta: 1.7	Not detected		
LIME1	dJ583P15.4, FLJ20406, LIME	ENSG00000203896	Lck interacting transmembrane adaptor 1	20	63736283-63739103	Predicted secreted proteins	Evidence at protein level	CAB015363	Approved				Urothelial cancer:6.92e-6 (favourable), Renal cancer:5.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		liver: 19.6;stomach: 17.6	kidney: 15.2	Cell line enhanced		MOLT-4: 31.1;RPMI-8226: 97.2;U-266/70: 55.2
LINC00176	DKFZp434G015, FLJ27267, NCRNA00176, PRR17	ENSG00000196421	Long intergenic non-protein coding RNA 176	20	64034344-64039962	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Not detected			parathyroid gland,spleen: 0.2	Group enriched	11	HDLM-2: 6.9;Hep G2: 33.0
LINC01125		ENSG00000228486	Long intergenic non-protein coding RNA 1125	2	97664217-97703064	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.7	skin: 2.4	Cell line enhanced		AF22: 1.7;HDLM-2: 1.8
LINGO1	FLJ14594, LERN1, LRRN6A	ENSG00000169783	Leucine rich repeat and Ig domain containing 1	15	77613027-77820900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074653	Enhanced		Approved	Plasma membrane	Renal cancer:3.23e-7 (unfavourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 130.8	placenta: 9.8	Cell line enhanced		AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK 293: 19.6;NTERA-2: 56.8
LIPA	CESD, LAL	ENSG00000107798	Lipase A, lysosomal acid type	10	89213569-89414557	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034892, HPA057052	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			spleen: 496.6	Mixed		
LIPC	HL, HTGL	ENSG00000166035	Lipase C, hepatic type	15	58410569-58569843	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	14	liver: 86.4	kidney: 6.3	Cell line enhanced		CACO-2: 6.9;EFO-21: 5.7;Hep G2: 16.4;HMC-1: 6.0;U-2197: 17.2
LIPF	HGL, HLAL	ENSG00000182333	Lipase F, gastric type	10	88664441-88678814	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045930	Enhanced					Tissue enriched	Tissue enriched	86	stomach: 22415.5	duodenum: 259.5	Cell line enhanced		HMC-1: 3.6;MOLT-4: 2.7;NTERA-2: 3.5;THP-1: 4.5;U-2 OS: 2.4;U-266/70: 2.4
LIPG	EDL	ENSG00000101670	Lipase G, endothelial type	18	49560699-49599182	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016966	Uncertain					Tissue enriched	Group enriched	11	placenta: 214.4;thyroid gland: 403.2	seminal vesicle: 29.1	Cell line enhanced		AN3-CA: 113.7;HaCaT: 167.5;RPTEC TERT1: 93.8;TIME: 201.4
LIPH	LPDLR, mPA-PLA1, mPA-PLA1alpha, PLA1B	ENSG00000163898	Lipase H	3	185506262-185552613	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049079	Approved				Renal cancer:9.20e-5 (favourable), Thyroid cancer:4.21e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Endometrial cancer:9.40e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 40.8;stomach: 45.0	colon: 35.7	Cell line enhanced		CAPAN-2: 65.0;RPTEC TERT1: 28.0;T-47d: 16.5
LIPK	bA186O14.2, LIPL2	ENSG00000204021	Lipase family member K	10	88724544-88752786	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	skin: 37.4	breast: 3.2	Cell line enriched	5	SK-BR-3: 1.9
LIPN	bA186O14.3, LIPL4	ENSG00000204020	Lipase family member N	10	88761406-88778242	Disease related genes, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	skin: 39.8	appendix: 5.7	Group enriched	7	Daudi: 1.0;HL-60: 3.5
LMAN2	C5orf8, GP36B, VIP36	ENSG00000169223	Lectin, mannose binding 2	5	177331562-177351852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003927	Approved				Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 164.8	Expressed in all		
LNX1	LNX, MPDZ, PDZRN2	ENSG00000072201	Ligand of numb-protein X 1	4	53459301-53701405	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002235, HPA071091	Approved		Supported	Cell Junctions<br>Cytosol	Renal cancer:3.08e-7 (favourable)	Expressed in all	Mixed			placenta: 39.4	Mixed		
LOX		ENSG00000113083	Lysyl oxidase	5	122063195-122078360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043930			Supported	Endoplasmic reticulum	Renal cancer:3.93e-8 (unfavourable), Urothelial cancer:3.32e-4 (unfavourable), Liver cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 29.6	Cell line enhanced		BJ: 799.4;fHDF/TERT166: 1126.5;U-138 MG: 458.1
LOXL1	LOL, LOXL	ENSG00000129038	Lysyl oxidase like 1	15	73925989-73952137	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042111, HPA063583	Approved		Approved	Endoplasmic reticulum	Glioma:1.33e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 16.8	Cell line enhanced		BJ hTERT+: 61.2
LOXL2	WS9-14	ENSG00000134013	Lysyl oxidase like 2	8	23297189-23425328	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025848, HPA036257, HPA056542	Approved		Approved	Nucleoplasm	Lung cancer:1.46e-7 (unfavourable), Renal cancer:2.91e-7 (unfavourable), Cervical cancer:9.83e-6 (unfavourable), Glioma:1.78e-4 (unfavourable), Pancreatic cancer:9.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 59.8	placenta: 53.3	Cell line enhanced		BJ: 809.1;U-87 MG: 911.1
LOXL3		ENSG00000115318	Lysyl oxidase like 3	2	74532414-74555690	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035281	Approved				Renal cancer:7.97e-8 (unfavourable)	Tissue enhanced	Mixed			placenta: 21.6	Cell line enhanced		U-138 MG: 238.3;WM-115: 524.2
LOXL4	FLJ21889, LOXC	ENSG00000138131	Lysyl oxidase like 4	10	98247690-98268250	Predicted secreted proteins	Evidence at protein level	CAB033876, HPA037609	Approved		Approved	Vesicles	Glioma:5.36e-4 (unfavourable), Ovarian cancer:9.57e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.8	Cell line enhanced		BJ hTERT+: 199.7;CAPAN-2: 260.1;U-2 OS: 57.0
LPA	LP, Lp(a)	ENSG00000198670	Lipoprotein(a)	6	160531483-160664259	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016072, HPA060604	Supported					Tissue enriched	Tissue enriched	25	liver: 41.5	seminal vesicle: 1.6	Not detected		
LPL	LIPD	ENSG00000175445	Lipoprotein lipase	8	19901717-19967258	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048749			Supported	Vesicles	Urothelial cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 976.8	heart muscle: 239.2	Cell line enriched	7	AF22: 363.8
LPO	SPO	ENSG00000167419	Lactoperoxidase	17	58218548-58268518	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028688	Enhanced	Supported				Not detected	Tissue enriched	221	salivary gland: 372.8	testis: 1.6	Cell line enriched	7	THP-1: 6.2
LRAT	LCA14	ENSG00000121207	Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)	4	154626945-154753118	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070726			Uncertain	Endoplasmic reticulum<br>Golgi apparatus		Mixed	Tissue enhanced		thyroid gland: 2.3	testis: 1.6	Cell line enriched	11	NTERA-2: 11.7
LRCOL1		ENSG00000204583	Leucine rich colipase like 1	12	132603150-132610543	Predicted secreted proteins	Evidence at transcript level						Liver cancer:7.04e-4 (favourable)	Tissue enhanced	Tissue enriched	62	epididymis: 54.5	lung: 0.8	Not detected		
LRFN4	FIGLER6, MGC3103, SALM3.	ENSG00000173621	Leucine rich repeat and fibronectin type III domain containing 4	11	66856647-66860475	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 13.3	Mixed		
LRFN5	C14orf146, FIGLER8, SALM5	ENSG00000165379	Leucine rich repeat and fibronectin type III domain containing 5	14	41607570-41904549	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001177	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 52.3	cervix, uterine: 16.8	Cell line enhanced		AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4
LRG1	LRG	ENSG00000171236	Leucine rich alpha-2-glycoprotein 1	19	4536409-4540474	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001888, HPA001889	Enhanced		Approved	Vesicles	Renal cancer:3.66e-6 (unfavourable), Thyroid cancer:3.49e-4 (favourable)	Tissue enriched	Tissue enriched	8	liver: 173.8	appendix,esophagus: 21.1	Cell line enhanced		THP-1: 15.8;U-937: 34.0
LRP1	A2MR, APOER, APR, CD91, LRP, LRP1A	ENSG00000123384	LDL receptor related protein 1	12	57128493-57213351	Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004182, CAB018621, HPA022903	Supported		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 123.8	Cell line enhanced		ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4
LRP11	bA350J20.3, MANSC3	ENSG00000120256	LDL receptor related protein 11	6	149818798-149864026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064002			Approved	Mitochondria	Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.2	Mixed		
LRP1B	LRP-DIT, LRPDIT	ENSG00000168702	LDL receptor related protein 1B	2	140231423-142131701	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069094, HPA074788	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 16.4;thyroid gland: 9.6	epididymis: 2.7	Cell line enhanced		ASC diff: 1.0;HEK 293: 1.5;U-138 MG: 1.8
LRP2	DBS, gp330	ENSG00000081479	LDL receptor related protein 2	2	169127109-169362685	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005980, HPA064792	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:3.43e-5 (favourable)	Group enriched	Group enriched	6	kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0	breast: 14.2	Group enriched	11	AF22: 39.4;CACO-2: 56.2
LRP4	CLSS, LRP-4, MEGF7, SOST2	ENSG00000134569	LDL receptor related protein 4	11	46856868-46918642	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011934, HPA012300	Approved		Uncertain	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		cerebral cortex: 35.4;skin: 37.9	parathyroid gland: 13.1	Cell line enhanced		AF22: 21.2
LRPAP1	A2MRAP, HBP44	ENSG00000163956	LDL receptor related protein associated protein 1	4	3506376-3532559	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA008001, CAB025518	Enhanced	Supported	Enhanced	Endoplasmic reticulum	Renal cancer:4.67e-11 (favourable)	Expressed in all	Expressed in all			placenta: 13.7	Expressed in all		
LRRC17	H_RG318M05.3, P37NB	ENSG00000128606	Leucine rich repeat containing 17	7	102912991-102944949	Predicted secreted proteins	Evidence at protein level	HPA030139			Approved	Nucleoplasm<br>Nuclear speckles<br>Plasma membrane	Renal cancer:4.12e-6 (unfavourable), Urothelial cancer:6.30e-4 (unfavourable)	Mixed	Tissue enhanced		ovary: 99.1	gallbladder: 46.8	Group enriched	5	LHCN-M2: 1100.6;RH-30: 248.7
LRRC32	D11S833E, GARP	ENSG00000137507	Leucine rich repeat containing 32	11	76657524-76670747	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055775, HPA058434			Supported	Nucleoplasm	Renal cancer:3.93e-5 (unfavourable), Urothelial cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.4	Group enriched	5	ASC diff: 78.8;ASC TERT1: 49.2;HSkMC: 32.0;HUVEC TERT2: 43.0;U-2197: 100.6
LRRC3B	LRP15	ENSG00000179796	Leucine rich repeat containing 3B	3	26622806-26710776	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015568	Approved					Group enriched	Group enriched	7	cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0	endometrium,ovary: 1.6	Cell line enhanced		NTERA-2: 1.6
LRRC4B	DKFZp761A179, HSM, LRIG4	ENSG00000131409	Leucine rich repeat containing 4B	19	50516892-50568045	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA058986	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 61.4	cervix, uterine: 12.9	Cell line enhanced		HMC-1: 29.7;SH-SY5Y: 31.3;U-2 OS: 28.7
LRRC70	LOC100130733, SLRN	ENSG00000186105	Leucine rich repeat containing 70	5	62578735-62581448	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013409	Uncertain					Mixed	Mixed			thyroid gland: 6.4	Group enriched	16	HUVEC TERT2: 13.7;TIME: 7.3
LRRCC1	CLERC, KIAA1764, VFL1	ENSG00000133739	Leucine rich repeat and coiled-coil centrosomal protein 1	8	85107147-85146076	Predicted intracellular proteins	Evidence at protein level	HPA012893	Uncertain					Expressed in all	Tissue enhanced		testis: 57.8	thyroid gland: 14.2	Cell line enhanced		HDLM-2: 38.0
LRRN3	FIGLER5, FLJ11129, NLRR3	ENSG00000173114	Leucine rich repeat neuronal 3	7	111091006-111125454	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043820, HPA046792	Uncertain		Approved	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6	lung: 11.6	Cell line enhanced		AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
LRRTM1	FLJ32082	ENSG00000162951	Leucine rich repeat transmembrane neuronal 1	2	80288351-80304749	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062660	Approved					Group enriched	Tissue enhanced		cerebral cortex: 13.3;salivary gland: 4.9	thyroid gland: 2.2	Cell line enhanced		SH-SY5Y: 1.4
LRRTM4	FLJ12568	ENSG00000176204	Leucine rich repeat transmembrane neuronal 4	2	76747719-77593319	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cerebral cortex: 21.3	epididymis: 2.4	Cell line enriched	7	Karpas-707: 91.1
LRTM2		ENSG00000166159	Leucine rich repeats and transmembrane domains 2	12	1820267-1836752	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055094	Uncertain					Not detected	Tissue enriched	47	cerebral cortex: 8.3	testis: 0.1	Group enriched	12	HEL: 7.7;SCLC-21H: 5.2
LSR	ILDR3, LISCH7	ENSG00000105699	Lipolysis stimulated lipoprotein receptor	19	35248330-35267964	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007270	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			stomach: 128.7	Cell line enhanced		A-431: 435.7
LST1	B144, D6S49E, LST-1	ENSG00000204482	Leukocyte specific transcript 1	6	31586124-31588909	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 68.7;spleen: 48.9	appendix: 32.1	Cell line enhanced		HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6
LTA	LT, TNFB, TNFSF1	ENSG00000226979	Lymphotoxin alpha	6	31572054-31574324	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA007729	Uncertain					Mixed	Tissue enhanced		lymph node: 1.5	spleen: 0.9	Not detected		
LTBP1		ENSG00000049323	Latent transforming growth factor beta binding protein 1	2	32946972-33399509	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005707, CAB025428	Approved		Approved	Cytosol	Renal cancer:7.79e-6 (unfavourable), Urothelial cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 261.1	Cell line enhanced		ASC TERT1: 399.0;U-87 MG: 250.3
LTBP2	C14orf141, LTBP3	ENSG00000119681	Latent transforming growth factor beta binding protein 2	14	74498170-74612378	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003415	Approved		Approved	Nucleus	Urothelial cancer:3.94e-4 (unfavourable)	Expressed in all	Mixed			lung: 75.1	Cell line enhanced		fHDF/TERT166: 185.0;TIME: 465.3
LTBP3	LTBP2	ENSG00000168056	Latent transforming growth factor beta binding protein 3	11	65538805-65558930	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA073170			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 104.2	Cell line enhanced		U-87 MG: 154.3
LTBP4	FLJ46318, FLJ90018, LTBP-4, LTBP-4L	ENSG00000090006	Latent transforming growth factor beta binding protein 4	19	40592883-40629818	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB015194	Approved				Ovarian cancer:2.36e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 244.9	Mixed		
LTBR	D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3	ENSG00000111321	Lymphotoxin beta receptor	12	6375045-6391571	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026202, HPA061617	Uncertain		Supported	Golgi apparatus	Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.5	Cell line enhanced		HHSteC: 330.0
LTF	HLF2	ENSG00000012223	Lactotransferrin	3	46435645-46485234	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008646, CAB016201, HPA057177, HPA059976	Enhanced				Renal cancer:6.30e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 2804.3;cervix, uterine: 1030.7	seminal vesicle: 532.6	Group enriched	10	RPMI-8226: 28.9;TIME: 11.6
LTK	TYK1	ENSG00000062524	Leukocyte receptor tyrosine kinase	15	41503638-41513887	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059545	Uncertain		Approved	Vesicles		Mixed	Mixed			placenta: 15.2	Cell line enhanced		HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LUM	LDC, SLRR2D	ENSG00000139329	Lumican	12	91102629-91111831	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001522, CAB025783	Supported				Renal cancer:1.75e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 929.5	placenta: 602.2	Cell line enhanced		BJ: 269.9;BJ hTERT+: 1272.0;fHDF/TERT166: 208.2
LUZP2		ENSG00000187398	Leucine zipper protein 2	11	24496970-25082631	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039007, HPA046161	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	5	adrenal gland: 8.6;cerebral cortex: 33.0	prostate: 3.8	Group enriched	6	HaCaT: 9.2;HAP1: 5.4
LY6E	RIG-E, SCA-2, TSA-1	ENSG00000160932	Lymphocyte antigen 6 family member E	8	143017982-143023832	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.74e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 564.1;MCF7: 492.5
LY6G5B	C6orf19, G5b	ENSG00000240053	Lymphocyte antigen 6 family member G5B	6	31670167-31673776	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048307	Approved					Mixed	Expressed in all			skin: 27.1	Expressed in all		
LY6G6D	C6orf23, G6D, Ly6-D, MEGT1, NG25	ENSG00000244355	Lymphocyte antigen 6 family member G6D	6	31715356-31717804	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054412	Uncertain					Tissue enriched	Tissue enhanced		seminal vesicle: 2.0	prostate: 0.8	Cell line enhanced		HEL: 1.6
LY6G6E	C6orf22, G6e	ENSG00000255552	Lymphocyte antigen 6 family member G6E	6	31711771-31714065	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA056234			Approved	Nucleus		Not detected	Tissue enhanced		skin: 1.2;thyroid gland: 1.0	bone marrow: 0.8	Cell line enriched	103	HEL: 21.3
LY6H	NMLY6	ENSG00000176956	Lymphocyte antigen 6 family member H	8	143157914-143160711	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	15	cerebral cortex: 38.0	duodenum: 2.5	Cell line enhanced		MOLT-4: 2.0;SCLC-21H: 1.5
LY6K	CT97, FLJ35226, HSJ001348	ENSG00000160886	Lymphocyte antigen 6 family member K	8	142700111-142705127	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017770, CAB075742, CAB075743	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Lung cancer:9.17e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 29.0	adipose tissue: 5.9	Cell line enhanced		A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
LY6L		ENSG00000261667	Lymphocyte antigen 6 family member L	8	143080457-143083001	Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		epididymis: 1.1	seminal vesicle: 0.7	Not detected		
LY86	dJ80N2.1, MD-1	ENSG00000112799	Lymphocyte antigen 86	6	6588108-6654983	Predicted secreted proteins	Evidence at protein level	CAB025000, HPA044895	Approved				Testis cancer:5.61e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 82.3	spleen: 66.3	Cell line enhanced		Daudi: 51.2;RPMI-8226: 162.0;THP-1: 62.7;U-937: 34.1
LY96	MD-2	ENSG00000154589	Lymphocyte antigen 96	8	73991352-74029087	Predicted secreted proteins	Evidence at protein level	HPA053060			Approved	Vesicles	Renal cancer:6.38e-11 (unfavourable)	Expressed in all	Mixed			spleen: 61.2	Cell line enhanced		Karpas-707: 119.4;U-87 MG: 82.4
LYG1	SALW1939	ENSG00000144214	Lysozyme g1	2	99284238-99304742	Predicted secreted proteins	Evidence at transcript level						Renal cancer:8.44e-4 (favourable)	Tissue enriched	Group enriched	5	kidney: 22.0;testis: 4.8	breast: 2.5	Mixed		
LYG2	LYGH	ENSG00000185674	Lysozyme g2	2	99242246-99255282	Predicted secreted proteins	Evidence at protein level	HPA039179	Uncertain					Mixed	Tissue enriched	6	testis: 2.5	skin: 0.4	Cell line enhanced		U-937: 1.9
LYNX1	SLURP2	ENSG00000180155	Ly6/neurotoxin 1	8	142771197-142777810	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:2.82e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 94.6	parathyroid gland: 58.6	Cell line enhanced		BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7
LYNX1		ENSG00000283992	Ly6/neurotoxin 1	8	142764338-142769844	Predicted secreted proteins, Transporters	Evidence at protein level								Group enriched	11	esophagus: 315.6;skin: 108.1	tonsil: 19.9	Group enriched	16	EFO-21: 5.6;HaCaT: 24.1
LYNX1		ENSG00000284505	Ly6/neurotoxin 1	8	142764334-142778224	Predicted secreted proteins, Transporters	Evidence at protein level								Tissue enhanced		esophagus: 5.8	skin: 4.0	Not detected		
LYPD1	LYPDC1, MGC29643	ENSG00000150551	LY6/PLAUR domain containing 1	2	132644853-132671579	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Group enriched	17	cerebral cortex: 27.2;fallopian tube: 127.3	salivary gland: 4.5	Cell line enhanced		hTEC/SVTERT24-B: 56.7;U-251 MG: 88.0;WM-115: 207.2
LYPD2	LYPDC2, RGTR430, UNQ430	ENSG00000197353	LY6/PLAUR domain containing 2	8	142750150-142752534	Predicted secreted proteins	Evidence at protein level	HPA028599	Uncertain				Cervical cancer:2.00e-4 (favourable), Head and neck cancer:2.63e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 99.1;tonsil: 24.0	stomach: 20.9	Group enriched	20	EFO-21: 9.5;HaCaT: 2.5
LYPD4	MGC42718	ENSG00000273111	LY6/PLAUR domain containing 4	19	41837074-41844697	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	749	testis: 165.3	bone marrow: 0.2	Not detected		
LYPD6	MGC52057	ENSG00000187123	LY6/PLAUR domain containing 6	2	149329985-149474148	Predicted secreted proteins	Evidence at protein level	HPA042805	Uncertain		Approved	Cytosol	Urothelial cancer:2.72e-4 (favourable), Ovarian cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 17.3;placenta: 22.5	breast: 12.0	Cell line enhanced		AN3-CA: 33.5;fHDF/TERT166: 36.6;LHCN-M2: 38.4;RT4: 30.7
LYPD8		ENSG00000259823	LY6/PLAUR domain containing 8	1	248718649-248755739	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	12	colon: 216.6;rectum: 141.8	appendix: 14.4	Not detected		
LYZ		ENSG00000090382	Lysozyme	12	69348341-69354234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	CAB000055, HPA048284, HPA066182	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Actin filaments	Head and neck cancer:7.45e-4 (favourable)	Expressed in all	Expressed in all			stomach: 9651.4	Group enriched	5	Hep G2: 633.5;THP-1: 321.5;U-937: 404.3
LYZL4	LYC4, MGC26768	ENSG00000157093	Lysozyme like 4	3	42397078-42410600	Predicted secreted proteins	Evidence at protein level	HPA038806	Approved					Not detected	Tissue enriched	58	testis: 43.8	cerebral cortex: 0.7	Not detected		
LYZL6	LYC1, PRO1485, TKAL754	ENSG00000275722	Lysozyme like 6	17	35934518-35943699	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025734, HPA053073	Supported					Not detected	Not detected			testis: 0.1	Not detected		
M6PR	CD-M6PR, CD-MPR	ENSG00000003056	Mannose-6-phosphate receptor, cation dependent	12	8940363-8949955	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034464, HPA040445	Approved				Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 175.3	Expressed in all		
MAD1L1	HsMAD1, MAD1, PIG9, TP53I9, TXBP181	ENSG00000002822	MAD1 mitotic arrest deficient like 1	7	1815793-2233243	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003635, CAB015338	Supported		Supported	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			lymph node: 23.3	Expressed in all		
MAG	GMA, S-MAG, SIGLEC-4A, SIGLEC4A	ENSG00000105695	Myelin associated glycoprotein	19	35292125-35313804	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009345, HPA012499	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 163.6	ovary: 27.5	Cell line enriched	31	WM-115: 35.4
MAGT1	DKFZp564K142, IAP, MRX95, OST3B	ENSG00000102158	Magnesium transporter 1	X	77826364-77895593	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049851	Approved				Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 137.3	Expressed in all		
MALSU1	C7orf30, mtRsfA	ENSG00000156928	Mitochondrial assembly of ribosomal large subunit 1	7	23298739-23311729	Predicted secreted proteins	Evidence at protein level	HPA020487, HPA052210	Approved		Enhanced	Mitochondria	Head and neck cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 5.2	Expressed in all		
MAMDC2	MGC21981	ENSG00000165072	MAM domain containing 2	9	70043581-70226970	Predicted secreted proteins	Evidence at protein level	HPA021814, HPA022249	Uncertain		Approved	Nuclear speckles<br>Plasma membrane	Thyroid cancer:7.78e-4 (unfavourable)	Mixed	Mixed			endometrium: 60.6	Cell line enhanced		ASC diff: 35.3;HHSteC: 44.9;LHCN-M2: 57.7;TIME: 54.7
MAN2B1	LAMAN, MANB	ENSG00000104774	Mannosidase alpha class 2B member 1	19	12646511-12666742	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041530, HPA053404	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.94e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 95.1	Expressed in all		
MAN2B2	KIAA0935	ENSG00000013288	Mannosidase alpha class 2B member 2	4	6575175-6623362	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA037005	Uncertain				Endometrial cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 37.7	Expressed in all		
MANBA		ENSG00000109323	Mannosidase beta	4	102631488-102760994	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA053478	Approved		Supported	Vesicles	Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.4	Expressed in all		
MANEAL	FLJ31434	ENSG00000185090	Mannosidase endo-alpha like	1	37793802-37801137	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063423			Approved	Golgi apparatus	Liver cancer:3.32e-4 (unfavourable), Head and neck cancer:5.28e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.2	adrenal gland: 9.5	Cell line enhanced		SCLC-21H: 167.3
MANF	ARMET, ARP	ENSG00000145050	Mesencephalic astrocyte derived neurotrophic factor	3	51385047-51389397	Predicted secreted proteins	Evidence at protein level	HPA011175	Approved		Supported	Endoplasmic reticulum	Head and neck cancer:9.58e-6 (unfavourable), Liver cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 125.4	Expressed in all		
MANSC1	FLJ10298, LOH12CR3	ENSG00000111261	MANSC domain containing 1	12	12326056-12350541	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007955, HPA007956	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.30e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Cell line enhanced		HUVEC TERT2: 42.6
MARK3	CTAK1, KP78, PAR-1A	ENSG00000075413	Microtubule affinity regulating kinase 3	14	103385392-103503831	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024652	Approved		Approved	Nuclear membrane	Melanoma:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 64.0	Expressed in all		
MASP1	CRARF, MASP, PRSS5	ENSG00000127241	Mannan binding lectin serine peptidase 1	3	187217285-187292022	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001617, HPA009641	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.20e-4 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 135.4	endometrium: 94.8	Group enriched	8	BJ: 107.2;BJ hTERT+: 389.0
MASP2	MASP1P1	ENSG00000009724	Mannan binding lectin serine peptidase 2	1	11026523-11047233	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA029313, HPA029314	Approved		Supported	Golgi apparatus	Liver cancer:1.60e-4 (favourable)	Tissue enriched	Tissue enriched	18	liver: 105.5	skin: 5.7	Cell line enhanced		Hep G2: 12.9
MATN1	CMP, CRTM	ENSG00000162510	Matrilin 1, cartilage matrix protein	1	30711277-30723587	Predicted secreted proteins	Evidence at protein level	HPA028580	Supported					Tissue enhanced	Not detected			ovary: 0.8	Not detected		
MATN2		ENSG00000132561	Matrilin 2	8	97868840-98036716	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033879	Approved				Thyroid cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 456.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 73.2;BJ hTERT+ SV40 Large T+ RasG12V: 104.0;HaCaT: 101.1;HBF TERT88: 97.3
MATN3	EDM5, HOA	ENSG00000132031	Matrilin 3	2	19992111-20012694	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA051250			Approved	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:4.74e-5 (unfavourable), Liver cancer:8.62e-5 (unfavourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 20.2;placenta: 16.5	seminal vesicle: 6.2	Cell line enriched	5	Hep G2: 98.9
MATN4		ENSG00000124159	Matrilin 4	20	45293445-45308529	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		breast: 3.0;pancreas: 5.9;skin: 3.5	cervix, uterine: 1.4	Cell line enhanced		NB-4: 1.7;U-937: 1.0
MAZ	Pur-1, ZF87, Zif87, ZNF801	ENSG00000103495	MYC associated zinc finger protein	16	29806106-29811164	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA048315, HPA059495, HPA065930	Approved		Enhanced	Nucleus	Thyroid cancer:2.22e-4 (unfavourable), Renal cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 197.0	Expressed in all		
MBL2	COLEC1, MBL	ENSG00000165471	Mannose binding lectin 2	10	52765380-52771700	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002027, CAB016782	Enhanced					Tissue enriched	Tissue enriched	1414	liver: 141.4	all non-specific tissues: 0.0	Cell line enriched	9	Hep G2: 1.5
MCCD1		ENSG00000204511	Mitochondrial coiled-coil domain 1	6	31528717-31530232	Predicted secreted proteins	Evidence at transcript level	HPA046948	Uncertain				Renal cancer:1.73e-4 (favourable)	Tissue enhanced	Tissue enriched	36	kidney: 3.5	all non-specific tissues: 0.0	Not detected		
MCF2L	ARHGEF14, DBS, KIAA0362, OST	ENSG00000126217	MCF.2 cell line derived transforming sequence like	13	112894378-113099739	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.14e-6 (favourable), Urothelial cancer:2.63e-5 (favourable), Pancreatic cancer:4.36e-5 (favourable), Endometrial cancer:6.01e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 62.4	Cell line enhanced		SCLC-21H: 77.5;SK-BR-3: 33.1;WM-115: 59.3
MCFD2	F5F8D, LMAN1IP, SDNSF	ENSG00000180398	Multiple coagulation factor deficiency 2	2	46901870-46941855	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022410, HPA034593	Supported				Urothelial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 206.7	Expressed in all		
MDGA1	GPIM, MAMDC3	ENSG00000112139	MAM domain containing glycosylphosphatidylinositol anchor 1	6	37630679-37699306	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031235, HPA050382	Approved		Supported	Golgi apparatus<br>Plasma membrane		Mixed	Mixed			parathyroid gland: 10.1	Mixed		
MDK	FLJ27379, MK, NEGF2	ENSG00000110492	Midkine (neurite growth-promoting factor 2)	11	46380756-46383837	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB010055, HPA057126	Uncertain		Approved	Vesicles	Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 524.3	Cell line enhanced		NTERA-2: 890.9;REH: 1226.8;SH-SY5Y: 1163.1
MEGF10	KIAA1780	ENSG00000145794	Multiple EGF like domains 10	5	127290831-127465737	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 15.8	adrenal gland: 2.2	Cell line enhanced		AF22: 31.3;RH-30: 37.5
MEGF6	EGFL3	ENSG00000162591	Multiple EGF like domains 6	1	3489920-3611495	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052129	Uncertain		Approved	Microtubules<br>Cytokinetic bridge	Colorectal cancer:3.08e-4 (unfavourable), Head and neck cancer:6.57e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 48.2	gallbladder: 17.0	Cell line enhanced		BJ: 37.3;HeLa: 26.6;U-2197: 36.2
MEIS3	DKFZp547H236, MRG2	ENSG00000105419	Meis homeobox 3	19	47403124-47419523	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA046699	Uncertain		Approved	Nucleoplasm	Renal cancer:1.78e-6 (unfavourable)	Mixed	Tissue enhanced		endometrium: 82.4	cerebral cortex: 64.8	Cell line enhanced		AF22: 74.7
MELTF	CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1	ENSG00000163975	Melanotransferrin	3	196988621-197029816	CD markers, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004880	Approved				Renal cancer:6.99e-11 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 32.3;salivary gland: 28.2	small intestine: 9.6	Cell line enhanced		A-431: 140.8;SK-MEL-30: 152.3
MEPE		ENSG00000152595	Matrix extracellular phosphoglycoprotein	4	87821411-87846817	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038003, HPA038004	Uncertain					Not detected	Tissue enriched	41	cerebral cortex: 4.0	all non-specific tissues: 0.0	Not detected		
MESDC2	BOCA, KIAA0081, MESD	ENSG00000117899	Mesoderm development candidate 2	15	80946289-80989878	Predicted secreted proteins	Evidence at protein level	HPA039414, HPA041721	Approved		Supported	Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Ovarian cancer:1.12e-4 (favourable), Endometrial cancer:2.31e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 55.7	Expressed in all		
MEST	PEG1	ENSG00000106484	Mesoderm specific transcript	7	130486171-130506296	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005623			Approved	Golgi apparatus<br>Cytosol	Renal cancer:6.20e-5 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 1087.6	adipose tissue: 131.8	Cell line enriched	5	AN3-CA: 10976.9
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
METRN	C16orf23, MGC2601	ENSG00000103260	Meteorin, glial cell differentiation regulator	16	715115-719655	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051164	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 64.7	fallopian tube: 38.3	Expressed in all		
METRNL		ENSG00000176845	Meteorin like, glial cell differentiation regulator	17	83079691-83095119	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023792	Uncertain					Expressed in all	Mixed			skin: 30.9	Cell line enhanced		U-138 MG: 117.7;U-2197: 151.1
METTL17	FLJ20859, METT11D1	ENSG00000165792	Methyltransferase like 17	14	20989770-20997035	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002955, HPA059802	Uncertain		Enhanced	Nucleus		Expressed in all	Expressed in all			adrenal gland: 23.7	Expressed in all		
METTL24	C6orf186, dJ71D21.2	ENSG00000053328	Methyltransferase like 24	6	110245928-110358272	Predicted secreted proteins	Evidence at transcript level	HPA037441, HPA037442	Uncertain					Mixed	Tissue enhanced		smooth muscle: 20.5	endometrium: 12.7	Cell line enhanced		SCLC-21H: 1.8;SH-SY5Y: 1.0
METTL7B	ALDI, MGC17301	ENSG00000170439	Methyltransferase like 7B	12	55681546-55684611	Predicted secreted proteins	Evidence at protein level	HPA038644	Enhanced		Supported	Vesicles<br>Microtubules	Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 137.1;liver: 122.2	small intestine: 52.1	Cell line enhanced		CAPAN-2: 42.8;EFO-21: 33.6;LHCN-M2: 33.5;U-87 MG: 35.3
METTL9	DREV1	ENSG00000197006	Methyltransferase like 9	16	21597218-21657473	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053588, HPA056347	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol	Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 92.0	Expressed in all		
MFAP2	MAGP, MAGP-1	ENSG00000117122	Microfibrillar associated protein 2	1	16974502-16980835	Predicted secreted proteins	Evidence at protein level	HPA007354	Enhanced				Renal cancer:2.52e-8 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 100.7	endometrium: 82.4	Cell line enhanced		HUVEC TERT2: 193.6;SH-SY5Y: 203.2
MFAP3		ENSG00000037749	Microfibrillar associated protein 3	5	154038906-154220478	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015883, HPA049198	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Cervical cancer:4.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.8	Expressed in all		
MFAP3L	KIAA0626, NYD-sp9	ENSG00000198948	Microfibrillar associated protein 3 like	4	169986597-170033031	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017986	Approved				Renal cancer:1.42e-8 (favourable)	Expressed in all	Tissue enhanced		testis: 74.1	epididymis: 47.4	Cell line enhanced		HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8
MFAP4		ENSG00000166482	Microfibrillar associated protein 4	17	19383442-19387240	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA054097	Supported		Approved	Endoplasmic reticulum	Renal cancer:6.83e-7 (unfavourable), Head and neck cancer:3.51e-4 (favourable), Ovarian cancer:4.64e-4 (unfavourable), Urothelial cancer:7.12e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 972.0	Cell line enhanced		ASC diff: 262.3;ASC TERT1: 405.8;fHDF/TERT166: 213.0;HHSteC: 224.2;HSkMC: 294.1;MOLT-4: 290.1;SH-SY5Y: 360.1
MFAP5	MAGP2, MP25	ENSG00000197614	Microfibrillar associated protein 5	12	8637346-8662888	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010553	Enhanced				Urothelial cancer:5.81e-4 (unfavourable), Stomach cancer:6.87e-4 (unfavourable)	Mixed	Expressed in all			smooth muscle: 207.1	Cell line enhanced		BEWO: 166.7;EFO-21: 142.4
MFGE8	BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10	ENSG00000140545	Milk fat globule-EGF factor 8 protein	15	88898683-88913411	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB002753, HPA002807	Uncertain		Approved	Cytosol	Renal cancer:6.06e-9 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 319.8	Cell line enhanced		ASC diff: 1212.9;ASC TERT1: 638.2;HSkMC: 676.6
MGA	FLJ12634, KIAA0518, MAD5, MXD5	ENSG00000174197	MGA, MAX dimerization protein	15	41621224-41773081	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA042278, HPA058183	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
MGAT4B	GnT-Ivb	ENSG00000161013	Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B	5	179797597-179806952	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052134	Uncertain				Glioma:8.53e-5 (unfavourable), Renal cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 153.7	Expressed in all		
MGP		ENSG00000111341	Matrix Gla protein	12	14881181-14885926	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013949	Approved				Renal cancer:4.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		breast: 4883.1	smooth muscle: 1900.4	Cell line enriched	5	AN3-CA: 9115.9
MGST2	MGST-II	ENSG00000085871	Microsomal glutathione S-transferase 2	4	139665768-139740745	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010707	Approved		Approved	Nucleoplasm	Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			liver: 178.3	Mixed		
MIA	CD-RAP	ENSG00000261857	Melanoma inhibitory activity	19	40771648-40777490	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA031950, HPA042369	Supported	Supported			Breast cancer:2.08e-4 (favourable)	Tissue enriched	Tissue enhanced		breast: 62.9;stomach: 50.0	salivary gland: 18.4	Group enriched	41	AN3-CA: 79.3;CAPAN-2: 63.4;SK-MEL-30: 198.0;WM-115: 233.6
MIA2	FLJ22404, TALI	ENSG00000150526	Melanoma inhibitory activity 2	14	39230231-39253639	Predicted secreted proteins	Evidence at protein level	HPA054066, HPA055459	Supported		Supported	Endoplasmic reticulum		Not detected	Tissue enhanced		epididymis: 3.7	parathyroid gland: 2.5	Cell line enhanced		CAPAN-2: 3.0
MIA3	FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077	ENSG00000154305	MIA family member 3, ER export factor	1	222618086-222668012	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055922, HPA056816	Enhanced		Enhanced	Vesicles	Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.5	Expressed in all		
MIER1	hMI-ER1, KIAA1610, MI-ER1	ENSG00000198160	MIER1 transcriptional regulator	1	66924895-66988619	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA019589, HPA050306	Enhanced		Enhanced	Nucleoplasm	Glioma:6.18e-8 (favourable), Colorectal cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 63.1	Expressed in all		
MINOS1-NBL1		ENSG00000270136	MINOS1-NBL1 readthrough	1	19596979-19658056	Predicted secreted proteins	Evidence at transcript level	HPA007394	Uncertain					Not detected	Tissue enhanced		duodenum: 16.2;small intestine: 17.2	adipose tissue: 13.7	Cell line enhanced		A-431: 25.2;BJ: 49.3;EFO-21: 25.9;HDLM-2: 32.5
MINPP1	MIPP	ENSG00000107789	Multiple inositol-polyphosphate phosphatase 1	10	87504875-87553460	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026859	Approved				Renal cancer:6.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 27.6	Mixed		
MLEC	KIAA0152	ENSG00000110917	Malectin	12	120686869-120701864	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:9.60e-6 (favourable), Stomach cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 162.3	Expressed in all		
MLN		ENSG00000096395	Motilin	6	33794673-33804011	Predicted secreted proteins	Evidence at protein level	HPA069392	Enhanced					Tissue enriched	Tissue enriched	6	duodenum: 253.3	small intestine: 42.3	Cell line enhanced		CACO-2: 2.4;TIME: 1.1
MLXIP	bHLHe36, KIAA0867, MIR, MONDOA	ENSG00000175727	MLX interacting protein	12	122078722-122147347	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA023084	Approved				Liver cancer:2.28e-4 (unfavourable), Renal cancer:2.92e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 24.4	Expressed in all		
MMP1	CLG	ENSG00000196611	Matrix metallopeptidase 1	11	102789920-102798160	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004920			Approved	Vesicles	Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 39.2;gallbladder: 126.4	urinary bladder: 29.1	Cell line enhanced		BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
MMP10	STMY2	ENSG00000166670	Matrix metallopeptidase 10	11	102770503-102780628	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002159	Uncertain		Approved	Plasma membrane<br>Cytosol	Urothelial cancer:7.12e-4 (favourable)	Tissue enhanced	Tissue enriched	40	endometrium: 443.1	appendix: 11.1	Cell line enhanced		BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
MMP11	STMY3	ENSG00000099953	Matrix metallopeptidase 11	22	23768226-23784316	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002593, HPA068864	Approved				Renal cancer:2.62e-4 (unfavourable)	Expressed in all	Group enriched	9	cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0	smooth muscle: 6.9	Cell line enhanced		AN3-CA: 17.4;REH: 7.4
MMP12	HME	ENSG00000262406	Matrix metallopeptidase 12	11	102862736-102875034	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 54.6;urinary bladder: 28.7	tonsil: 17.3	Group enriched	11	BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
MMP13	CLG3	ENSG00000137745	Matrix metallopeptidase 13	11	102942995-102955734	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		lung: 1.5;urinary bladder: 1.3	appendix: 0.3	Cell line enhanced		HaCaT: 15.8;PC-3: 6.2
MMP17	MT4-MMP	ENSG00000198598	Matrix metallopeptidase 17	12	131828393-131851783	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 24.0	skin: 8.2	Group enriched	5	REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
MMP19	MMP18, RASI-1	ENSG00000123342	Matrix metallopeptidase 19	12	55835433-55842966	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA070804			Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:8.56e-9 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 64.2;gallbladder: 97.3	placenta: 28.2	Cell line enriched	7	BEWO: 141.1
MMP2	CLG4, CLG4A, TBE-1	ENSG00000087245	Matrix metallopeptidase 2	16	55389700-55506691	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001939, CAB002788	Approved		Uncertain	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		gallbladder: 1682.1	urinary bladder: 910.7	Cell line enhanced		ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MMP20		ENSG00000137674	Matrix metallopeptidase 20	11	102576835-102625332	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.1	appendix,breast,kidney,tonsil: 0.1	Not detected		
MMP21		ENSG00000154485	Matrix metallopeptidase 21	10	125766453-125775821	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	27	epididymis: 59.2	ovary: 2.1	Not detected		
MMP25	MMP20, MMPL1, MT6-MMP	ENSG00000008516	Matrix metallopeptidase 25	16	3046681-3060726	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025177	Uncertain				Head and neck cancer:1.09e-5 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 23.3;bone marrow: 24.7;spleen: 20.7	adipose tissue: 6.4	Cell line enriched	11	HMC-1: 95.7
MMP26	endometase, MGC126590, MGC126592	ENSG00000167346	Matrix metallopeptidase 26	11	4704927-4992429	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	63	endometrium: 23.9	prostate,testis: 0.3	Not detected		
MMP27		ENSG00000137675	Matrix metallopeptidase 27	11	102691487-102705806	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA069097	Approved					Not detected	Group enriched	5	breast: 6.0;skin: 2.8	bone marrow: 0.8	Not detected		
MMP28	EPILYSIN, MM28, MMP-25, MMP-28	ENSG00000271447	Matrix metallopeptidase 28	17	35756249-35795707	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:6.28e-6 (unfavourable)	Mixed	Tissue enhanced		testis: 6.5	adipose tissue: 4.2	Cell line enriched	9	HaCaT: 32.1
MMP3	STMY, STMY1	ENSG00000149968	Matrix metallopeptidase 3	11	102835801-102843803	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007875	Uncertain		Supported	Vesicles	Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 26.5;endometrium: 58.6	urinary bladder: 9.0	Group enriched	15	BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
MMP7	MPSL1, PUMP-1	ENSG00000137673	Matrix metallopeptidase 7	11	102520508-102530753	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025869, HPA051358	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 820.8	breast: 201.7	Cell line enhanced		A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMP8	CLG1	ENSG00000118113	Matrix metallopeptidase 8	11	102711795-102727050	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021221, HPA022935	Enhanced					Tissue enriched	Tissue enriched	103	bone marrow: 335.8	endometrium: 3.2	Cell line enriched	10	WM-115: 69.6
MMP9	CLG4B	ENSG00000100985	Matrix metallopeptidase 9	20	46008908-46016561	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201	Enhanced		Approved	Cytosol	Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 252.6;lymph node: 117.7	appendix: 82.8	Cell line enriched	8	NB-4: 227.3
MMRN1	ECM, EMILIN4, GPIa*, MMRN	ENSG00000138722	Multimerin 1	4	89879532-89954629	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035769	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.77e-4 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)	Mixed	Mixed			placenta: 57.5	Cell line enriched	11	HUVEC TERT2: 1035.6
MMRN2	EMILIN3, EndoGlyx-1, FLJ13465	ENSG00000173269	Multimerin 2	10	86935540-86969481	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020741	Approved		Approved	Vesicles		Expressed in all	Expressed in all			placenta: 101.6	Cell line enhanced		CAPAN-2: 78.1;HUVEC TERT2: 155.0;TIME: 182.9
MOXD1	dJ248E1.1, DKFZP564G202, MOX	ENSG00000079931	Monooxygenase DBH like 1	6	132296055-132401545	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035740	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 106.1;smooth muscle: 114.5	seminal vesicle: 53.7	Cell line enhanced		ASC diff: 111.5;fHDF/TERT166: 149.9;HBF TERT88: 116.1;U-2197: 280.6
MPIG6B	C6orf25, G6b, G6b-B, NG31	ENSG00000204420	Megakaryocyte and platelet inhibitory receptor G6b	6	31718594-31726714	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA073017			Uncertain	Golgi apparatus		Mixed	Not detected			skin: 0.8	Cell line enriched	16	HEL: 5.4
MPO		ENSG00000005381	Myeloperoxidase	17	58269856-58280935	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000059, HPA021147, HPA061464	Enhanced		Supported	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	82	bone marrow: 2499.6	salivary gland: 30.6	Group enriched	98	HL-60: 2786.8;NB-4: 2892.7
MPZL1	FLJ21047, PZR	ENSG00000197965	Myelin protein zero like 1	1	167721192-167791919	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026966, HPA063538	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 111.6	Expressed in all		
MR1	HLALS	ENSG00000153029	Major histocompatibility complex, class I-related	1	181033425-181061938	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048304			Supported	Plasma membrane		Expressed in all	Mixed			thyroid gland: 28.2	Mixed		
MRPL32	bMRP-59b, HSPC283, L32mt, MRP-L32	ENSG00000106591	Mitochondrial ribosomal protein L32	7	42932200-42948958	Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA048965	Uncertain					Expressed in all	Expressed in all			adrenal gland: 72.1	Expressed in all		
MRPL52		ENSG00000172590	Mitochondrial ribosomal protein L52	14	22829879-22835037	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA012319	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			appendix: 72.1	Expressed in all		
MRPS22	C3orf5, GIBT, GK002, MRP-S22	ENSG00000175110	Mitochondrial ribosomal protein S22	3	139005806-139357223	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA006083, HPA007830	Enhanced		Supported	Mitochondria	Endometrial cancer:1.35e-5 (unfavourable), Pancreatic cancer:1.55e-5 (unfavourable), Prostate cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 69.5	Expressed in all		
MRPS28	HSPC007, MRP-S28, MRPS35	ENSG00000147586	Mitochondrial ribosomal protein S28	8	79918717-80030289	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA027202	Approved		Enhanced	Mitochondria	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 114.1	Expressed in all		
MS4A13		ENSG00000204979	Membrane spanning 4-domains A13	11	60515413-60542721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA045017, HPA063626	Uncertain					Not detected	Tissue enriched	54	testis: 5.3	all non-specific tissues: 0.0	Cell line enhanced		U-266/70: 1.4
MSH5	G7	ENSG00000204410	MutS homolog 5	6	31739948-31762834	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062688			Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Mixed			skin: 1.7	Mixed		
MSLN	CAK1, MPF	ENSG00000102854	Mesothelin	16	760762-768865	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002216, HPA017172	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)	Tissue enhanced	Group enriched	9	fallopian tube: 445.8;lung: 105.4	epididymis: 29.1	Cell line enhanced		CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2
MSMB	IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94	ENSG00000263639	Microseminoprotein beta	10	46033307-46046269	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB026357, HPA051257	Enhanced				Urothelial cancer:7.19e-4 (favourable)	Tissue enriched	Tissue enriched	26	prostate: 15294.0	stomach: 588.5	Cell line enhanced		BEWO: 24.7;NB-4: 13.6;RPMI-8226: 7.7;SH-SY5Y: 6.3;U-2197: 11.3
MSRA		ENSG00000175806	Methionine sulfoxide reductase A	8	10054268-10428891	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023804, HPA053069	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			kidney: 113.1	Mixed		
MSRB2	CBS-1, CBS1, CGI-131, MSRB, PILB	ENSG00000148450	Methionine sulfoxide reductase B2	10	23095506-23122013	Predicted secreted proteins	Evidence at protein level	HPA027933	Enhanced					Expressed in all	Mixed			heart muscle: 28.1	Mixed		
MSRB3	DFNB74, DKFZp686C1178, FLJ36866	ENSG00000174099	Methionine sulfoxide reductase B3	12	65278643-65488244	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014432	Uncertain				Renal cancer:8.85e-8 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable), Cervical cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 181.5	Mixed		
MST1	D3F15S2, DNF15S2, HGFL, MSP, NF15S2	ENSG00000173531	Macrophage stimulating 1	3	49683947-49689501	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024036	Uncertain				Pancreatic cancer:7.14e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 144.2	duodenum: 51.1	Cell line enhanced		Hep G2: 57.1;U-266/70: 16.6
MSTN	GDF8	ENSG00000138379	Myostatin	2	190055697-190062729	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB009963	Approved				Glioma:3.98e-4 (favourable)	Tissue enriched	Tissue enhanced		skeletal muscle: 3.4	cerebral cortex,endometrium: 1.3	Group enriched	13	LHCN-M2: 21.5;RH-30: 50.3
MTMR14	C3orf29, FLJ22405, FLJ90311, hEDTP, hJumpy	ENSG00000163719	Myotubularin related protein 14	3	9649433-9702393	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA054063	Approved				Renal cancer:2.74e-4 (favourable), Liver cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 41.8	Expressed in all		
MTTP	ABL, MTP	ENSG00000138823	Microsomal triglyceride transfer protein	4	99563761-99623999	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051170, HPA054862	Uncertain		Approved	Cytosol		Tissue enriched	Group enriched	16	duodenum: 236.3;liver: 133.9;small intestine: 292.6	testis: 13.5	Cell line enhanced		AF22: 10.2;Hep G2: 8.0
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced				Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced				Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced		A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
MUC20	FLJ14408, KIAA1359	ENSG00000176945	Mucin 20, cell surface associated	3	195720882-195741123	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042249			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.57e-4 (favourable)	Mixed	Mixed			colon: 10.4	Cell line enriched	7	SK-BR-3: 20.9
MUC3A	MUC3	ENSG00000169894	Mucin 3A, cell surface associated	7	100949555-100968346	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010871	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1	rectum: 13.1	Cell line enhanced		CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
MUC5AC	MUC5	ENSG00000215182	Mucin 5AC, oligomeric mucus/gel-forming	11	1157953-1201138	Predicted secreted proteins	Evidence at protein level	CAB002774, CAB009395, HPA040456, HPA040615	Enhanced		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	61	stomach: 179.1	cervix, uterine: 2.9	Cell line enriched	18	A549: 18.0
MUC5B	MG1, MUC5	ENSG00000117983	Mucin 5B, oligomeric mucus/gel-forming	11	1223066-1262172	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008246, CAB009396	Enhanced		Supported	Vesicles		Mixed	Group enriched	11	cervix, uterine: 350.5;gallbladder: 344.7	colon: 31.8	Cell line enriched	7	PC-3: 111.2
MUC6		ENSG00000184956	Mucin 6, oligomeric mucus/gel-forming	11	1012821-1036706	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002165	Enhanced					Tissue enhanced	Group enriched	24	duodenum: 15.4;seminal vesicle: 40.2;stomach: 24.0	epididymis: 1.1	Not detected		
MUC7	FLJ27047, MG2	ENSG00000171195	Mucin 7, secreted	4	70430492-70482997	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA006411	Enhanced					Group enriched	Tissue enriched	1464	salivary gland: 11361.9	ovary: 7.7	Not detected		
MUCL1	SBEM	ENSG00000172551	Mucin like 1	12	54830519-54858393	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039093	Enhanced					Tissue enriched	Tissue enriched	43	breast: 3798.1	salivary gland: 89.1	Cell line enhanced		MCF7: 1.5;SK-BR-3: 3.5
MXRA5	DKFZp564I1922	ENSG00000101825	Matrix remodeling associated 5	X	3308565-3346641	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA000508	Uncertain		Uncertain	Mitochondria	Glioma:2.56e-4 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 57.1	skin: 35.2	Cell line enhanced		BJ hTERT+: 102.1;fHDF/TERT166: 46.4;HaCaT: 46.3
MXRA7	FLJ46603, PS1TP1, TMAP1	ENSG00000182534	Matrix remodeling associated 7	17	76672551-76711016	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044819	Uncertain		Approved	Nucleus<br>Endoplasmic reticulum	Urothelial cancer:1.80e-5 (unfavourable), Liver cancer:4.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 456.4	Cell line enhanced		U-87 MG: 650.2
MYBBP1A	FLJ37886, P160, PAP2	ENSG00000132382	MYB binding protein 1a	17	4538897-4555631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005466	Supported		Supported	Nucleoli<br>Vesicles	Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 21.6	Expressed in all		
MYDGF	C19orf10, IL-25, IL-27, IL25, IL27, IL27w, R33729_1, SF20	ENSG00000074842	Myeloid derived growth factor	19	4641374-4670370	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041872, HPA046744	Approved				Renal cancer:4.99e-12 (unfavourable), Endometrial cancer:6.50e-7 (favourable)	Expressed in all	Expressed in all			epididymis: 134.0	Expressed in all		
MYH15	KIAA1000	ENSG00000144821	Myosin heavy chain 15	3	108380369-108529322	Predicted intracellular proteins	Evidence at protein level	HPA034871	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria		Not detected	Tissue enhanced		cerebral cortex: 1.9	testis: 0.8	Cell line enhanced		Karpas-707: 1.7;PC-3: 4.7;SH-SY5Y: 1.9;U-87 MG: 1.9
MYOC	GLC1A, JOAG1, TIGR	ENSG00000034971	Myocilin	1	171635417-171652683	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA027364	Approved					Tissue enriched	Tissue enhanced		adipose tissue: 45.4	esophagus: 21.4	Not detected		
MYRFL	bcm1377, C12orf15, C12orf28, FLJ25056	ENSG00000166268	Myelin regulatory factor-like	12	69825304-69959097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049340	Approved		Approved	Nucleoli		Mixed	Group enriched	5	duodenum: 23.7;small intestine: 24.0	testis: 4.3	Cell line enhanced		NTERA-2: 5.2;T-47d: 11.1
MZB1	HSPC190, MEDA-7, MGC29506, PACAP, pERp1	ENSG00000170476	Marginal zone B and B1 cell specific protein	5	139387480-139390081	Predicted secreted proteins	Evidence at protein level	HPA043745, HPA052694	Enhanced				Renal cancer:1.15e-8 (unfavourable), Head and neck cancer:4.60e-5 (favourable), Endometrial cancer:7.27e-4 (favourable)	Mixed	Mixed			lymph node: 160.4	Cell line enhanced		Karpas-707: 505.9;RPMI-8226: 1791.3
N4BP2L2	CG005, PFAAP5	ENSG00000244754	NEDD4 binding protein 2 like 2	13	32432417-32538885	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039338, HPA039434, HPA059327	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 57.6	Expressed in all		
NAA38	LSMD1, MGC14151, PFAAP2	ENSG00000183011	N(alpha)-acetyltransferase 38, NatC auxiliary subunit	17	7856685-7885238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059189			Supported	Nucleus		Expressed in all	Expressed in all			testis: 78.3	Expressed in all		
NAAA	ASAHL	ENSG00000138744	N-acylethanolamine acid amidase	4	75913657-75941051	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026135	Approved				Endometrial cancer:1.93e-4 (favourable), Pancreatic cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			prostate: 114.9	Mixed		
NAGA	D22S674	ENSG00000198951	Alpha-N-acetylgalactosaminidase	22	42058354-42070842	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000649	Enhanced					Expressed in all	Expressed in all			parathyroid gland: 63.7	Expressed in all		
NAGLU	NAG	ENSG00000108784	N-acetyl-alpha-glucosaminidase	17	42536172-42544449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038815	Supported	Approved			Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.5	Expressed in all		
NAPSA	KAP, Kdap, NAP1, NAPA	ENSG00000131400	Napsin A aspartic peptidase	19	50358477-50365830	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009591, HPA045280, HPA047236, HPA047744	Enhanced				Renal cancer:1.21e-4 (favourable)	Tissue enriched	Tissue enriched	14	lung: 1412.2	kidney: 101.4	Cell line enriched	23	U-698: 27.1
NAXE	AIBP, APOA1BP, MGC119143, MGC119144, MGC119145, YJEFN1	ENSG00000163382	NAD(P)HX epimerase	1	156591762-156594299	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043766, HPA048164	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 112.2	Expressed in all		
NBL1	D1S1733E, DAN, DAND1, NB, NO3	ENSG00000158747	Neuroblastoma 1, DAN family BMP antagonist	1	19640554-19658456	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007394, CAB026132	Uncertain					Expressed in all	Expressed in all			ovary: 552.0	Cell line enhanced		SK-MEL-30: 357.2
NBPF26		ENSG00000273136	Neuroblastoma breakpoint family member 26	1	120723923-120841481	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 51.6	Mixed		
NCAM1	CD56, NCAM	ENSG00000149294	Neural cell adhesion molecule 1	11	112961247-113278436	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000142, CAB018071, HPA039835	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 334.9	heart muscle: 87.5	Cell line enhanced		RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
NCAN	CSPG3	ENSG00000130287	Neurocan	19	19211973-19252233	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036814	Enhanced		Uncertain	Vesicles<br>Centrosome		Tissue enriched	Tissue enriched	101	cerebral cortex: 183.5	testis: 1.8	Cell line enhanced		AF22: 1.0;SCLC-21H: 2.7;SH-SY5Y: 1.7
NCSTN	APH2, KIAA0253	ENSG00000162736	Nicastrin	1	160343272-160358952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021982, HPA054846, HPA070642	Approved		Approved	Cytosol	Renal cancer:7.75e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 143.2	Expressed in all		
NDNF	C4orf31, FLJ23191	ENSG00000173376	Neuron derived neurotrophic factor	4	121035613-121073021	Predicted secreted proteins	Evidence at protein level	HPA048881			Supported	Vesicles	Renal cancer:3.26e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 159.9;placenta: 86.6	ovary: 52.7	Cell line enhanced		fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4
NDP	EVR2, norrin	ENSG00000124479	NDP, norrin cystine knot growth factor	X	43948776-43973504	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003095	Uncertain		Supported	Nucleus<br>Nucleoli<br>Vesicles		Tissue enhanced	Tissue enhanced		ovary: 53.3	fallopian tube: 31.3	Cell line enriched	16	U-87 MG: 67.6
NDUFA10	CI-42k	ENSG00000130414	NADH:ubiquinone oxidoreductase subunit A10	2	239892450-240025402	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059529, HPA067045, CAB070846	Approved		Supported	Mitochondria	Renal cancer:2.09e-7 (favourable), Melanoma:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 63.8	Expressed in all		
NDUFB5	CI-SGDH, MGC12314, SGDH	ENSG00000136521	NADH:ubiquinone oxidoreductase subunit B5	3	179604690-179627647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005640	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 136.7	Expressed in all		
NDUFS3	CI-30	ENSG00000213619	NADH:ubiquinone oxidoreductase core subunit S3	11	47565336-47584562	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004484	Approved		Supported	Nuclear bodies<br>Mitochondria	Renal cancer:2.61e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.2	Expressed in all		
NDUFS8	CI-23k, TYKY	ENSG00000110717	NADH:ubiquinone oxidoreductase core subunit S8	11	68030617-68036644	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018524	Approved		Supported	Mitochondria	Renal cancer:3.27e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 152.6	Expressed in all		
NECTIN1	CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12	ENSG00000110400	Nectin cell adhesion molecule 1	11	119623408-119729084	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016135, HPA026846	Approved					Expressed in all	Tissue enhanced		esophagus: 108.6;skin: 161.7	cerebral cortex: 50.3	Cell line enhanced		HaCaT: 203.5
NELL1	FLJ45906, IDH3GL	ENSG00000165973	Neural EGFL like 1	11	20669551-21575681	Predicted secreted proteins	Evidence at protein level	HPA051535	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 22.9;kidney: 18.8	prostate: 8.8	Cell line enhanced		HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2
NELL2	NRP2	ENSG00000184613	Neural EGFL like 2	12	44508275-44921848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035714, HPA035715	Uncertain		Approved	Vesicles	Pancreatic cancer:5.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 204.1;fallopian tube: 96.7	prostate: 46.5	Cell line enhanced		AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
NENF	CIR2, SCIRP10, SPUF	ENSG00000117691	Neudesin neurotrophic factor	1	212432887-212446379	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA026763, HPA028488	Uncertain		Enhanced	Nucleus	Renal cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 82.9	Expressed in all		
NETO1	BCTL1, BTCL1	ENSG00000166342	Neuropilin and tolloid like 1	18	72742314-72868146	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA064630			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	16	cerebral cortex: 64.0	spleen: 4.1	Cell line enhanced		MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0
NFASC	FLJ46866, KIAA0756, NF, NRCAML	ENSG00000163531	Neurofascin	1	204828651-205022822	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008832	Enhanced				Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.7	seminal vesicle: 22.4	Cell line enhanced		BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5
NGF	NGFB	ENSG00000134259	Nerve growth factor	1	115285918-115338236	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:8.08e-7 (unfavourable), Head and neck cancer:1.80e-4 (unfavourable)	Mixed	Tissue enhanced		ovary: 12.3	smooth muscle: 5.9	Cell line enhanced		BJ: 73.7;BJ hTERT+ SV40 Large T+: 28.4;hTEC/SVTERT24-B: 29.7;U-2197: 55.6
NGRN	DSC92	ENSG00000182768	Neugrin, neurite outgrowth associated	15	90265659-90278141	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041367	Approved					Expressed in all	Mixed			thyroid gland: 7.1	Expressed in all		
NID1	entactin, NID	ENSG00000116962	Nidogen 1	1	235975830-236065162	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010044	Approved				Renal cancer:5.38e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 326.5	Cell line enhanced		ASC diff: 1062.5;ASC TERT1: 502.4;HSkMC: 444.4
NID2		ENSG00000087303	Nidogen 2	14	52004803-52069228	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052460, HPA058772	Enhanced		Supported	Plasma membrane	Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 88.5	thyroid gland: 54.1	Cell line enhanced		ASC diff: 198.6;BJ: 133.5;HHSteC: 134.5;HSkMC: 435.7
NKAIN4	bA261N11.2, C20orf58, FAM77A	ENSG00000101198	Sodium/potassium transporting ATPase interacting 4	20	63240784-63272694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029876	Approved				Endometrial cancer:3.14e-4 (unfavourable)	Tissue enriched	Tissue enriched	13	cerebral cortex: 71.8	kidney: 5.5	Cell line enhanced		BEWO: 23.2;MOLT-4: 33.2
NLGN3	ASPGX1, AUTSX1, HNL3, KIAA1480	ENSG00000196338	Neuroligin 3	X	71144831-71171201	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003183, HPA004066	Enhanced		Supported	Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	seminal vesicle: 17.3	Cell line enhanced		AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
NLGN4Y	KIAA0951	ENSG00000165246	Neuroligin 4, Y-linked	Y	14522638-14845650	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA001651	Approved					Mixed	Tissue enhanced		prostate: 11.4;seminal vesicle: 12.5	cerebral cortex: 7.5	Cell line enhanced		BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
NMB	MGC17211, MGC2277, MGC3936	ENSG00000197696	Neuromedin B	15	84655129-84658563	Predicted secreted proteins	Evidence at protein level	CAB019302	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane	Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 46.2;cerebral cortex: 47.2	thyroid gland: 14.8	Cell line enhanced		A-431: 46.7
NME3	DR-nm23, NDPKC, NM23-H3	ENSG00000103024	NME/NM23 nucleoside diphosphate kinase 3	16	1770286-1771730	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041113, HPA052733	Approved		Approved	Nucleoplasm<br>Cytosol	Breast cancer:6.81e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 36.1	Cell line enhanced		HEK 293: 64.8
NMS		ENSG00000204640	Neuromedin S	2	100470482-100483280	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Group enriched	7	HL-60: 6.6;HMC-1: 4.2
NMU		ENSG00000109255	Neuromedin U	4	55595229-55636698	Predicted secreted proteins	Evidence at protein level	HPA025926	Uncertain				Renal cancer:4.07e-10 (unfavourable), Endometrial cancer:2.60e-5 (unfavourable)	Mixed	Group enriched	6	esophagus: 34.9;skin: 45.4	tonsil: 6.8	Cell line enhanced		HaCaT: 336.7;K-562: 278.2
NOA1	C4orf14, hAtNOS1, hNOA1, MGC3232, MTG3	ENSG00000084092	Nitric oxide associated 1	4	56963370-56978823	Predicted secreted proteins	Evidence at protein level	HPA035838, HPA035839	Approved		Supported	Mitochondria	Renal cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 16.9	Expressed in all		
NODAL		ENSG00000156574	Nodal growth differentiation factor	10	70432315-70447951	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045201	Uncertain					Tissue enriched	Tissue enhanced		testis: 2.9	skin: 1.2	Cell line enhanced		CACO-2: 1.6;SH-SY5Y: 1.5
NOG	SYM1, SYNS1	ENSG00000183691	Noggin	17	56593699-56595590	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA061318	Approved				Pancreatic cancer:6.86e-5 (unfavourable), Endometrial cancer:6.66e-4 (favourable)	Mixed	Group enriched	5	cerebral cortex: 7.3;placenta: 15.8	lymph node: 2.2	Cell line enhanced		EFO-21: 117.5;LHCN-M2: 32.2;PC-3: 35.7;U-2 OS: 40.3
NOMO3		ENSG00000103226	NODAL modulator 3	16	16232495-16294814	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Mixed	Mixed			skin: 1.9	Mixed		
NOTCH3	CADASIL, CASIL	ENSG00000074181	Notch 3	19	15159038-15200981	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005393, HPA044392	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable)	Expressed in all	Mixed			skin: 93.6	Cell line enhanced		AF22: 65.5;MCF7: 51.9
NOTUM		ENSG00000185269	NOTUM, palmitoleoyl-protein carboxylesterase	17	81952507-81961840	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	56	placenta: 192.5	liver: 3.4	Cell line enriched	16	Hep G2: 284.8
NOV	CCN3, IGFBP9	ENSG00000136999	Nephroblastoma overexpressed	8	119416306-119424353	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018449, HPA019684, CAB034423	Enhanced		Supported	Vesicles		Expressed in all	Tissue enriched	39	adrenal gland: 1392.1	prostate: 35.4	Cell line enhanced		BJ hTERT+: 99.0;U-2197: 116.0
NPB	PPL7, PPNPB	ENSG00000183979	Neuropeptide B	17	81900745-81902905	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.6	Cell line enhanced		PC-3: 2.3;RH-30: 1.8;SH-SY5Y: 2.2;U-2 OS: 2.4
NPC2	EDDM1, HE1, NP-C2	ENSG00000119655	NPC intracellular cholesterol transporter 2	14	74476192-74494177	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA000835	Enhanced				Colorectal cancer:4.83e-5 (unfavourable), Stomach cancer:2.66e-4 (unfavourable), Liver cancer:3.13e-4 (unfavourable), Thyroid cancer:6.55e-4 (favourable)	Expressed in all	Tissue enriched	19	epididymis: 16336.0	lung: 849.0	Expressed in all		
NPFF	FMRFAL	ENSG00000139574	Neuropeptide FF-amide peptide precursor	12	53506690-53507638	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	1231	epididymis: 1000.1	duodenum: 0.8	Cell line enriched	6	HHSteC: 11.2
NPHS1	CNF, NPHN	ENSG00000161270	NPHS1, nephrin	19	35825964-35869287	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB035555	Enhanced					Mixed	Tissue enhanced		kidney: 17.7;lymph node: 5.4;pancreas: 5.5	tonsil: 2.3	Cell line enhanced		HMC-1: 1.1
NPNT	EGFL6L, POEM	ENSG00000168743	Nephronectin	4	105894775-106004027	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003711, HPA050203	Supported		Approved	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:8.28e-8 (favourable)	Expressed in all	Tissue enhanced		lung: 168.4;thyroid gland: 276.0	prostate: 136.5	Cell line enhanced		BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1
NPPA	ANP, PND	ENSG00000175206	Natriuretic peptide A	1	11845709-11848345	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058269	Enhanced	Supported				Tissue enriched	Tissue enriched	1345	heart muscle: 24003.4	epididymis: 17.8	Cell line enhanced		SCLC-21H: 13.6;SH-SY5Y: 11.7
NPPB		ENSG00000120937	Natriuretic peptide B	1	11857464-11858931	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	1857	heart muscle: 3255.2	testis: 1.7	Group enriched	7	BEWO: 134.5;CACO-2: 309.8
NPPC	CNP	ENSG00000163273	Natriuretic peptide C	2	231921820-231926403	Predicted secreted proteins, Transporters	Evidence at protein level	HPA035362	Uncertain					Mixed	Tissue enhanced		prostate: 6.9	cerebral cortex: 3.0	Cell line enhanced		HEK 293: 7.7;NTERA-2: 3.9;SCLC-21H: 6.4;SK-MEL-30: 18.9
NPS		ENSG00000214285	Neuropeptide S	10	127549369-127552639	Predicted secreted proteins	No evidence	CAB020139	Uncertain					Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
NPTX1		ENSG00000171246	Neuronal pentraxin 1	17	80467148-80477843	Predicted secreted proteins	Evidence at protein level	HPA077062	Enhanced					Tissue enhanced	Tissue enriched	28	cerebral cortex: 122.5	adrenal gland: 4.3	Cell line enhanced		HAP1: 33.7;SiHa: 44.5;U-138 MG: 85.8;WM-115: 120.6
NPTX2		ENSG00000106236	Neuronal pentraxin 2	7	98617297-98629868	Predicted secreted proteins	Evidence at protein level	CAB020801, HPA049799, HPA058320	Supported		Approved	Golgi apparatus<br>Actin filaments<br>Centrosome	Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3	cervix, uterine: 12.1	Cell line enriched	8	LHCN-M2: 600.5
NPVF	C7orf9, RFRP	ENSG00000105954	Neuropeptide VF precursor	7	25224570-25228486	Predicted secreted proteins	Evidence at protein level	HPA041733	Approved					Not detected	Not detected			tonsil: 0.3	Not detected		
NPW	PPL8	ENSG00000183971	Neuropeptide W	16	2009926-2020755	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA064874	Approved					Mixed	Tissue enhanced		liver: 5.2;stomach: 2.9	epididymis: 1.7	Cell line enhanced		NB-4: 29.9;RPMI-8226: 57.2;SCLC-21H: 161.6
NPY	PYY4	ENSG00000122585	Neuropeptide Y	7	24284163-24291865	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016733, CAB034368, HPA036636, HPA044572, HPA056798	Supported	Supported	Enhanced	Golgi apparatus	Endometrial cancer:5.78e-4 (unfavourable)	Tissue enriched	Group enriched	18	adrenal gland: 153.2;cerebral cortex: 211.6;prostate: 495.0	appendix: 16.1	Cell line enriched	39	SH-SY5Y: 696.9
NRCAM	Bravo, KIAA0343	ENSG00000091129	Neuronal cell adhesion molecule	7	108147623-108456717	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012606	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 180.4	adrenal gland: 49.5	Cell line enhanced		A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8
NRG1	GGF, HGL, HRG, NDF, NRG1-IT2	ENSG00000157168	Neuregulin 1	8	31639386-32767959	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010964	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 20.0	Cell line enhanced		A549: 130.4;hTEC/SVTERT24-B: 101.2
NRN1L	MRCC2446, UNQ2446	ENSG00000188038	Neuritin 1 like	16	67884805-67888855	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA041761	Uncertain					Not detected	Mixed			skin: 3.3	Cell line enriched	5	BEWO: 31.0
NRP1	CD304, NRP, VEGF165R	ENSG00000099250	Neuropilin 1	10	33177492-33336262	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004511, HPA030278	Approved		Uncertain	Mitochondria	Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 194.1	Cell line enhanced		U-87 MG: 437.4
NRP2	VEGF165R2	ENSG00000118257	Neuropilin 2	2	205681990-205798133	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039980, HPA054974	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 84.4	Cell line enhanced		CAPAN-2: 119.6;U-251 MG: 195.9
NRXN1	Hs.22998, KIAA0578	ENSG00000179915	Neurexin 1	2	49918505-51225575	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071400			Approved	Nucleoli<br>Plasma membrane		Tissue enriched	Tissue enriched	12	cerebral cortex: 154.0	seminal vesicle: 12.9	Cell line enriched	9	SCLC-21H: 42.8
NRXN2		ENSG00000110076	Neurexin 2	11	64606174-64723188	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	cerebral cortex: 142.6	testis: 17.0	Cell line enhanced		REH: 43.5;SCLC-21H: 27.0;U-2 OS: 27.6;U-87 MG: 18.3
NT5E	CALJA, CD73, eN, eNT, NT5	ENSG00000135318	5'-nucleotidase ecto	6	85449584-85495791	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017357	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 172.7	smooth muscle: 106.3	Cell line enhanced		LHCN-M2: 772.3;U-87 MG: 800.0
NTF3	NGF2	ENSG00000185652	Neurotrophin 3	12	5432112-5521536	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA032001	Approved					Mixed	Tissue enhanced		ovary: 13.5	spleen: 6.2	Cell line enhanced		BJ hTERT+: 9.1;BJ hTERT+ SV40 Large T+: 13.6;BJ hTERT+ SV40 Large T+ RasG12V: 18.8;HBF TERT88: 17.3
NTF4	GLC1O, NT-4/5, NTF5	ENSG00000225950	Neurotrophin 4	19	49061066-49065054	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA049376			Approved	Golgi apparatus		Mixed	Tissue enhanced		skin: 36.6	prostate: 11.4	Cell line enhanced		CAPAN-2: 12.1;HaCaT: 27.5;hTCEpi: 36.4
NTM	HNT, IGLON2, NTRI	ENSG00000182667	Neurotrimin	11	131370478-132336822	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024875	Enhanced				Renal cancer:1.10e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 116.0	lung: 39.1	Cell line enhanced		LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5
NTN1	NTN1L	ENSG00000065320	Netrin 1	17	9021542-9244000	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056419	Approved					Mixed	Mixed			esophagus: 21.2	Cell line enhanced		BEWO: 26.7;T-47d: 15.6;U-2 OS: 15.2;U-251 MG: 18.3;WM-115: 12.7
NTN3	NTN2L	ENSG00000162068	Netrin 3	16	2471499-2474145	Predicted secreted proteins	Evidence at protein level	HPA050817	Uncertain					Mixed	Not detected			testis: 0.6	Group enriched	5	REH: 4.8;SCLC-21H: 7.6;SH-SY5Y: 3.8
NTN4		ENSG00000074527	Netrin 4	12	95657807-95791152	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049832	Approved				Renal cancer:8.12e-9 (favourable), Urothelial cancer:6.67e-5 (favourable), Pancreatic cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 246.4	kidney: 118.6	Cell line enhanced		BJ hTERT+: 407.7;TIME: 235.1
NTN5		ENSG00000142233	Netrin 5	19	48661407-48673081	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Mixed			endometrium,fallopian tube,ovary: 1.5	Not detected		
NTNG1	KIAA0976, Lmnt1	ENSG00000162631	Netrin G1	1	107140007-107483458	Predicted secreted proteins	Evidence at protein level	HPA065954			Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 8.6	seminal vesicle: 6.7	Cell line enhanced		ASC TERT1: 34.3;fHDF/TERT166: 19.6;RPTEC TERT1: 20.8;U-138 MG: 22.6;U-87 MG: 25.0
NTNG2	KIAA1857, Lmnt2, NTNG1	ENSG00000196358	Netrin G2	9	132161676-132244534	Predicted secreted proteins	Evidence at protein level	HPA061242, HPA065089, HPA071290	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge<br>Midbody ring<br>Cytosol	Prostate cancer:6.06e-4 (favourable)	Mixed	Group enriched	6	bone marrow: 26.5;cerebral cortex: 18.5;parathyroid gland: 16.3;prostate: 10.0	spleen: 3.1	Cell line enhanced		HMC-1: 14.1;NB-4: 24.3;U-937: 7.7
NTS		ENSG00000133636	Neurotensin	12	85874295-85882992	Predicted secreted proteins	Evidence at protein level	HPA026664	Enhanced				Cervical cancer:9.94e-5 (favourable), Endometrial cancer:5.10e-4 (unfavourable)	Tissue enhanced	Group enriched	9	small intestine: 189.6;stomach: 43.5	lymph node: 13.4	Cell line enhanced		HEL: 45.5;NTERA-2: 10.8
NUBPL	C14orf127, FLJ12660, huInd1, IND1	ENSG00000151413	Nucleotide binding protein like	14	31489956-31861224	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029203	Approved		Approved	Mitochondria	Renal cancer:3.64e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.0	Expressed in all		
NUCB1	Calnuc, NUC	ENSG00000104805	Nucleobindin 1	19	48900050-48923372	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008176	Enhanced		Supported	Golgi apparatus<br>Microtubules		Expressed in all	Expressed in all			parathyroid gland: 227.7	Expressed in all		
NUCB2	NEFA	ENSG00000070081	Nucleobindin 2	11	17208153-17349974	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008395, HPA008530, CAB015931	Approved	Approved	Enhanced	Golgi apparatus	Endometrial cancer:8.27e-6 (favourable), Renal cancer:3.94e-5 (unfavourable), Ovarian cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 733.1	Expressed in all		
NUDT9	MGC3037	ENSG00000170502	Nudix hydrolase 9	4	87422582-87459454	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036917, HPA044866	Approved				Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 85.9	Expressed in all		
NUP214	CAIN, CAN, D9S46E, N214	ENSG00000126883	Nucleoporin 214	9	131125561-131234670	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA048789			Supported	Nucleus<br>Vesicles<br>Focal adhesion sites	Renal cancer:2.39e-5 (favourable)	Expressed in all	Expressed in all			testis: 123.0	Expressed in all		
NXPH1		ENSG00000122584	Neurexophilin 1	7	8433955-8752963	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA020062	Uncertain					Group enriched	Group enriched	81	adrenal gland: 52.1;cerebral cortex: 47.2	breast: 0.6	Cell line enhanced		Karpas-707: 7.7;SCLC-21H: 1.3;WM-115: 3.3
NXPH2	NPH2	ENSG00000144227	Neurexophilin 2	2	138670772-138780348	Predicted secreted proteins	Evidence at transcript level	HPA034759	Approved					Mixed	Group enriched	9	cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0	endometrium: 0.9	Cell line enhanced		AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7
NXPH3	NPH3	ENSG00000182575	Neurexophilin 3	17	49575858-49583827	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 15.6	seminal vesicle: 9.6	Cell line enhanced		BEWO: 14.1;BJ: 4.0
NXPH4	NPH4	ENSG00000182379	Neurexophilin 4	12	57216795-57226449	Predicted secreted proteins	Evidence at transcript level						Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.3;prostate: 7.1;skin: 12.2	placenta: 3.8	Cell line enhanced		AN3-CA: 71.1;RH-30: 60.3
NYX	CLRP, CSNB1, CSNB1A, CSNB4	ENSG00000188937	Nyctalopin	X	41447434-41475710	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			kidney: 0.3	Cell line enhanced		HDLM-2: 2.3
OAF	MGC52117	ENSG00000184232	Out at first homolog	11	120210767-120230332	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047412	Uncertain		Approved	Nucleus	Head and neck cancer:5.71e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 80.2	Cell line enhanced		Hep G2: 127.6
OBP2A	hOBPIIa, LCN13, OBP	ENSG00000122136	Odorant binding protein 2A	9	135546139-135549969	Predicted secreted proteins	Evidence at protein level	HPA055955	Uncertain					Tissue enriched	Group enriched	19	fallopian tube: 35.5;testis: 7.6	skin: 1.1	Group enriched	8	U-266/70: 1.0;U-266/84: 3.7
OBP2B	hOBPIIb, LCN14	ENSG00000171102	Odorant binding protein 2B	9	133205277-133209250	Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enhanced		breast: 1.8;testis: 6.8	fallopian tube: 1.4	Not detected		
OC90	PLA2L	ENSG00000253117	Otoconin 90	8	132024220-132059380	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OCLN	PPP1R115	ENSG00000197822	Occludin	5	69492292-69558104	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005933, CAB013075, CAB068212, CAB068213, CAB068214	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:6.59e-11 (favourable)	Mixed	Tissue enhanced		thyroid gland: 78.7	lung: 39.8	Cell line enhanced		CAPAN-2: 60.2;HaCaT: 48.8
ODAM	APin, FLJ20513	ENSG00000109205	Odontogenic, ameloblast asssociated	4	70196496-70204576	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036543			Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	13	salivary gland: 136.2	smooth muscle: 10.1	Cell line enriched	13	Hep G2: 21.4
OGG1	HMMH, HOGG1, MUTM, OGH1	ENSG00000114026	8-oxoguanine DNA glycosylase	3	9749944-9788219	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027514, CAB047301	Approved		Enhanced	Nucleoplasm	Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 30.5	Expressed in all		
OGN	mimecan, OIF, SLRR3A	ENSG00000106809	Osteoglycin	9	92383967-92404696	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013132	Approved		Supported	Endoplasmic reticulum	Renal cancer:1.92e-4 (unfavourable), Urothelial cancer:2.03e-4 (unfavourable), Ovarian cancer:4.04e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 374.3;parathyroid gland: 604.4	gallbladder: 276.4	Cell line enhanced		ASC TERT1: 17.1;HSkMC: 8.0;MOLT-4: 27.9
OIT3	FLJ39116, LZP	ENSG00000138315	Oncoprotein induced transcript 3	10	72893581-72933033	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	liver: 53.4	spleen: 6.5	Cell line enhanced		CACO-2: 1.7;Hep G2: 1.5
OLFM1	AMY, NOE1, NOELIN, OlfA	ENSG00000130558	Olfactomedin 1	9	135075422-135121179	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057444			Approved	Nucleus<br>Nucleoli<br>Cytosol	Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 729.9	epididymis: 86.4	Cell line enhanced		NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2
OLFM2	NOE2, OlfC	ENSG00000105088	Olfactomedin 2	19	9853718-9936552	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049961, HPA057771	Uncertain		Approved	Nucleoplasm	Renal cancer:2.21e-4 (unfavourable), Colorectal cancer:3.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 124.0;skin: 111.2	adipose tissue: 36.8	Cell line enhanced		AN3-CA: 23.7;SH-SY5Y: 25.7;U-2 OS: 30.2;WM-115: 25.2
OLFM3	NOE3	ENSG00000118733	Olfactomedin 3	1	101802574-101997030	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050297			Uncertain	Vesicles		Mixed	Tissue enriched	15	cerebral cortex: 26.7	adrenal gland: 1.8	Group enriched	11	AF22: 5.5;HAP1: 4.0;HEL: 3.2;SCLC-21H: 2.6;SH-SY5Y: 2.3
OLFM4	GC1, GW112, OlfD	ENSG00000102837	Olfactomedin 4	13	53028759-53052057	Predicted secreted proteins	Evidence at protein level	HPA077718	Enhanced				Breast cancer:8.77e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8	colon: 445.0	Cell line enhanced		BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
OLFML1	UNQ564	ENSG00000183801	Olfactomedin like 1	11	7485388-7511377	Predicted secreted proteins	Evidence at protein level	HPA039735	Uncertain				Renal cancer:4.28e-8 (unfavourable)	Expressed in all	Mixed			ovary: 60.1	Group enriched	7	BEWO: 29.5;U-2197: 19.0
OLFML2A	FLJ00237	ENSG00000185585	Olfactomedin like 2A	9	124777158-124814885	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021180, HPA022254	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.73e-5 (unfavourable)	Expressed in all	Mixed			spleen: 47.5	Cell line enhanced		ASC TERT1: 112.2;WM-115: 64.5
OLFML2B	DKFZP586L151	ENSG00000162745	Olfactomedin like 2B	1	161983192-162023854	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054136, HPA062739	Approved		Approved	Cytosol	Renal cancer:1.01e-12 (unfavourable), Liver cancer:4.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 76.9	placenta: 58.7	Cell line enhanced		HSkMC: 82.6;RH-30: 85.9
OLFML3	HNOEL-iso, OLF44	ENSG00000116774	Olfactomedin like 3	1	113979391-114035572	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027991			Supported	Vesicles	Renal cancer:3.45e-5 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 266.9	Cell line enhanced		ASC diff: 395.8;BJ hTERT+: 302.6;HSkMC: 419.4;LHCN-M2: 496.4
OMD	osteoadherin, SLRR2C	ENSG00000127083	Osteomodulin	9	92414245-92424461	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA005731, HPA069948		Approved	Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Mixed	Mixed			cervix, uterine: 36.4	Group enriched	13	ASC diff: 6.2;ASC TERT1: 5.9
OMG	OMGP	ENSG00000126861	Oligodendrocyte myelin glycoprotein	17	31272013-31297539	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008206, HPA012693	Enhanced					Group enriched	Tissue enriched	318	cerebral cortex: 137.4	bone marrow: 0.4	Not detected		
OOSP2	FLJ36198, PLAC1L, TMEM122	ENSG00000149507	Oocyte secreted protein 2	11	60040275-60048044	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050914	Enhanced					Not detected	Tissue enriched	487	testis: 48.6	all non-specific tissues: 0.0	Not detected		
OPCML	IGLON1, OBCAM, OPCM	ENSG00000183715	Opioid binding protein/cell adhesion molecule like	11	132414977-133532519	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	8	cerebral cortex: 63.0	parathyroid gland: 7.5	Cell line enhanced		BJ: 7.9;HDLM-2: 1.8
OPRPN	BPLP, PRL1, PROL1	ENSG00000171199	Opiorphin prepropeptide	4	70397882-70410194	Predicted secreted proteins	Evidence at protein level	HPA065711	Approved					Tissue enhanced	Group enriched	10	breast: 33.1;salivary gland: 18.9	epididymis: 2.5	Not detected		
OPTC		ENSG00000188770	Opticin	1	203494143-203508864	Predicted secreted proteins	Evidence at protein level	HPA034951, HPA034952	Enhanced					Tissue enriched	Not detected			testis: 0.6	Not detected		
ORM1		ENSG00000229314	Orosomucoid 1	9	114323056-114326475	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB006265, HPA046438, HPA047725, HPA057726	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.35e-4 (unfavourable)	Tissue enriched	Tissue enriched	69	liver: 10591.2	bone marrow: 152.4	Cell line enriched	11	Hep G2: 797.0
ORM2	AGP-B, AGP-B', AGP2	ENSG00000228278	Orosomucoid 2	9	114329869-114333252	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046438, HPA047725, HPA057726	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.23e-9 (unfavourable)	Tissue enriched	Tissue enriched	96	liver: 3772.7	prostate: 39.2	Cell line enriched	195	Hep G2: 567.8
OS9	ERLEC2, OS-9	ENSG00000135506	OS9, endoplasmic reticulum lectin	12	57693955-57721557	Predicted secreted proteins, Transporters	Evidence at protein level	CAB011518, HPA013694	Supported		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 295.8	Cell line enriched	11	RH-30: 3430.4
OSCAR		ENSG00000170909	Osteoclast associated, immunoglobulin-like receptor	19	54094668-54102692	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 9.0;lung: 14.1	appendix: 3.3	Cell line enhanced		EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0
OSM	MGC20461	ENSG00000099985	Oncostatin M	22	30262829-30266840	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.03e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 78.7	appendix: 20.1	Cell line enhanced		HDLM-2: 14.6;HMC-1: 9.7;NB-4: 4.2
OSMR	OSMRB	ENSG00000145623	Oncostatin M receptor	5	38845858-38945596	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017278	Approved		Approved	Nucleoli	Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Mixed		
OSR2	FLJ90037	ENSG00000164920	Odd-skipped related transciption factor 2	8	98944403-98952104	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052425, HPA063486	Uncertain		Approved	Nucleus<br>Plasma membrane	Head and neck cancer:2.44e-5 (favourable)	Mixed	Tissue enhanced		endometrium: 205.3;fallopian tube: 144.6	ovary: 102.9	Cell line enriched	13	ASC diff: 372.1
OSTN		ENSG00000188729	Osteocrin	3	191199241-191265615	Predicted secreted proteins	Evidence at protein level	CAB024997, CAB025649, HPA030878	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.4	cervix, uterine,epididymis: 2.0	Cell line enriched	30	U-2197: 36.4
OTOA	CT108, DFNB22	ENSG00000155719	Otoancorin	16	21678514-21760729	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041405	Uncertain					Not detected	Group enriched	13	spleen: 2.6;testis: 6.0	epididymis: 0.3	Not detected		
OTOG	FLJ46346, mlemp, OTGN	ENSG00000188162	Otogelin	11	17547373-17647150	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	16	testis: 1.6	all non-specific tissues: 0.0	Cell line enriched	12	CACO-2: 7.7
OTOGL	C12orf64, FLJ90579	ENSG00000165899	Otogelin like	12	80209453-80379090	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040364, HPA053392	Uncertain		Approved	Cytosol		Tissue enhanced	Tissue enriched	5	kidney: 6.2	heart muscle: 1.1	Cell line enhanced		SCLC-21H: 1.6;U-2 OS: 1.0;U-87 MG: 2.6
OTOL1	C1QTNF15	ENSG00000182447	Otolin 1	3	161496808-161503942	Predicted secreted proteins	No evidence	HPA041030	Uncertain					Not detected	Not detected			cerebral cortex: 0.8	Not detected		
OTOR	FDP, MIAL, MIAL1	ENSG00000125879	Otoraplin	20	16748358-16770062	Predicted secreted proteins	Evidence at protein level	HPA024335	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Group enriched	50	SH-SY5Y: 2.8;SK-BR-3: 9.6;T-47d: 2.3
OTOS	OTOSP	ENSG00000178602	Otospiralin	2	240139026-240144562	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	16	thyroid gland: 74.1	cerebral cortex: 4.6	Not detected		
OVCH1	OVCH	ENSG00000187950	Ovochymase 1	12	29412474-29497686	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040253	Uncertain					Not detected	Group enriched	5	lung: 6.8;testis: 4.3;thyroid gland: 1.7	spleen: 0.8	Group enriched	6	Daudi: 3.9;HEL: 1.0
OVCH2	OVTN	ENSG00000183378	Ovochymase 2 (gene/pseudogene)	11	7689438-7706421	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	22	epididymis: 205.6	skin: 9.5	Cell line enriched	7	REH: 20.7
OVGP1	CHIT5, MUC9	ENSG00000085465	Oviductal glycoprotein 1	1	111414314-111427777	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062205	Enhanced				Urothelial cancer:3.93e-5 (favourable), Endometrial cancer:1.36e-4 (favourable)	Group enriched	Tissue enriched	118	fallopian tube: 3146.3	endometrium: 26.7	Cell line enhanced		HEK 293: 4.3
OXCT1	OXCT, SCOT	ENSG00000083720	3-oxoacid CoA-transferase 1	5	41730065-41870519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012047, HPA061425	Enhanced		Enhanced	Mitochondria	Renal cancer:1.86e-8 (favourable), Liver cancer:1.03e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 162.3	cerebral cortex: 98.7	Cell line enhanced		SiHa: 338.4
OXT	OT, OT-NPI, OXT-NPI	ENSG00000101405	Oxytocin/neurophysin I prepropeptide	20	3071620-3072517	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA071892	Supported	Supported				Tissue enriched	Tissue enhanced		liver: 2.1;small intestine: 1.1	duodenum: 1.1	Cell line enhanced		CACO-2: 1.3;HMC-1: 1.0
P3H1	GROS1, LEPRE1, LEPRECAN, MGC117314	ENSG00000117385	Prolyl 3-hydroxylase 1	1	42746335-42767084	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012113, HPA016980	Approved		Approved	Nucleoli<br>Vesicles	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 53.5	smooth muscle: 28.8	Expressed in all		
P3H2	FLJ10718, LEPREL1, MLAT4	ENSG00000090530	Prolyl 3-hydroxylase 2	3	189956728-190122437	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007890, HPA013355	Approved					Expressed in all	Mixed			prostate: 60.8	Cell line enhanced		HaCaT: 97.1;RPTEC TERT1: 83.3
P3H3	GRCB, HSU47926, LEPREL2	ENSG00000110811	Prolyl 3-hydroxylase 3	12	6828410-6839851	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA043695	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 11.7	endometrium: 6.2	Cell line enhanced		BJ: 33.3
P3H4	LEPREL4, NO55, SC65	ENSG00000141696	Prolyl 3-hydroxylase family member 4 (non-enzymatic)	17	41801947-41812604	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.48e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 18.3	Mixed		
P4HA1	C-P4Halpha(I), P4HA	ENSG00000122884	Prolyl 4-hydroxylase subunit alpha 1	10	73007217-73096974	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA007599, HPA026593	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles<br>Mitochondria	Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 91.7	Expressed in all		
P4HA2	C-P4Halpha(II)	ENSG00000072682	Prolyl 4-hydroxylase subunit alpha 2	5	132191838-132295315	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA016997, HPA027824, CAB062557	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles	Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 95.3	Mixed		
P4HA3	C-P4Halpha(III)	ENSG00000149380	Prolyl 4-hydroxylase subunit alpha 3	11	74235801-74311657	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA007897	Approved				Renal cancer:3.34e-9 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)	Mixed	Tissue enhanced		smooth muscle: 14.5	gallbladder: 8.9	Cell line enhanced		BJ: 16.3;HUVEC TERT2: 31.5;TIME: 22.1
P4HB	DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB	ENSG00000185624	Prolyl 4-hydroxylase subunit beta	17	81843159-81860694	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012463, HPA018884	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:2.30e-11 (unfavourable)	Expressed in all	Expressed in all			small intestine: 504.4	Expressed in all		
PAEP	GD, GdA, GdF, GdS, MGC138509, MGC142288, PAEG, PEP, PP14	ENSG00000122133	Progestagen associated endometrial protein	9	135561756-135566955	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016762, HPA020108, HPA029473	Enhanced				Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-6 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	endometrium: 437.0	seminal vesicle: 61.5	Cell line enriched	6	SK-MEL-30: 16.7
PALB2	FANCN, FLJ21816	ENSG00000083093	Partner and localizer of BRCA2	16	23603160-23641310	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB014895, HPA057000	Approved		Supported	Nucleoplasm	Pancreatic cancer:2.35e-5 (unfavourable), Colorectal cancer:2.83e-5 (favourable)	Expressed in all	Mixed			testis: 14.5	Expressed in all		
PAM	PAL, PHM	ENSG00000145730	Peptidylglycine alpha-amidating monooxygenase	5	102753981-103031105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026119, HPA042260	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 947.8	Cell line enhanced		fHDF/TERT166: 553.5
PAMR1	DKFZP586H2123, RAMP	ENSG00000149090	Peptidase domain containing associated with muscle regeneration 1	11	35431823-35530300	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 87.0;endometrium: 92.2	placenta: 76.1	Cell line enhanced		ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6
PAPLN	MGC50452	ENSG00000100767	Papilin, proteoglycan like sulfated glycoprotein	14	73237497-73274640	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048682, HPA053453	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			spleen: 20.6	Cell line enhanced		HHSteC: 12.9;HSkMC: 20.5
PAPPA	ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1	ENSG00000182752	Pappalysin 1	9	116153804-116402322	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001667, CAB016724	Enhanced		Uncertain	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	7	placenta: 104.5	parathyroid gland: 14.8	Cell line enhanced		ASC diff: 34.3;HSkMC: 99.9;U-138 MG: 35.8
PAPPA2	PAPP-A2, PAPPE, PLAC3	ENSG00000116183	Pappalysin 2	1	176463171-176845605	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018412, HPA018430	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	8	placenta: 82.7	cervix, uterine: 10.8	Cell line enriched	6	U-87 MG: 19.4
PARP15	FLJ40597, pART7	ENSG00000173200	Poly(ADP-ribose) polymerase family member 15	3	122577602-122639047	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035757			Approved	Mitochondria		Mixed	Tissue enhanced		lymph node: 55.0;spleen: 60.4;tonsil: 48.1	appendix: 35.3	Cell line enhanced		HEL: 7.8;TIME: 8.4
PATE1	PATE	ENSG00000171053	Prostate and testis expressed 1	11	125746293-125749867	Predicted secreted proteins	Evidence at protein level	HPA076587	Uncertain					Not detected	Tissue enriched	8	epididymis: 2299.3	seminal vesicle: 297.8	Cell line enhanced		BEWO: 1.3;NB-4: 1.5
PATE2	C11orf38, LVLF3112, PATE-M, UNQ3112	ENSG00000196844	Prostate and testis expressed 2	11	125776113-125778819	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	11	epididymis: 550.7	seminal vesicle: 50.7	Not detected		
PATE3	HEL-127, PATE-DJ	ENSG00000236027	Prostate and testis expressed 3	11	125788111-125791600	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	29	epididymis: 189.9	seminal vesicle: 6.4	Not detected		
PATE4	FLJ41047, PATE-B	ENSG00000237353	Prostate and testis expressed 4	11	125833316-125840069	Predicted secreted proteins	Evidence at protein level	HPA045632	Approved					Not detected	Tissue enriched	8	seminal vesicle: 148.4	epididymis: 18.3	Not detected		
PAX2		ENSG00000075891	Paired box 2	10	100735603-100829941	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB013024, HPA047704, HPA070751	Enhanced		Supported	Nucleoli<br>Golgi apparatus	Endometrial cancer:4.56e-4 (unfavourable)	Group enriched	Group enriched	5	epididymis: 37.1;fallopian tube: 19.0;kidney: 25.3;seminal vesicle: 20.0	cervix, uterine: 4.9	Group enriched	8	AN3-CA: 16.6;EFO-21: 23.1;RPTEC TERT1: 13.3
PCCB		ENSG00000114054	Propionyl-CoA carboxylase beta subunit	3	136250306-136337896	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036939, HPA036940	Enhanced				Renal cancer:6.47e-7 (favourable)	Expressed in all	Expressed in all			liver: 103.1	Expressed in all		
PCDH1	pc42	ENSG00000156453	Protocadherin 1	5	141853111-141879246	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047720, HPA050538	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 40.3	Cell line enhanced		CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1
PCDH15	CDHR15, DFNB23, USH1F	ENSG00000150275	Protocadherin related 15	10	53802771-55627942	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074437		Supported				Tissue enriched	Tissue enhanced		adrenal gland: 25.0;cerebral cortex: 12.2	kidney: 8.1	Cell line enhanced		U-2 OS: 1.1;U-266/70: 2.5
PCDHA1		ENSG00000204970	Protocadherin alpha 1	5	140786136-141012347	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035969	Enhanced		Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 2.8;testis: 1.4	adrenal gland: 0.4	Cell line enriched	6	T-47d: 8.6
PCDHA10	CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10	ENSG00000250120	Protocadherin alpha 10	5	140855883-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 17.5	thyroid gland: 4.3	Cell line enriched	10	EFO-21: 16.6
PCDHA11	CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11	ENSG00000249158	Protocadherin alpha 11	5	140868183-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077160			Approved	Vesicles<br>Cell Junctions<br>Cytoplasmic bodies		Not detected	Tissue enhanced		cerebral cortex: 7.6;parathyroid gland: 3.8	testis: 1.8	Cell line enhanced		AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
PCDHA6	CNR2, CNRS2, CRNR2, PCDH-ALPHA6	ENSG00000081842	Protocadherin alpha 6	5	140827958-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059326, HPA078110	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		cerebral cortex: 4.8	parathyroid gland: 1.9	Cell line enhanced		AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
PCDHB12	PCDH-BETA12	ENSG00000120328	Protocadherin beta 12	5	141208697-141212571	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Mixed			endometrium: 3.6	Cell line enhanced		EFO-21: 2.8;RH-30: 3.1
PCDHGA11	PCDH-GAMMA-A11	ENSG00000253873	Protocadherin gamma subfamily A, 11	5	141421047-141512979	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex,placenta: 3.2	Cell line enhanced		ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4
PCOLCE	PCPE, PCPE1	ENSG00000106333	Procollagen C-endopeptidase enhancer	7	100602177-100608175	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017623, HPA042927	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 216.8	gallbladder: 145.9	Cell line enhanced		ASC TERT1: 496.8;BJ hTERT+: 447.9;HSkMC: 595.6;SH-SY5Y: 617.5;U-2197: 961.3
PCOLCE2	PCPE2	ENSG00000163710	Procollagen C-endopeptidase enhancer 2	3	142815922-142889203	Predicted secreted proteins	Evidence at protein level	HPA013203	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.96e-5 (unfavourable), Urothelial cancer:1.08e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 81.7;placenta: 57.9	heart muscle: 42.3	Cell line enhanced		ASC diff: 37.5;U-2197: 58.5;U-266/70: 47.2
PCSK1	NEC1, PC1, PC3, SPC3	ENSG00000175426	Proprotein convertase subtilisin/kexin type 1	5	96390415-96434143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048564	Approved				Glioma:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 33.6	adrenal gland: 8.3	Group enriched	6	SCLC-21H: 26.6;U-138 MG: 18.8;U-87 MG: 15.5
PCSK1N	BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII	ENSG00000102109	Proprotein convertase subtilisin/kexin type 1 inhibitor	X	48831094-48835633	Predicted secreted proteins	Evidence at protein level	HPA003925, HPA064734	Enhanced		Approved	Vesicles	Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 93.6;kidney: 65.7	adrenal gland: 28.5	Cell line enhanced		HEK 293: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2
PCSK2	NEC2, PC2, SPC2	ENSG00000125851	Proprotein convertase subtilisin/kexin type 2	20	17226107-17484578	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049627	Enhanced		Approved	Vesicles		Group enriched	Tissue enhanced		adrenal gland: 37.5;cerebral cortex: 31.7	skin: 16.5	Group enriched	6	AF22: 59.2;SCLC-21H: 18.5
PCSK4	DKFZp434B217, MGC34749, PC4, SPC5	ENSG00000115257	Proprotein convertase subtilisin/kexin type 4	19	1481428-1490752	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005572	Uncertain				Endometrial cancer:9.45e-5 (favourable)	Expressed in all	Tissue enriched	9	testis: 41.3	fallopian tube: 4.8	Cell line enhanced		AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8
PCSK5	PC5, PC6, SPC6	ENSG00000099139	Proprotein convertase subtilisin/kexin type 5	9	75890644-76362339	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031072	Enhanced		Supported	Golgi apparatus	Renal cancer:9.61e-5 (unfavourable)	Mixed	Mixed			small intestine: 28.1	Cell line enhanced		BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5
PCSK9	FH3, HCHOLA3, NARC-1	ENSG00000169174	Proprotein convertase subtilisin/kexin type 9	1	55039548-55064852	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.40e-4 (unfavourable)	Mixed	Tissue enhanced		liver: 6.1;lung: 11.1	colon: 3.4	Cell line enhanced		A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
PCYOX1	KIAA0908, PCL1	ENSG00000116005	Prenylcysteine oxidase 1	2	70257386-70281191	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035193	Approved				Renal cancer:1.89e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 141.1	Expressed in all		
PCYOX1L	MGC3265	ENSG00000145882	Prenylcysteine oxidase 1 like	5	149358007-149369653	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037463, HPA038402	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enhanced		parathyroid gland: 21.4	cerebral cortex: 12.5	Mixed		
PDE2A		ENSG00000186642	Phosphodiesterase 2A	11	72576141-72674591	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009752, HPA031192	Enhanced		Supported	Cytosol	Liver cancer:1.76e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 141.8;spleen: 184.3	adipose tissue: 62.1	Cell line enriched	6	HeLa: 340.7
PDE7A	HCP1	ENSG00000205268	Phosphodiesterase 7A	8	65717510-65842322	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018770, HPA027340	Approved				Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 68.9	Expressed in all		
PDF		ENSG00000258429	Peptide deformylase (mitochondrial)	16	69328621-69330595	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA063409	Approved		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:2.73e-4 (unfavourable), Cervical cancer:4.63e-4 (unfavourable), Renal cancer:6.11e-4 (favourable), Lung cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 7.8	Expressed in all		
PDGFA	PDGF-A, PDGF1	ENSG00000197461	Platelet derived growth factor subunit A	7	497258-520296	Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005579	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.8	Cell line enhanced		WM-115: 307.1
PDGFB	SIS, SSV	ENSG00000100311	Platelet derived growth factor subunit B	22	39223359-39244751	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB011604, HPA011972, CAB018341	Supported		Approved	Vesicles	Lung cancer:3.67e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 59.7	lung: 28.6	Cell line enhanced		EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5
PDGFC	fallotein, SCDGF	ENSG00000145431	Platelet derived growth factor C	4	156760454-156971394	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA009134	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 40.6	endometrium: 16.8	Cell line enhanced		fHDF/TERT166: 47.4;U-138 MG: 41.4
PDGFD	IEGF, MSTP036, SCDGF-B	ENSG00000170962	Platelet derived growth factor D	11	103907186-104164379	Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA046183, HPA066271	Approved		Approved	Golgi apparatus<br>Vesicles	Stomach cancer:9.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 140.5;ovary: 96.6	gallbladder: 53.7	Group enriched	6	ASC diff: 96.8;HHSteC: 36.1
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
PDGFRL	PRLTS	ENSG00000104213	Platelet derived growth factor receptor like	8	17576433-17644071	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA052801			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Mixed			breast: 49.2	Cell line enhanced		AN3-CA: 131.2;BJ hTERT+: 93.6;HSkMC: 44.1
PDIA2	PDA2, PDI, PDIP, PDIR	ENSG00000185615	Protein disulfide isomerase family A member 2	16	283152-287215	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051692, HPA053492	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	7	pancreas: 523.1	stomach: 71.9	Cell line enhanced		HAP1: 4.0;HEK 293: 7.9;Hep G2: 4.4;MCF7: 3.6;SH-SY5Y: 3.9
PDIA3	ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC	ENSG00000167004	Protein disulfide isomerase family A member 3	15	43746392-43773279	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002645, HPA003230, CAB011199, CAB075744	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
PDIA4	ERP70, ERP72	ENSG00000155660	Protein disulfide isomerase family A member 4	7	149003062-149028641	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA006139, HPA006140, CAB017368	Supported		Supported	Endoplasmic reticulum	Renal cancer:5.20e-9 (unfavourable), Glioma:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 372.1	Expressed in all		
PDIA5	FLJ30401, PDIR	ENSG00000065485	Protein disulfide isomerase family A member 5	3	123067062-123225227	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030353, HPA030355	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)	Expressed in all	Mixed			placenta: 70.8	Mixed		
PDIA6	ERp5, P5, TXNDC7	ENSG00000143870	Protein disulfide isomerase family A member 6	2	10783391-10837977	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034347, HPA034652, HPA034653	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 591.9	Expressed in all		
PDILT	PDIA7	ENSG00000169340	Protein disulfide isomerase like, testis expressed	16	20359170-20404737	Predicted secreted proteins	Evidence at protein level	HPA041913	Approved					Not detected	Tissue enriched	5	testis: 31.2	stomach: 6.1	Group enriched	6	HBEC3-KT: 9.1;hTCEpi: 7.4;hTERT-HME1: 2.4
PDYN	ADCA, PENKB, SCA23	ENSG00000101327	Prodynorphin	20	1978757-1994285	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049841, HPA053342	Approved	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 63.3	testis: 5.5	Not detected		
PDZRN4	DKFZp434B0417, FLJ33777, IMAGE5767589, LNX4	ENSG00000165966	PDZ domain containing ring finger 4	12	41188448-41574590	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042101	Enhanced					Tissue enhanced	Tissue enhanced		seminal vesicle: 19.6	prostate: 9.3	Cell line enriched	6	U-266/70: 2.7
PEAR1	FLJ00193, JEDI, MEGF12	ENSG00000187800	Platelet endothelial aggregation receptor 1	1	156893698-156916434	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035217	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Renal cancer:4.31e-4 (unfavourable)	Expressed in all	Mixed			placenta: 16.9	Cell line enhanced		HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3
PEBP4	CORK1, hPEBP4, MGC22776	ENSG00000134020	Phosphatidylethanolamine binding protein 4	8	22713251-23000000	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025064	Uncertain					Group enriched	Tissue enhanced		epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0	thyroid gland: 96.3	Cell line enriched	7	U-266/70: 3.0
PECAM1	CD31	ENSG00000261371	Platelet and endothelial cell adhesion molecule 1	17	64319415-64413776	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004690	Supported				Renal cancer:8.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 659.7	Cell line enhanced		HUVEC TERT2: 644.6;TIME: 437.4
PENK		ENSG00000181195	Proenkephalin	8	56436674-56446734	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013138, CAB016390	Enhanced					Tissue enhanced	Group enriched	9	adrenal gland: 566.0;testis: 208.0	prostate: 41.3	Cell line enhanced		ASC diff: 10.8;ASC TERT1: 6.5;BJ: 7.7;THP-1: 5.8
PET117	CSRP2BP	ENSG00000232838	PET117 homolog	20	18137873-18143169	Predicted secreted proteins	Evidence at protein level	HPA047716	Approved				Liver cancer:4.76e-6 (unfavourable), Renal cancer:4.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
PF4	CXCL4, SCYB4	ENSG00000163737	Platelet factor 4	4	73981077-73982124	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026008, HPA052485	Enhanced					Tissue enhanced	Group enriched	5	bone marrow: 53.7;spleen: 13.4	placenta: 6.5	Cell line enriched	13	HEL: 37.2
PF4V1	CXCL4L1, CXCL4V1, SCYB4V1	ENSG00000109272	Platelet factor 4 variant 1	4	73853189-73854155	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052485	Supported					Tissue enhanced	Tissue enhanced		spleen: 3.9	urinary bladder: 2.8	Cell line enhanced		CAPAN-2: 1.2;EFO-21: 2.0
PFKP	PFK-C, PFKF	ENSG00000067057	Phosphofructokinase, platelet	10	3066333-3137712	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018257, HPA056484	Uncertain		Supported	Cytosol	Liver cancer:8.72e-6 (unfavourable), Head and neck cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 285.1	Mixed		
PGA3		ENSG00000229859	Pepsinogen 3, group I (pepsinogen A)	11	61203307-61213098	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026358, HPA046875	Enhanced					Tissue enriched	Tissue enriched	716	stomach: 6775.4	cerebral cortex: 9.4	Group enriched	5	HMC-1: 7.5;THP-1: 1.9
PGA4		ENSG00000229183	Pepsinogen 4, group I (pepsinogen A)	11	61222216-61231927	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046875	Supported					Not detected	Tissue enriched	2994	stomach: 34510.3	cerebral cortex: 11.5	Group enriched	7	BJ hTERT+: 12.2;THP-1: 5.2
PGA5		ENSG00000256713	Pepsinogen 5, group I (pepsinogen A)	11	61241042-61251448	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046875	Supported					Tissue enriched	Tissue enriched	684	stomach: 3513.1	cerebral cortex: 5.1	Cell line enriched	13	BJ hTERT+: 23.3
PGAP3	CAB2, MGC9753, PER1, PERLD1, PP1498	ENSG00000161395	Post-GPI attachment to proteins 3	17	39671122-39696797	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016591	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.6	Cell line enhanced		SK-BR-3: 99.2
PGC		ENSG00000096088	Progastricsin	6	41736711-41754109	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031717, HPA031718	Enhanced		Supported	Nucleus		Tissue enhanced	Tissue enriched	17	stomach: 22276.5	duodenum: 1302.2	Cell line enriched	11	Hep G2: 171.0
PGF	D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760	ENSG00000119630	Placental growth factor	14	74941834-74955784	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041624			Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 71.1;thyroid gland: 64.5	cervix, uterine: 30.1	Group enriched	6	BEWO: 398.0;HUVEC TERT2: 164.7
PGLYRP1	PGLYRP, PGRP, PGRP-S, PGRPS, TAG7, TNFSF3L	ENSG00000008438	Peptidoglycan recognition protein 1	19	46019153-46023065	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045702	Enhanced					Not detected	Tissue enriched	57	bone marrow: 421.1	spleen: 7.4	Cell line enhanced		A549: 2.9
PGLYRP2	PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like	ENSG00000161031	Peptidoglycan recognition protein 2	19	15468645-15498956	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033468, HPA043568, HPA046311, HPA075237	Approved		Approved	Cell Junctions		Tissue enriched	Tissue enriched	17	liver: 133.2	testis: 7.8	Group enriched	8	MCF7: 5.7;T-47d: 6.8
PGLYRP3	PGLYRPIalpha, PGRP-Ialpha, PGRPIA	ENSG00000159527	Peptidoglycan recognition protein 3	1	153297862-153310718	Predicted secreted proteins	Evidence at protein level	HPA030369	Uncertain					Tissue enhanced	Group enriched	9	esophagus: 42.8;skin: 87.1	tonsil: 6.8	Group enriched	15	HaCaT: 3.4;HDLM-2: 1.4;hTCEpi: 1.0
PGLYRP4	PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67	ENSG00000163218	Peptidoglycan recognition protein 4	1	153330120-153348840	Predicted secreted proteins	Evidence at protein level	CAB025879			Approved	Vesicles<br>Plasma membrane		Group enriched	Group enriched	6	esophagus: 5.8;skin: 18.2	tonsil: 2.1	Cell line enhanced		HaCaT: 3.4;HDLM-2: 2.4;Karpas-707: 1.4
PHACTR1	dJ257A7.2, KIAA1733, RPEL1	ENSG00000112137	Phosphatase and actin regulator 1	6	12716805-13290484	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029755, HPA029756, HPA029757	Enhanced		Uncertain	Plasma membrane	Renal cancer:5.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 26.6	bone marrow: 15.6	Cell line enhanced		HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3
PHGDH	PDG, PGDH, SERA	ENSG00000092621	Phosphoglycerate dehydrogenase	1	119659798-119744215	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003681, HPA021241, HPA024031, CAB068216	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 216.7	skin: 115.9	Mixed		
PI15	P25TI	ENSG00000137558	Peptidase inhibitor 15	8	74824537-74855029	Predicted secreted proteins	Evidence at protein level	HPA006593, HPA030057	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		appendix: 73.2;prostate: 50.5;smooth muscle: 67.8	endometrium: 33.0	Group enriched	9	AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5
PI3	cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14	ENSG00000124102	Peptidase inhibitor 3	20	45174876-45176544	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009449, HPA017737	Enhanced		Approved	Plasma membrane	Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)	Tissue enhanced	Group enriched	15	esophagus: 2285.4;tonsil: 1739.8	appendix: 133.6	Group enriched	7	EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0
PIANP	C12orf53, DKFZp547D2210, PANP	ENSG00000139200	PILR alpha associated neural protein	12	6693792-6700800	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010631	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 64.3	endometrium: 13.4	Cell line enhanced		NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2
PIEZO2	C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771	ENSG00000154864	Piezo type mechanosensitive ion channel component 2	18	10666483-11148762	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015986, HPA031974, HPA031975, HPA040616	Enhanced		Approved	Vesicles	Renal cancer:9.57e-7 (unfavourable)	Mixed	Mixed			lung: 12.8	Cell line enhanced		AF22: 17.1;BJ hTERT+ SV40 Large T+ RasG12V: 24.8;HeLa: 26.7;U-266/70: 19.5
PIGK	GPI8, hGPI8	ENSG00000142892	Phosphatidylinositol glycan anchor biosynthesis class K	1	77088990-77219430	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056383, HPA057040	Uncertain				Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
PIGL		ENSG00000108474	Phosphatidylinositol glycan anchor biosynthesis class L	17	16217191-16351797	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012739	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.47e-4 (unfavourable), Prostate cancer:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis,thyroid gland: 14.7	Mixed		
PIGT		ENSG00000124155	Phosphatidylinositol glycan anchor biosynthesis class T	20	45416067-45456934	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
PIGZ	FLJ12768, MGC52163, SMP3	ENSG00000119227	Phosphatidylinositol glycan anchor biosynthesis class Z	3	196946343-196969060	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA058599, HPA059920	Approved		Uncertain	Vesicles	Renal cancer:5.60e-5 (unfavourable)	Expressed in all	Tissue enhanced		colon: 18.5;rectum: 18.1	cerebral cortex: 10.9	Mixed		
PIK3IP1	HGFL, MGC17330	ENSG00000100100	Phosphoinositide-3-kinase interacting protein 1	22	31281593-31292534	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 121.1	Cell line enhanced		U-698: 23.5
PILRA	FDF03	ENSG00000085514	Paired immunoglobin like type 2 receptor alpha	7	100367530-100400099	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056132	Approved				Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 52.4	lung: 43.8	Cell line enhanced		ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4
PILRB	FDFACT1, FDFACT2	ENSG00000121716	Paired immunoglobin-like type 2 receptor beta	7	100352176-100367733	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026750	Approved		Approved	Mitochondria	Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
PINLYP		ENSG00000234465	Phospholipase A2 inhibitor and LY6/PLAUR domain containing	19	43576800-43583964	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA061218	Uncertain		Approved	Vesicles		Mixed	Mixed			fallopian tube: 27.7	Cell line enhanced		HEL: 65.4;HMC-1: 40.9;REH: 27.1;THP-1: 24.6
PIP	GCDFP-15, GCDFP15, GPIP4	ENSG00000159763	Prolactin induced protein	7	143132077-143139746	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002661, HPA009177	Enhanced				Renal cancer:5.96e-5 (favourable)	Tissue enriched	Group enriched	618	breast: 4504.1;salivary gland: 6904.2;seminal vesicle: 4198.4	cervix, uterine: 8.4	Cell line enriched	415	T-47d: 649.3
PIWIL4	FLJ36156, HIWI2, Miwi2	ENSG00000134627	Piwi like RNA-mediated gene silencing 4	11	94543840-94621421	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036587, HPA036588, HPA057508	Enhanced		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		testis: 24.3	bone marrow: 15.5	Cell line enhanced		NB-4: 58.5;THP-1: 13.6
PKDCC	SgK493, Vlk	ENSG00000162878	Protein kinase domain containing, cytoplasmic	2	42048020-42058528	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA026427, HPA026442, HPA026526	Uncertain					Expressed in all	Mixed			adipose tissue: 27.4	Cell line enhanced		AN3-CA: 72.7;ASC diff: 41.5;CACO-2: 78.1;HHSteC: 43.5
PKHD1	ARPKD, FCYT, TIGM1	ENSG00000170927	Polycystic kidney and hepatic disease 1 (autosomal recessive)	6	51615300-52087625	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031227	Approved				Renal cancer:9.74e-8 (favourable)	Group enriched	Group enriched	5	epididymis: 5.7;kidney: 15.3	pancreas: 1.9	Cell line enriched	7	RPTEC TERT1: 8.1
PLA1A	ps-PLA1	ENSG00000144837	Phospholipase A1 member A	3	119597842-119629811	Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA059740			Approved	Nuclear speckles	Cervical cancer:2.81e-7 (favourable)	Group enriched	Group enriched	5	epididymis: 164.9;parathyroid gland: 38.9;seminal vesicle: 93.1	liver: 19.6	Cell line enriched	15	SK-MEL-30: 19.7
PLA2G10	GXPLA2	ENSG00000069764	Phospholipase A2 group X	16	14672545-14694669	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041893	Uncertain				Endometrial cancer:5.74e-5 (favourable)	Mixed	Tissue enhanced		colon: 6.9;rectum: 6.5;stomach: 10.4	duodenum: 2.2	Cell line enhanced		CAPAN-2: 1.3
PLA2G12A	PLA2G12	ENSG00000123739	Phospholipase A2 group XIIA	4	109709989-109730077	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA035908, HPA035909	Approved				Renal cancer:2.54e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.0	Expressed in all		
PLA2G12B	PLA2G13	ENSG00000138308	Phospholipase A2 group XIIB	10	72935170-72954778	Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA057745, HPA059562	Approved		Approved	Vesicles		Tissue enriched	Group enriched	10	duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9	lung: 3.9	Group enriched	6	CACO-2: 10.3;Hep G2: 14.2
PLA2G15	GXVPLA2, LLPL, LYPLA3	ENSG00000103066	Phospholipase A2 group XV	16	68245304-68261062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041702, HPA041727	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 37.5	Expressed in all		
PLA2G1B	PLA2, PLA2A, PPLA2	ENSG00000170890	Phospholipase A2 group IB	12	120322111-120327789	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB022329, HPA047822, HPA060803	Enhanced		Enhanced	Cytosol		Tissue enriched	Tissue enriched	246	pancreas: 23843.3	ovary: 96.9	Cell line enhanced		Hep G2: 1.7;U-2 OS: 1.8
PLA2G2A	PLA2B, PLA2L	ENSG00000188257	Phospholipase A2 group IIA	1	19975431-19980416	Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA015236	Enhanced		Uncertain	Nucleus<br>Nucleoli	Melanoma:1.49e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 108.4;rectum: 177.5;small intestine: 233.7	duodenum: 85.7	Group enriched	11	Hep G2: 50.2;RT4: 53.3
PLA2G2C		ENSG00000187980	Phospholipase A2 group IIC	1	20161253-20177424	Predicted secreted proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enhanced		esophagus: 1.2	testis: 0.6	Cell line enhanced		HL-60: 1.2;U-698: 1.2;U-937: 1.3
PLA2G2D	sPLA2S	ENSG00000117215	Phospholipase A2 group IID	1	20111939-20119566	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 118.5;tonsil: 54.0	appendix: 20.5	Cell line enriched	6	RPMI-8226: 5.9
PLA2G2E		ENSG00000188784	Phospholipase A2 group IIE	1	19920009-19923617	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA064085	Uncertain					Not detected	Tissue enriched	11	tonsil: 2.3	small intestine: 0.2	Not detected		
PLA2G4F	PLA2G4F/Z	ENSG00000168907	Phospholipase A2 group IVF	15	42139034-42156636	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042713, HPA056752	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:2.00e-4 (unfavourable)	Mixed	Tissue enriched	5	skin: 92.5	lung: 18.4	Cell line enhanced		hTCEpi: 1.4;RT4: 6.6
PLA2G5		ENSG00000127472	Phospholipase A2 group V	1	20028179-20091190	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA053361	Approved					Group enriched	Tissue enhanced		heart muscle: 48.6	seminal vesicle: 19.8	Cell line enhanced		U-138 MG: 1.0;U-2197: 2.1
PLA2G7	LDL-PLA2, PAFAH	ENSG00000146070	Phospholipase A2 group VII	6	46704201-46735693	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035916			Uncertain	Vesicles		Expressed in all	Mixed			spleen: 37.5	Cell line enhanced		NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7
PLA2R1	CLEC13C, PLA2-R, PLA2G1R, PLA2IR	ENSG00000153246	Phospholipase A2 receptor 1	2	159932006-160062610	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB068217, CAB068218	Approved		Approved	Cytosol	Stomach cancer:3.08e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 70.6	parathyroid gland: 34.5	Cell line enhanced		ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6
PLAC1	CT92, OOSP2L	ENSG00000170965	Placenta specific 1	X	134565838-134764322	Predicted secreted proteins	Evidence at protein level	HPA063425	Enhanced					Mixed	Tissue enriched	21	placenta: 37.7	testis: 1.7	Cell line enhanced		HEK 293: 18.2;hTCEpi: 11.1
PLAC9		ENSG00000189129	Placenta specific 9	10	80131682-80145359	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043469	Uncertain				Ovarian cancer:6.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 87.5	breast: 68.4	Cell line enhanced		ASC diff: 67.4;ASC TERT1: 59.6;BEWO: 31.0
PLAT		ENSG00000104368	Plasminogen activator, tissue type	8	42175233-42207724	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003412, CAB009335	Supported		Approved	Actin filaments	Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Tissue enriched	5	parathyroid gland: 709.4	urinary bladder: 135.9	Cell line enhanced		CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
PLAU	UPA, URK	ENSG00000122861	Plasminogen activator, urokinase	10	73909177-73917497	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008719	Approved				Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 60.3	Cell line enhanced		CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9
PLAUR	CD87, UPAR, URKR	ENSG00000011422	Plasminogen activator, urokinase receptor	19	43646095-43670547	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050843, CAB073533	Uncertain		Supported	Plasma membrane	Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 428.5	Cell line enhanced		U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLBD1	FLJ22662	ENSG00000121316	Phospholipase B domain containing 1	12	14503661-14568349	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040303	Approved				Liver cancer:2.81e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 167.1	Cell line enhanced		BEWO: 77.7;CAPAN-2: 186.4
PLEKHH3	FLJ21019	ENSG00000068137	Pleckstrin homology, MyTH4 and FERM domain containing H3	17	42667914-42676994	Predicted intracellular proteins	Evidence at protein level	HPA046234	Uncertain		Approved	Golgi apparatus	Renal cancer:9.62e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 11.6	Cell line enhanced		T-47d: 46.9
PLG		ENSG00000122194	Plasminogen	6	160702238-160753315	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000668, CAB016678, HPA021602, HPA048823, HPA053770	Supported		Uncertain	Vesicles	Renal cancer:4.22e-4 (favourable)	Tissue enriched	Tissue enriched	6	liver: 1749.3	kidney: 313.4	Cell line enhanced		RH-30: 1.0
PLGLB1	PLGL, PRP-B	ENSG00000183281	Plasminogen-like B1	2	87002559-87021852	Predicted secreted proteins	Evidence at transcript level	HPA053770			Approved	Vesicles		Tissue enriched	Tissue enriched	8	liver: 120.5	skin: 15.4	Mixed		
PLGLB2	PLGP1	ENSG00000125551	Plasminogen-like B2	2	87748087-87758793	Predicted secreted proteins	Evidence at transcript level	HPA053770			Approved	Vesicles		Tissue enriched	Tissue enriched	161	liver: 245.3	skin: 1.5	Mixed		
PLOD1	LH1, LLH, PLOD	ENSG00000083444	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	1	11934205-11975538	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA049137, HPA055799	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
PLOD2	LH2	ENSG00000152952	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2	3	146069440-146163653	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025898, HPA069126	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 150.8	Cell line enhanced		HBF TERT88: 615.2;U-87 MG: 554.9
PLOD3	LH3	ENSG00000106397	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	7	101205977-101218420	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001236	Uncertain				Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 48.1	Expressed in all		
PLTP	BPIFE	ENSG00000100979	Phospholipid transfer protein	20	45898621-45912155	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB032873	Approved				Renal cancer:9.52e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 635.6	Cell line enhanced		HSkMC: 229.0;U-87 MG: 331.6
PLXNA4	DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B	ENSG00000221866	Plexin A4	7	132123332-132648688	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029919, HPA052141, HPA075592	Approved		Approved	Plasma membrane	Endometrial cancer:1.61e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 15.2;cervix, uterine: 12.5	cerebral cortex: 10.4	Cell line enhanced		ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
PLXNB2	KIAA0315, MM1, PLEXB2	ENSG00000196576	Plexin B2	22	50274979-50307627	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003100	Uncertain				Stomach cancer:4.75e-4 (favourable), Ovarian cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 120.9	Mixed		
PM20D1	Cps1, FLJ32569	ENSG00000162877	Peptidase M20 domain containing 1	1	205828022-205850132	Enzymes, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		kidney: 6.0;pancreas: 16.6	skin: 3.9	Cell line enriched	10	Karpas-707: 1.3
PMCH	MCH	ENSG00000183395	Pro-melanin concentrating hormone	12	102196459-102197845	Predicted secreted proteins	Evidence at protein level	HPA046055, HPA061884	Enhanced					Tissue enhanced	Tissue enhanced		lymph node: 1.1	appendix: 0.7	Cell line enriched	9	HDLM-2: 40.8
PMEL	D12S53E, gp100, Pmel17, SI, SIL, SILV	ENSG00000185664	Premelanosome protein	12	55954105-55973317	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031649	Enhanced				Renal cancer:3.70e-4 (favourable)	Tissue enriched	Tissue enriched	12	skin: 133.4	breast: 10.6	Cell line enriched	55	SK-MEL-30: 6730.3
PMEPA1	STAG1, TMEPAI	ENSG00000124225	Prostate transmembrane protein, androgen induced 1	20	57648392-57711536	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA072291			Supported	Vesicles	Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 146.1;prostate: 179.6	endometrium: 60.3	Cell line enhanced		SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
PNLIP	PL	ENSG00000175535	Pancreatic lipase	10	116545931-116567855	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062430, HPA062494	Enhanced					Tissue enriched	Tissue enriched	325	pancreas: 93703.0	ovary: 288.0	Cell line enhanced		U-2 OS: 1.3
PNLIPRP1	PLRP1	ENSG00000187021	Pancreatic lipase related protein 1	10	116590385-116609175	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	373	pancreas: 2295.1	ovary: 6.1	Not detected		
PNLIPRP3		ENSG00000203837	Pancreatic lipase related protein 3	10	116427867-116477957	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA046202, HPA052009	Uncertain					Tissue enhanced	Tissue enhanced		breast: 12.0;skin: 5.4	esophagus: 1.8	Cell line enriched	14	hTCEpi: 233.8
PNOC	N/OFQ, NOP, PPNOC	ENSG00000168081	Prepronociceptin	8	28316986-28343355	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044507, HPA056724	Enhanced				Endometrial cancer:2.94e-6 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 44.2;fallopian tube: 26.3;lymph node: 28.9	tonsil: 21.4	Group enriched	6	Daudi: 27.2;Karpas-707: 20.9;RPMI-8226: 7.7;U-698: 15.7
PNPLA4	DXS1283E, GS2, iPLA2eta	ENSG00000006757	Patatin like phospholipase domain containing 4	X	7898247-7927739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003656	Approved				Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.2	Mixed		
PODNL1	FLJ23447, SLRR5B	ENSG00000132000	Podocan like 1	19	13931187-13953392	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042807	Approved				Glioma:2.06e-8 (unfavourable), Urothelial cancer:4.49e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 12.3	skin: 8.5	Cell line enhanced		HSkMC: 17.5;SiHa: 21.2;U-2 OS: 16.8
POFUT1	FUT12, KIAA0180, O-Fuc-T, O-FUT	ENSG00000101346	Protein O-fucosyltransferase 1	20	32207880-32238667	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054519, HPA059935	Approved		Approved	Centrosome		Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
POFUT2	C21orf80, FUT13, KIAA0958	ENSG00000186866	Protein O-fucosyltransferase 2	21	45263928-45287898	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044297	Uncertain				Renal cancer:8.66e-12 (unfavourable), Colorectal cancer:4.55e-7 (unfavourable), Liver cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 24.3	Expressed in all		
POGLUT1	9630046K23Rik, C3orf9, hCLP46, KDELCL1, KTELC1, MDS010, MDSRP, MGC32995, Rumi	ENSG00000163389	Protein O-glucosyltransferase 1	3	119468938-119494708	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037855, HPA037856	Approved				Renal cancer:7.02e-7 (unfavourable), Urothelial cancer:2.23e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 16.5	Expressed in all		
POLL		ENSG00000166169	DNA polymerase lambda	10	101578882-101588270	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066704			Enhanced	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 49.9	Mixed		
POMC	ACTH, CLIP, LPH, MSH, NPP, POC	ENSG00000115138	Proopiomelanocortin	2	25160853-25168903	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002762, HPA046135, HPA063644	Enhanced				Pancreatic cancer:5.70e-4 (favourable)	Tissue enriched	Tissue enhanced		testis: 6.8	pancreas: 5.3	Cell line enhanced		HMC-1: 1.2;THP-1: 1.2
POMGNT2	AGO61, C3orf39, FLJ14566, GTDC2	ENSG00000144647	Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)	3	43079232-43106076	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA034870, HPA040989	Uncertain				Renal cancer:4.00e-7 (favourable), Liver cancer:1.26e-5 (unfavourable), Colorectal cancer:8.13e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 35.7	Mixed		
PON1	ESA, PON	ENSG00000005421	Paraoxonase 1	7	95297676-95324707	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001610	Uncertain				Liver cancer:7.24e-7 (favourable)	Tissue enriched	Tissue enriched	69	liver: 233.6	adrenal gland: 3.3	Not detected		
POSTN	OSF-2, periostin, PN	ENSG00000133110	Periostin	13	37562583-37598844	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA012306	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.83e-7 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Stomach cancer:4.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 246.4	Group enriched	7	hTEC/SVTERT24-B: 490.4;U-138 MG: 610.6;U-2197: 396.9
PPBP	b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1	ENSG00000163736	Pro-platelet basic protein	4	73987038-73988197	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008354, CAB017624	Supported				Cervical cancer:6.17e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 110.6	spleen: 24.3	Cell line enhanced		HBEC3-KT: 1.6;HEL: 6.2;RPTEC TERT1: 1.1
PPIC	CYPC	ENSG00000168938	Peptidylprolyl isomerase C	5	123023250-123036741	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA039163	Approved				Liver cancer:4.78e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 77.6	Mixed		
PPP1CC	PP1C, PP1gamma	ENSG00000186298	Protein phosphatase 1 catalytic subunit gamma	12	110719680-110742939	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022645	Uncertain				Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 257.5	Expressed in all		
PPT1	CLN1, INCL, PPT	ENSG00000131238	Palmitoyl-protein thioesterase 1	1	40072705-40097703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021546	Supported				Liver cancer:6.98e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 193.0	Expressed in all		
PPT2		ENSG00000221988	Palmitoyl-protein thioesterase 2	6	32153441-32163680	Predicted secreted proteins	Evidence at protein level						Endometrial cancer:5.03e-5 (unfavourable)	Expressed in all	Mixed			skin: 8.6	Cell line enhanced		ASC diff: 16.4;EFO-21: 16.9;HEK 293: 29.1;SK-MEL-30: 16.2
PPY	PNP	ENSG00000108849	Pancreatic polypeptide	17	43940804-43942468	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016735, HPA032122	Enhanced					Tissue enriched	Tissue enhanced		pancreas: 35.3;parathyroid gland: 33.7	rectum,skin: 8.3	Cell line enhanced		BEWO: 3.6;EFO-21: 3.2;U-2 OS: 4.0
PRADC1	C2orf7, hPAP21, MGC13004, PAP21	ENSG00000135617	Protease associated domain containing 1	2	73228006-73233238	Predicted secreted proteins	Evidence at protein level	HPA051066	Approved					Expressed in all	Expressed in all			heart muscle: 46.8	Expressed in all		
PRAP1	UPA	ENSG00000165828	Proline rich acidic protein 1	10	133347146-133352683	Predicted secreted proteins	Evidence at protein level	HPA038713, HPA052451	Supported		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Group enriched	Group enriched	6	duodenum: 928.6;liver: 297.4;small intestine: 1097.7	kidney: 125.6	Group enriched	5	CACO-2: 18.2;Hep G2: 64.2
PRB1	PM, PMF, PMS, PRB1L, PRB1M	ENSG00000251655	Proline rich protein BstNI subfamily 1	12	11351823-11395566	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	4399	salivary gland: 6733.7	skin: 1.5	Not detected		
PRB2	cP7, PRPPRB1, Ps	ENSG00000121335	Proline rich protein BstNI subfamily 2	12	11391540-11501041	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	4978	salivary gland: 4971.2	bone marrow,skin: 0.9	Not detected		
PRB3	PRG	ENSG00000197870	Proline rich protein BstNI subfamily 3	12	11265924-11269805	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	3949	salivary gland: 5770.7	skin: 1.4	Cell line enriched	5	NTERA-2: 2.2
PRB4		ENSG00000230657	Proline rich protein BstNI subfamily 4	12	11307083-11310435	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	3551	salivary gland: 1351.8	skin,testis: 0.3	Cell line enriched	23	CACO-2: 2.2
PRCD	RP36	ENSG00000214140	Photoreceptor disc component	17	76527586-76553578	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			parathyroid gland: 3.1	Cell line enhanced		BEWO: 1.4;Hep G2: 1.5;HHSteC: 1.1;HSkMC: 1.2;SH-SY5Y: 1.4
PRCP	HUMPCP, PCP	ENSG00000137509	Prolylcarboxypeptidase	11	82823502-82970584	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017065	Approved				Renal cancer:2.65e-6 (favourable)	Expressed in all	Expressed in all			placenta: 222.7	Expressed in all		
PRDX4	AOE37-2	ENSG00000123131	Peroxiredoxin 4	X	23664262-23686399	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008659, CAB027389, CAB047362	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.33e-6 (unfavourable)	Expressed in all	Expressed in all			pancreas: 239.5	Expressed in all		
PRELP	prolargin, SLRR2A	ENSG00000188783	Proline and arginine rich end leucine rich repeat protein	1	203475828-203491352	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.62e-6 (unfavourable), Colorectal cancer:9.70e-5 (unfavourable), Urothelial cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 108.0	Group enriched	7	ASC diff: 12.4;BJ: 6.5;fHDF/TERT166: 9.1
PRF1	HPLH2, P1, PFP	ENSG00000180644	Perforin 1	10	70597348-70602775	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002436, HPA037940	Approved		Approved	Cytosol	Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 52.8	lymph node: 20.8	Cell line enriched	16	HDLM-2: 221.2
PRG2	BMPG, MBP, proMBP	ENSG00000186652	Proteoglycan 2, pro eosinophil major basic protein	11	57386794-57390657	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038515	Supported					Not detected	Tissue enriched	30	placenta: 3880.8	bone marrow: 130.2	Group enriched	50	HL-60: 2682.8;HMC-1: 4472.2;NB-4: 6716.6
PRG3	MBP2, MBPH	ENSG00000156575	Proteoglycan 3, pro eosinophil major basic protein 2	11	57376769-57381150	Predicted secreted proteins	Evidence at protein level	HPA064183	Enhanced					Not detected	Tissue enriched	45	bone marrow: 29.3	liver,spleen: 0.6	Cell line enriched	64	HMC-1: 174.6
PRG4	bG174L6.2, CACP, FLJ32635, HAPO, JCAP, MSF, SZP	ENSG00000116690	Proteoglycan 4	1	186296279-186314562	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA028523	Uncertain					Tissue enriched	Tissue enriched	6	liver: 97.4	lung: 15.4	Cell line enhanced		ASC diff: 195.2;hTEC/SVTERT24-B: 44.2;SiHa: 34.4
PRH1	Pa	ENSG00000231887	Proline rich protein HaeIII subfamily 1	12	10824960-11171544	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	2295	salivary gland: 17934.0	ovary: 7.8	Cell line enhanced		CAPAN-2: 1.6
PRH2	Pr	ENSG00000134551	Proline rich protein HaeIII subfamily 2	12	10929236-10932341	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1858	salivary gland: 16591.4	ovary: 8.9	Not detected		
PRKCSH	G19P1, GIIB, PCLD, PLD1, VASAP-60	ENSG00000130175	Protein kinase C substrate 80K-H	19	11435288-11450968	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004465, HPA041940, HPA043560	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:7.69e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 237.6	Expressed in all		
PRL		ENSG00000172179	Prolactin	6	22287244-22297501	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023353, HPA042416, HPA062017	Enhanced		Uncertain	Cytosol		Not detected	Group enriched	9	endometrium: 10.7;placenta: 27.2	testis: 2.2	Cell line enhanced		Daudi: 11.1;SCLC-21H: 6.5;U-937: 2.1
PRLH	PRH	ENSG00000071677	Prolactin releasing hormone	2	237566574-237567175	Predicted secreted proteins	Evidence at protein level	HPA014976	Supported					Tissue enhanced	Not detected			fallopian tube,heart muscle: 0.6	Cell line enhanced		A549: 2.1;MCF7: 1.3;RPMI-8226: 1.0
PRLR		ENSG00000113494	Prolactin receptor	5	35048756-35230589	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 70.9	kidney: 33.1	Cell line enriched	22	T-47d: 356.8
PRNP	AltPrP, CD230, CJD, GSS, PRIP, PRP	ENSG00000171867	Prion protein	20	4686236-4701590	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA042754, HPA043398	Enhanced		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 619.4	Cell line enhanced		WM-115: 985.1
PRNT	M8	ENSG00000180259	Prion protein (testis specific)	20	4731282-4740668	Predicted secreted proteins	Evidence at transcript level	HPA045000	Uncertain					Not detected	Tissue enriched	110	testis: 10.9	all non-specific tissues: 0.0	Not detected		
PROC		ENSG00000115718	Protein C, inactivator of coagulation factors Va and VIIIa	2	127418427-127429246	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005550, CAB016721, CAB016792	Supported					Tissue enriched	Tissue enriched	12	liver: 140.4	kidney: 12.0	Cell line enriched	12	Hep G2: 105.5
PROK1	EGVEGF, PK1, PRK1	ENSG00000143125	Prokineticin 1	1	110451200-110457354	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	ovary: 239.3;placenta: 75.8;testis: 119.4	seminal vesicle: 15.2	Cell line enriched	9	ASC diff: 16.3
PROK2	BV8, KAL4, MIT1, PK2	ENSG00000163421	Prokineticin 2	3	71771656-71785206	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA041408	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 30.3;bone marrow: 52.7;testis: 24.1	adipose tissue: 11.2	Group enriched	5	HL-60: 8.9;NB-4: 6.1;NTERA-2: 6.5;U-266/70: 11.1;U-266/84: 17.7;U-937: 7.9
PROM1	AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4	ENSG00000007062	Prominin 1	4	15963076-16084378	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004922, CAB011525, HPA031053	Enhanced				Renal cancer:2.56e-5 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 67.2	gallbladder: 47.5	Cell line enhanced		AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7
PROS1	PROS	ENSG00000184500	Protein S (alpha)	3	93873033-93974066	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007724, HPA023974	Enhanced				Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 177.6	heart muscle: 78.3	Cell line enhanced		ASC diff: 98.8;SK-MEL-30: 127.4
PROZ	PZ	ENSG00000126231	Protein Z, vitamin K dependent plasma glycoprotein	13	113158654-113172383	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052006	Enhanced				Liver cancer:3.46e-4 (favourable)	Tissue enriched	Group enriched	14	kidney: 14.5;liver: 27.4	testis: 1.5	Cell line enhanced		HaCaT: 1.9;Hep G2: 2.4
PRR27	C4orf40	ENSG00000187533	Proline rich 27	4	70133616-70176799	Predicted secreted proteins	Evidence at protein level	HPA036150, HPA036151	Enhanced					Tissue enriched	Tissue enriched	1077	salivary gland: 402.8	ovary: 0.3	Not detected		
PRR4	LPRP, PROL4	ENSG00000111215	Proline rich 4 (lacrimal)	12	10845849-11171613	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042133	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	23	salivary gland: 1528.2	stomach: 65.1	Cell line enhanced		HDLM-2: 1.4;HHSteC: 1.7
PRRG2	PRGP2	ENSG00000126460	Proline rich and Gla domain 2	19	49580646-49591015	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010702	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.82e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.5	Cell line enhanced		CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9
PRRT3	FLJ33674	ENSG00000163704	Proline rich transmembrane protein 3	3	9945542-9952394	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035127, HPA035128	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 19.4;parathyroid gland: 27.8	fallopian tube: 12.2	Cell line enhanced		MCF7: 17.7;SK-BR-3: 25.1
PRRT4		ENSG00000224940	Proline rich transmembrane protein 4	7	128350325-128361685	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046373, HPA052681	Uncertain		Approved	Nucleoplasm<br>Peroxisomes<br>Plasma membrane		Mixed	Group enriched	12	adipose tissue: 15.7;bone marrow: 41.2	cerebral cortex: 2.2	Cell line enriched	8	SH-SY5Y: 239.1
PRSS1	TRY1	ENSG00000204983	Protease, serine 1	7	142749468-142753076	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025487, CAB025538, HPA062452, HPA063471	Enhanced				Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)	Tissue enriched	Tissue enriched	318	pancreas: 81683.0	ovary: 257.2	Cell line enhanced		EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7
PRSS12	BSSP-3, MRT1	ENSG00000164099	Protease, serine 12	4	118280038-118353003	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035054, HPA035055	Uncertain		Approved	Nucleus<br>Actin filaments	Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)	Mixed	Mixed			cervix, uterine: 22.4	Cell line enhanced		SH-SY5Y: 228.5;THP-1: 67.4
PRSS2	TRY2	ENSG00000275896	Protease, serine 2	7	142760398-142774564	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Breast cancer:2.32e-4 (favourable)	Tissue enriched	Tissue enriched	53	pancreas: 30215.4	small intestine: 567.7	Group enriched	6	RPMI-8226: 46.1;U-2 OS: 14.3
PRSS21	ESP-1, TEST1	ENSG00000007038	Protease, serine 21	16	2817180-2826304	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008477	Enhanced		Approved	Cytosol		Tissue enhanced	Tissue enriched	10	testis: 49.5	bone marrow: 4.7	Cell line enhanced		CAPAN-2: 22.0;HEL: 25.5;HeLa: 48.0;K-562: 30.5;U-698: 70.6
PRSS22	BSSP-4, hBSSP-4, SP001LA	ENSG00000005001	Protease, serine 22	16	2852727-2858170	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA049161	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		esophagus: 7.7;stomach: 11.1	salivary gland: 3.1	Cell line enhanced		CAPAN-2: 67.3;SK-BR-3: 14.6;T-47d: 16.5
PRSS23	SIG13, SPUVE	ENSG00000150687	Protease, serine 23	11	86791059-86952910	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030591	Uncertain				Head and neck cancer:2.12e-4 (unfavourable), Renal cancer:3.06e-4 (unfavourable), Pancreatic cancer:5.56e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 397.1	Cell line enhanced		HUVEC TERT2: 503.9;TIME: 926.9
PRSS27	CAPH2, MPN	ENSG00000172382	Protease, serine 27	16	2712418-2720551	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB024920	Approved					Tissue enhanced	Tissue enriched	7	esophagus: 210.7	tonsil: 28.1	Cell line enhanced		BEWO: 6.1;SK-BR-3: 18.9;T-47d: 14.0
PRSS3	PRSS4, TRY3, TRY4	ENSG00000010438	Protease, serine 3	9	33750466-33799231	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:4.30e-4 (unfavourable)	Group enriched	Tissue enriched	64	pancreas: 6301.2	small intestine: 99.1	Cell line enriched	9	PC-3: 632.8
PRSS33	EOS	ENSG00000103355	Protease, serine 33	16	2783953-2787948	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA058082	Uncertain					Tissue enhanced	Tissue enriched	7	fallopian tube: 7.4	small intestine: 1.0	Group enriched	10	HMC-1: 2.4;SK-MEL-30: 4.5;U-2 OS: 2.1
PRSS35	C6orf158, dJ223E3.1, MGC46520	ENSG00000146250	Protease, serine 35	6	83512538-83525704	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA038787, HPA038788	Uncertain					Tissue enhanced	Tissue enhanced		ovary: 12.9	cerebral cortex: 9.9	Cell line enhanced		CACO-2: 71.2;HAP1: 13.2;RPTEC TERT1: 18.6
PRSS36	FLJ90661	ENSG00000178226	Protease, serine 36	16	31138925-31150094	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA036079	Uncertain				Cervical cancer:2.97e-7 (favourable)	Mixed	Mixed			skin: 1.2	Cell line enhanced		HeLa: 1.4
PRSS37		ENSG00000165076	Protease, serine 37	7	141836286-141841487	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA020541	Enhanced					Not detected	Tissue enriched	162	testis: 55.3	skin: 0.3	Not detected		
PRSS38	MPN2	ENSG00000185888	Protease, serine 38	1	227815693-227846470	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA028003, HPA055809	Enhanced					Not detected	Tissue enriched	41	testis: 4.2	epididymis: 0.1	Not detected		
PRSS41	TESSP1	ENSG00000215148	Protease, serine 41	16	2798485-2805302	Enzymes, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	6	testis: 1.6	stomach: 0.2	Cell line enriched	11	BEWO: 1.7
PRSS42	TESSP2	ENSG00000178055	Protease, serine 42	3	46829542-46834095	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA046925	Uncertain					Not detected	Group enriched	6	epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9	breast,cervix, uterine,prostate,seminal vesicle: 0.7	Cell line enhanced		NTERA-2: 1.0
PRSS48	ESSPL	ENSG00000189099	Protease, serine 48	4	151277171-151291453	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA053801	Uncertain					Not detected	Tissue enhanced		testis: 1.4	skin: 0.4	Not detected		
PRSS50	CT20, TSP50	ENSG00000206549	Protease, serine 50	3	46712115-46812574	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA040768	Supported					Mixed	Tissue enhanced		epididymis: 5.7;parathyroid gland: 4.1	skeletal muscle,testis,thyroid gland: 2.0	Not detected		
PRSS50	CT20, TSP50	ENSG00000283706	Protease, serine 50	3	46712115-46717907	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA040768	Supported						Tissue enriched	14	testis: 38.7	thyroid gland: 2.7	Cell line enhanced		HMC-1: 1.2
PRSS51		ENSG00000253649	Protease, serine 51	8	10482878-10547585	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		breast: 1.0;testis: 1.1	cerebral cortex: 0.5	Cell line enhanced		U-2 OS: 1.4
PRSS53	POL3S	ENSG00000151006	Protease, serine 53	16	31083425-31089628	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA034955, HPA034956	Uncertain					Mixed	Tissue enhanced		skin: 1.1	prostate: 0.5	Cell line enhanced		SCLC-21H: 5.5
PRSS54	CT67, FLJ25339, KLKBL4	ENSG00000103023	Protease, serine 54	16	58279997-58295047	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041549	Enhanced					Not detected	Tissue enriched	461	testis: 63.1	cerebral cortex,urinary bladder: 0.1	Not detected		
PRSS55	CT153, T-SP1, UNQ9391	ENSG00000184647	Protease, serine 55	8	10525546-10554166	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	92	testis: 26.1	epididymis: 0.2	Not detected		
PRSS56		ENSG00000237412	Protease, serine 56	2	232520463-232525716	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skeletal muscle: 3.4	testis: 0.8	Not detected		
PRSS57	PRSSL1, UNQ782	ENSG00000185198	Protease, serine 57	19	685546-695498	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	173	bone marrow: 103.3	spleen: 0.5	Group enriched	9	NB-4: 239.3;THP-1: 126.5
PRSS58	TRYX3	ENSG00000258223	Protease, serine 58	7	142252143-142258058	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	123	testis: 21.1	cervix, uterine,smooth muscle: 0.1	Not detected		
PRSS8		ENSG00000052344	Protease, serine 8	16	31131433-31135762	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030436, HPA063533	Uncertain		Uncertain	Cytosol	Renal cancer:2.05e-10 (favourable)	Mixed	Mixed			small intestine: 164.8	Cell line enhanced		BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6
PRTG	FLJ25756, IGDCC5	ENSG00000166450	Protogenin	15	55611546-55743090	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA032138	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 18.2	testis: 6.7	Cell line enriched	6	AF22: 148.8
PRTN3	ACPA, AGP7, C-ANCA, MBT, P29, PR-3	ENSG00000196415	Proteinase 3	19	840960-848175	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005938, CAB017558	Enhanced					Tissue enhanced	Tissue enriched	724	bone marrow: 616.4	spleen: 0.8	Cell line enriched	6	THP-1: 696.6
PSAP	GLBA, SAP1	ENSG00000197746	Prosaposin	10	71816298-71851375	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004426, CAB004647	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 1912.4	Expressed in all		
PSAPL1		ENSG00000178597	Prosaposin-like 1 (gene/pseudogene)	4	7430294-7434973	Predicted secreted proteins	Evidence at protein level	HPA038013, HPA038482	Approved		Enhanced	Cytosol		Mixed	Group enriched	7	skin: 52.7;stomach: 36.5	breast: 6.4	Cell line enhanced		CACO-2: 13.5;HaCaT: 3.9;hTCEpi: 3.9;RPMI-8226: 16.8
PSG1	CD66f, PBG1, PSBG1, PSGGA	ENSG00000231924	Pregnancy specific beta-1-glycoprotein 1	19	42866464-42879822	CD markers, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Tissue enhanced	Tissue enriched	377	placenta: 362.6	smooth muscle,spleen: 0.9	Cell line enriched	23	U-2197: 384.6
PSG11	MGC22484, PSG13, PSG14	ENSG00000243130	Pregnancy specific beta-1-glycoprotein 11	19	43007656-43026512	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042240, HPA046327	Enhanced					Not detected	Tissue enriched	77	placenta: 74.1	smooth muscle: 0.9	Cell line enriched	29	U-2197: 15.6
PSG2	CEA, PSBG2, PSG1, PSGGB	ENSG00000242221	Pregnancy specific beta-1-glycoprotein 2	19	43064211-43083045	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	222	placenta: 343.4	smooth muscle: 1.5	Group enriched	6	BJ: 9.2;fHDF/TERT166: 18.4;HBF TERT88: 34.3;U-2197: 42.9
PSG3		ENSG00000221826	Pregnancy specific beta-1-glycoprotein 3	19	42721638-42740569	Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	162	placenta: 188.8	testis: 1.1	Cell line enriched	6	U-2197: 1.2
PSG4		ENSG00000243137	Pregnancy specific beta-1-glycoprotein 4	19	43192702-43207299	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Mixed	Group enriched	8	parathyroid gland: 244.5;placenta: 193.0	colon: 28.0	Group enriched	7	fHDF/TERT166: 409.2;U-2197: 129.9
PSG5	FL-NCA-3, PSG	ENSG00000204941	Pregnancy specific beta-1-glycoprotein 5	19	43166256-43186536	Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Mixed	Tissue enriched	108	placenta: 157.6	smooth muscle: 1.4	Group enriched	8	BJ: 363.6;fHDF/TERT166: 1157.5
PSG6		ENSG00000170848	Pregnancy specific beta-1-glycoprotein 6	19	42902079-42919563	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	75	placenta: 70.2	bone marrow: 0.9	Cell line enriched	18	U-2197: 134.3
PSG7		ENSG00000221878	Pregnancy specific beta-1-glycoprotein 7 (gene/pseudogene)	19	42924132-42937178	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enhanced		placenta: 5.8;skin: 1.4	smooth muscle: 0.9	Cell line enhanced		BJ: 1.3;HBF TERT88: 2.2;U-2197: 1.7
PSG8		ENSG00000124467	Pregnancy specific beta-1-glycoprotein 8	19	42752686-42855691	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Tissue enriched	Tissue enriched	12	placenta: 9.1	parathyroid gland: 0.7	Not detected		
PSG9	PSG11, PSGII	ENSG00000183668	Pregnancy specific beta-1-glycoprotein 9	19	43211791-43269530	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	118	placenta: 147.0	smooth muscle: 1.2	Cell line enhanced		BJ: 4.4;BJ hTERT+ SV40 Large T+: 4.2;HBF TERT88: 9.0;T-47d: 4.0;U-2197: 9.0
PSORS1C2	C6orf17, SPR1	ENSG00000204538	Psoriasis susceptibility 1 candidate 2	6	31137536-31139350	Predicted secreted proteins	Evidence at protein level	HPA061228	Enhanced					Tissue enhanced	Tissue enriched	65	skin: 24.0	testis: 0.3	Not detected		
PSPN	PSP	ENSG00000125650	Persephin	19	6375148-6379058	Predicted secreted proteins	Evidence at transcript level	CAB025366	Approved					Expressed in all	Mixed			cerebral cortex,epididymis,parathyroid gland,thyroid gland: 1.4	Mixed		
PTGDS	L-PGDS, PGDS	ENSG00000107317	Prostaglandin D2 synthase	9	136975092-136981742	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004938, CAB009916	Approved		Supported	Nucleoplasm	Renal cancer:1.19e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 2581.3	Group enriched	7	HHSteC: 440.4;HSkMC: 186.3
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 13.9	appendix: 8.2	Cell line enhanced		BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
PTGS1	COX1, PGHS-1, PTGHS	ENSG00000095303	Prostaglandin-endoperoxide synthase 1	9	122370530-122395703	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002834, CAB020315	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 161.6	fallopian tube: 86.1	Cell line enhanced		ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
PTGS2	COX2	ENSG00000073756	Prostaglandin-endoperoxide synthase 2	1	186671791-186680427	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB000113, HPA001335	Approved		Supported	Endoplasmic reticulum	Renal cancer:9.79e-4 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 180.6	cervix, uterine: 99.3	Group enriched	7	BJ: 78.6;BJ hTERT+: 327.8
PTH	PTH1	ENSG00000152266	Parathyroid hormone	11	13492055-13496181	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000072, CAB023409, CAB026363, HPA048540	Enhanced					Not detected	Tissue enriched	109145	parathyroid gland: 59340.8	thyroid gland: 0.5	Not detected		
PTH2	TIP39	ENSG00000142538	Parathyroid hormone 2	19	49422414-49423441	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
PTHLH	HHM, PLP, PTHR, PTHRP	ENSG00000087494	Parathyroid hormone like hormone	12	27958084-27972705	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA035982	Approved	Approved	Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		breast: 23.9	esophagus: 18.0	Group enriched	7	HaCaT: 256.2;HBEC3-KT: 257.7;U-251 MG: 64.3
PTK7	CCK4	ENSG00000112655	Protein tyrosine kinase 7 (inactive)	6	43076268-43161719	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003222	Approved					Expressed in all	Mixed			endometrium: 117.3	Mixed		
PTN	HBGF8, HBNF, NEGF1	ENSG00000105894	Pleiotrophin	7	137227341-137343865	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB017685	Enhanced				Renal cancer:1.35e-4 (favourable)	Tissue enriched	Tissue enhanced		parathyroid gland: 725.3	cerebral cortex: 269.6	Cell line enriched	12	AF22: 1551.5
PTPN5	PTPSTEP, STEP, STEP61	ENSG00000110786	Protein tyrosine phosphatase, non-receptor type 5	11	18727928-18792721	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031014, HPA072091	Supported		Approved	Endoplasmic reticulum		Group enriched	Tissue enriched	15	cerebral cortex: 58.8	testis: 3.8	Cell line enhanced		NTERA-2: 1.7
PTPRA	HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA	ENSG00000132670	Protein tyrosine phosphatase, receptor type A	20	2864184-3039076	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029412, CAB034366, HPA069480	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.29e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 167.4	Expressed in all		
PTPRB	PTPB	ENSG00000127329	Protein tyrosine phosphatase, receptor type B	12	70515866-70637440	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004782, HPA067868	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)	Expressed in all	Mixed			lung: 54.0	Cell line enhanced		EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRC	CD45, GP180, LCA, T200	ENSG00000081237	Protein tyrosine phosphatase, receptor type C	1	198638671-198757283	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000052, HPA000440, CAB002800, CAB056154, CAB068221	Enhanced				Renal cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 372.4	Cell line enhanced		Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5
PTPRCAP	CD45-AP, LPAP	ENSG00000213402	Protein tyrosine phosphatase, receptor type C associated protein	11	67435510-67438067	Predicted secreted proteins	Evidence at protein level	HPA043734	Enhanced					Not detected	Tissue enhanced		appendix: 64.0;lymph node: 91.4;spleen: 84.9	tonsil: 29.0	Cell line enhanced		Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1
PTPRD	HPTP, PTPD	ENSG00000153707	Protein tyrosine phosphatase, receptor type D	9	8314246-10612723	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054829	Uncertain		Approved	Vesicles	Renal cancer:7.45e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 32.7;parathyroid gland: 47.0	ovary: 11.7	Cell line enhanced		AF22: 27.3;RH-30: 9.9
PTPRF	LAR	ENSG00000142949	Protein tyrosine phosphatase, receptor type F	1	43525187-43623666	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012710	Uncertain		Approved	Golgi apparatus	Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)	Expressed in all	Mixed			skin: 128.2	Mixed		
PTPRJ	CD148, DEP1, HPTPeta	ENSG00000149177	Protein tyrosine phosphatase, receptor type J	11	47980558-48170841	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006026	Approved				Renal cancer:1.13e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Mixed		
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
PTPRS		ENSG00000105426	Protein tyrosine phosphatase, receptor type S	19	5158495-5340803	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054747			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 70.7	Cell line enhanced		AN3-CA: 112.7;HaCaT: 110.4
PTTG1IP	C21orf1, C21orf3, PBF	ENSG00000183255	Pituitary tumor-transforming 1 interacting protein	21	44849585-44873903	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034146, HPA061827	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 243.5	Expressed in all		
PTX3	TNFAIP5, TSG-14	ENSG00000163661	Pentraxin 3	3	157436789-157443628	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA069320	Approved				Endometrial cancer:8.35e-9 (unfavourable), Lung cancer:8.75e-6 (unfavourable), Head and neck cancer:6.36e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 164.6;appendix: 54.2	bone marrow: 52.6	Cell line enhanced		ASC TERT1: 1187.1;HHSteC: 1837.3;HSkMC: 1660.2;hTEC/SVTERT24-B: 1235.3;TIME: 1387.2;U-2197: 1444.5
PTX4	C16orf38	ENSG00000251692	Pentraxin 4	16	1485886-1488981	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA064718, HPA073694	Uncertain		Uncertain	Cytosol		Not detected	Not detected			testis: 0.8	Group enriched	6	HL-60: 16.9;NB-4: 9.9
PVR	CD155, HVED, Necl-5, NECL5, PVS, Tage4	ENSG00000073008	Poliovirus receptor	19	44643798-44663583	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012568	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.0	Cell line enhanced		TIME: 147.4
PXDN	D2S448, D2S448E, KIAA0230, MG50, PRG2, PXN	ENSG00000130508	Peroxidasin	2	1631887-1744852	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012375	Approved				Endometrial cancer:2.75e-4 (unfavourable), Cervical cancer:6.28e-4 (unfavourable), Stomach cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 87.2	adipose tissue: 66.9	Mixed		
PXDNL	FLJ25471, PMR1	ENSG00000147485	Peroxidasin like	8	51319578-51809445	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007919			Approved	Nucleoplasm<br>Cytosol	Breast cancer:3.27e-5 (unfavourable)	Mixed	Group enriched	8	epididymis: 11.5;heart muscle: 24.1;testis: 9.0	adipose tissue: 1.8	Group enriched	7	AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
PXYLP1	ACPL2, FLJ23751	ENSG00000155893	2-phosphoxylose phosphatase 1	3	141228726-141367753	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017243	Approved					Expressed in all	Expressed in all			epididymis: 180.6	Mixed		
PYY	PYY1	ENSG00000131096	Peptide YY	17	43952738-44004469	Predicted secreted proteins	Evidence at protein level	HPA010973, CAB016734	Enhanced					Group enriched	Group enriched	15	colon: 52.6;rectum: 39.2;small intestine: 27.4	duodenum: 2.5	Cell line enhanced		HMC-1: 2.6
PZP	CPAMD6	ENSG00000126838	PZP, alpha-2-macroglobulin like	12	9148840-9208370	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA041403, HPA041471	Supported					Tissue enhanced	Tissue enriched	12	liver: 45.9	testis: 3.8	Group enriched	7	HeLa: 3.2;SiHa: 2.6
QPCT	GCT, QC	ENSG00000115828	Glutaminyl-peptide cyclotransferase	2	37344574-37373322	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008406	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		adrenal gland: 158.9;epididymis: 121.6	skin: 41.1	Cell line enhanced		SCLC-21H: 130.6;SK-MEL-30: 299.7;U-266/84: 218.7
QPRT	QPRTase	ENSG00000103485	Quinolinate phosphoribosyltransferase	16	29679008-29698699	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011887	Approved				Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 112.3	Cell line enhanced		EFO-21: 469.3
QRFP	26RFa, P518	ENSG00000188710	Pyroglutamylated RFamide peptide	9	130892702-130896812	Predicted secreted proteins	Evidence at transcript level	HPA043377	Uncertain					Mixed	Tissue enhanced		prostate: 1.3	esophagus: 1.2	Cell line enhanced		U-138 MG: 3.5
QSOX1	QSCN6	ENSG00000116260	Quiescin sulfhydryl oxidase 1	1	180154834-180204030	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042127, HPA056243	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 233.0	Expressed in all		
R3HDML	dJ881L22.3	ENSG00000101074	R3H domain containing like	20	44336986-44351235	Predicted secreted proteins	Evidence at protein level	HPA070264	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 2.2;small intestine: 2.7	testis: 0.8	Not detected		
RAET1G	ULBP5	ENSG00000203722	Retinoic acid early transcript 1G	6	149916878-149923121	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062673			Approved	Vesicles	Lung cancer:5.35e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 8.2;esophagus: 9.5	skin: 3.4	Cell line enhanced		HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
RAMP2		ENSG00000131477	Receptor activity modifying protein 2	17	42758447-42763041	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052020			Approved	Vesicles		Expressed in all	Mixed			lung: 178.6	Cell line enhanced		ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RAPGEF5	GFR, KIAA0277, MR-GEF	ENSG00000136237	Rap guanine nucleotide exchange factor 5	7	22118238-22357144	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA057821, HPA076772	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:3.52e-5 (favourable), Endometrial cancer:9.44e-4 (unfavourable)	Expressed in all	Tissue enriched	12	parathyroid gland: 1205.9	placenta: 97.1	Cell line enhanced		HUVEC TERT2: 37.6;SCLC-21H: 40.3;TIME: 21.0;U-698: 26.6
RARRES1	LXNL, TIG1	ENSG00000118849	Retinoic acid receptor responder 1	3	158696892-158732696	Predicted secreted proteins	Evidence at protein level	HPA003892	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:5.88e-6 (unfavourable)	Expressed in all	Mixed			appendix: 78.0	Cell line enriched	11	CAPAN-2: 1010.9
RARRES2	HP10433, TIG2	ENSG00000106538	Retinoic acid receptor responder 2	7	150338317-150341674	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049359			Uncertain	Cytosol	Renal cancer:6.83e-4 (unfavourable), Glioma:6.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 1522.8	parathyroid gland: 915.7	Group enriched	8	AF22: 120.4;Hep G2: 124.8;HHSteC: 130.5;NTERA-2: 372.4
RBM3	IS1-RNPL	ENSG00000102317	RNA binding motif (RNP1, RRM) protein 3	X	48574449-48579066	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003624, CAB062559	Enhanced		Enhanced	Nucleoplasm	Colorectal cancer:3.07e-7 (favourable)	Expressed in all	Expressed in all			breast: 237.2	Expressed in all		
RBP3	D10S64, D10S65, D10S66, RP66	ENSG00000265203	Retinol binding protein 3	10	47348371-47357875	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041301, HPA044239	Supported					Not detected	Not detected			duodenum: 0.4	Not detected		
RBP4		ENSG00000138207	Retinol binding protein 4	10	93591687-93601744	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001641, CAB004555	Supported				Liver cancer:1.74e-8 (favourable), Endometrial cancer:1.50e-4 (unfavourable)	Tissue enriched	Tissue enriched	10	liver: 6109.2	adipose tissue: 630.9	Cell line enhanced		CACO-2: 219.3;Hep G2: 755.1;PC-3: 113.0
RCN1	FLJ37041, PIG20, Rcal, RCN	ENSG00000049449	Reticulocalbin 1	11	31812391-32105755	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038474, HPA062104	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:2.70e-13 (unfavourable), Lung cancer:7.13e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 470.5	Mixed		
RCN2	E6BP, ERC-55, ERC55, TCBP49	ENSG00000117906	Reticulocalbin 2	15	76931619-76954392	Predicted secreted proteins	Evidence at protein level	HPA030694, HPA030695	Enhanced	Supported	Enhanced	Endoplasmic reticulum	Liver cancer:7.36e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 391.5	Expressed in all		
RCN3	RLP49	ENSG00000142552	Reticulocalbin 3	19	49527618-49546962	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043134, HPA050402	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:5.80e-12 (unfavourable)	Expressed in all	Expressed in all			small intestine: 45.0	Cell line enhanced		ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6
RDH11	ARSDR1, MDT1, SDR7C1	ENSG00000072042	Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)	14	67676801-67695814	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB046011	Enhanced				Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Tissue enriched	Tissue enriched	7	prostate: 941.3	parathyroid gland: 125.7	Expressed in all		
RDH12	FLJ30273, LCA13, RP53, SDR7C2	ENSG00000139988	Retinol dehydrogenase 12 (all-trans/9-cis/11-cis)	14	67701886-67734452	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		gallbladder: 27.7;skin: 58.2	kidney: 13.6	Not detected		
RDH13	SDR7C3	ENSG00000160439	Retinol dehydrogenase 13	19	55039108-55071291	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042006	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:2.09e-4 (favourable)	Expressed in all	Mixed			placenta: 3.5	Mixed		
RDH5	HSD17B9, RDH1, SDR9C5	ENSG00000135437	Retinol dehydrogenase 5	12	55720367-55724705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063345			Approved	Vesicles		Mixed	Tissue enhanced		adipose tissue: 97.7	liver: 30.0	Cell line enhanced		ASC diff: 19.5;ASC TERT1: 17.1;hTEC/SVTERT24-B: 15.2;LHCN-M2: 12.8;U-87 MG: 26.2
RDH8	PRRDH, SDR28C2	ENSG00000080511	Retinol dehydrogenase 8 (all-trans)	19	10013249-10022279	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Group enriched	Group enriched	11	kidney: 1.2;testis: 1.8	appendix: 0.1	Not detected		
REG1A	PSP, PSPS, PSPS1, PTP, REG	ENSG00000115386	Regenerating family member 1 alpha	2	79120362-79123419	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025138, HPA045549, HPA045579	Enhanced					Group enriched	Group enriched	9	duodenum: 7122.5;pancreas: 10867.0;small intestine: 4615.5	stomach: 847.5	Cell line enhanced		BEWO: 11.1;EFO-21: 16.2;HDLM-2: 13.2;RPMI-8226: 20.2;SH-SY5Y: 12.6;U-2 OS: 28.7
REG1B	PSPS2, REGH, REGI-BETA, REGL	ENSG00000172023	Regenerating family member 1 beta	2	79085030-79088019	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045549, HPA045579	Supported					Tissue enhanced	Tissue enhanced		duodenum: 734.2;small intestine: 435.2	pancreas: 181.6	Cell line enhanced		EFO-21: 6.0;HDLM-2: 3.9;U-2 OS: 15.6;U-251 MG: 3.2
REG3A	HIP, PAP, PAP1, PBCGF, REG-III, REG3	ENSG00000172016	Regenerating family member 3 alpha	2	79157003-79159753	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA047894, HPA048334, HPA060705	Supported		Approved	Cytosol		Tissue enhanced	Group enriched	56	duodenum: 5635.7;small intestine: 8081.8	stomach: 122.0	Cell line enhanced		BEWO: 18.5;EFO-21: 17.0;HDLM-2: 16.3;RPMI-8226: 17.5;SH-SY5Y: 16.7;U-2 OS: 30.9
REG3G	LPPM429, PAP1B, UNQ429	ENSG00000143954	Regenerating family member 3 gamma	2	79025686-79028505	Predicted secreted proteins	Evidence at protein level	HPA047894, HPA048334, HPA060705	Uncertain		Approved	Cytosol		Tissue enriched	Group enriched	15	epididymis: 201.5;testis: 107.2	pancreas: 10.0	Not detected		
REG4	GISP, REG-IV, RELP	ENSG00000134193	Regenerating family member 4	1	119794018-119811660	Predicted secreted proteins	Evidence at protein level	CAB025867, HPA046555	Enhanced					Group enriched	Group enriched	9	colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5	appendix: 39.6	Group enriched	24	PC-3: 85.3;RT4: 20.5
RELN	PRO1598, RL	ENSG00000189056	Reelin	7	103471784-103989516	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046512			Approved	Plasma membrane<br>Focal adhesion sites		Tissue enhanced	Tissue enhanced		liver: 17.8	cerebral cortex: 7.3	Cell line enhanced		Hep G2: 43.5;PC-3: 11.6;SCLC-21H: 17.5;SH-SY5Y: 17.2;TIME: 29.6
RELT	FLJ14993, TNFRSF19L	ENSG00000054967	RELT tumor necrosis factor receptor	11	73376264-73397474	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062824, HPA071518			Supported	Nucleus	Renal cancer:4.07e-11 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 95.8	spleen: 17.2	Mixed		
REN		ENSG00000143839	Renin	1	204154819-204190324	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005131, CAB025903	Approved				Renal cancer:6.45e-5 (unfavourable)	Tissue enriched	Tissue enhanced		kidney: 51.2;placenta: 21.0	endometrium: 8.9	Cell line enhanced		BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
RETN	ADSF, FIZZ3, RETN1	ENSG00000104918	Resistin	19	7669044-7670454	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	bone marrow: 159.4	lung: 26.0	Group enriched	8	NB-4: 327.2;U-937: 187.7
RETNLB	FIZZ2, HXCP2, RELMb	ENSG00000163515	Resistin like beta	3	108743424-108757384	Predicted secreted proteins	Evidence at transcript level	HPA049152	Approved				Colorectal cancer:6.86e-5 (favourable)	Tissue enriched	Tissue enhanced		colon: 73.5;rectum: 270.7	small intestine: 36.9	Not detected		
RETSAT	FLJ20296	ENSG00000042445	Retinol saturase	2	85342088-85354620	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007961, HPA046513	Uncertain		Approved	Nucleoli	Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 265.4	Expressed in all		
RFNG		ENSG00000169733	RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	17	82047902-82051831	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011564, HPA031673	Uncertain		Supported	Nucleus	Pancreatic cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 19.7	Expressed in all		
RGL4	Rgr	ENSG00000159496	Ral guanine nucleotide dissociation stimulator like 4	22	23688136-23699176	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035979	Uncertain		Approved	Centrosome		Not detected	Tissue enriched	8	bone marrow: 107.4	lymph node: 12.9	Cell line enhanced		MOLT-4: 21.0;U-937: 47.3
RGMA	RGM, RGMa	ENSG00000182175	Repulsive guidance molecule family member a	15	93035273-93089204	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012343, HPA039880, HPA044222	Approved		Supported	Nucleoplasm<br>Cytosol	Lung cancer:2.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 116.6;smooth muscle: 84.8	skeletal muscle: 42.6	Cell line enhanced		AF22: 49.7;NTERA-2: 22.5
RGMB	DRAGON, FLJ90406	ENSG00000174136	Repulsive guidance molecule family member b	5	98768650-98798643	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016993			Approved	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 43.6	Cell line enhanced		BJ: 267.0;HBF TERT88: 210.1
RIDA	HRSP12, P14.5, PSP, UK114	ENSG00000132541	Reactive intermediate imine deaminase A homolog	8	98102344-98117241	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022856, HPA023489	Enhanced				Liver cancer:9.61e-6 (favourable)	Expressed in all	Group enriched	9	kidney: 454.6;liver: 698.7	cerebral cortex: 62.3	Expressed in all		
RIMS1	CORD7, KIAA0340, RAB3IP2, RIM, RIM1	ENSG00000079841	Regulating synaptic membrane exocytosis 1	6	71886703-72403143	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 30.2	testis: 7.5	Cell line enhanced		EFO-21: 8.3;LHCN-M2: 8.3;RPTEC TERT1: 11.5;SH-SY5Y: 11.4
RLN1	H1	ENSG00000107018	Relaxin 1	9	5334969-5339873	Plasma proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	64	prostate: 40.0	testis: 0.6	Cell line enhanced		HEL: 1.0
RLN2	bA12D24.1.1, bA12D24.1.2, H2, RLXH2	ENSG00000107014	Relaxin 2	9	5299868-5304969	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 8.1	prostate: 6.0	Cell line enhanced		HEL: 19.0;T-47d: 5.6;U-266/84: 6.9
RLN3	H3, RXN3, ZINS4	ENSG00000171136	Relaxin 3	19	14028148-14031042	Predicted secreted proteins	Evidence at protein level	HPA043731	Uncertain					Not detected	Group enriched	6	parathyroid gland: 2.9;testis: 3.3	spleen: 0.5	Not detected		
RMDN1	CGI-90, FAM82B, FLJ20665, RMD1	ENSG00000176623	Regulator of microtubule dynamics 1	8	86468257-86514357	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026495	Approved		Supported	Actin filaments<br>Centrosome	Renal cancer:8.51e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 83.5	Mixed		
RNASE1	RAC1, RNS1	ENSG00000129538	Ribonuclease A family member 1, pancreatic	14	20801228-20803278	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001140	Supported		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			pancreas: 1946.8	Group enriched	6	HUVEC TERT2: 239.6;RT4: 91.0;TIME: 122.8
RNASE10	RAH1, RNASE9	ENSG00000182545	Ribonuclease A family member 10 (inactive)	14	20505537-20511169	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA052593	Uncertain					Group enriched	Mixed			testis: 3.8	Cell line enhanced		SiHa: 7.3;U-2 OS: 11.5
RNASE11	C14orf6, RAJ1	ENSG00000173464	Ribonuclease A family member 11 (inactive)	14	20583559-20609884	Predicted secreted proteins	Evidence at protein level	HPA003724	Uncertain					Not detected	Tissue enriched	7	epididymis: 541.2	testis: 82.0	Not detected		
RNASE12	RAI1	ENSG00000258436	Ribonuclease A family member 12 (inactive)	14	20590193-20590823	Predicted secreted proteins	Evidence at protein level	HPA044175, HPA059465	Enhanced		Uncertain	Vesicles<br>Microtubules		Not detected	Tissue enriched	252	epididymis: 1052.1	seminal vesicle: 4.1	Not detected		
RNASE13	RAL1	ENSG00000206150	Ribonuclease A family member 13 (inactive)	14	21032820-21034785	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	248	epididymis: 380.3	salivary gland: 1.5	Not detected		
RNASE2	EDN, RAF3, RNS2	ENSG00000169385	Ribonuclease A family member 2	14	20955452-20956436	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA044983	Enhanced				Renal cancer:3.28e-13 (unfavourable)	Tissue enriched	Tissue enriched	73	bone marrow: 995.8	smooth muscle: 13.6	Group enriched	286	HL-60: 411.9;NB-4: 325.9;THP-1: 920.7;U-937: 968.9
RNASE3	ECP, RAF1, RNS3	ENSG00000169397	Ribonuclease A family member 3	14	20891399-20892348	Predicted secreted proteins	Evidence at protein level	HPA056183	Enhanced					Tissue enriched	Tissue enriched	300	bone marrow: 572.3	skin: 1.9	Cell line enhanced		HL-60: 114.0;THP-1: 41.0;U-937: 225.8
RNASE4	RAB1	ENSG00000258818	Ribonuclease A family member 4	14	20684100-20701215	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:9.62e-5 (favourable)	Tissue enhanced	Tissue enhanced		liver: 232.5	prostate: 117.7	Cell line enhanced		ASC diff: 59.9;ASC TERT1: 68.7;Hep G2: 89.2;HSkMC: 42.8
RNASE6	RAD1, RNaseK6, RNS6	ENSG00000169413	Ribonuclease A family member k6	14	20781051-20782467	Predicted secreted proteins	Evidence at protein level	HPA000698	Approved					Expressed in all	Mixed			lymph node: 90.2	Cell line enriched	6	RPMI-8226: 36.0
RNASE7	RAE1	ENSG00000165799	Ribonuclease A family member 7	14	21042226-21044234	Predicted secreted proteins	Evidence at protein level	HPA005690, CAB062560, CAB068225	Enhanced					Tissue enhanced	Tissue enhanced		esophagus: 72.0;skin: 29.2;tonsil: 19.6	gallbladder: 11.1	Cell line enhanced		HBEC3-KT: 17.9;hTCEpi: 7.6;hTERT-HME1: 40.4
RNASE8	RAE2	ENSG00000173431	Ribonuclease A family member 8	14	21057822-21058455	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	105	salivary gland: 27.2	skin: 0.2	Not detected		
RNASE9	h461, RAK1	ENSG00000188655	Ribonuclease A family member 9 (inactive)	14	20556093-20560931	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1199	epididymis: 119.9	all non-specific tissues: 0.0	Not detected		
RNASEH1		ENSG00000171865	Ribonuclease H1	2	3544793-3558616	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043037	Uncertain				Liver cancer:7.83e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 10.9	Expressed in all		
RNASET2	bA514O12.3, FLJ10907, RNASE6PL	ENSG00000026297	Ribonuclease T2	6	166929504-166957191	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029013, HPA066509	Approved				Renal cancer:1.70e-14 (unfavourable)	Expressed in all	Expressed in all			spleen: 279.9	Cell line enhanced		EFO-21: 187.2;THP-1: 346.2
RNF146	dactylidin, dJ351K20.1, DKFZp434O1427	ENSG00000118518	Ring finger protein 146	6	127266610-127288567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027158, HPA027209	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 94.6	Expressed in all		
RNF148	MGC35222	ENSG00000235631	Ring finger protein 148	7	122701664-122702967	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	228	testis: 73.5	lung: 0.3	Cell line enhanced		Karpas-707: 1.9
RNF150	KIAA1214	ENSG00000170153	Ring finger protein 150	4	140859807-141212877	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037987	Uncertain				Breast cancer:1.41e-4 (favourable)	Mixed	Mixed			endometrium,fallopian tube: 21.3	Cell line enhanced		fHDF/TERT166: 21.9;SH-SY5Y: 42.3
RNF167	DKFZP566H073	ENSG00000108523	Ring finger protein 167	17	4940008-4945222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049810	Approved		Approved	Cytosol	Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Expressed in all		
RNPEP		ENSG00000176393	Arginyl aminopeptidase	1	201982372-202006147	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036074, HPA036075, HPA061487	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			duodenum: 66.5	Expressed in all		
ROBO1	DUTT1, FLJ21882, SAX3	ENSG00000169855	Roundabout guidance receptor 1	3	78597240-79767815	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013524, HPA052968, HPA074461	Uncertain		Enhanced	Plasma membrane	Liver cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 32.9	Mixed		
ROR1	NTRKR1	ENSG00000185483	Receptor tyrosine kinase like orphan receptor 1	1	63774022-64181498	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057016			Uncertain	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		parathyroid gland: 52.0	endometrium: 12.1	Cell line enhanced		ASC TERT1: 35.2;NTERA-2: 43.3
RP1-302G2.5		ENSG00000262179	Homo sapiens uncharacterized LOC101929726 (LOC101929726), transcript variant 2, mRNA.	6	44216939-44218236	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		adipose tissue: 5.7	stomach: 2.0	Cell line enriched	31	RH-30: 132.6
RP11-1236K1.1		ENSG00000233050		8	12064389-12071747	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	47	epididymis: 4.7	all non-specific tissues: 0.0	Not detected		
RP11-14J7.7		ENSG00000259060	Probable ribonuclease 11 precursor 	14	20582892-20609795	Predicted secreted proteins	Evidence at transcript level							Not detected	Group enriched	34	epididymis: 5.4;testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-196G11.1		ENSG00000255439		16	31083439-31094956	Predicted secreted proteins	Evidence at transcript level	HPA042720	Uncertain		Approved	Endoplasmic reticulum		Not detected	Not detected			skin: 0.5	Mixed		
RP11-303E16.10		ENSG00000284512		16	81022316-81096284	Predicted secreted proteins	Evidence at protein level	HPA041368	Uncertain		Approved	Vesicles			Tissue enriched	7	testis: 12.0	cerebral cortex: 1.6	Mixed		
RP11-350O14.18		ENSG00000261793		9	137168854-137171984	Predicted secreted proteins	Evidence at transcript level							Not detected	Group enriched	7	prostate: 17.4;salivary gland: 23.0	small intestine: 2.8	Cell line enhanced		REH: 9.4;RPMI-8226: 11.9;SK-BR-3: 8.3;T-47d: 6.0
RP11-726G1.1		ENSG00000214776		12	9467552-9576275	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enhanced		parathyroid gland: 1.0;testis: 1.8	endometrium,lymph node: 0.4	Cell line enhanced		U-698: 4.3;WM-115: 2.1
RP11-80H18.3		ENSG00000255154	Hydroxyacyl-thioester dehydratase type 2, mitochondrial 	3	58306262-58318574	Predicted intracellular proteins	Evidence at protein level	HPA066812			Supported	Nucleoli<br>Mitochondria		Not detected	Expressed in all			thyroid gland: 14.6	Expressed in all		
RP11-812E19.9		ENSG00000259680		16	33844784-33845229	Predicted secreted proteins	Evidence at transcript level						Head and neck cancer:6.96e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 23.0	urinary bladder: 12.1	Not detected		
RP11-977G19.10		ENSG00000144785		12	56285916-56316059	Predicted secreted proteins	Evidence at protein level	HPA038466	Uncertain					Not detected	Mixed			cerebral cortex: 7.9	Mixed		
RP11-98L5.5		ENSG00000236543		9	135604345-135618952	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	34	skin: 22.9	parathyroid gland,seminal vesicle: 0.6	Cell line enriched	21	BEWO: 7.4
RP4-576H24.4		ENSG00000260861		20	1540144-1620009	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		appendix: 3.3;cerebral cortex: 4.5	testis: 2.5	Cell line enhanced		HL-60: 2.6;HMC-1: 5.9;NB-4: 1.4;THP-1: 1.8;U-937: 1.5
RP4-608O15.3		ENSG00000276911		1	196819745-196959210	Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726, HPA049813	Supported					Not detected	Tissue enriched	527	liver: 203.7	kidney: 0.3	Not detected		
RPN2	RIBIIR, RPN-II, RPNII, SWP1	ENSG00000118705	Ribophorin II	20	37178410-37241623	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008297, CAB019277, HPA025922	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 364.2	Expressed in all		
RPS27L		ENSG00000185088	Ribosomal protein S27 like	15	63125872-63158021	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA066851			Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:9.08e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 222.3	Expressed in all		
RS1	RS, XLRS1	ENSG00000102104	Retinoschisin 1	X	18639910-18672109	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA059546	Supported					Not detected	Group enriched	7	cerebral cortex: 1.1;lung: 1.6	lymph node,spleen,thyroid gland: 0.1	Not detected		
RSPO1	FLJ40906, RSPONDIN	ENSG00000169218	R-spondin 1	1	37611350-37634923	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046154	Uncertain					Tissue enriched	Tissue enhanced		endometrium: 43.4;fallopian tube: 33.1	smooth muscle: 21.2	Cell line enhanced		NTERA-2: 1.3
RSPO2	MGC35555	ENSG00000147655	R-spondin 2	8	107899316-108083648	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024764, CAB025900, HPA053068	Approved					Mixed	Tissue enhanced		cerebral cortex: 20.2;placenta: 25.7	prostate: 15.8	Cell line enhanced		HEK 293: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2
RSPO3	FLJ14440, THSD2	ENSG00000146374	R-spondin 3	6	127118604-127197765	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA029957	Approved					Mixed	Tissue enhanced		endometrium: 103.2;smooth muscle: 102.9	placenta: 73.2	Cell line enhanced		A549: 24.0;U-138 MG: 5.6;U-87 MG: 5.4
RSPO4	C20orf182, dJ824F16.3	ENSG00000101282	R-spondin 4	20	958452-1002264	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA048887	Uncertain				Endometrial cancer:2.98e-6 (unfavourable)	Mixed	Tissue enhanced		lung: 6.8	testis: 2.4	Cell line enhanced		BEWO: 3.0;NTERA-2: 6.4;SK-BR-3: 3.3;U-2 OS: 7.7
RSPRY1	KIAA1972	ENSG00000159579	Ring finger and SPRY domain containing 1	16	57186137-57240475	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003729	Approved				Head and neck cancer:8.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
RTBDN	FLJ36353	ENSG00000132026	Retbindin	19	12825478-12835428	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052511			Approved	Endoplasmic reticulum		Mixed	Group enriched	6	adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5	stomach: 1.2	Cell line enhanced		SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
RTN4RL1	DKFZp547J144, NgR3, NGRH2	ENSG00000185924	Reticulon 4 receptor like 1	17	1934677-2025345	Predicted secreted proteins	Evidence at protein level	HPA044428	Uncertain				Renal cancer:7.69e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 12.5	skin: 6.2	Cell line enhanced		fHDF/TERT166: 8.4;HaCaT: 9.4;hTCEpi: 7.2;T-47d: 12.5
RTN4RL2	NgR2, NGRH1	ENSG00000186907	Reticulon 4 receptor-like 2	11	57460549-57477534	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.05e-7 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 48.7;thyroid gland: 36.2	liver,parathyroid gland: 6.6	Cell line enhanced		HMC-1: 38.9;Karpas-707: 48.5;REH: 38.5;RPMI-8226: 93.4
SAA1	PIG4, SAA, TP53I4	ENSG00000173432	Serum amyloid A1	11	18266174-18269977	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.57e-12 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 3976.7;liver: 1183.1	cervix, uterine: 635.0	Group enriched	5	HBEC3-KT: 868.8;HHSteC: 212.1
SAA2		ENSG00000134339	Serum amyloid A2	11	18239223-18248643	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.30e-8 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 713.3;cervix, uterine: 414.7;liver: 581.2	appendix: 211.6	Cell line enhanced		A-431: 25.4;EFO-21: 20.0;HaCaT: 23.6;HBEC3-KT: 41.5
SAA4	C-SAA, CSAA	ENSG00000148965	Serum amyloid A4, constitutive	11	18231349-18236893	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026061, HPA060139	Supported					Tissue enriched	Tissue enriched	42	liver: 776.2	cervix, uterine: 18.6	Cell line enriched	14	Hep G2: 15.6
SAR1A	SAR1, Sara, SARA1	ENSG00000079332	Secretion associated Ras related GTPase 1A	10	70147289-70170523	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006923, CAB022545, HPA048368	Supported		Supported	Endoplasmic reticulum	Head and neck cancer:7.00e-5 (unfavourable), Liver cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 116.4	Expressed in all		
SARAF	MGC8721, TMEM66	ENSG00000133872	Store-operated calcium entry associated regulatory factor	8	30063012-30083208	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040400			Supported	Endoplasmic reticulum<br>Rods & Rings	Lung cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 287.0	Expressed in all		
SARM1	KIAA0524, SAMD2, SARM	ENSG00000004139	Sterile alpha and TIR motif containing 1	17	28364356-28404049	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024359, HPA024759	Uncertain		Approved	Vesicles		Mixed	Mixed			duodenum: 7.5	Cell line enhanced		CACO-2: 26.9
SATB1		ENSG00000182568	SATB homeobox 1	3	18345387-18445588	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA051769, CAB056144	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.96e-7 (favourable), Pancreatic cancer:8.97e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.6	Cell line enhanced		HDLM-2: 421.9;REH: 115.4;THP-1: 129.6
SBSN	HLAR698, UNQ698	ENSG00000189001	Suprabasin	19	35523367-35528351	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062568, HPA067734	Enhanced		Approved	Vesicles		Group enriched	Group enriched	12	esophagus: 1055.9;skin: 2690.8	tonsil: 151.8	Cell line enhanced		ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4
SBSPON	C8orf84, RPESP	ENSG00000164764	Somatomedin B and thrombospondin type 1 domain containing	8	73064540-73124088	Predicted secreted proteins	Evidence at protein level	HPA029595, CAB034214, CAB034332	Uncertain		Approved	Vesicles	Breast cancer:7.18e-4 (favourable), Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enhanced		prostate: 23.8	urinary bladder: 16.2	Group enriched	6	BJ: 7.6;RPTEC TERT1: 12.1
SCARF1	KIAA0149, SREC	ENSG00000074660	Scavenger receptor class F member 1	17	1633858-1645747	Predicted secreted proteins	Evidence at protein level	HPA072936	Enhanced					Expressed in all	Tissue enhanced		spleen: 16.6	lung: 8.0	Cell line enhanced		HEL: 5.0;HUVEC TERT2: 15.4;REH: 8.9;TIME: 19.1
SCG2	CHGC, SgII, SN	ENSG00000171951	Secretogranin II	2	223596940-223602503	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011893, HPA075062	Enhanced	Supported			Renal cancer:7.01e-10 (unfavourable), Pancreatic cancer:5.58e-4 (favourable)	Group enriched	Group enriched	8	adrenal gland: 446.7;cerebral cortex: 232.0	duodenum: 45.1	Cell line enhanced		ASC TERT1: 35.0;HSkMC: 31.4;SCLC-21H: 52.8;SH-SY5Y: 20.7;WM-115: 32.8
SCG3	FLJ90833, SgIII	ENSG00000104112	Secretogranin III	15	51681353-51721031	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006880, CAB033274, HPA053715	Enhanced	Approved	Enhanced	Vesicles		Group enriched	Tissue enriched	13	cerebral cortex: 278.4	adrenal gland: 21.9	Group enriched	8	NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1
SCG5	7B2, SGNE1, SgV	ENSG00000166922	Secretogranin V	15	32641676-32697098	Predicted secreted proteins	Evidence at protein level	HPA013136, HPA074618	Enhanced				Renal cancer:4.51e-9 (unfavourable), Head and neck cancer:9.64e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 233.7;parathyroid gland: 192.7	adrenal gland: 80.4	Group enriched	6	HHSteC: 22.6;HSkMC: 24.3;NTERA-2: 15.6;SCLC-21H: 37.1;SH-SY5Y: 38.6;U-87 MG: 46.3
SCGB1A1	CC10, CC16, CCSP, UGB	ENSG00000149021	Secretoglobin family 1A member 1	11	62405103-62423195	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025686, HPA031828	Supported					Tissue enriched	Tissue enriched	9	lung: 4742.5	fallopian tube: 521.2	Cell line enriched	70	HaCaT: 1741.2
SCGB1C1	RYD5	ENSG00000188076	Secretoglobin family 1C member 1	11	193080-194573	Predicted secreted proteins	No evidence							Tissue enhanced	Not detected			bone marrow: 0.4	Not detected		
SCGB1C2		ENSG00000268320	Secretoglobin family 1C member 2	17	137526-139067	Predicted secreted proteins	No evidence							Tissue enhanced	Not detected			appendix,testis: 0.2	Not detected		
SCGB1D1	LIPA, LPHA, MGC71958	ENSG00000168515	Secretoglobin family 1D member 1	11	62190216-62193539	Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enhanced		cervix, uterine: 2.0;fallopian tube: 1.3	endometrium: 0.5	Cell line enriched	43	SCLC-21H: 7.1
SCGB1D2	LIPB, LPHB	ENSG00000124935	Secretoglobin family 1D member 2	11	62242210-62244808	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA035318	Approved				Endometrial cancer:3.46e-6 (favourable), Renal cancer:8.03e-6 (favourable)	Group enriched	Group enriched	9	breast: 1446.3;cervix, uterine: 5193.3	epididymis: 385.3	Cell line enriched	7	SCLC-21H: 11.2
SCGB1D4	IIS	ENSG00000197745	Secretoglobin family 1D member 4	11	62296277-62299064	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	6	cervix, uterine: 76.0;epididymis: 55.4;fallopian tube: 74.8	endometrium: 11.8	Not detected		
SCGB2A1	LPHC, MGB2, MGC71973, UGB3	ENSG00000124939	Secretoglobin family 2A member 1	11	62208668-62213939	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA034584	Enhanced				Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 2863.6;epididymis: 1665.3	fallopian tube: 381.7	Cell line enhanced		EFO-21: 8.1;NB-4: 1.3;SCLC-21H: 1.9
SCGB2A2	MGB1, MGC71974, UGB2	ENSG00000110484	Secretoglobin family 2A member 2	11	62270155-62273156	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026270	Supported				Endometrial cancer:9.57e-8 (favourable)	Tissue enriched	Tissue enriched	7	breast: 3687.7	cervix, uterine: 507.6	Cell line enriched	95	SK-BR-3: 13.3
SCGB2B2	SCGB4A2, SCGBL	ENSG00000205209	Secretoglobin family 2B member 2	19	34593329-34675699	Predicted secreted proteins	Evidence at transcript level	HPA046806	Uncertain					Not detected	Mixed			epididymis: 3.2	Mixed		
SCGB3A1	HIN-1, HIN1, LU105, PnSP-2, UGRP2	ENSG00000161055	Secretoglobin family 3A member 1	5	180590103-180591540	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	6	breast: 125.3;cervix, uterine: 345.8;lung: 301.1;salivary gland: 193.1	stomach: 40.9	Cell line enhanced		NB-4: 1.3
SCGB3A2	LU103, PNSP1, UGRP1	ENSG00000164265	Secretoglobin family 3A member 2	5	147870682-147882191	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	188	lung: 1867.1	thyroid gland: 9.9	Cell line enhanced		A-431: 76.2;EFO-21: 49.6;NTERA-2: 60.1;PC-3: 279.6
SCN1B		ENSG00000105711	Sodium voltage-gated channel beta subunit 1	19	35030466-35040449	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.38e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 145.1	cerebral cortex: 52.4	Cell line enhanced		A549: 15.7;TIME: 21.3
SCN3B	HSA243396	ENSG00000166257	Sodium voltage-gated channel beta subunit 3	11	123629187-123655244	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041707			Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enriched	11	cerebral cortex: 132.1	adrenal gland: 11.5	Cell line enhanced		hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
SCPEP1	RISC	ENSG00000121064	Serine carboxypeptidase 1	17	56978105-57006768	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039102, HPA057200	Approved		Approved	Golgi apparatus	Liver cancer:1.96e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 621.6	Expressed in all		
SCRG1	SCRG-1	ENSG00000164106	Stimulator of chondrogenesis 1	4	173384701-173406380	Predicted secreted proteins	Evidence at protein level	HPA012882	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 24.4;testis: 15.5	smooth muscle: 11.0	Group enriched	13	HSkMC: 4.3;WM-115: 17.6
SCT		ENSG00000070031	Secretin	11	626431-627143	Predicted secreted proteins	Evidence at protein level	HPA050961	Enhanced				Colorectal cancer:3.70e-4 (unfavourable)	Mixed	Group enriched	6	duodenum: 34.9;small intestine: 7.8	spleen: 3.4	Cell line enhanced		HSkMC: 1.1
SCUBE1		ENSG00000159307	Signal peptide, CUB domain and EGF like domain containing 1	22	43197283-43343388	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003190	Approved					Mixed	Tissue enhanced		ovary: 24.9	testis: 13.8	Cell line enhanced		AN3-CA: 7.2;HMC-1: 43.8;THP-1: 13.8
SCUBE2	Cegb1, Cegf1, FLJ16792	ENSG00000175356	Signal peptide, CUB domain and EGF like domain containing 2	11	9020391-9138114	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA006353, HPA029871	Uncertain				Breast cancer:2.41e-4 (favourable)	Expressed in all	Mixed			epididymis: 63.1	Cell line enhanced		HAP1: 6.0;SK-MEL-30: 6.6;T-47d: 26.8
SCUBE3	CEGF3, FLJ34743	ENSG00000146197	Signal peptide, CUB domain and EGF like domain containing 3	6	35214419-35253079	Predicted secreted proteins	Evidence at protein level	HPA040606	Uncertain		Supported	Plasma membrane	Thyroid cancer:1.38e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	thyroid gland: 49.4	seminal vesicle: 6.8	Cell line enhanced		AF22: 27.2;ASC diff: 56.0;ASC TERT1: 76.2;HSkMC: 37.2;hTEC/SVTERT24-B: 32.0;U-138 MG: 30.4;WM-115: 26.3
SDC1	CD138, SDC, SYND1, syndecan	ENSG00000115884	Syndecan 1	2	20200797-20225433	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002424, HPA006185	Approved		Supported	Focal adhesion sites	Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 250.7;skin: 287.9	liver: 144.7	Cell line enhanced		U-266/84: 739.8
SDF2		ENSG00000132581	Stromal cell derived factor 2	17	28648356-28662189	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042799			Approved	Vesicles	Liver cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 27.8	Expressed in all		
SDF2L1	AP000553.C22.4, OTTHUMT00000075032	ENSG00000128228	Stromal cell derived factor 2 like 1	22	21642261-21644298	Predicted secreted proteins	Evidence at protein level	HPA005638	Approved				Endometrial cancer:4.98e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 45.4	Expressed in all		
SDF4	Cab45	ENSG00000078808	Stromal cell derived factor 4	1	1216908-1232031	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA011249, CAB015227	Enhanced		Enhanced	Golgi apparatus	Cervical cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 128.7	Expressed in all		
SDHA	FP, SDH2, SDHF	ENSG00000073578	Succinate dehydrogenase complex flavoprotein subunit A	5	218241-256700	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034929, HPA041981, HPA064582	Enhanced		Enhanced	Mitochondria	Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 248.9	Expressed in all		
SDHD	cybS, PGL, PGL1	ENSG00000204370	Succinate dehydrogenase complex subunit D	11	112086773-112120013	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045727	Approved				Renal cancer:1.99e-10 (favourable)	Expressed in all	Expressed in all			kidney: 305.5	Expressed in all		
SEC16A	KIAA0310, p250, Sec16L	ENSG00000148396	SEC16 homolog A, endoplasmic reticulum export factor	9	136440096-136483759	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005684	Supported		Supported	Endoplasmic reticulum<br>Golgi apparatus	Endometrial cancer:1.30e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.6	Expressed in all		
SEC16B	LZTR2, PGPR-p117, RGPR, Sec16S	ENSG00000120341	SEC16 homolog B, endoplasmic reticulum export factor	1	177923956-177984303	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054292, HPA072913	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments		Not detected	Tissue enhanced		duodenum: 28.2;small intestine: 30.9	liver: 18.8	Cell line enhanced		CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3
SEC31A	ABP125, ABP130, KIAA0905, SEC31L1	ENSG00000138674	SEC31 homolog A, COPII coat complex component	4	82818661-82901166	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005457	Approved		Supported	Vesicles<br>Cytosol	Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 281.0	Expressed in all		
SECTM1	K12	ENSG00000141574	Secreted and transmembrane 1	17	82321024-82334074	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051214	Approved					Expressed in all	Tissue enhanced		small intestine: 96.6	duodenum: 64.4	Cell line enhanced		SiHa: 125.5;U-2197: 82.3
SEL1L	IBD2, SEL1L1	ENSG00000071537	SEL1L ERAD E3 ligase adaptor subunit	14	81471549-81533861	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024267	Approved					Expressed in all	Expressed in all			thyroid gland: 90.5	Expressed in all		
SELENOF	SEP15	ENSG00000183291	Selenoprotein F	1	86862445-86914424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054937			Approved	Nucleoli<br>Cytosol	Liver cancer:1.98e-5 (unfavourable), Colorectal cancer:6.53e-4 (favourable), Head and neck cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 361.7	Expressed in all		
SELENOM	SELM, SEPM	ENSG00000198832	Selenoprotein M	22	31104772-31120069	Predicted secreted proteins	Evidence at protein level	CAB008667, HPA019601	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.55e-6 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 200.8	Cell line enhanced		HHSteC: 154.4
SELENOP	SELP, SeP, SEPP, SEPP1	ENSG00000250722	Selenoprotein P	5	42799880-42887392	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036287	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:6.97e-6 (favourable)	Expressed in all	Expressed in all			liver: 2947.1	Cell line enhanced		Hep G2: 350.2;HSkMC: 307.3;T-47d: 109.6
SEMA3A	coll-1, Hsema-I, SEMA1, SEMAD, SemD	ENSG00000075213	Semaphorin 3A	7	83955777-84492724	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029447, HPA052235	Approved		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:2.69e-5 (unfavourable)	Mixed	Mixed			placenta: 14.5	Cell line enhanced		AF22: 127.3;BJ: 86.5;fHDF/TERT166: 86.7
SEMA3B	LUCA-1, SemA, sema5, SEMAA, semaV	ENSG00000012171	Semaphorin 3B	3	50267558-50277546	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030651	Approved				Breast cancer:1.27e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 75.5	Cell line enhanced		Hep G2: 74.9;WM-115: 171.7
SEMA3C	SEMAE, SemE	ENSG00000075223	Semaphorin 3C	7	80742538-80922359	Predicted secreted proteins	Evidence at protein level	HPA042418	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:4.08e-5 (unfavourable), Head and neck cancer:5.72e-5 (unfavourable)	Mixed	Mixed			prostate: 103.0	Cell line enhanced		T-47d: 248.8;U-2197: 317.7
SEMA3E	coll-5, KIAA0331, M-SemaK, SEMAH	ENSG00000170381	Semaphorin 3E	7	83363906-83649010	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029419, HPA063804	Uncertain	Supported	Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			prostate: 8.7	Cell line enhanced		SK-BR-3: 29.4;U-2 OS: 21.3
SEMA3F	Sema4, SEMAK	ENSG00000001617	Semaphorin 3F	3	50155045-50189075	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035008	Approved				Liver cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 89.1	Cell line enhanced		HUVEC TERT2: 156.4;SK-BR-3: 129.8;TIME: 276.8
SEMA3G	FLJ00014, sem2	ENSG00000010319	Semaphorin 3G	3	52433053-52445085	Predicted secreted proteins	Evidence at protein level	HPA001761	Uncertain				Renal cancer:8.86e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 82.2	placenta: 42.3	Cell line enhanced		ASC diff: 18.3;HUVEC TERT2: 6.5
SEMA4A	CORD10, FLJ12287, SEMAB, SemB	ENSG00000196189	Semaphorin 4A	1	156147366-156177752	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053726, HPA066006, HPA069136	Supported		Enhanced	Nucleus	Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 62.3	Cell line enhanced		Karpas-707: 108.3;U-698: 46.5
SEMA4B	KIAA1745, MGC131831, SEMAC, SemC	ENSG00000185033	Semaphorin 4B	15	90160604-90229679	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013372	Approved				Renal cancer:3.33e-8 (unfavourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 49.3	Expressed in all		
SEMA4C	Semacl1, Semaf, SEMAI	ENSG00000168758	Semaphorin 4C	2	96859716-96870757	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011090	Approved				Renal cancer:9.50e-7 (unfavourable), Colorectal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.9	Cell line enriched	6	BEWO: 298.1
SEMA4D	C9orf164, CD100, coll-4, FLJ39737, SEMAJ	ENSG00000187764	Semaphorin 4D	9	89360787-89498130	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015662, HPA023277	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 72.4	Cell line enhanced		HDLM-2: 124.4;HMC-1: 86.7;MOLT-4: 98.7
SEMA4F	SEMAM, SEMAW	ENSG00000135622	Ssemaphorin 4F	2	74654228-74683853	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064095, HPA065969	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.1	Mixed		
SEMA4G	FLJ20590, KIAA1619	ENSG00000095539	Semaphorin 4G	10	100969518-100985871	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038362, HPA077752	Uncertain		Uncertain	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		rectum: 92.7	duodenum: 53.8	Cell line enhanced		A549: 28.9;CACO-2: 25.3;Hep G2: 76.9
SEMA5A	SEMAF, semF	ENSG00000112902	Semaphorin 5A	5	9035026-9546075	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004632	Approved				Renal cancer:3.66e-8 (favourable), Head and neck cancer:2.45e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 19.3	Cell line enhanced		BJ hTERT+: 52.1;fHDF/TERT166: 29.1;RT4: 54.3
SEMA6A	HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ	ENSG00000092421	Semaphorin 6A	5	116443616-116574934	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031265, HPA031267	Approved		Supported	Nucleus<br>Intermediate filaments	Liver cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 49.1	Cell line enhanced		AF22: 36.5;AN3-CA: 41.0;BEWO: 36.9;HAP1: 53.6;NTERA-2: 115.0
SEMA6C	KIAA1869	ENSG00000143434	Semaphorin 6C	1	151131685-151146664	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA076150, HPA077625			Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 111.3	testis: 33.8	Cell line enhanced		AF22: 13.8;HUVEC TERT2: 20.6
SEMA6D	FLJ11598, KIAA1479	ENSG00000137872	Semaphorin 6D	15	47184101-47774223	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043109			Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:5.96e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 63.6	small intestine: 44.3	Cell line enhanced		BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
SEMG1	CT103, SEMG	ENSG00000124233	Semenogelin I	20	45206997-45209772	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042476, HPA064892	Enhanced					Tissue enriched	Tissue enriched	17692	seminal vesicle: 41483.3	cervix, uterine: 2.3	Cell line enhanced		NTERA-2: 1.2;THP-1: 2.0
SEMG2	SGII	ENSG00000124157	Semenogelin II	20	45221300-45224458	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042767, HPA042835	Enhanced					Tissue enriched	Tissue enriched	18571	seminal vesicle: 14103.4	cervix, uterine,kidney: 0.7	Not detected		
SEPT9	AF17q25, KIAA0991, MSF, MSF1, PNUTL4, SeptD1	ENSG00000184640	Septin 9	17	77280569-77500596	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042564, HPA050627	Approved		Enhanced	Actin filaments	Liver cancer:1.61e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 268.9	Expressed in all		
SERPINA1	A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1	ENSG00000197249	Serpin family A member 1	14	94376747-94390693	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000927, HPA001292, CAB013211, CAB016648, CAB073396	Enhanced		Enhanced	Vesicles	Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)	Tissue enriched	Tissue enriched	20	liver: 17144.0	small intestine: 857.0	Cell line enriched	6	Hep G2: 3254.2
SERPINA10	PZI, ZPI	ENSG00000140093	Serpin family A member 10	14	94280455-94293271	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048739			Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.00e-4 (favourable)	Tissue enriched	Tissue enriched	89	liver: 193.7	bone marrow: 2.1	Cell line enriched	6	Hep G2: 13.4
SERPINA11		ENSG00000186910	Serpin family A member 11	14	94442464-94452790	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.30e-4 (favourable)	Tissue enriched	Tissue enriched	30	liver: 255.9	cervix, uterine: 8.6	Cell line enriched	8	Hep G2: 11.7
SERPINA12	OL-64, Vaspin	ENSG00000165953	Serpin family A member 12	14	94487274-94517844	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	skin: 349.1	breast: 35.5	Cell line enhanced		Hep G2: 1.5
SERPINA3	AACT, ACT	ENSG00000196136	Serpin family A member 3	14	94612377-94624055	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000893, HPA002560, CAB016647	Enhanced				Breast cancer:8.92e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 515.4;liver: 2304.3	gallbladder: 228.3	Cell line enriched	6	Hep G2: 302.6
SERPINA4	KAL, kallistatin, KLST, KST, PI4	ENSG00000100665	Serpin family A member 4	14	94561091-94569913	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003607	Approved				Endometrial cancer:2.95e-4 (favourable)	Group enriched	Tissue enhanced		gallbladder: 72.6;liver: 242.7	epididymis: 42.8	Group enriched	36	CACO-2: 4.7;Hep G2: 16.4
SERPINA5	PAI3, PCI, PLANH3, PROCI	ENSG00000188488	Serpin family A member 5	14	94561442-94593120	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA056919			Approved	Mitochondria	Endometrial cancer:7.72e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 514.2;liver: 405.3;testis: 818.8	gallbladder: 250.7	Cell line enriched	10	Hep G2: 176.3
SERPINA6	CBG	ENSG00000170099	Serpin family A member 6	14	94304248-94323394	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017864	Approved				Endometrial cancer:6.96e-5 (favourable)	Tissue enriched	Tissue enriched	6	liver: 217.2	gallbladder: 33.9	Cell line enriched	15	T-47d: 583.2
SERPINA7	TBG	ENSG00000123561	Serpin family A member 7	X	106032442-106038738	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002803	Approved					Tissue enriched	Tissue enriched	288	liver: 216.0	small intestine: 0.7	Cell line enriched	406	Hep G2: 71.5
SERPINA9	CENTERIN, GCET1, SERPINA11b	ENSG00000170054	Serpin family A member 9	14	94462717-94479689	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	appendix: 17.1;lymph node: 50.4;tonsil: 66.3	epididymis: 4.5	Cell line enriched	49	Daudi: 50.2
SERPINC1	AT3, ATIII, MGC22579	ENSG00000117601	Serpin family C member 1	1	173903804-173917378	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001816, CAB016790, HPA024007	Supported				Liver cancer:3.40e-5 (favourable)	Tissue enriched	Tissue enriched	670	liver: 2517.8	kidney: 3.7	Cell line enriched	26	Hep G2: 55.1
SERPIND1	D22S673, HC-II, HC2, HCF2, HLS2	ENSG00000099937	Serpin family D member 1	22	20773879-20787720	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008639, HPA055767	Supported		Approved	Vesicles	Endometrial cancer:4.09e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 585.3	parathyroid gland: 36.2	Cell line enriched	8	Hep G2: 126.1
SERPINE1	PAI, PAI1, PLANH1	ENSG00000106366	Serpin family E member 1	7	101127089-101139266	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050039, CAB068501	Uncertain		Approved	Cytosol	Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 580.3;placenta: 600.2	adipose tissue: 215.8	Cell line enhanced		TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
SERPINE2	GDN, nexin, PI7, PN1, PNI	ENSG00000135919	Serpin family E member 2	2	223975112-224039319	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:6.48e-5 (unfavourable)	Tissue enriched	Tissue enriched	7	placenta: 1628.0	cerebral cortex: 235.8	Cell line enhanced		fHDF/TERT166: 5130.1;SK-MEL-30: 2298.5;WM-115: 2211.8
SERPINE3		ENSG00000253309	Serpin family E member 3	13	51335773-51364735	Predicted secreted proteins	Evidence at protein level	HPA051904, HPA055804	Uncertain					Not detected	Tissue enhanced		skin: 1.0	small intestine: 0.8	Not detected		
SERPINF1	EPC-1, PEDF, PIG35	ENSG00000132386	Serpin family F member 1	17	1761959-1777574	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005825	Approved				Renal cancer:1.40e-8 (unfavourable), Cervical cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 739.1	Cell line enhanced		ASC diff: 752.1;ASC TERT1: 594.5;Hep G2: 362.7;HHSteC: 306.9;HSkMC: 845.8
SERPINF2	A2AP, AAP, ALPHA-2-PI, API, PLI	ENSG00000167711	Serpin family F member 2	17	1742836-1755268	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001885, CAB024863	Approved		Uncertain	Nucleoplasm<br>Vesicles	Liver cancer:2.26e-5 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 117.4;liver: 452.5	kidney: 63.3	Cell line enriched	24	Hep G2: 99.1
SERPING1	C1-INH, C1IN, C1NH, HAE1, HAE2	ENSG00000149131	Serpin family G member 1	11	57597387-57614853	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026161, HPA048738	Supported				Renal cancer:1.55e-4 (unfavourable), Ovarian cancer:8.03e-4 (favourable), Colorectal cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 1365.0	Group enriched	5	ASC diff: 881.8;ASC TERT1: 462.5;HSkMC: 802.1
SERPINH1	CBP1, CBP2, colligen, HSP47, SERPINH2	ENSG00000149257	Serpin family H member 1	11	75562056-75572783	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004441, HPA029198	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:3.22e-15 (unfavourable), Head and neck cancer:1.85e-4 (unfavourable), Cervical cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.1	Mixed		
SERPINI1	neuroserpin, PI12	ENSG00000163536	Serpin family I member 1	3	167735243-167825568	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001565, CAB026059, HPA056092	Enhanced		Approved	Cytosol	Liver cancer:4.25e-4 (unfavourable)	Expressed in all	Tissue enriched	10	cerebral cortex: 322.1	kidney: 31.3	Mixed		
SERPINI2	MEPI, PANCPIN, PI14, TSA2004	ENSG00000114204	Serpin family I member 2	3	167441789-167479004	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	47	pancreas: 288.1	fallopian tube: 6.1	Group enriched	10	THP-1: 6.0;U-937: 1.2
SEZ6L2	FLJ90517, PSK-1	ENSG00000174938	Seizure related 6 homolog like 2	16	29871159-29899547	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064471	Enhanced				Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.4;parathyroid gland: 58.4	adrenal gland: 30.6	Cell line enhanced		EFO-21: 72.2
SFRP1	FRP, FRP-1, SARP2	ENSG00000104332	Secreted frizzled related protein 1	8	41261958-41309497	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008116, HPA064870	Approved		Approved	Nucleoli<br>Cytosol	Head and neck cancer:1.55e-4 (favourable), Urothelial cancer:3.12e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 357.2;cervix, uterine: 325.0	endometrium: 231.0	Cell line enhanced		BJ hTERT+: 563.8;HBF TERT88: 268.7;RPTEC TERT1: 319.1;WM-115: 275.2
SFRP2	FRP-2, SARP1, SDF-5	ENSG00000145423	Secreted frizzled related protein 2	4	153780592-153789120	Predicted secreted proteins	Evidence at protein level	HPA002652			Approved	Intermediate filaments	Renal cancer:8.56e-6 (unfavourable), Urothelial cancer:4.39e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 489.6;urinary bladder: 512.1	esophagus: 234.0	Cell line enhanced		AF22: 221.7;ASC diff: 57.2;HSkMC: 100.0;NTERA-2: 312.3
SFRP4	FRP-4, frpHE	ENSG00000106483	Secreted frizzled related protein 4	7	37905932-38025695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009712, HPA050585	Enhanced				Renal cancer:1.36e-5 (unfavourable)	Expressed in all	Group enriched	5	cervix, uterine: 935.5;endometrium: 776.1;fallopian tube: 338.6	smooth muscle: 130.5	Cell line enhanced		ASC diff: 6.5;HSkMC: 2.7;U-937: 2.9
SFRP5	SARP3	ENSG00000120057	Secreted frizzled related protein 5	10	97766751-97771952	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		duodenum: 30.9;pancreas: 31.2;small intestine: 29.4	adrenal gland: 12.9	Cell line enhanced		A549: 2.3;CACO-2: 10.5;RPMI-8226: 3.2;SCLC-21H: 2.4
SFTA2	SFTPG	ENSG00000196260	Surfactant associated 2	6	30931353-30955636	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.26e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	lung: 53.8	esophagus: 5.2	Group enriched	5	CACO-2: 7.9;CAPAN-2: 4.5
SFTPA1	COLEC4, SFTP1, SP-A, SP-A1	ENSG00000122852	Surfactant protein A1	10	79610939-79615455	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB016793, HPA042638, HPA045752, HPA049368	Supported					Tissue enriched	Tissue enriched	1180	lung: 10513.5	adrenal gland: 8.9	Group enriched	6	RPMI-8226: 29.9;U-2197: 6.8
SFTPA2	COLEC5, SP-A2	ENSG00000185303	Surfactant protein A2	10	79555852-79560402	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002439, HPA042638, HPA045752, HPA049368	Enhanced					Tissue enriched	Tissue enriched	383	lung: 15972.2	prostate: 41.7	Group enriched	18	BEWO: 7.1;NB-4: 5.1;RPMI-8226: 17.9;U-2197: 13.9
SFTPB	SFTP3, SP-B	ENSG00000168878	Surfactant protein B	2	85657314-85668741	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002440, HPA034820, HPA062148	Enhanced				Endometrial cancer:1.71e-6 (unfavourable), Renal cancer:2.99e-6 (unfavourable)	Group enriched	Tissue enriched	912	lung: 5318.7	adrenal gland: 5.8	Cell line enhanced		BEWO: 2.8;U-2197: 6.3
SFTPD	COLEC7, SFTP4, SP-D	ENSG00000133661	Surfactant protein D	10	79937740-79982614	Predicted secreted proteins	Evidence at protein level	CAB004578, HPA044582, HPA056768	Enhanced					Tissue enriched	Tissue enriched	56	lung: 782.5	bone marrow: 13.8	Cell line enhanced		BEWO: 1.3;hTCEpi: 2.3;MCF7: 1.1
SGCA	A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1	ENSG00000108823	Sarcoglycan alpha	17	50164214-50175931	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007537	Uncertain					Mixed	Tissue enhanced		heart muscle: 79.5;skeletal muscle: 181.4	seminal vesicle: 38.3	Cell line enriched	13	LHCN-M2: 65.0
SGSH	HSS, MPS3A, SFMD	ENSG00000181523	N-sulfoglucosamine sulfohydrolase	17	80206716-80220923	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023436, HPA023451	Enhanced				Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 36.3	Mixed		
SH2B1	FLJ30542, SH2B	ENSG00000178188	SH2B adaptor protein 1	16	28846600-28874212	Predicted intracellular proteins	Evidence at protein level	HPA076175			Approved	Vesicles	Renal cancer:2.81e-6 (favourable), Urothelial cancer:1.60e-4 (favourable), Pancreatic cancer:4.38e-4 (favourable), Lung cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 105.8	Expressed in all		
SH3RF3	FLJ00204, POSH2, SH3MD4	ENSG00000172985	SH3 domain containing ring finger 3	2	109129348-109504632	Predicted secreted proteins	Evidence at protein level	HPA044822, HPA048444	Approved		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Ovarian cancer:2.33e-4 (unfavourable)	Expressed in all	Mixed			placenta: 7.6	Cell line enhanced		TIME: 19.3;U-266/84: 20.2
SHBG	ABP, MGC126834, MGC138391, TEBG	ENSG00000129214	Sex hormone binding globulin	17	7613946-7633383	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		liver: 33.0;testis: 13.7	small intestine: 7.4	Cell line enhanced		ASC diff: 3.0;HSkMC: 3.1
SHE		ENSG00000169291	Src homology 2 domain containing E	1	154469772-154502113	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037417	Approved					Tissue enhanced	Mixed			testis: 31.9	Group enriched	6	HUVEC TERT2: 42.7;TIME: 11.5
SHH	HHG1, HLP3, HPE3, MCOPCB5, SMMCI, TPT, TPTPS	ENSG00000164690	Sonic hedgehog	7	155799986-155812273	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:8.62e-5 (favourable)	Mixed	Tissue enhanced		adrenal gland: 12.0;stomach: 10.5;urinary bladder: 13.5	cervix, uterine: 6.8	Cell line enhanced		CAPAN-2: 4.7;EFO-21: 8.5;PC-3: 3.8;RT4: 21.2
SHKBP1	PP203, Sb1	ENSG00000160410	SH3KBP1 binding protein 1	19	40576851-40591399	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041887	Uncertain		Approved	Cell Junctions		Expressed in all	Expressed in all			spleen: 53.4	Expressed in all		
SIAE	CSE-C, LSE, MGC87009, YSG2	ENSG00000110013	Sialic acid acetylesterase	11	124633113-124695707	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038052, HPA038053	Approved				Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)	Expressed in all	Expressed in all			rectum: 114.5	Mixed		
SIDT2	CGI-40	ENSG00000149577	SID1 transmembrane family member 2	11	117178733-117197445	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052352	Approved				Renal cancer:4.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 60.8	Expressed in all		
SIGLEC10	MGC126774, PRO940, SIGLEC-10, SLG2	ENSG00000142512	Sialic acid binding Ig like lectin 10	19	51410021-51417803	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025807, HPA027093	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 48.4;spleen: 36.9	lymph node: 22.1	Cell line enhanced		Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
SIGLEC6	CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6	ENSG00000105492	Sialic acid binding Ig like lectin 6	19	51519525-51531856	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009084, HPA018198	Enhanced					Tissue enhanced	Tissue enriched	25	placenta: 147.9	lung: 6.0	Cell line enriched	7	HMC-1: 401.5
SIGLEC7	CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2	ENSG00000168995	Sialic acid binding Ig like lectin 7	19	51142299-51153526	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 21.0	appendix: 14.4	Group enriched	10	Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4
SIGMAR1	OPRS1, SR-BP1	ENSG00000147955	Sigma non-opioid intracellular receptor 1	9	34634722-34637809	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013470, HPA018002, HPA024071	Approved				Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 67.8	Expressed in all		
SIL1	BAP, MSS, ULG5	ENSG00000120725	SIL1 nucleotide exchange factor	5	138946720-139293557	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011949	Enhanced				Glioma:3.77e-4 (unfavourable), Endometrial cancer:4.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 60.1	Expressed in all		
SIRPB1	CD172b, SIRP-BETA-1	ENSG00000101307	Signal regulatory protein beta 1	20	1563521-1620061	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047463	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		appendix: 38.7;bone marrow: 33.7	lung: 28.0	Cell line enhanced		HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
SIRPD	dJ576H24.4, PTPNS1L2	ENSG00000125900	Signal regulatory protein delta	20	1534251-1558843	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042663	Enhanced					Not detected	Tissue enriched	18	testis: 72.6	appendix: 3.9	Cell line enhanced		HL-60: 1.1;HMC-1: 1.5;NB-4: 1.5;THP-1: 3.5
SIRT3	SIR2L3	ENSG00000142082	Sirtuin 3	11	215458-236931	Predicted intracellular proteins	Evidence at protein level	HPA026809, CAB037142	Approved				Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 50.7	Expressed in all		
SLAIN1	C13orf32, FLJ30046	ENSG00000139737	SLAIN motif family member 1	13	77697854-77764242	Predicted intracellular proteins	Evidence at protein level	HPA040798			Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Ovarian cancer:9.07e-4 (favourable)	Tissue enhanced	Expressed in all			cerebral cortex: 217.1	Cell line enhanced		HL-60: 61.7;MOLT-4: 72.0;SCLC-21H: 69.0
SLAMF1	CD150, SLAM	ENSG00000117090	Signaling lymphocytic activation molecule family member 1	1	160608100-160647295	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002438, HPA069319	Enhanced					Mixed	Tissue enhanced		appendix: 15.4;lymph node: 21.1;tonsil: 14.3	spleen: 7.9	Cell line enriched	134	HDLM-2: 142.1
SLAMF7	19A, CD319, CRACC, CS1	ENSG00000026751	SLAM family member 7	1	160739057-160754821	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015445, HPA055945, HPA061654	Enhanced		Approved	Vesicles	Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)	Mixed	Mixed			spleen: 58.3	Group enriched	7	SK-MEL-30: 45.6;U-266/70: 216.2
SLC10A3	DXS253E, P3	ENSG00000126903	Solute carrier family 10 member 3	X	154487306-154490690	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA021656	Approved		Approved	Intermediate filaments	Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.0	Expressed in all		
SLC22A1	OCT1	ENSG00000175003	Solute carrier family 22 member 1	6	160121789-160158718	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029846	Approved				Liver cancer:1.35e-5 (favourable)	Tissue enriched	Tissue enriched	253	liver: 286.8	gallbladder: 1.1	Not detected		
SLC25A14	BMCP1, UCP5	ENSG00000102078	Solute carrier family 25 member 14	X	130339888-130373361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060316			Approved	Mitochondria	Renal cancer:5.52e-6 (unfavourable), Urothelial cancer:1.39e-5 (favourable), Cervical cancer:1.72e-5 (favourable), Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.4	Expressed in all		
SLC25A25	KIAA1896, MCSC, PCSCL	ENSG00000148339	Solute carrier family 25 member 25	9	128068201-128109245	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020381	Uncertain		Supported	Vesicles<br>Mitochondria	Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 62.9	Expressed in all		
SLC35E3	BLOV1	ENSG00000175782	Solute carrier family 35 member E3	12	68746106-68793964	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA049403	Uncertain				Endometrial cancer:1.78e-4 (favourable)	Expressed in all	Mixed			skin: 6.1	Mixed		
SLC39A10	DKFZp564L2123, FLJ90515, KIAA1265	ENSG00000196950	Solute carrier family 39 member 10	2	195575977-195737702	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036512, HPA036513, HPA066087	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.7;thyroid gland: 79.2	prostate: 30.8	Expressed in all		
SLC39A11	C17orf26	ENSG00000133195	Solute carrier family 39 member 11	17	72645949-73092712	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021455			Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 60.1	Expressed in all		
SLC39A14	KIAA0062, NET34, ZIP14	ENSG00000104635	Solute carrier family 39 member 14	8	22367249-22434129	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016508	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)	Expressed in all	Mixed			liver: 203.0	Expressed in all		
SLC39A4	AEZ, AWMS2, ZIP4	ENSG00000147804	Solute carrier family 39 member 4	8	144409742-144416895	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.04e-4 (favourable)	Expressed in all	Group enriched	8	duodenum: 134.2;small intestine: 95.7	kidney: 14.3	Group enriched	9	CAPAN-2: 50.5;Hep G2: 102.1
SLC39A5		ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7
SLC3A1	ATR1, CSNU1, D2H, NBAT, RBAT	ENSG00000138079	Solute carrier family 3 member 1	2	44275458-44321494	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA038360, HPA071102	Enhanced		Approved	Nuclear bodies<br>Mitochondria	Renal cancer:3.67e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 688.2	small intestine: 148.9	Cell line enriched	14	RPTEC TERT1: 80.7
SLC4A5	NBC4	ENSG00000188687	Solute carrier family 4 member 5	2	74216242-74343414	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036621	Approved					Tissue enriched	Group enriched	6	testis: 30.9;thyroid gland: 44.9	skin: 6.3	Cell line enhanced		U-266/70: 7.2
SLC51A	OSTalpha	ENSG00000163959	Solute carrier family 51 alpha subunit	3	196211487-196243178	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA039123	Enhanced				Liver cancer:7.54e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 29.3;liver: 35.1;small intestine: 71.3	colon: 9.9	Cell line enhanced		REH: 3.4
SLC52A2	D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2	ENSG00000185803	Solute carrier family 52 member 2	8	144354135-144361272	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063036	Approved				Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.8	Expressed in all		
SLC6A16	NTT5	ENSG00000063127	Solute carrier family 6 member 16	19	49289638-49325225	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076812			Supported	Golgi apparatus		Mixed	Tissue enriched	18	testis: 162.8	lymph node: 8.8	Cell line enhanced		AF22: 18.0
SLC6A8	CRTR, CT1	ENSG00000130821	Solute carrier family 6 member 8	X	153688099-153696593	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 89.2	Mixed		
SLC8A1	NCX1	ENSG00000183023	Solute carrier family 8 member A1	2	40097270-40611053	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022694, HPA070007	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		heart muscle: 78.0	seminal vesicle: 37.6	Cell line enhanced		BJ: 24.4;fHDF/TERT166: 54.5
SLC8B1	FLJ22233, NCKX6, NCLX, SLC24A6	ENSG00000089060	Solute carrier family 8 member B1	12	113298759-113359493	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA040668	Approved				Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 48.4	Mixed		
SLIT1	MEGF4, SLIL1, Slit-1, slit1, SLIT3	ENSG00000187122	Slit guidance ligand 1	10	96998038-97185920	Predicted secreted proteins	Evidence at protein level	HPA006879			Approved	Plasma membrane		Group enriched	Tissue enriched	14	cerebral cortex: 60.0	thyroid gland: 4.2	Cell line enriched	11	MOLT-4: 64.7
SLIT2	SLIL3, Slit-2	ENSG00000145147	Slit guidance ligand 2	4	20253260-20620561	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB007590, HPA019511, HPA023088	Uncertain				Renal cancer:6.51e-4 (favourable)	Mixed	Mixed			lung: 49.5	Cell line enhanced		BJ hTERT+: 175.8;BJ hTERT+ SV40 Large T+: 96.6;fHDF/TERT166: 96.4;HBF TERT88: 115.2
SLIT3	MEGF5, SLIL2, Slit-3, SLIT1, slit2	ENSG00000184347	Slit guidance ligand 3	5	168661733-169301129	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051630	Approved		Supported	Cell Junctions	Renal cancer:2.45e-5 (unfavourable)	Mixed	Mixed			parathyroid gland: 99.9	Cell line enhanced		ASC diff: 212.7;fHDF/TERT166: 89.9;RT4: 80.4;SH-SY5Y: 77.7
SLITRK3	KIAA0848	ENSG00000121871	SLIT and NTRK like family member 3	3	165186720-165197109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017636, HPA048042	Enhanced		Approved	Mitochondria		Tissue enriched	Tissue enhanced		cerebral cortex: 17.3;endometrium: 12.3	fallopian tube: 9.8	Cell line enhanced		AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7
SLPI	ALK1, ALP, BLPI, HUSI, HUSI-I, WAP4, WFDC4	ENSG00000124107	Secretory leukocyte peptidase inhibitor	20	45252239-45254564	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002303, HPA027774	Enhanced				Renal cancer:6.91e-5 (unfavourable)	Expressed in all	Tissue enriched	9	cervix, uterine: 41087.8	seminal vesicle: 4333.6	Cell line enhanced		EFO-21: 1622.9;hTCEpi: 1467.1;SiHa: 660.2
SLURP1	ANUP, ARS, ArsB, LY6LS, MDM	ENSG00000126233	Secreted LY6/PLAUR domain containing 1	8	142740944-142742411	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050967	Approved					Tissue enhanced	Group enriched	33	esophagus: 740.6;skin: 297.1	tonsil: 15.7	Cell line enhanced		HaCaT: 1.1;MCF7: 1.1;T-47d: 2.4
SMARCA2	BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2	ENSG00000080503	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2	9	1980290-2193624	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029981, CAB037276	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Intermediate filaments	Renal cancer:1.26e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 328.7	Cell line enriched	7	HDLM-2: 1364.0
SMG6	C17orf31, EST1A, KIAA0732, SMG-6	ENSG00000070366	SMG6, nonsense mediated mRNA decay factor	17	2059839-2303771	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042932	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:1.30e-6 (favourable)	Expressed in all	Expressed in all			ovary: 47.3	Expressed in all		
SMIM7	C19orf42, MGC2747	ENSG00000214046	Small integral membrane protein 7	19	16630751-16660442	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043127	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 55.4	Expressed in all		
SMOC1		ENSG00000198732	SPARC related modular calcium binding 1	14	69854131-70032366	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA004153, CAB034427	Approved		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 135.8	prostate: 66.2	Cell line enhanced		AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4
SMOC2	SMAP2	ENSG00000112562	SPARC related modular calcium binding 2	6	168441151-168673445	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033979	Uncertain				Renal cancer:1.16e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 183.6	Cell line enhanced		AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8
SMPDL3A	ASM3A, ASML3a, FLJ20177, yR36GH4.1	ENSG00000172594	Sphingomyelin phosphodiesterase acid like 3A	6	122789049-122809720	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030148	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Colorectal cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 81.9	Mixed		
SMPDL3B	ASML3B	ENSG00000130768	Sphingomyelin phosphodiesterase acid like 3B	1	27934993-27959157	Predicted secreted proteins	Evidence at protein level	HPA030561			Approved	Golgi apparatus<br>Cytosol		Mixed	Mixed			rectum: 25.6	Cell line enhanced		BEWO: 44.0;CAPAN-2: 31.4;SK-BR-3: 34.4;T-47d: 31.2
SMR3A	PBI, PRL5, PROL5	ENSG00000109208	Submaxillary gland androgen regulated protein 3A	4	70360761-70367158	Predicted secreted proteins	Evidence at protein level	HPA044567	Enhanced					Tissue enhanced	Tissue enriched	24	salivary gland: 24.1	thyroid gland: 0.9	Not detected		
SMR3B	P-B, PRL3, PROL3	ENSG00000171201	Submaxillary gland androgen regulated protein 3B	4	70370093-70390244	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1608	salivary gland: 85397.1	ovary: 53.0	Cell line enriched	34	EFO-21: 3.9
SNED1	FLJ00133, Snep, SST3	ENSG00000162804	Sushi, nidogen and EGF like domains 1	2	240998838-241095568	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036414, HPA036415	Uncertain					Mixed	Mixed			endometrium: 29.8	Cell line enhanced		ASC TERT1: 290.9;HSkMC: 154.1
SNX14	RGS-PX2	ENSG00000135317	Sorting nexin 14	6	85505496-85594156	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017639	Approved		Supported	Cytosol	Head and neck cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 156.6	Expressed in all		
SOD3	EC-SOD	ENSG00000109610	Superoxide dismutase 3	4	24789912-24800842	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042110	Supported					Expressed in all	Tissue enhanced		adipose tissue: 179.2	fallopian tube: 66.5	Cell line enhanced		ASC diff: 41.5;PC-3: 46.6;RPTEC TERT1: 158.1
SOST	DAND6, VBCH	ENSG00000167941	Sclerostin	17	43753731-43758788	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025660	Approved					Group enriched	Tissue enriched	16	kidney: 10.3	lung: 0.6	Cell line enriched	37	HaCaT: 4.6
SOSTDC1	DAND7, DKFZp564D206, USAG1	ENSG00000171243	Sclerostin domain containing 1	7	16461481-16530580	Predicted secreted proteins	Evidence at protein level						Renal cancer:3.22e-5 (favourable), Ovarian cancer:8.69e-4 (favourable), Urothelial cancer:8.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 57.1;stomach: 53.4	kidney: 23.0	Cell line enhanced		AF22: 8.0;EFO-21: 11.2;NTERA-2: 4.7;RPTEC TERT1: 16.9
SPACA3	ALLP17, CT54, LYC3, LYZL3, SLLP1	ENSG00000141316	Sperm acrosome associated 3	17	32970376-32997877	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023633	Enhanced					Tissue enhanced	Tissue enriched	17	testis: 77.5	pancreas: 4.5	Cell line enriched	17	U-266/70: 72.1
SPACA4	SAMP14	ENSG00000177202	Sperm acrosome associated 4	19	48606743-48607714	Predicted secreted proteins	Evidence at protein level	HPA041927, HPA061302	Enhanced					Mixed	Tissue enriched	18	testis: 64.9	stomach: 3.5	Not detected		
SPACA5	dJ54B20.3, LYC5, LYZL5, PNPK6288, SLLP2, UNQ6288	ENSG00000171489	Sperm acrosome associated 5	X	48004336-48009729	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA044747, HPA047149	Supported					Not detected	Tissue enriched	10	testis: 13.6	thyroid gland: 1.4	Not detected		
SPACA5B	LYZL5B	ENSG00000171478	Sperm acrosome associated 5B	X	48130657-48132613	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA044747, HPA047149	Supported					Not detected	Tissue enriched	149	testis: 16.5	fallopian tube: 0.1	Not detected		
SPACA7	C13orf28	ENSG00000153498	Sperm acrosome associated 7	13	112376319-112434689	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048349	Enhanced					Not detected	Tissue enriched	73	testis: 50.2	bone marrow,skin: 0.6	Not detected		
SPAG11A	EDDM2A, HE2	ENSG00000178287	Sperm associated antigen 11A	8	7847876-7868867	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023842	Supported					Not detected	Tissue enriched	12587	epididymis: 6263.0	fallopian tube,seminal vesicle: 0.4	Group enriched	8	BEWO: 1.8;NB-4: 5.5;RPMI-8226: 1.4;SH-SY5Y: 1.3
SPAG11B	EDDM2B, EP2, EP2C, EP2D, HE2	ENSG00000164871	Sperm associated antigen 11B	8	7442684-7463674	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023842	Supported					Not detected	Tissue enriched	5739	epididymis: 6744.6	seminal vesicle: 1.1	Group enriched	7	BEWO: 3.9;NB-4: 5.5;RPMI-8226: 2.2;SH-SY5Y: 3.8
SPARC	ON	ENSG00000113140	Secreted protein acidic and cysteine rich	5	151661096-151687165	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002306, HPA002989, HPA003020	Supported				Renal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 3240.9	Cell line enhanced		ASC diff: 3432.3;BJ: 3597.1;fHDF/TERT166: 5254.9;WM-115: 4850.9
SPARCL1	MAST9	ENSG00000152583	SPARC like 1	4	87473335-87531061	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026225	Enhanced				Urothelial cancer:3.33e-4 (unfavourable), Colorectal cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2035.8	Cell line enhanced		AF22: 23.6;U-266/70: 7.1
SPATA20	FLJ21347, SSP411, Tisp78	ENSG00000006282	Spermatogenesis associated 20	17	50543058-50555852	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022023, HPA027144, HPA031442	Enhanced		Approved	Nucleoplasm	Urothelial cancer:9.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 97.7	Mixed		
SPESP1	SP-ESP	ENSG00000258484	Sperm equatorial segment protein 1	15	68818221-68946811	Predicted secreted proteins	Evidence at protein level	HPA045936, HPA051040	Enhanced					Expressed in all	Tissue enriched	7	testis: 128.4	placenta: 18.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 16.1;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;HBF TERT88: 20.5;RPTEC TERT1: 19.6;SCLC-21H: 23.0;WM-115: 30.5
SPINK1	PCTT, PSTI, Spink3, TATI	ENSG00000164266	Serine peptidase inhibitor, Kazal type 1	5	147824568-147831786	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026366, HPA027498	Enhanced				Renal cancer:5.44e-7 (unfavourable), Urothelial cancer:2.15e-5 (favourable)	Tissue enhanced	Tissue enriched	8	pancreas: 7127.3	stomach: 927.5	Group enriched	9	CACO-2: 208.3;RT4: 548.2
SPINK13	HESPINTOR, LiESP6, MGC149260, SPINK5L3	ENSG00000214510	Serine peptidase inhibitor, Kazal type 13 (putative)	5	148268180-148286254	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA036456	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:4.03e-10 (unfavourable)	Group enriched	Tissue enriched	8	epididymis: 309.7	seminal vesicle: 37.3	Cell line enriched	13	HeLa: 304.5
SPINK14	SPINK5L2	ENSG00000196800	Serine peptidase inhibitor, Kazal type 14 (putative)	5	148169733-148175398	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		breast: 1.1;rectum: 1.2	cervix, uterine: 0.7	Not detected		
SPINK2	HUSI-II	ENSG00000128040	Serine peptidase inhibitor, Kazal type 2	4	56809860-56821742	Predicted secreted proteins	Evidence at protein level	CAB020824, HPA026813	Enhanced				Lung cancer:2.82e-4 (favourable)	Group enriched	Tissue enriched	15	epididymis: 6416.1	testis: 428.6	Cell line enhanced		Daudi: 15.0;NB-4: 11.4;U-266/70: 67.9
SPINK4	MGC133107, PEC-60	ENSG00000122711	Serine peptidase inhibitor, Kazal type 4	9	33218365-33248567	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007286	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Colorectal cancer:8.85e-5 (favourable)	Group enriched	Group enriched	6	colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5	appendix: 107.1	Cell line enriched	8	HMC-1: 152.9
SPINK5	DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI	ENSG00000133710	Serine peptidase inhibitor, Kazal type 5	5	148025683-148137289	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA009067, HPA011351, CAB015347	Enhanced		Enhanced	Vesicles		Tissue enhanced	Group enriched	26	esophagus: 1130.0;skin: 383.9;tonsil: 270.0	breast: 22.9	Cell line enhanced		HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8
SPINK6	BUSI2, MGC21394, UNQ844	ENSG00000178172	Serine peptidase inhibitor, Kazal type 6	5	148202794-148215137	Predicted secreted proteins	Evidence at protein level	HPA011039	Uncertain				Head and neck cancer:7.16e-4 (favourable)	Group enriched	Not detected			epididymis: 0.9	Group enriched	73	HeLa: 1936.6;SiHa: 1473.3
SPINK7	ECG2, ECRG2	ENSG00000145879	Serine peptidase inhibitor, Kazal type 7 (putative)	5	148312419-148315922	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036294	Enhanced					Group enriched	Group enriched	25	esophagus: 416.8;tonsil: 106.3	cervix, uterine: 10.5	Not detected		
SPINK8		ENSG00000229453	Serine peptidase inhibitor, Kazal type 8 (putative)	3	48306842-48328341	Predicted secreted proteins	Evidence at transcript level	HPA053151	Uncertain				Breast cancer:8.47e-4 (unfavourable)	Group enriched	Tissue enriched	7	breast: 58.2	bone marrow: 7.7	Cell line enriched	49	SK-BR-3: 55.0
SPINK9		ENSG00000204909	Serine peptidase inhibitor, Kazal type 9	5	148321203-148339849	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038288	Uncertain					Tissue enhanced	Mixed			testis: 10.6	Mixed		
SPINT1	HAI, MANSC2	ENSG00000166145	Serine peptidase inhibitor, Kunitz type 1	15	40844018-40858207	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006903, HPA031178	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 217.3	Cell line enhanced		BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3
SPINT2	HAI-2, Kop	ENSG00000167642	Serine peptidase inhibitor, Kunitz type 2	19	38244035-38292614	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011101, CAB018969	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol	Renal cancer:3.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 539.2	Cell line enhanced		A-431: 736.5;CAPAN-2: 1060.7
SPINT3	HKIB9	ENSG00000101446	Serine peptidase inhibitor, Kunitz type 3	20	45512461-45515624	Predicted secreted proteins	Evidence at protein level	HPA026852	Enhanced					Not detected	Group enriched	32	epididymis: 5.8;seminal vesicle: 15.4	skin: 0.3	Not detected		
SPINT4	C20orf137, dJ601O1.1	ENSG00000149651	Serine peptidase inhibitor, Kunitz type 4	20	45722351-45725830	Predicted secreted proteins	Evidence at protein level	HPA046703	Enhanced					Not detected	Tissue enriched	1619	epididymis: 347.0	seminal vesicle: 0.2	Not detected		
SPOCK1	SPOCK, testican-1, TIC1	ENSG00000152377	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1	5	136975298-137598379	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007450, HPA026770	Uncertain		Approved	Vesicles	Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 209.2	prostate: 108.0	Cell line enhanced		AF22: 299.3;ASC diff: 403.2;HUVEC TERT2: 508.1;U-138 MG: 298.1
SPOCK2	KIAA0275, testican-2	ENSG00000107742	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2	10	72059035-72089032	Predicted secreted proteins	Evidence at protein level	HPA044605	Supported		Uncertain	Nuclear speckles	Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 161.8;lung: 127.8	lymph node: 75.1	Group enriched	8	Hep G2: 33.9;SCLC-21H: 79.9
SPOCK3	testican-3	ENSG00000196104	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3	4	166733384-167234796	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA075020			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Tissue enhanced	Tissue enriched	7	parathyroid gland: 800.5	prostate: 120.0	Cell line enhanced		PC-3: 2.4;RH-30: 6.7;SCLC-21H: 3.5
SPON1	f-spondin, KIAA0762	ENSG00000262655	Spondin 1	11	13962689-14267884	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038584, HPA077546	Approved		Approved	Nucleus<br>Nucleoli<br>Actin filaments<br>Microtubule ends<br>Cytokinetic bridge	Urothelial cancer:1.88e-4 (unfavourable), Renal cancer:3.12e-4 (favourable)	Expressed in all	Tissue enhanced		gallbladder: 167.6	fallopian tube: 104.8	Group enriched	39	EFO-21: 209.9;RPTEC TERT1: 476.8
SPON2	DIL1	ENSG00000159674	Spondin 2	4	1166932-1208962	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040170, HPA066095	Uncertain		Approved	Vesicles	Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable)	Tissue enriched	Tissue enhanced		endometrium: 105.2;prostate: 113.0	cervix, uterine: 53.6	Group enriched	6	HHSteC: 216.0;HSkMC: 330.1
SPP1	BNSP, BSPI, ETA-1, OPN	ENSG00000118785	Secreted phosphoprotein 1	4	87975650-87983426	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002212, HPA027540, HPA027541	Enhanced		Supported	Golgi apparatus	Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7	cerebral cortex: 795.2	Group enriched	6	EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5
SPP2	SPP24	ENSG00000072080	Secreted phosphoprotein 2	2	234050679-234077134	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:2.33e-6 (favourable)	Tissue enriched	Tissue enriched	2145	liver: 265.4	kidney,testis: 0.1	Not detected		
SPRN	bA108K14.1, FLJ41197, Shadoo, Sprn	ENSG00000203772	Shadow of prion protein homolog (zebrafish)	10	133420666-133424572	Predicted secreted proteins, Transporters	Evidence at transcript level						Urothelial cancer:1.58e-7 (favourable), Pancreatic cancer:1.54e-6 (favourable), Renal cancer:3.95e-4 (unfavourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 24.8	testis: 2.8	Mixed		
SPTY2D1-AS1		ENSG00000247595	SPTY2D1 antisense RNA 1	11	18588781-18610255	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	21	testis: 366.7	skin: 17.2	Mixed		
SPX	C12orf39, MGC10946, NPQ, spexin	ENSG00000134548	Spexin hormone	12	21526307-21537377	Predicted secreted proteins	Evidence at protein level						Renal cancer:1.31e-6 (favourable)	Tissue enhanced	Group enriched	6	adipose tissue: 53.7;placenta: 13.5	thyroid gland: 6.1	Cell line enhanced		CACO-2: 11.2;HBEC3-KT: 4.9;hTERT-HME1: 6.9;U-2 OS: 4.4
SRGN	PPG, PRG, PRG1	ENSG00000122862	Serglycin	10	69088106-69104811	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000759	Enhanced				Renal cancer:3.18e-5 (unfavourable)	Expressed in all	Group enriched	6	appendix: 1121.8;bone marrow: 5139.0	gallbladder: 509.4	Cell line enhanced		HL-60: 3514.5;THP-1: 2938.4;TIME: 2120.9;U-937: 2758.4
SRL		ENSG00000185739	Sarcalumenin	16	4189374-4242080	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041535, HPA045520	Enhanced					Group enriched	Group enriched	17	heart muscle: 161.0;skeletal muscle: 178.8	esophagus: 10.2	Cell line enriched	11	HSkMC: 2.9
SRPX	ETX1	ENSG00000101955	Sushi repeat containing protein, X-linked	X	38149336-38220924	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:7.80e-13 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable), Urothelial cancer:3.36e-4 (unfavourable)	Group enriched	Tissue enhanced		adipose tissue: 162.7	placenta: 122.1	Cell line enhanced		ASC diff: 2526.0;ASC TERT1: 571.9;HSkMC: 899.7;HUVEC TERT2: 659.1
SRPX2	SRPUL	ENSG00000102359	Sushi repeat containing protein, X-linked 2	X	100644166-100675788	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038786	Uncertain		Uncertain	Microtubules	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Mixed			adipose tissue: 18.8	Cell line enhanced		ASC diff: 191.6;ASC TERT1: 83.0;HSkMC: 77.9;HUVEC TERT2: 65.3
SSC4D	S4D-SRCRB, SRCRB-S4D, SRCRB4D	ENSG00000146700	Scavenger receptor cysteine rich family member with 4 domains	7	76389334-76409695	Predicted secreted proteins	Evidence at transcript level	HPA062611	Uncertain				Endometrial cancer:2.83e-6 (unfavourable), Renal cancer:4.71e-4 (unfavourable), Glioma:6.31e-4 (unfavourable)	Mixed	Group enriched	5	kidney: 1.4;parathyroid gland: 4.2;thyroid gland: 2.0	cervix, uterine: 0.5	Group enriched	12	EFO-21: 6.3;Hep G2: 6.5;U-2 OS: 27.2
SSC5D	FLJ35258, S5D-SRCRB	ENSG00000179954	Scavenger receptor cysteine rich family member with 5 domains	19	55488404-55519098	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042008	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.26e-8 (unfavourable)	Mixed	Mixed			smooth muscle: 32.1	Cell line enhanced		ASC TERT1: 22.1;BJ: 26.4;fHDF/TERT166: 24.8;U-87 MG: 32.1
SSPO	FLJ36112, KIAA0543, SCO-spondin	ENSG00000197558	SCO-spondin	7	149776042-149833979	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.4	Not detected		
SSR2	TLAP, TRAPB	ENSG00000163479	Signal sequence receptor subunit 2	1	156009048-156020959	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-7 (unfavourable), Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 551.1	Expressed in all		
SST	SMST	ENSG00000157005	Somatostatin	3	187668906-187670399	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000075, HPA019472, CAB034105	Enhanced	Supported			Endometrial cancer:1.93e-5 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 211.9;duodenum: 376.3;stomach: 305.7	small intestine: 142.4	Group enriched	5	EFO-21: 20.9;U-2 OS: 42.8
ST3GAL4	CGS23, FLJ11867, NANTA3, SAT3, SIAT4, SIAT4C, STZ	ENSG00000110080	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	11	126355640-126440344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049827	Approved					Expressed in all	Mixed			epididymis: 106.8	Expressed in all		
ST6GALNAC2	SIAT7, SIAT7B, SIATL1, ST6GalNAII, STHM	ENSG00000070731	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	17	76565379-76586956	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048849	Uncertain				Pancreatic cancer:6.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 68.6;skin: 50.8	testis: 38.9	Cell line enhanced		BEWO: 20.9;HaCaT: 23.9;hTCEpi: 48.8;MCF7: 20.9;SK-MEL-30: 70.3
ST6GALNAC5	MGC3184, SIAT7E, ST6GalNAcV	ENSG00000117069	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5	1	76867441-77065711	Predicted secreted proteins	Evidence at protein level	HPA065593, HPA070354	Uncertain		Approved	Vesicles		Tissue enhanced	Mixed			lung: 8.8	Cell line enhanced		AF22: 7.6;fHDF/TERT166: 7.3;SH-SY5Y: 7.0;U-2 OS: 7.8
ST8SIA2	HsT19690, SIAT8B, ST8SIA-II, STX	ENSG00000140557	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	15	92393828-92468728	Predicted secreted proteins	Evidence at protein level	HPA054518	Approved		Approved	Microtubule organizing center		Mixed	Tissue enhanced		cerebral cortex: 2.1;heart muscle: 2.4	cervix, uterine: 1.2	Cell line enhanced		AF22: 25.4;LHCN-M2: 6.4;RH-30: 11.3;RPMI-8226: 6.1;WM-115: 7.1
ST8SIA4	PST, PST1, SIAT8D	ENSG00000113532	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4	5	100806935-100903266	Predicted secreted proteins	Evidence at protein level	HPA051126, HPA053995	Approved		Approved	Golgi apparatus	Renal cancer:7.80e-7 (unfavourable)	Expressed in all	Mixed			appendix: 19.3	Cell line enhanced		AF22: 40.7;HDLM-2: 64.4;Karpas-707: 41.2;RPMI-8226: 30.6
ST8SIA6	SIAT8F	ENSG00000148488	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6	10	17318383-17454330	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011635, HPA072708	Uncertain		Uncertain	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		breast: 13.4;lung: 18.1	epididymis: 9.1	Cell line enriched	8	HMC-1: 442.5
STATH	STR	ENSG00000126549	Statherin	4	69995930-70002570	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA044569	Enhanced					Group enriched	Tissue enriched	1719	salivary gland: 44726.6	ovary: 26.0	Not detected		
STC1	STC	ENSG00000159167	Stanniocalcin 1	8	23841915-23854807	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018625, HPA023918	Approved				Renal cancer:1.23e-6 (unfavourable), Glioma:9.44e-5 (unfavourable), Lung cancer:1.53e-4 (unfavourable), Stomach cancer:5.55e-4 (unfavourable), Head and neck cancer:6.32e-4 (unfavourable), Cervical cancer:8.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 78.0	endometrium: 53.9	Cell line enhanced		BJ hTERT+: 280.7;hTEC/SVTERT24-B: 201.5;U-87 MG: 608.6
STC2	STC-2	ENSG00000113739	Stanniocalcin 2	5	173314713-173329503	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045372	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.17e-8 (unfavourable), Head and neck cancer:1.76e-6 (unfavourable), Liver cancer:3.07e-5 (unfavourable), Breast cancer:7.40e-5 (favourable), Stomach cancer:7.57e-4 (unfavourable)	Tissue enriched	Tissue enhanced		breast: 164.6	placenta: 33.2	Cell line enhanced		LHCN-M2: 707.5;T-47d: 753.9;U-138 MG: 321.3
STMND1	FLJ23152	ENSG00000230873	Stathmin domain containing 1	6	17102258-17131372	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA067970	Enhanced		Approved	Actin filaments		Group enriched	Tissue enhanced		fallopian tube: 33.7;testis: 12.3	gallbladder: 9.4	Group enriched	6	HEK 293: 2.6;SCLC-21H: 7.8;T-47d: 7.6
STRC	DFNB16	ENSG00000242866	Stereocilin	15	43599398-43618800	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048083	Enhanced					Not detected	Tissue enhanced		cerebral cortex: 1.4;epididymis: 1.6;testis: 1.7	skin: 0.8	Not detected		
STXBP2	Hunc18b, UNC18B	ENSG00000076944	Syntaxin binding protein 2	19	7636881-7647873	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015564, HPA063868	Approved		Enhanced	Cytosol	Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable)	Expressed in all	Mixed			bone marrow: 125.3	Mixed		
SULF1	hSulf-1, KIAA1077, SULF-1	ENSG00000137573	Sulfatase 1	8	69466624-69660915	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054728	Supported				Renal cancer:1.06e-7 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 105.4	prostate: 85.8	Cell line enhanced		BJ: 265.6;BJ hTERT+: 341.5;fHDF/TERT166: 405.6;WM-115: 176.0
SULF2	HSULF-2, KIAA1247, SULF-2	ENSG00000196562	Sulfatase 2	20	47656348-47786616	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002325	Approved				Cervical cancer:6.43e-5 (unfavourable), Renal cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 166.9	Cell line enhanced		EFO-21: 318.0;hTCEpi: 589.4;MCF7: 529.8
SUMF1	FGE, UNQ3037	ENSG00000144455	Sulfatase modifying factor 1	3	3700814-4467281	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA038025	Uncertain				Renal cancer:4.79e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
SUMF2	DKFZp566I1024	ENSG00000129103	Sulfatase modifying factor 2	7	56064002-56080670	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024040, CAB025743, HPA074892	Enhanced		Uncertain	Vesicles<br>Plasma membrane	Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 160.7	Expressed in all		
SUSD1	DKFZP761E1824	ENSG00000106868	Sushi domain containing 1	9	112040785-112175408	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048554	Approved		Approved	Nucleoplasm	Renal cancer:3.63e-6 (favourable)	Expressed in all	Mixed			placenta: 21.5	Cell line enhanced		HEL: 50.2
SUSD5	KIAA0527	ENSG00000173705	Sushi domain containing 5	3	33150042-33219215	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052788	Uncertain		Uncertain	Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 11.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 26.7;HUVEC TERT2: 60.2;LHCN-M2: 23.3;TIME: 23.4
SVEP1	bA427L11.3, C9orf13, FLJ13529, POLYDOM	ENSG00000165124	Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1	9	110365251-110579880	Predicted secreted proteins	Evidence at protein level	HPA020610, HPA021520	Uncertain				Stomach cancer:8.33e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 87.2	adipose tissue: 36.7	Cell line enhanced		ASC diff: 101.0;ASC TERT1: 59.3;BJ hTERT+: 50.6;HHSteC: 45.2;HSkMC: 48.5
SYCN	FLJ27441, INSSA1, SYL	ENSG00000179751	Syncollin	19	39202831-39204266	Predicted secreted proteins	Evidence at protein level	HPA047654	Enhanced					Tissue enriched	Tissue enriched	401	pancreas: 6057.1	ovary: 15.0	Not detected		
TAC1	NKNA, NPK, TAC2	ENSG00000006128	Tachykinin precursor 1	7	97731908-97740472	Predicted secreted proteins	Evidence at protein level	CAB004588, HPA014429	Approved					Mixed	Tissue enhanced		cerebral cortex: 77.7;spleen: 47.0	appendix: 13.2	Cell line enriched	14	U-266/70: 16.5
TAC3	NKB, NKNB, ZNEUROK1	ENSG00000166863	Tachykinin 3	12	57010000-57028883	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045919	Supported	Approved	Approved	Vesicles		Tissue enriched	Tissue enriched	23	placenta: 617.0	cerebral cortex: 27.2	Cell line enhanced		K-562: 13.1;SCLC-21H: 2.7
TAC4	HK-1, PPT-C, Pptc	ENSG00000176358	Tachykinin 4 (hemokinin)	17	49838309-49848017	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 2.0	liver: 1.0	Cell line enhanced		A549: 2.3;BEWO: 5.7;CACO-2: 2.9
TAPBP	TAPA	ENSG00000231925	TAP binding protein	6	33299694-33314387	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007066	Approved				Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.7	Cell line enhanced		CAPAN-2: 67.6
TAPBPL	FLJ10143, TAPBP-R, TAPBPR	ENSG00000139192	TAP binding protein like	12	6451690-6466517	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039545	Uncertain				Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.2	Cell line enhanced		CAPAN-2: 58.5
TBCA		ENSG00000171530	Tubulin folding cofactor A	5	77691166-77868780	Predicted intracellular proteins	Evidence at protein level	HPA036487	Approved		Supported	Nucleoli<br>Microtubules		Expressed in all	Expressed in all			adrenal gland: 305.8	Expressed in all		
TBL2	DKFZP43N024, WBSCR13, WS-betaTRP	ENSG00000106638	Transducin beta like 2	7	73568932-73578791	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007477, HPA051533			Supported	Cytosol	Renal cancer:1.88e-5 (unfavourable), Head and neck cancer:4.93e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 83.8	parathyroid gland: 13.0	Expressed in all		
TCF12	bHLHb20, HEB, HsT17266, HTF4	ENSG00000140262	Transcription factor 12	15	56918623-57299281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB004432, HPA065827	Approved		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:5.24e-5 (unfavourable), Melanoma:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 116.2	Expressed in all		
TCN1	TC1, TCI	ENSG00000134827	Transcobalamin 1	11	59852800-59866575	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.56e-8 (unfavourable), Breast cancer:1.90e-4 (favourable)	Tissue enhanced	Tissue enhanced		bone marrow: 123.8;gallbladder: 254.4;salivary gland: 315.5	stomach: 75.5	Cell line enhanced		CAPAN-2: 4.7;HaCaT: 4.6;PC-3: 6.4;SiHa: 7.7
TCN2	D22S676, D22S750, TC2	ENSG00000185339	Transcobalamin 2	22	30606838-30627278	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000837			Approved	Cytosol	Liver cancer:2.64e-4 (unfavourable), Cervical cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			kidney: 122.6	Cell line enhanced		ASC TERT1: 84.6;HUVEC TERT2: 123.3;Karpas-707: 137.2
TCTN1	FLJ21127, JBTS13, TECT1	ENSG00000204852	Tectonic family member 1	12	110614027-110649430	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039687, HPA040036	Approved		Approved	Nucleoplasm<br>Actin filaments	Endometrial cancer:1.13e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 42.2	Mixed		
TCTN3	C10orf61, DKFZP564D116, JBTS18, TECT3	ENSG00000119977	Tectonic family member 3	10	95663396-95694143	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026987	Approved		Approved	Microtubules	Endometrial cancer:5.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
TDP2	TTRAP	ENSG00000111802	Tyrosyl-DNA phosphodiesterase 2	6	24649977-24667033	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB073398, HPA074011	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Ovarian cancer:2.53e-7 (favourable), Urothelial cancer:1.47e-5 (favourable), Prostate cancer:1.86e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 189.4	Expressed in all		
TEK	CD202b, TIE-2, TIE2, VMCM, VMCM1	ENSG00000120156	TEK receptor tyrosine kinase	9	27109141-27230175	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010359, HPA073265	Approved		Supported	Plasma membrane<br>Microtubule organizing center	Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 65.9	lung: 42.6	Group enriched	8	HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TEPP		ENSG00000159648	Testis, prostate and placenta expressed	16	57976435-57988116	Predicted secreted proteins	Evidence at protein level	HPA062092	Enhanced					Tissue enhanced	Tissue enriched	9	testis: 7.3	thyroid gland: 0.8	Not detected		
TEX101	CT131, MGC4766, SGRG, SPATA44	ENSG00000131126	Testis expressed 101	19	43401496-43418597	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041915, HPA042513	Enhanced					Mixed	Tissue enriched	108	testis: 173.9	skin: 1.6	Not detected		
TEX2	HT008, KIAA1738, TMEM96	ENSG00000136478	Testis expressed 2	17	64147227-64263301	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020648, HPA057116	Approved		Approved	Nucleus	Colorectal cancer:3.90e-6 (favourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
TF	PRO1557, PRO2086	ENSG00000091513	Transferrin	3	133745956-133779006	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001527, HPA005692, CAB009538	Enhanced		Uncertain	Mitochondria	Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable)	Tissue enriched	Tissue enriched	14	liver: 5391.9	cerebral cortex: 385.9	Cell line enriched	50	Hep G2: 842.8
TFAM	TCF6, TCF6L2	ENSG00000108064	Transcription factor A, mitochondrial	10	58385022-58399221	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA040648, HPA063684	Supported		Enhanced	Mitochondria	Renal cancer:2.22e-5 (favourable), Ovarian cancer:2.74e-4 (favourable), Endometrial cancer:8.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 62.3	Expressed in all		
TFF1	BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2	ENSG00000160182	Trefoil factor 1	21	42362282-42366594	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002170, HPA003425	Enhanced				Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable)	Group enriched	Tissue enriched	32	stomach: 6419.9	gallbladder: 203.1	Cell line enriched	49	MCF7: 8447.1
TFF2	SML1	ENSG00000160181	Trefoil factor 2	21	42346357-42351128	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB025834, HPA036705	Enhanced				Liver cancer:1.99e-4 (unfavourable)	Group enriched	Group enriched	29	duodenum: 1027.1;stomach: 5110.7	gallbladder: 107.1	Group enriched	20	CAPAN-2: 32.8;PC-3: 124.0
TFF3	HITF, ITF	ENSG00000160180	Trefoil factor 3	21	42311667-42315651	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020681, HPA035464	Enhanced		Approved	Nucleus<br>Nucleoli	Endometrial cancer:5.60e-6 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1	small intestine: 457.0	Cell line enhanced		MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5
TFPI	EPI, LACI, TFI, TFPI1	ENSG00000003436	Tissue factor pathway inhibitor	2	187464230-187565760	Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA005575, CAB020842	Supported		Approved	Intermediate filaments<br>Cytosol	Cervical cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 267.0	Cell line enhanced		HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9
TFPI2	PP5, REF1, TFPI-2	ENSG00000105825	Tissue factor pathway inhibitor 2	7	93885397-93890991	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010142, HPA049158	Enhanced				Breast cancer:8.33e-7 (favourable), Endometrial cancer:5.42e-4 (favourable), Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Tissue enriched	23	placenta: 1208.2	ovary: 52.0	Cell line enhanced		EFO-21: 1987.5;hTEC/SVTERT24-B: 1055.6;U-138 MG: 999.0;U-2197: 850.7;U-87 MG: 1680.0
TG	AITD3, TGN	ENSG00000042832	Thyroglobulin	8	132866958-133134903	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000077, HPA002740, CAB056155	Enhanced					Tissue enriched	Tissue enriched	1104	thyroid gland: 15620.0	gallbladder: 14.1	Cell line enhanced		HDLM-2: 1.9;Karpas-707: 4.0;PC-3: 2.6
TGFB1	CED, DPD1, TGFB, TGFbeta	ENSG00000105329	Transforming growth factor beta 1	19	41301587-41353911	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000361, CAB073543	Approved		Uncertain	Cytosol	Renal cancer:1.19e-8 (unfavourable), Head and neck cancer:3.38e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 83.5	Mixed		
TGFB2		ENSG00000092969	Transforming growth factor beta 2	1	218346235-218444619	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		prostate: 30.4	placenta: 20.4	Cell line enhanced		EFO-21: 58.6;U-2 OS: 64.1
TGFB3	ARVD, ARVD1	ENSG00000119699	Transforming growth factor beta 3	14	75958099-75982991	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA063582			Approved	Vesicles	Renal cancer:4.01e-7 (unfavourable)	Expressed in all	Mixed			placenta: 84.9	Group enriched	5	SCLC-21H: 28.0;SK-BR-3: 99.2;T-47d: 87.5
TGFBI	BIGH3, CDB1, CDGG1, CSD1, CSD2, CSD3, LCD1	ENSG00000120708	Transforming growth factor beta induced	5	136028895-136063818	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008612, HPA017019	Enhanced				Renal cancer:7.82e-10 (unfavourable), Cervical cancer:1.03e-5 (unfavourable), Ovarian cancer:1.14e-5 (unfavourable), Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			placenta: 607.8	Cell line enhanced		fHDF/TERT166: 2100.5;HSkMC: 1955.4;U-87 MG: 3543.6
TGFBR1	ACVRLK4, ALK-5, ALK5, ESS1, MSSE	ENSG00000106799	Transforming growth factor beta receptor 1	9	99104038-99154192	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002441, CAB031481, HPA056473	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 69.8	Expressed in all		
TGFBR3	betaglycan, BGCAN	ENSG00000069702	Transforming growth factor beta receptor 3	1	91680343-91906335	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008257, CAB018971	Supported		Uncertain	Cytosol	Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			ovary: 99.9	Cell line enhanced		ASC diff: 152.4;ASC TERT1: 75.3;U-2197: 71.9
THBS1	THBS, THBS-1, TSP, TSP-1, TSP1	ENSG00000137801	Thrombospondin 1	15	39581079-39599466	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB033678, HPA059756	Approved		Approved	Plasma membrane	Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 573.9	Cell line enhanced		fHDF/TERT166: 2033.2;HUVEC TERT2: 2095.4;TIME: 3015.4
THBS2	TSP2	ENSG00000186340	Thrombospondin 2	6	169215780-169254044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017716, HPA044304	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:3.77e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 113.4	endometrium: 71.2	Cell line enhanced		ASC diff: 282.6;ASC TERT1: 196.5;BJ hTERT+ SV40 Large T+ RasG12V: 134.9;hTEC/SVTERT24-B: 150.4
THBS3		ENSG00000169231	Thrombospondin 3	1	155195588-155209051	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006293, HPA073242	Approved		Approved	Vesicles	Renal cancer:2.38e-12 (unfavourable), Endometrial cancer:1.44e-4 (unfavourable), Colorectal cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.6	Cell line enhanced		SCLC-21H: 49.1
THBS4		ENSG00000113296	Thrombospondin 4	5	79991311-80083287	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004597, HPA042426	Approved		Approved	Vesicles	Urothelial cancer:3.33e-4 (unfavourable)	Expressed in all	Group enriched	6	adipose tissue: 234.3;heart muscle: 113.6;smooth muscle: 388.9	thyroid gland: 44.6	Cell line enhanced		AF22: 3.1;SCLC-21H: 2.9;THP-1: 4.7;U-2 OS: 3.0
THOC3	MGC5469, TEX1	ENSG00000051596	THO complex 3	5	175917873-176034680	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042764, HPA044009, HPA045071	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			epididymis: 77.2	Expressed in all		
THPO	MGDF, MPLLG, TPO	ENSG00000090534	Thrombopoietin	3	184371935-184378144	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.48e-6 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 8.9	testis: 3.9	Cell line enhanced		CACO-2: 4.9;Hep G2: 10.6;K-562: 2.5;RPMI-8226: 2.8
THSD4	ADAMTSL6, FLJ13710, FVSY9334, PRO34005	ENSG00000187720	Thrombospondin type 1 domain containing 4	15	71096952-71783383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026845			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 160.5	fallopian tube: 59.6	Cell line enhanced		BJ hTERT+: 43.1;TIME: 54.2
THY1	CD90	ENSG00000154096	Thy-1 cell surface antigen	11	119417378-119424985	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003733, CAB068243, CAB068244	Enhanced		Approved	Nucleus<br>Plasma membrane	Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 421.8;smooth muscle: 434.2	gallbladder: 161.0	Cell line enhanced		BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
TIE1	JTK14, TIE	ENSG00000066056	Tyrosine kinase with immunoglobulin like and EGF like domains 1	1	43300993-43323108	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		placenta: 70.6	lung: 40.1	Cell line enhanced		EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
TIMMDC1	C3orf1, FLJ22597	ENSG00000113845	Translocase of inner mitochondrial membrane domain containing 1	3	119498532-119525090	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053214, HPA055846	Uncertain		Enhanced	Nucleus<br>Mitochondria	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
TIMP1	CLGI, EPO, TIMP	ENSG00000102265	TIMP metallopeptidase inhibitor 1	X	47582313-47586789	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022360, HPA053417	Approved		Approved	Golgi apparatus	Renal cancer:2.90e-11 (unfavourable), Colorectal cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 2036.7	Expressed in all		
TIMP2	CSC-21K	ENSG00000035862	TIMP metallopeptidase inhibitor 2	17	78852977-78925387	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010203	Approved					Expressed in all	Expressed in all			ovary: 1178.9	Cell line enhanced		ASC TERT1: 1134.2
TIMP3	SFD	ENSG00000100234	TIMP metallopeptidase inhibitor 3	22	32801701-32863043	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level						Ovarian cancer:1.90e-5 (unfavourable), Renal cancer:1.50e-4 (favourable)	Mixed	Tissue enhanced		placenta: 1439.9	adipose tissue: 729.9	Cell line enhanced		BJ: 988.6;fHDF/TERT166: 830.6;WM-115: 879.2
TIMP4		ENSG00000157150	TIMP metallopeptidase inhibitor 4	3	12153051-12159351	Plasma proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	5	adipose tissue: 138.8	cerebral cortex: 27.5	Cell line enhanced		ASC diff: 99.5;HSkMC: 45.7;NTERA-2: 37.0;U-87 MG: 36.7
TINAGL1	ARG1, LCN7, LIECG3, P3ECSL, TINAGRP	ENSG00000142910	Tubulointerstitial nephritis antigen like 1	1	31576485-31587686	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048695	Approved				Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 268.9	adipose tissue: 102.6	Cell line enhanced		BEWO: 313.9;EFO-21: 383.9;TIME: 309.9
TLL2		ENSG00000095587	Tolloid like 2	10	96364606-96513918	Enzymes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 1.9	heart muscle: 1.0	Cell line enriched	8	RPTEC TERT1: 15.3
TLR1	CD281, KIAA0012, rsc786	ENSG00000174125	Toll like receptor 1	4	38790677-38856817	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			appendix: 37.2	Cell line enhanced		Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4
TLR3	CD283	ENSG00000164342	Toll like receptor 3	4	186069152-186088069	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025658	Enhanced				Pancreatic cancer:3.09e-4 (unfavourable)	Mixed	Mixed			placenta: 24.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.4;CAPAN-2: 42.4
TM2D3	BLP2, FLJ22604	ENSG00000184277	TM2 domain containing 3	15	101621444-101652391	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054064	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 97.2	Expressed in all		
TM7SF3		ENSG00000064115	Transmembrane 7 superfamily member 3	12	26973195-27014434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057640			Supported	Nucleus<br>Cytosol	Renal cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 190.9	Expressed in all		
TM9SF1	HMP70, MP70	ENSG00000100926	Transmembrane 9 superfamily member 1	14	24189143-24195687	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059249	Supported		Approved	Golgi apparatus	Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
TMED1	Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L	ENSG00000099203	Transmembrane p24 trafficking protein 1	19	10832438-10836318	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018507	Uncertain				Renal cancer:8.66e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.6	Expressed in all		
TMED2	P24A, p24b1, p24beta1, RNP24	ENSG00000086598	Transmembrane p24 trafficking protein 2	12	123584531-123598577	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA014060	Approved		Supported	Vesicles	Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 328.1	Expressed in all		
TMED3	C15orf22, p24B, p24g4, p24gamma4	ENSG00000166557	Transmembrane p24 trafficking protein 3	15	79311062-79427432	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049314, HPA076949	Approved		Supported	Golgi apparatus	Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 163.2	Mixed		
TMED4	HNLF, p24a3, p24alpha3	ENSG00000158604	Transmembrane p24 trafficking protein 4	7	44577894-44582287	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 190.7	Expressed in all		
TMED5	CGI-100, p24g2, p24gamma2	ENSG00000117500	Transmembrane p24 trafficking protein 5	1	93149742-93180728	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050289	Approved					Expressed in all	Expressed in all			kidney: 28.2	Expressed in all		
TMED7	CGI-109, FLJ90481, p24g3, p24gamma3	ENSG00000134970	Transmembrane p24 trafficking protein 7	5	115613508-115632992	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008960, CAB025883	Supported					Expressed in all	Expressed in all			thyroid gland: 138.8	Expressed in all		
TMED7-TICAM2		ENSG00000251201	TMED7-TICAM2 readthrough	5	115578642-115626161	Predicted secreted proteins	Evidence at protein level	HPA008960	Uncertain					Not detected	Mixed			placenta: 4.7	Mixed		
TMEM108	CT124, MGC3040	ENSG00000144868	Transmembrane protein 108	3	133038391-133397792	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063350	Uncertain		Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 25.8	adrenal gland: 15.0	Cell line enhanced		HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
TMEM119		ENSG00000183160	Transmembrane protein 119	12	108589846-108598320	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051870, HPA052650	Enhanced				Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 93.0	gallbladder: 55.2	Cell line enhanced		ASC diff: 378.8;ASC TERT1: 106.4;BJ hTERT+: 134.8;HSkMC: 171.1
TMEM155	FLJ30834	ENSG00000164112	Transmembrane protein 155	4	121758933-121765427	Predicted secreted proteins	Evidence at transcript level	HPA077585	Approved					Mixed	Group enriched	6	cerebral cortex: 27.6;placenta: 5.7	lymph node: 3.0	Cell line enhanced		fHDF/TERT166: 4.0;HAP1: 2.2;LHCN-M2: 5.5;MOLT-4: 5.1
TMEM205	MBC3205, UNQ501	ENSG00000105518	Transmembrane protein 205	19	11342776-11346518	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA041504	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 258.0	Expressed in all		
TMEM213		ENSG00000214128	Transmembrane protein 213	7	138797952-138838101	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054059	Enhanced				Renal cancer:5.54e-7 (favourable)	Tissue enriched	Group enriched	9	kidney: 80.7;salivary gland: 22.6	breast: 5.7	Not detected		
TMEM25	FLJ14399	ENSG00000149582	Transmembrane protein 25	11	118531041-118547280	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012163, HPA051562	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			duodenum: 47.0	Cell line enhanced		T-47d: 41.7
TMEM52		ENSG00000178821	Transmembrane protein 52	1	1917590-1919273	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 38.8;skeletal muscle: 105.7	adrenal gland: 24.4	Cell line enhanced		Hep G2: 13.9;RPMI-8226: 25.7
TMEM52B	C12orf59, FLJ31166	ENSG00000165685	Transmembrane protein 52B	12	10170542-10191801	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058096	Enhanced		Approved	Focal adhesion sites		Tissue enriched	Tissue enriched	21	kidney: 183.5	placenta: 8.6	Cell line enriched	8	CACO-2: 79.4
TMEM59	C1orf8, HSPC001	ENSG00000116209	Transmembrane protein 59	1	54026681-54053504	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 650.0	Expressed in all		
TMEM67	JBTS6, MGC26979, MKS3, NPHP11	ENSG00000164953	Transmembrane protein 67	8	93754844-93819234	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:7.62e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.5	testis: 12.5	Mixed		
TMEM87A	DKFZP564G2022	ENSG00000103978	Transmembrane protein 87A	15	42210452-42273663	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018104, HPA018189	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			prostate: 124.3	Expressed in all		
TMEM94	KIAA0195	ENSG00000177728	Transmembrane protein 94	17	75441159-75500090	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008423, HPA050660	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.2	Expressed in all		
TMEM95	MGC129793, UNQ9390	ENSG00000182896	Transmembrane protein 95	17	7355123-7357219	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	48	testis: 9.9	gallbladder: 0.2	Not detected		
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946			Approved	Mitochondria		Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected		
TMPRSS12	CT151, MGC57341	ENSG00000186452	Transmembrane protease, serine 12	12	50842920-50887884	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	75	testis: 39.5	epididymis: 0.5	Not detected		
TMUB1	C7orf21, SB144	ENSG00000164897	Transmembrane and ubiquitin like domain containing 1	7	151081080-151083546	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029429	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 52.2	Expressed in all		
TMX3	FLJ20793, KIAA1830, PDIA13, TXNDC10	ENSG00000166479	Thioredoxin related transmembrane protein 3	18	68673688-68715298	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014157	Uncertain				Renal cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.4	Expressed in all		
TNC	DFNA56, HXB, MGC167029, TN	ENSG00000041982	Tenascin C	9	115019578-115118257	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004592, HPA004823	Approved					Expressed in all	Tissue enhanced		appendix: 239.3;smooth muscle: 528.9	adipose tissue: 78.7	Cell line enhanced		BJ hTERT+: 628.6;hTEC/SVTERT24-B: 625.8;U-87 MG: 679.1;WM-115: 1198.9
TNFAIP6	TSG-6, TSG6	ENSG00000123610	TNF alpha induced protein 6	2	151357592-151380048	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB032719, HPA050884	Approved				Cervical cancer:8.18e-5 (unfavourable), Urothelial cancer:9.16e-5 (unfavourable), Renal cancer:5.59e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 38.7;gallbladder: 31.8	adipose tissue: 18.7	Cell line enhanced		BJ hTERT+: 54.6;HHSteC: 33.8;hTEC/SVTERT24-B: 54.8;U-2197: 41.1
TNFRSF11A	CD265, FEO, LOH18CR1, PDB2, RANK	ENSG00000141655	TNF receptor superfamily member 11a	18	62325287-62391292	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010391, HPA027728, HPA047976	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 30.6	small intestine: 20.5	Cell line enhanced		HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
TNFRSF11B	OCIF, OPG, TR1	ENSG00000164761	TNF receptor superfamily member 11b	8	118923557-118952200	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB034939	Approved				Urothelial cancer:3.88e-4 (unfavourable), Cervical cancer:6.22e-4 (unfavourable), Renal cancer:6.79e-4 (favourable)	Expressed in all	Tissue enriched	5	thyroid gland: 140.4	kidney: 25.7	Cell line enhanced		BJ: 369.9;BJ hTERT+: 1312.6;fHDF/TERT166: 188.6
TNFRSF12A	CD266, FN14, TweakR	ENSG00000006327	TNF receptor superfamily member 12A	16	3018445-3022383	Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007853	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 199.0	Mixed		
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
TNFRSF18	AITR, CD357, GITR	ENSG00000186891	TNF receptor superfamily member 18	1	1203508-1206691	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008025	Approved				Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 43.3	parathyroid gland: 18.0	Group enriched	11	RPMI-8226: 148.8;SCLC-21H: 173.4
TNFRSF1A	CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60	ENSG00000067182	TNF receptor superfamily member 1A	12	6328757-6342114	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004102, CAB010309	Approved				Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 141.2	Mixed		
TNFRSF1B	CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80	ENSG00000028137	TNF receptor superfamily member 1B	1	12167003-12209228	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004796	Approved				Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 100.4	spleen: 77.8	Cell line enhanced		CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0
TNFRSF25	APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR	ENSG00000215788	TNF receptor superfamily member 25	1	6461151-6466195	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069834			Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 29.6	spleen: 12.1	Cell line enhanced		HDLM-2: 24.6;RPMI-8226: 17.9
TNFRSF6B	DcR3, M68, TR6	ENSG00000243509	TNF receptor superfamily member 6b	20	63696668-63698684	Predicted secreted proteins	Evidence at protein level	HPA047154	Uncertain					Not detected	Tissue enriched	6	appendix: 19.0	tonsil: 3.1	Cell line enhanced		HBEC3-KT: 20.3;RPTEC TERT1: 82.5;TIME: 57.1
TNFSF15	MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A	ENSG00000181634	Tumor necrosis factor superfamily member 15	9	114784635-114806126	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012948, HPA046522	Approved		Approved	Nucleus<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			duodenum: 9.5	Cell line enhanced		HaCaT: 11.6;hTEC/SVTERT24-B: 8.5;HUVEC TERT2: 13.6;RT4: 12.9;TIME: 6.2
TNN		ENSG00000120332	Tenascin N	1	175067858-175148066	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010907, HPA026726, HPA026764	Uncertain					Tissue enhanced	Tissue enhanced		adipose tissue: 12.4	breast: 4.1	Group enriched	11	AF22: 5.6;NB-4: 2.3;THP-1: 7.4;U-266/70: 2.1;U-937: 1.6
TNR		ENSG00000116147	Tenascin R	1	175315194-175743770	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022343, HPA027134, HPA027150, HPA029859	Enhanced					Tissue enriched	Tissue enriched	38	cerebral cortex: 70.6	adrenal gland: 1.8	Cell line enhanced		SH-SY5Y: 1.9;U-937: 1.1
TNXB	TNXB1, TNXB2, TNXBS, XB, XBS	ENSG00000168477	Tenascin XB	6	32041154-32115334	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 91.6	endometrium: 18.6	Cell line enhanced		ASC diff: 8.6;ASC TERT1: 14.3;U-2197: 15.6;U-87 MG: 8.2
TOMM7	Tom7	ENSG00000196683	Translocase of outer mitochondrial membrane 7	7	22812628-22822852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:6.30e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 677.6	Expressed in all		
TOR1A	DQ2, DYT1	ENSG00000136827	Torsin family 1 member A	9	129812944-129824134	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB012473, HPA051195	Approved		Supported	Nuclear membrane<br>Vesicles	Lung cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
TOR1B	DQ1, MGC4386	ENSG00000136816	Torsin family 1 member B	9	129803153-129811281	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013403, HPA013697, CAB022709	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			rectum: 24.4	Expressed in all		
TOR2A	FLJ14771, TORP1	ENSG00000160404	Torsin family 2 member A	9	127731524-127735317	Predicted secreted proteins	Evidence at protein level	HPA071229	Approved				Stomach cancer:7.51e-4 (favourable)	Expressed in all	Mixed			bone marrow: 16.5	Expressed in all		
TOR3A	ADIR, ADIR2, FLJ22345	ENSG00000186283	Torsin family 3 member A	1	179081377-179098023	Predicted secreted proteins	Evidence at protein level	HPA028766	Approved				Renal cancer:4.78e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 39.6	Expressed in all		
TPO	TPX	ENSG00000115705	Thyroid peroxidase	2	1374223-1543711	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007987, CAB009587	Enhanced					Tissue enriched	Tissue enriched	103	thyroid gland: 1817.4	spleen: 17.6	Cell line enhanced		Karpas-707: 6.9;RPMI-8226: 2.9
TPP1	CLN2, SCAR7	ENSG00000166340	Tripeptidyl peptidase 1	11	6612763-6619461	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037709, HPA044868	Enhanced				Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 206.9	Expressed in all		
TPSAB1	TPS1, TPS2, TPSB1	ENSG00000172236	Tryptase alpha/beta 1	16	1240696-1242554	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016369, CAB022175, HPA049153, HPA049554	Supported				Head and neck cancer:9.62e-6 (favourable)	Mixed	Tissue enhanced		gallbladder: 211.6	lung: 158.5	Cell line enriched	163	HMC-1: 3406.5
TPSB2		ENSG00000197253	Tryptase beta 2 (gene/pseudogene)	16	1227272-1230184	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA049153, HPA049554	Supported					Mixed	Tissue enhanced		gallbladder: 156.9	lung: 117.5	Cell line enriched	7	HMC-1: 262.0
TPSD1		ENSG00000095917	Tryptase delta 1	16	1256059-1258998	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB002215, CAB032871, HPA040182, HPA049554	Supported		Uncertain	Nuclear speckles		Mixed	Tissue enhanced		lung: 26.9	gallbladder: 20.3	Group enriched	46	HEL: 25.4;HMC-1: 36.4
TPST2	TANGO13B	ENSG00000128294	Tyrosylprotein sulfotransferase 2	22	26521983-26596717	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021054	Approved				Renal cancer:2.34e-6 (unfavourable), Endometrial cancer:8.08e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 135.8	Expressed in all		
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved					Group enriched	Tissue enhanced		colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced		BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3
TRABD2B	TIKI2	ENSG00000269113	TraB domain containing 2B	1	47760528-47996895	Predicted secreted proteins	Evidence at protein level	HPA045817	Approved					Tissue enriched	Tissue enhanced		kidney: 7.7	seminal vesicle: 4.8	Group enriched	5	HeLa: 4.4;U-2197: 12.9
TREH	MGC129621, TRE, TREA	ENSG00000118094	Trehalase	11	118657316-118679690	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA039913, HPA042045	Enhanced				Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 60.6;small intestine: 72.6	kidney: 13.5	Cell line enhanced		BEWO: 1.5
TREM1	CD354, TREM-1	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	6	41267926-41286719	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005563	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 67.7;bone marrow: 63.0;lung: 103.1	adipose tissue: 26.9	Cell line enriched	11	U-87 MG: 24.5
TREM2	TREM-2, Trem2a, Trem2b, Trem2c	ENSG00000095970	Triggering receptor expressed on myeloid cells 2	6	41158506-41163186	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010917, HPA012571	Approved				Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.0;lung: 40.5	adrenal gland: 16.1	Cell line enhanced		HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
TRH		ENSG00000170893	Thyrotropin releasing hormone	3	129974305-129977938	Predicted secreted proteins	Evidence at protein level	HPA035596	Enhanced					Tissue enhanced	Group enriched	9	cervix, uterine: 32.1;endometrium: 27.4	fallopian tube: 3.4	Not detected		
TRIO	ARHGEF23	ENSG00000038382	Trio Rho guanine nucleotide exchange factor	5	14143702-14532128	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008157, HPA064664	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 47.2	Cell line enhanced		hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3
TSHB		ENSG00000134200	Thyroid stimulating hormone beta	1	115029824-115034309	Predicted secreted proteins	Evidence at protein level	CAB022202, HPA042681	Supported					Not detected	Not detected			gallbladder: 0.5	Not detected		
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TSKU	E2IG4, LRRC54, TSK	ENSG00000182704	Tsukushi, small leucine rich proteoglycan	11	76782251-76798154	Predicted secreted proteins	Evidence at protein level	HPA008164	Approved		Approved	Nucleus<br>Nuclear bodies	Renal cancer:2.80e-8 (unfavourable), Prostate cancer:1.66e-4 (favourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:3.66e-4 (favourable)	Expressed in all	Expressed in all			liver: 114.4	Cell line enhanced		A549: 150.8;ASC diff: 186.5
TSPAN31	SAS	ENSG00000135452	Tetraspanin 31	12	57738013-57750211	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057489	Approved				Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.5	Expressed in all		
TSPAN6	T245, TM4SF6, TSPAN-6	ENSG00000000003	Tetraspanin 6	X	100627109-100639991	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004109	Approved		Approved	Cytosol		Expressed in all	Mixed			fallopian tube: 102.1	Cell line enhanced		NTERA-2: 165.6;RT4: 203.5
TSPEAR	C21orf29, DFNB98, MGC11251, TSP-EAR	ENSG00000175894	Thrombospondin type laminin G domain and EAR repeats	21	44497892-44711580	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034203, CAB034204, HPA052995	Approved					Mixed	Tissue enhanced		parathyroid gland: 2.7;testis: 2.6	spleen: 1.9	Cell line enhanced		Karpas-707: 8.0;RPMI-8226: 4.6;SH-SY5Y: 4.0;U-266/70: 4.9;U-266/84: 5.1
TTC13	FLJ22584	ENSG00000143643	Tetratricopeptide repeat domain 13	1	230906243-230978875	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018022, HPA051558	Uncertain		Approved	Nucleoplasm	Renal cancer:1.60e-11 (unfavourable), Pancreatic cancer:4.59e-5 (favourable), Head and neck cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
TTC39C	C18orf17, FLJ33761, HsT2697	ENSG00000168234	Tetratricopeptide repeat domain 39C	18	23992773-24135610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065705, HPA065713	Approved		Approved	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			liver: 47.8	Mixed		
TTR	CTS, CTS1, HsT2651, PALB	ENSG00000118271	Transthyretin	18	31591726-31599021	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002517, HPA002550, CAB062567, CAB073406	Supported		Approved	Golgi apparatus		Group enriched	Tissue enriched	27	liver: 6343.2	pancreas: 235.0	Group enriched	7	CACO-2: 68.3;EFO-21: 26.5;Hep G2: 87.1;U-2 OS: 38.2
TWSG1	TSG	ENSG00000128791	Twisted gastrulation BMP signaling modulator 1	18	9334767-9402420	Predicted secreted proteins	Evidence at protein level	HPA014898	Uncertain		Supported	Centrosome<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 116.3	Expressed in all		
TXNDC12	AGR1, ERP18, ERP19, hAG-1, PDIA16, TLP19	ENSG00000117862	Thioredoxin domain containing 12	1	52020131-52056171	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.40e-12 (unfavourable), Liver cancer:1.28e-5 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable), Colorectal cancer:4.44e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 49.8	Expressed in all		
TXNDC15	2310047H23Rik, C5orf14, FLJ22625	ENSG00000113621	Thioredoxin domain containing 15	5	134873803-134901525	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015483	Approved		Approved	Golgi apparatus	Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 85.3	Expressed in all		
TXNDC5	EndoPDI, ERp46, FLJ21353, FLJ90810, Hcc-2, MGC3178, PDIA15	ENSG00000239264	Thioredoxin domain containing 5	6	7881517-7910814	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034677, HPA034678	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			urinary bladder: 312.7	Expressed in all		
TYRP1	b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP	ENSG00000107165	Tyrosinase related protein 1	9	12685439-12710290	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000937, CAB002520	Enhanced		Supported	Vesicles		Tissue enriched	Group enriched	6	heart muscle: 40.2;skin: 169.1	kidney: 17.0	Cell line enriched	51	SK-MEL-30: 1084.9
UBR3	DKFZp434P117, FLJ37422, KIAA2024, ZNF650	ENSG00000144357	Ubiquitin protein ligase E3 component n-recognin 3 (putative)	2	169827458-170084131	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035390	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
UBXN8	D8S2298E, REP8, UBXD6	ENSG00000104691	UBX domain protein 8	8	30732247-30767006	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017725, HPA077538	Approved		Supported	Nucleoplasm<br>Nucleoli<br>Endoplasmic reticulum	Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.4	Expressed in all		
UCMA	C10orf49	ENSG00000165623	Upper zone of growth plate and cartilage matrix associated	10	13221767-13234334	Predicted secreted proteins	Evidence at transcript level	HPA046718	Uncertain					Tissue enhanced	Tissue enhanced		ovary: 1.4	heart muscle: 0.4	Not detected		
UCN	UI, UROC	ENSG00000163794	Urocortin	2	27307400-27308445	Predicted secreted proteins	Evidence at protein level	CAB010911	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.84e-7 (unfavourable), Colorectal cancer:8.10e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2.8	Cell line enhanced		U-266/70: 14.8
UCN2	SRP, UCN-II, UCNI, URP	ENSG00000145040	Urocortin 2	3	48561727-48563773	Predicted secreted proteins	Evidence at protein level	HPA066841	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	8	skin: 15.5	endometrium: 2.0	Cell line enhanced		hTCEpi: 19.9;hTEC/SVTERT24-B: 21.7;SiHa: 20.5;WM-115: 55.5
UCN3	SPC, UCNIII	ENSG00000178473	Urocortin 3	10	5365009-5374692	Predicted secreted proteins	Evidence at protein level	HPA038281	Uncertain					Group enriched	Tissue enhanced		duodenum: 9.3;small intestine: 7.5	stomach: 3.6	Cell line enriched	10	SCLC-21H: 1.5
UGGT2	FLJ10873, FLJ11485, HUGT2, MGC117360, MGC150689, MGC87276, UGCGL2	ENSG00000102595	UDP-glucose glycoprotein glucosyltransferase 2	13	95801580-96053482	Predicted secreted proteins	Evidence at protein level	HPA047955	Uncertain				Lung cancer:5.47e-4 (unfavourable), Liver cancer:9.99e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.7	Mixed		
UGT1A10	UGT1J	ENSG00000242515	UDP glucuronosyltransferase family 1 member A10	2	233636454-233773305	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:4.55e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 49.7;duodenum: 80.9;small intestine: 59.1	rectum: 39.6	Cell line enriched	108	RT4: 416.9
UGT2A1		ENSG00000173610	UDP glucuronosyltransferase family 2 member A1 complex locus	4	69588417-69653249	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017261, HPA045108	Uncertain					Tissue enhanced	Group enriched	7	kidney: 8.1;liver: 5.5	skin: 0.9	Not detected		
UGT2B28		ENSG00000135226	UDP glucuronosyltransferase family 2 member B28	4	69280499-69295050	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	12	breast: 267.2	gallbladder: 21.5	Group enriched	9	Daudi: 2.1;NB-4: 1.7
UGT2B4	UGT2B11	ENSG00000156096	UDP glucuronosyltransferase family 2 member B4	4	69480165-69526014	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033260, HPA045108	Enhanced					Tissue enriched	Tissue enriched	78	liver: 655.5	heart muscle: 8.3	Cell line enriched	11	RH-30: 4.5
UGT2B7	UGT2B9	ENSG00000171234	UDP glucuronosyltransferase family 2 member B7	4	69051363-69112987	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain				Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)	Group enriched	Group enriched	13	kidney: 1326.3;liver: 825.7	fallopian tube: 79.7	Cell line enhanced		EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
UGT3A1	FLJ34658	ENSG00000145626	UDP glycosyltransferase family 3 member A1	5	35951010-36001028	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047697, HPA056290	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		kidney: 53.4;liver: 29.2	duodenum: 9.5	Cell line enriched	51	RH-30: 26.5
UGT3A2		ENSG00000168671	UDP glycosyltransferase family 3 member A2	5	36035017-36071358	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059475	Uncertain		Approved	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		skin: 11.9;testis: 4.6	bone marrow: 3.2	Cell line enhanced		HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
ULBP3	RAET1N	ENSG00000131019	UL16 binding protein 3	6	150063150-150069095	Predicted secreted proteins	Evidence at protein level	HPA056541, HPA063007	Approved		Uncertain	Vesicles<br>Microtubule organizing center		Mixed	Tissue enhanced		testis: 11.9;thyroid gland: 8.8	fallopian tube: 3.9	Mixed		
UMOD		ENSG00000169344	Uromodulin	16	20333052-20356301	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009446, HPA043420, HPA054721	Enhanced					Tissue enriched	Tissue enriched	726	kidney: 2392.4	cerebral cortex: 3.2	Not detected		
UNC5C		ENSG00000182168	Unc-5 netrin receptor C	4	95162504-95549206	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 20.0	adrenal gland: 11.6	Group enriched	6	AF22: 17.6;SH-SY5Y: 82.9
UPK3B	FLJ32198, MGC10902, p35, UPIIIb	ENSG00000243566	Uroplakin 3B	7	76510428-76516521	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010506	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Group enriched	11	esophagus: 12.4;lung: 29.8;urinary bladder: 11.0	tonsil: 1.6	Group enriched	8	A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
USP3		ENSG00000140455	Ubiquitin specific peptidase 3	15	63504511-63594640	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053275, HPA060513, HPA077975			Supported	Nucleoplasm	Urothelial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 32.1	Expressed in all		
USP40	FLJ10785	ENSG00000085982	Ubiquitin specific peptidase 40	2	233475520-233566782	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005821	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 31.5	Mixed		
UTP4	CIRH1A, CIRHIN, FLJ14728, KIAA1988, NAIC, TEX292	ENSG00000141076	UTP4, small subunit processome component	16	69131291-69231130	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041139, HPA043542	Approved		Supported	Nucleoli fibrillar center	Liver cancer:8.18e-7 (unfavourable), Ovarian cancer:2.88e-5 (favourable), Head and neck cancer:9.05e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.0	Expressed in all		
UTS2	PRO1068, U-II, UCN2, UII	ENSG00000049247	Urotensin 2	1	7843083-7853512	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017000	Uncertain					Mixed	Tissue enhanced		adrenal gland: 3.9	bone marrow,lymph node: 1.9	Group enriched	17	CACO-2: 17.2;HEL: 6.6;HMC-1: 5.3;THP-1: 17.9
UTS2B	U2B, URP, UTS2D	ENSG00000188958	Urotensin 2B	3	191267168-191330536	Predicted secreted proteins	Evidence at transcript level	HPA026992	Uncertain		Uncertain	Mitochondria		Not detected	Mixed			duodenum: 5.3	Mixed		
VASH1	KIAA1036	ENSG00000071246	Vasohibin 1	14	76762189-76783015	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000653	Uncertain				Pancreatic cancer:6.56e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 34.4	Cell line enhanced		AF22: 50.3;HUVEC TERT2: 78.5
VCAN	CSPG2, PG-M	ENSG00000038427	Versican	5	83471465-83582303	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004726, CAB008979	Enhanced		Supported	Vesicles	Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 105.5;placenta: 104.6	smooth muscle: 67.1	Cell line enhanced		AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9
VEGFA	VEGF, VEGF-A, VPF	ENSG00000112715	Vascular endothelial growth factor A	6	43770184-43786487	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005429, CAB039240, HPA069116, CAB069907	Supported				Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 452.5	Expressed in all		
VEGFB	VEGFL, VRF	ENSG00000173511	Vascular endothelial growth factor B	11	64234538-64238793	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Expressed in all	Expressed in all			adipose tissue: 195.0	Expressed in all		
VEGFC	VRP	ENSG00000150630	Vascular endothelial growth factor C	4	176683538-176792727	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters	Evidence at protein level						Lung cancer:7.88e-5 (unfavourable), Renal cancer:1.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 51.7	placenta: 30.7	Cell line enhanced		BJ: 135.8;HBF TERT88: 122.6;hTEC/SVTERT24-B: 129.0;LHCN-M2: 120.0
VEGFD	FIGF, VEGF-D	ENSG00000165197	Vascular endothelial growth factor D	X	15345591-15384376	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA027342	Uncertain					Mixed	Tissue enhanced		breast: 25.0;lung: 59.3	adipose tissue: 13.2	Cell line enhanced		ASC diff: 2.3;ASC TERT1: 2.0;HSkMC: 2.1
VGF	SCG7, SgVII	ENSG00000128564	VGF nerve growth factor inducible	7	101162509-101165593	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA055177, HPA072505	Enhanced		Supported	Golgi apparatus<br>Vesicles	Endometrial cancer:4.25e-4 (unfavourable), Glioma:4.43e-4 (unfavourable)	Tissue enriched	Tissue enriched	22	cerebral cortex: 46.1	adipose tissue: 2.0	Group enriched	11	SH-SY5Y: 182.3;SK-MEL-30: 372.7;U-2 OS: 87.3;WM-115: 139.3
VIP		ENSG00000146469	Vasoactive intestinal peptide	6	152750798-152759765	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017324, CAB018649, HPA072701	Supported		Approved	Endoplasmic reticulum		Group enriched	Group enriched	5	appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1	duodenum: 16.8	Cell line enhanced		SH-SY5Y: 2.8;TIME: 1.6
VIPR2	VPAC2, VPAC2R	ENSG00000106018	Vasoactive intestinal peptide receptor 2	7	159028175-159144957	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062707	Approved					Tissue enhanced	Tissue enhanced		seminal vesicle: 28.3	epididymis: 14.9	Cell line enhanced		HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8
VIT		ENSG00000205221	Vitrin	2	36696690-36814792	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 35.7	adipose tissue: 18.5	Cell line enhanced		ASC diff: 23.1;ASC TERT1: 45.7;BJ: 27.8;fHDF/TERT166: 87.0;THP-1: 23.9
VKORC1	VKCFD2	ENSG00000167397	Vitamin K epoxide reductase complex subunit 1	16	31090842-31095980	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042720	Approved		Supported	Endoplasmic reticulum	Renal cancer:2.09e-10 (unfavourable)	Expressed in all	Expressed in all			liver: 141.4	Expressed in all		
VLDLR	CARMQ1, CHRMQ1, VLDLRCH	ENSG00000147852	Very low density lipoprotein receptor	9	2621834-2660053	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032462, HPA051312	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Endometrial cancer:5.95e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 110.0;parathyroid gland: 124.0	fallopian tube: 43.7	Cell line enhanced		BEWO: 60.5
VMO1		ENSG00000182853	Vitelline membrane outer layer 1 homolog	17	4785285-4786433	Predicted secreted proteins	Evidence at protein level	HPA023038	Uncertain				Renal cancer:1.34e-6 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 34.4	spleen: 14.6	Cell line enhanced		A549: 2.7;MCF7: 3.0
VNN1	Tiff66	ENSG00000112299	Vanin 1	6	132681590-132714049	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064145	Approved				Renal cancer:2.52e-4 (unfavourable)	Tissue enhanced	Group enriched	5	duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3	kidney: 27.5	Cell line enhanced		EFO-21: 10.3
VNN2	FOAP-4, GPI-80	ENSG00000112303	Vanin 2	6	132743870-132763459	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.72e-7 (unfavourable)	Mixed	Tissue enhanced		spleen: 76.9	lymph node: 45.0	Cell line enriched	6	Daudi: 40.8
VNN3	HSA238982	ENSG00000093134	Vanin 3	6	132722787-132734765	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		bone marrow: 35.3;liver: 15.2	spleen: 9.5	Not detected		
VOPP1	DKFZp564K0822, ECop, FLJ20532, GASP	ENSG00000154978	Vesicular, overexpressed in cancer, prosurvival protein 1	7	55436056-55572988	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.99e-8 (unfavourable), Liver cancer:4.35e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 110.2	Mixed		
VPREB1	CD179A, VpreB	ENSG00000169575	Pre-B lymphocyte 1	22	22244675-22245515	CD markers, Predicted secreted proteins	Evidence at protein level	HPA055886	Uncertain					Not detected	Tissue enriched	15	bone marrow: 17.1	tonsil: 1.1	Group enriched	13	Daudi: 5.6;MOLT-4: 13.7;RPMI-8226: 3.1
VPREB3	8HS20	ENSG00000128218	Pre-B lymphocyte 3	22	23752743-23754468	Predicted secreted proteins	Evidence at protein level	HPA003041	Supported					Expressed in all	Tissue enhanced		lymph node: 117.3;tonsil: 95.8	spleen: 61.1	Cell line enhanced		Daudi: 168.5;REH: 255.6;U-698: 50.4
VPS37B	FLJ12750	ENSG00000139722	VPS37B, ESCRT-I subunit	12	122865328-122896444	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038217, HPA038218	Enhanced				Renal cancer:1.35e-6 (favourable)	Expressed in all	Expressed in all			esophagus: 34.8	Mixed		
VSIG1	MGC44287	ENSG00000101842	V-set and immunoglobulin domain containing 1	X	108044970-108079184	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001445, HPA036310, HPA036311	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	10	stomach: 185.7;testis: 91.1	gallbladder: 14.3	Cell line enhanced		HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
VSIG10		ENSG00000176834	V-set and immunoglobulin domain containing 10	12	118063593-118136026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062022			Approved	Microtubule organizing center<br>Cytosol	Liver cancer:1.76e-4 (unfavourable), Melanoma:7.53e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 27.7	Cell line enhanced		HAP1: 35.3
VSTM1	UNQ3033	ENSG00000189068	V-set and transmembrane domain containing 1	19	54040825-54063953	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059365			Approved	Vesicles		Mixed	Tissue enriched	38	bone marrow: 35.4	urinary bladder: 0.9	Not detected		
VSTM2A	MGC33530, VSTM2	ENSG00000170419	V-set and transmembrane domain containing 2A	7	54542325-54571080	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA021404, HPA024134	Uncertain				Renal cancer:5.34e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 12.7;cerebral cortex: 40.8;prostate: 15.5	stomach: 4.8	Cell line enhanced		Karpas-707: 1.3;SCLC-21H: 6.9;SH-SY5Y: 4.3
VSTM2B		ENSG00000187135	V-set and transmembrane domain containing 2B	19	29526499-29564479	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	20	cerebral cortex: 42.3	cervix, uterine: 2.1	Group enriched	7	SCLC-21H: 1.3;SK-MEL-30: 6.2
VSTM2L	C20orf102, dJ1118M15.2	ENSG00000132821	V-set and transmembrane domain containing 2 like	20	37903104-37945350	Predicted secreted proteins	Evidence at protein level	HPA043832	Uncertain				Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 55.1	gallbladder: 26.8	Cell line enhanced		CAPAN-2: 58.1;HDLM-2: 86.5;SK-BR-3: 59.9
VSTM4	C10orf72, FLJ31737	ENSG00000165633	V-set and transmembrane domain containing 4	10	49014245-49115509	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA017279	Uncertain		Approved	Nucleus<br>Vesicles	Urothelial cancer:4.25e-4 (unfavourable)	Tissue enriched	Mixed			adrenal gland: 54.8	Cell line enhanced		RH-30: 9.1;U-138 MG: 10.5;U-2197: 22.4;U-87 MG: 11.4
VTN	VN	ENSG00000109072	Vitronectin	17	28367276-28373091	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016695, CAB016765, HPA060933	Supported		Supported	Endoplasmic reticulum<br>Vesicles	Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable)	Tissue enriched	Tissue enriched	28	liver: 2554.5	gallbladder: 91.2	Cell line enriched	9	CACO-2: 1044.7
VWA1	FLJ22215, VWA-1, WARP	ENSG00000179403	Von Willebrand factor A domain containing 1	1	1434861-1442882	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		seminal vesicle: 293.3	prostate: 129.1	Cell line enhanced		CAPAN-2: 120.1;Hep G2: 57.0;SCLC-21H: 56.1;T-47d: 57.5
VWA2	AMACO, CCSP-2, FLJ16213, FLJ45857, NET42	ENSG00000165816	Von Willebrand factor A domain containing 2	10	114239330-114291513	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037847	Uncertain					Mixed	Tissue enhanced		fallopian tube: 11.0	stomach: 7.8	Group enriched	6	CAPAN-2: 5.9;HaCaT: 2.7;SCLC-21H: 2.1
VWA5B1	FLJ32784	ENSG00000158816	Von Willebrand factor A domain containing 5B1	1	20290919-20354894	Predicted intracellular proteins	Evidence at protein level	HPA027496, HPA028405, HPA064829	Enhanced		Approved	Plasma membrane<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 5.0	epididymis: 1.6	Cell line enriched	10	SCLC-21H: 1.4
VWA7	C6orf27, G7c, NG37	ENSG00000204396	Von Willebrand factor A domain containing 7	6	31765590-31777294	Predicted secreted proteins	Evidence at transcript level	HPA046954, HPA054262	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.35e-8 (favourable)	Mixed	Tissue enhanced		fallopian tube: 9.1	parathyroid gland: 1.9	Cell line enhanced		U-266/70: 1.0
VWC2	PSST739, UNQ739	ENSG00000188730	Von Willebrand factor C domain containing 2	7	49773661-49921950	Predicted secreted proteins	Evidence at protein level	HPA055243	Approved					Not detected	Tissue enhanced		heart muscle: 3.2;ovary: 6.1	cerebral cortex: 1.8	Not detected		
VWC2L		ENSG00000174453	Von Willebrand factor C domain containing protein 2-like	2	214411065-214578959	Predicted secreted proteins	Evidence at protein level	HPA044815, HPA059414	Uncertain					Not detected	Tissue enriched	31	cerebral cortex: 3.1	all non-specific tissues: 0.0	Not detected		
VWCE	FLJ32009, URG11, VWC1	ENSG00000167992	Von Willebrand factor C and EGF domains	11	61258286-61295424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040401, HPA043921	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Tissue enhanced		fallopian tube: 5.1;ovary: 5.8	liver: 3.7	Cell line enhanced		Hep G2: 14.6;HSkMC: 8.6;REH: 11.0
VWDE	FLJ14712	ENSG00000146530	Von Willebrand factor D and EGF domains	7	12330885-12403941	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026619, HPA036044	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 3.9	breast,epididymis,heart muscle: 1.1	Cell line enhanced		K-562: 7.1;NTERA-2: 3.7;SCLC-21H: 7.1
VWF	F8VWF	ENSG00000110799	Von Willebrand factor	12	5948874-6124770	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB001694, HPA001815, HPA002082, CAB072874, CAB072875	Supported				Stomach cancer:2.31e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 155.1	lung: 115.9	Cell line enriched	57	HUVEC TERT2: 468.1
WDPCP	BBS15, C2orf86, fritz, hFrtz	ENSG00000143951	WD repeat containing planar cell polarity effector	2	63121383-63827843	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044144	Uncertain		Approved	Cell Junctions		Mixed	Mixed			testis: 11.4	Expressed in all		
WDR25	C14orf67, MGC4645	ENSG00000176473	WD repeat domain 25	14	100376418-100530303	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003113	Approved		Supported	Nucleoplasm	Renal cancer:3.89e-5 (favourable), Liver cancer:7.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.6	Mixed		
WDR81	CAMRQ2, FLJ33817, PPP1R166, SORF-2	ENSG00000167716	WD repeat domain 81	17	1716523-1738599	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023044	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:3.30e-4 (favourable)	Expressed in all	Mixed			ovary,spleen: 10.4	Mixed		
WFDC1	PS20	ENSG00000103175	WAP four-disulfide core domain 1	16	84294646-84329851	Predicted secreted proteins	Evidence at transcript level	HPA031411	Uncertain					Mixed	Tissue enhanced		placenta: 121.8;seminal vesicle: 135.6	prostate: 88.4	Cell line enhanced		AN3-CA: 24.0;BJ: 15.1;HEL: 13.6;HeLa: 16.0
WFDC10A	C20orf146, dJ688G8.3, WAP10	ENSG00000180305	WAP four-disulfide core domain 10A	20	45629526-45631196	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	354	epididymis: 175.8	seminal vesicle: 0.4	Not detected		
WFDC10B	WAP12	ENSG00000182931	WAP four-disulfide core domain 10B	20	45684653-45705019	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	12	epididymis: 33.3	testis: 2.7	Cell line enhanced		PC-3: 1.8
WFDC11	WAP11	ENSG00000180083	WAP four-disulfide core domain 11	20	45648563-45670270	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	14	epididymis: 115.8	testis: 8.5	Group enriched	6	HeLa: 5.5;RPMI-8226: 3.6;U-937: 1.1
WFDC12	C20orf122, dJ211D12.4, WAP2	ENSG00000168703	WAP four-disulfide core domain 12	20	45123425-45124465	Predicted secreted proteins	Evidence at protein level						Renal cancer:5.65e-4 (unfavourable)	Group enriched	Tissue enriched	12	skin: 49.7	seminal vesicle: 4.3	Not detected		
WFDC13	C20orf138, dJ601O1.3, WAP13	ENSG00000168634	WAP four-disulfide core domain 13	20	45702016-45708817	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	319	epididymis: 106.6	seminal vesicle: 0.3	Not detected		
WFDC2	dJ461P17.6, EDDM4, HE4, WAP5	ENSG00000101443	WAP four-disulfide core domain 2	20	45469706-45481532	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042302	Enhanced		Approved	Cytosol	Renal cancer:4.44e-5 (favourable), Glioma:5.87e-5 (unfavourable)	Expressed in all	Tissue enriched	6	cervix, uterine: 6567.2	seminal vesicle: 1051.7	Group enriched	8	A-431: 90.4;CAPAN-2: 165.0;EFO-21: 144.7;HaCaT: 121.3;RPTEC TERT1: 108.5
WFDC3	dJ447F3.3, WAP14	ENSG00000124116	WAP four-disulfide core domain 3	20	45747944-45791932	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	19	testis: 31.9	breast: 1.7	Cell line enhanced		PC-3: 1.1
WFDC5	dJ211D12.5, WAP1	ENSG00000175121	WAP four-disulfide core domain 5	20	45109452-45115172	Predicted secreted proteins	Evidence at transcript level						Renal cancer:2.32e-5 (unfavourable)	Tissue enhanced	Tissue enriched	35	skin: 468.5	breast: 13.2	Not detected		
WFDC6	C20orf171, dJ461P17.11, WAP6	ENSG00000243543	WAP four-disulfide core domain 6	20	45534196-45539495	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Group enriched	16	epididymis: 323.7;testis: 83.8	fallopian tube: 12.5	Cell line enriched	7	U-87 MG: 2.6
WFDC8	C20orf170, dJ461P17.1, WAP8	ENSG00000158901	WAP four-disulfide core domain 8	20	45551153-45579326	Predicted secreted proteins	Evidence at protein level	HPA042710, HPA071119	Enhanced					Not detected	Tissue enriched	436	epididymis: 487.6	seminal vesicle: 1.1	Cell line enriched	6	U-87 MG: 2.6
WFDC9	dJ688G8.2, WAP9	ENSG00000180205	WAP four-disulfide core domain 9	20	45607939-45631268	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	405	epididymis: 1257.7	seminal vesicle: 3.1	Not detected		
WFIKKN1	C16orf12, RJD2, WFDC20A, WFIKKN	ENSG00000127578	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1	16	629239-634116	Predicted secreted proteins	Evidence at protein level	CAB025858, HPA043362, HPA044237	Uncertain					Mixed	Not detected			cerebral cortex,endometrium,lung,spleen: 0.1	Cell line enhanced		EFO-21: 4.2;NTERA-2: 1.3
WFIKKN2	WFDC20B, WFIKKNRP	ENSG00000173714	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2	17	50834650-50842348	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	17	ovary: 76.5	testis: 4.4	Not detected		
WHRN	CIP98, DFNB31, PDZD7B, USH2D	ENSG00000095397	Whirlin	9	114402080-114505450	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002480, CAB033194	Uncertain				Pancreatic cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 73.0	testis: 44.4	Cell line enhanced		Karpas-707: 96.9;U-266/70: 64.0;U-266/84: 64.8
WIF1		ENSG00000156076	WNT inhibitory factor 1	12	65050626-65121566	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039104	Approved					Tissue enhanced	Tissue enriched	6	lung: 159.4	cerebral cortex: 26.4	Cell line enhanced		HEK 293: 1.9;NTERA-2: 2.7
WISP1	CCN4	ENSG00000104415	WNT1 inducible signaling pathway protein 1	8	133191039-133230344	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA007121, CAB012205	Uncertain		Approved	Cytosol	Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 22.1	Cell line enhanced		HSkMC: 85.7;hTEC/SVTERT24-B: 73.5;U-2197: 64.2
WISP2	CCN5, CT58, CTGF-L	ENSG00000064205	WNT1 inducible signaling pathway protein 2	20	44714844-44728509	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019273	Approved					Tissue enhanced	Tissue enhanced		cervix, uterine: 459.5;ovary: 167.2	breast: 70.0	Cell line enhanced		ASC TERT1: 71.5;HeLa: 40.1;U-2197: 313.4
WISP3	CCN6	ENSG00000112761	WNT1 inducible signaling pathway protein 3	6	112054072-112070969	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062438, HPA078340			Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		epididymis: 3.0;skin: 2.0	fallopian tube: 1.8	Cell line enhanced		RT4: 4.6;THP-1: 1.2;U-2197: 1.2
WNK1	HSAN2, HSN2, PPP1R167, PRKWNK1	ENSG00000060237	WNK lysine deficient protein kinase 1	12	752593-911452	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046541, HPA059157	Enhanced		Supported	Cytosol	Ovarian cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 92.4	Expressed in all		
WNT1	INT1	ENSG00000125084	Wnt family member 1	12	48978453-48981676	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.3	lymph node: 1.0	Not detected		
WNT10B	SHFM6, WNT-12	ENSG00000169884	Wnt family member 10B	12	48965340-48971763	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA055048, HPA062539	Enhanced		Approved	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 11.6	skin: 3.0	Cell line enhanced		T-47d: 7.6
WNT16		ENSG00000002745	Wnt family member 16	7	121325367-121341104	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA027030	Uncertain					Mixed	Group enriched	7	cervix, uterine: 8.6;skin: 24.3	seminal vesicle: 2.5	Cell line enhanced		CAPAN-2: 2.0;HEK 293: 4.9;hTEC/SVTERT24-B: 1.6;U-2197: 2.4
WNT2	INT1L1, IRP	ENSG00000105989	Wnt family member 2	7	117276631-117323289	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA020920			Approved	Vesicles		Mixed	Group enriched	6	endometrium: 23.8;placenta: 93.2	lung: 9.2	Cell line enriched	6	U-2197: 19.1
WNT3A		ENSG00000154342	Wnt family member 3A	1	228007051-228061260	Predicted secreted proteins	Evidence at protein level						Cervical cancer:6.11e-5 (favourable)	Mixed	Tissue enriched	6	placenta: 23.2	lung: 3.8	Group enriched	9	HEK 293: 1.1;U-2 OS: 3.9
WNT5A	hWNT5A	ENSG00000114251	Wnt family member 5A	3	55465715-55490539	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Colorectal cancer:2.94e-5 (favourable)	Expressed in all	Tissue enhanced		endometrium: 45.3	urinary bladder: 35.4	Cell line enhanced		BJ: 189.9;BJ hTERT+: 249.3;SiHa: 371.6;U-87 MG: 239.2
WNT5B		ENSG00000111186	Wnt family member 5B	12	1529891-1647243	Predicted secreted proteins	Evidence at protein level	HPA061991			Approved	Vesicles		Expressed in all	Tissue enhanced		prostate: 34.7	seminal vesicle: 27.9	Cell line enhanced		BJ: 195.3;BJ hTERT+ SV40 Large T+: 154.0;BJ hTERT+ SV40 Large T+ RasG12V: 132.9;HBF TERT88: 139.5;hTEC/SVTERT24-B: 144.8;U-138 MG: 140.4
WNT6		ENSG00000115596	Wnt family member 6	2	218859821-218874233	Predicted secreted proteins	Evidence at protein level	HPA070759	Approved					Tissue enhanced	Tissue enhanced		placenta: 2.9	spleen: 1.5	Cell line enriched	6	BEWO: 33.5
WNT8A	WNT8D	ENSG00000061492	Wnt family member 8A	5	138083892-138092365	Predicted secreted proteins	Evidence at transcript level	HPA038539	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Not detected			testis: 0.7	Not detected		
WNT8B		ENSG00000075290	Wnt family member 8B	10	100463041-100483744	Predicted secreted proteins	Evidence at transcript level	HPA036570	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.1;parathyroid gland: 1.5;testis: 1.2	kidney: 0.6	Cell line enhanced		AF22: 2.3;SCLC-21H: 1.3
WNT9A	WNT14	ENSG00000143816	Wnt family member 9A	1	227918656-227947898	Plasma proteins, Predicted secreted proteins	Evidence at transcript level						Ovarian cancer:1.06e-4 (unfavourable)	Mixed	Mixed			heart muscle: 7.2	Cell line enhanced		HaCaT: 14.4;RH-30: 16.0;SCLC-21H: 17.7;SiHa: 15.7
WNT9B	WNT14B, WNT15	ENSG00000158955	Wnt family member 9B	17	46833201-46886730	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058361, HPA059572	Approved					Not detected	Tissue enhanced		parathyroid gland: 3.1;seminal vesicle: 9.4	skin: 1.4	Not detected		
WSB1	DKFZp564A122, DKFZp564B0482, SWIP1	ENSG00000109046	WD repeat and SOCS box containing 1	17	27294076-27315926	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003293	Approved		Approved	Mitochondria	Renal cancer:1.02e-7 (unfavourable), Liver cancer:4.07e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.4	Expressed in all		
XCL1	ATAC, LPTN, LTN, SCM-1, SCM-1a, SCYC1	ENSG00000143184	X-C motif chemokine ligand 1	1	168576473-168582077	Predicted secreted proteins	Evidence at protein level	HPA057725	Approved					Mixed	Tissue enhanced		spleen: 5.7	endometrium: 3.3	Cell line enhanced		CACO-2: 2.4;Hep G2: 2.5;SCLC-21H: 4.0;U-266/70: 3.7
XCL2	SCM-1b, SCYC2	ENSG00000143185	X-C motif chemokine ligand 2	1	168540765-168543997	Predicted secreted proteins	Evidence at protein level	HPA057725	Approved				Renal cancer:8.36e-9 (unfavourable), Lung cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		spleen: 14.1	bone marrow: 8.4	Cell line enhanced		CACO-2: 2.1
XPNPEP2		ENSG00000122121	X-prolyl aminopeptidase 2	X	129738974-129769538	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000339, CAB025136, CAB025269	Enhanced					Group enriched	Group enriched	12	duodenum: 128.1;kidney: 175.9;small intestine: 231.5	liver: 14.3	Cell line enhanced		ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
XXbac-BPG116M5.17		ENSG00000244255		6	31927698-31952048	Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832	Approved					Not detected	Tissue enhanced		liver: 3.3;lung: 2.9	spleen: 1.2	Not detected		
XXbac-BPG181M17.5		ENSG00000248993		6	32937364-32953122	Predicted secreted proteins	Evidence at protein level	HPA012298	Uncertain					Not detected	Not detected			small intestine: 0.4	Not detected		
XXbac-BPG32J3.20		ENSG00000204422		6	31686962-31714072	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.9	Cell line enriched	29	HEL: 4.7
XYLT1	PXYLT1, XT-I	ENSG00000103489	Xylosyltransferase 1	16	17101769-17470881	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA007478, HPA007966	Approved					Mixed	Mixed			cervix, uterine: 12.2	Cell line enhanced		ASC diff: 38.1;U-2197: 54.3
ZG16	hZG16, JCLN, JCLN1, ZG16A	ENSG00000174992	Zymogen granule protein 16	16	29778240-29782973	Predicted secreted proteins	Evidence at protein level	HPA052066, HPA052512	Enhanced					Tissue enriched	Group enriched	6	colon: 363.4;rectum: 502.4;small intestine: 121.4	duodenum: 57.7	Cell line enhanced		SK-BR-3: 1.7
ZG16B	HRPE773, JCLN2, PRO1567	ENSG00000162078	Zymogen granule protein 16B	16	2830169-2839585	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041125, HPA053549	Enhanced		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:3.48e-6 (favourable)	Tissue enhanced	Tissue enriched	225	salivary gland: 19471.0	prostate: 86.7	Cell line enhanced		MCF7: 20.7;SK-BR-3: 18.1;T-47d: 20.8
ZIC4		ENSG00000174963	Zic family member 4	3	147386046-147406860	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at transcript level	HPA030194	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Group enriched	6	cerebral cortex: 4.3;skin: 1.4	skeletal muscle: 0.5	Cell line enhanced		AF22: 17.0;SH-SY5Y: 5.5
ZNF207		ENSG00000010244	Zinc finger protein 207	17	32350117-32381886	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017013, HPA063908	Enhanced		Enhanced	Nucleus	Renal cancer:4.17e-8 (unfavourable), Liver cancer:7.30e-8 (unfavourable), Colorectal cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 151.3	Expressed in all		
ZNF236		ENSG00000130856	Zinc finger protein 236	18	76822607-76970727	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008600	Uncertain					Expressed in all	Mixed			testis: 13.3	Mixed		
ZNF26	FLJ20755, KOX20	ENSG00000198393	Zinc finger protein 26	12	132986365-133032952	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA018329, HPA042406	Uncertain		Approved	Nuclear bodies<br>Mitochondria		Mixed	Mixed			epididymis: 6.9	Mixed		
ZNF419	ZAPHIR, ZNF419A	ENSG00000105136	Zinc finger protein 419	19	57487711-57496097	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA003152, HPA003274	Uncertain		Supported	Nucleus<br>Nucleoli fibrillar center	Urothelial cancer:2.53e-5 (favourable), Prostate cancer:6.47e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.2	Mixed		
ZNF433	FLJ40981	ENSG00000197647	Zinc finger protein 433	19	12014732-12035741	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA073724	Uncertain		Approved	Nuclear bodies	Renal cancer:8.33e-15 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
ZNF570	FLJ30791	ENSG00000171827	Zinc finger protein 570	19	37467585-37488652	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at transcript level	HPA028881	Uncertain		Approved	Nucleoplasm	Renal cancer:4.06e-5 (favourable)	Expressed in all	Mixed			testis: 10.7	Mixed		
ZNF691	Zfp691	ENSG00000164011	Zinc finger protein 691	1	42846573-42852477	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA062527	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:7.33e-6 (unfavourable), Pancreatic cancer:6.25e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.5	Expressed in all		
ZNF85	HPF4, HTF1	ENSG00000105750	Zinc finger protein 85	19	20923222-20950697	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044760	Uncertain		Supported	Nucleus	Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 28.0	thyroid gland: 12.0	Mixed		
ZPBP2	MGC41930, ZPBPL	ENSG00000186075	Zona pellucida binding protein 2	17	39868164-39877896	Predicted secreted proteins	Evidence at protein level	HPA027997, HPA053070	Enhanced					Not detected	Tissue enriched	230	testis: 209.2	tonsil: 0.9	Cell line enhanced		U-698: 3.4
